



(51) International Patent Classification:

A01H 5/00 (2006.01) C12N 15/82 (2006.01)
C12N 15/52 (2006.01)

CARLSON, Dale, R. [US/US]; 600 Sawcut Lane, Apex,
NC 27502 (US).

(21) International Application Number:

PCT/US2010/047571

(74) Agent: CARROLL, Lawrence, J.; Womble Carlyle Sandridge & Rice, PLLC, P.O. Box 7037, Atlanta, GA 30357 (US).

(22) International Filing Date:

1 September 2010 (01.09.2010)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/238,906 1 September 2009 (01.09.2009) US
61/365,298 16 July 2010 (16.07.2010) US

(71) Applicant (for all designated States except US): BASF AGROCHEMICAL PRODUCTS, B.V. [NL/NL]; Groningensingel 1, NL-6835 EA Arnhem (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MANKIN, Scots, L. [US/US]; 4800 Deerwood Drive, Raleigh, NC 27612 (US). SCHOF, Ulrich [DE/US]; 100 Hoboken Court, Apex, NC 27523 (US). HONG, Haiping [CA/US]; 117 Melling Place, Cary, NC 27519 (US). WENCK, Allan, R. [US/US]; 4315 Etta Road, Durham, NC 27705 (US). NEUTEBOOM, Leon [NL/US]; 10 Seabury Way, Youngsville, NC 27596 (US). WHITT, Sherry, R. [US/US]; 11412 Dunleith Drive, Raleigh, NC 27614 (US).


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

[Continued on next page]

(54) Title: HERBICIDE-TOLERANT PLANTS

FIGURE 1



(57) Abstract: The present invention provides herbicide-tolerant plants. The present invention also provides methods for controlling the growth of weeds by applying an herbicide to which herbicide-tolerant plants of the invention are tolerant. Plants of the invention may express an acetyl-Coenzyme A carboxylase enzyme that is tolerant to the action of acetyl-Coenzyme A carboxylase enzyme inhibitors.



-
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- Published:**
- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

HERBICIDE-TOLERANT PLANTS

BACKGROUND OF THE INVENTION

- [0001] Rice is one of the most important food crops in the world, particularly in Asia. Rice is a cereal grain produced by plants in the genus *Oryza*. The two most frequently cultivated species are *Oryza sativa* and *Oryza glaberrima*, with *O. sativa* being the most frequently cultivated domestic rice. In addition to the two domestic species, the genus *Oryza* contains more than 20 wild species. One of these wild species, *Oryza rufipogon* ("red rice" also referred to as *Oryza sativa* subsp. *rufipogon*) presents a major problem in commercial cultivation. Red rice produces red coated seeds. After harvest, rice seeds are milled to remove their hull. After milling, domestic rice is white while wild red rice appears discolored. The presence of discolored seeds reduces the value of the rice crop. Since red rice belongs to the same species as cultivated rice (*Oryza sativa*), their genetic makeup is very similar. This genetic similarity has made herbicidal control of red rice difficult.
- [0002] Domestic rice tolerant to imidazolinone herbicides have been developed and are currently marketed under the tradename CLEARFIELD®. Imidazolinone herbicides inhibit a plant's acetohydroxyacid synthase (AHAS) enzyme. When cultivating CLEARFIELD® rice, it is possible to control red rice and other weeds by application of imidazolinone herbicides. Unfortunately, imidazolinone herbicide-tolerant red rice and weeds have developed.
- [0003] Acetyl-Coenzyme A carboxylase (ACCase; EC 6.4.1.2) enzymes synthesize malonyl-CoA as the start of the de novo fatty acid synthesis pathway in plant chloroplasts. ACCase in grass chloroplasts is a multifunctional, nuclear-genome-encoded, very large, single polypeptide, transported into the plastid via an N-terminal transit peptide. The active form in grass chloroplasts is a homomeric protein, likely a homodimer.
- [0004] ACCase enzymes in grasses are inhibited by three classes of herbicidal active ingredients. The two most prevalent classes are aryloxyphenoxypropanoates ("FOPs") and cyclohexanediones ("DIMs"). In addition to these two classes, a third class phenylpyrazolines ("DENS") has been described.

[0005] A number of ACCase-inhibitor-tolerance (AIT) mutations have been found in monocot weed species exhibiting tolerance toward one or more DIM or FOP herbicides. Further, an AIT maize has been marketed by BASF. All such mutations are found in the carboxyltransferase domain of the ACCase enzyme, and these appear to be located in a substrate binding pocket, altering access to the catalytic site.

[0006] DIMs and FOPs are important herbicides and it would be advantageous if rice could be provided that exhibits tolerance to these classes of herbicide. Currently, these classes of herbicide are of limited value in rice agriculture. In some cases, herbicide-tolerance-inducing mutations create a severe fitness penalty in the tolerant plant. Therefore, there remains a need in the art for an AIT rice that also exhibits no fitness penalty. This need and others are met by the present invention.

BRIEF SUMMARY OF THE INVENTION

[0007] The present invention relates to herbicide-tolerant plants and methods of producing and treating herbicide-tolerant plants. In one embodiment, the present invention provides a rice plant tolerant to at least one herbicide that inhibits acetyl-Coenzyme A carboxylase activity at levels of herbicide that would normally inhibit the growth of a rice plant. Typically, an herbicide-tolerant rice plant of the invention expresses an acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence differs from an amino acid sequence of an acetyl-Coenzyme A carboxylase of a wild-type rice plant. By convention, mutations within monocot ACCase amino acid residues are typically referred to in reference to their position in the *Alopecurus myosuroides* (blackgrass) plastidic monomeric ACCase sequence (Genbank CAC84161.1) and denoted with an (*Am*). Examples of amino acid positions at which an acetyl-Coenzyme A carboxylase of an herbicide-tolerant plant of the invention differs from the acetyl-Coenzyme A carboxylase of the corresponding wild-type plant include, but are not limited to, one or more of the following positions: 1,781(*Am*), 1,785(*Am*), 1,786(*Am*), 1,811(*Am*), 1,824(*Am*), 1,864(*Am*), 1,999(*Am*), 2,027(*Am*), 2,039(*Am*), 2,041(*Am*), 2,049(*Am*), 2,059(*Am*), 2,074(*Am*), 2,075(*Am*), 2,078(*Am*), 2,079(*Am*), 2,080(*Am*), 2,081(*Am*), 2,088(*Am*), 2,095(*Am*), 2,096(*Am*), or 2,098(*Am*). Examples of differences at these amino acid positions include, but are not limited to, one or more of the following: the amino acid at position 1,781(*Am*) is other than

isoleucine; the amino acid at position 1,785(*Am*) is other than alanine; the amino acid at position 1,786(*Am*) is other than alanine; the amino acid at position 1,811(*Am*) is other than isoleucine; the amino acid position 1,824(*Am*) is other than glutamine; the amino acid position 1,864(*Am*) is other than valine; the amino acid at position 1,999(*Am*) is other than tryptophan; the amino acid at position 2,027(*Am*) is other than tryptophan; the amino acid position 2,039(*Am*) is other than glutamic acid; the amino acid at position 2,041(*Am*) is other than isoleucine; the amino acid at position 2,049(*Am*) is other than valine; the amino acid position 2,059(*Am*) is other than an alanine; the amino acid at position 2,074(*Am*) is other than tryptophan; the amino acid at position 2,075(*Am*) is other than valine; the amino acid at position 2,078(*Am*) is other than aspartate; the amino acid position at position 2,079(*Am*) is other than serine; the amino acid at position 2,080(*Am*) is other than lysine; the amino acid position at position 2,081(*Am*) is other than isoleucine; the amino acid at position 2,088(*Am*) is other than cysteine; the amino acid at position 2,095(*Am*) is other than lysine; the amino acid at position 2,096(*Am*) is other than glycine; or the amino acid at position 2,098(*Am*) is other than valine. In some embodiments, the present invention provides a rice plant expressing an acetyl-Coenzyme A carboxylase enzyme comprising an amino acid sequence that comprises one or more of the following: the amino acid at position 1,781(*Am*) is leucine, threonine, valine, or alanine; the amino acid at position 1,785(*Am*) is glycine; the amino acid at position 1,786(*Am*) is proline; the amino acid at position 1,811(*Am*) is asparagine; the amino acid at position 1,824(*Am*) is proline; the amino acid at position 1,864(*Am*) is phenylalanine; the amino acid at position 1,999(*Am*) is cysteine or glycine; the amino acid at position 2,027(*Am*) is cysteine; the amino acid at position 2,039(*Am*) is glycine; the amino acid at position 2,041(*Am*) is asparagine; the amino acid at position 2049(*Am*) is phenylalanine; the amino acid at position 2,059(*Am*) is valine; the amino acid at position 2,074(*Am*) is leucine; the amino acid at position 2,075(*Am*) is leucine, isoleucine or methionine; the amino acid at position 2,078(*Am*) is glycine, or threonine; the amino acid at position 2,079(*Am*) is phenylalanine; the amino acid at position 2,080(*Am*) is glutamic acid; the amino acid at position 2,080(*Am*) is deleted; the amino acid at position 2,081(*Am*) is deleted; the amino acid at position 2,088(*Am*) is arginine, or tryptophan; the amino acid at position 2,095(*Am*) is glutamic acid; the amino acid at position 2,096(*Am*) is alanine, or

serine; or the amino acid at position 2,098(*Am*) is alanine, glycine, proline, histidine, or serine.

[0008] The present invention also provides methods of producing herbicide-tolerant plants and plants produced by such methods. An example of a plant produced by the methods of the invention is an herbicide-tolerant rice plant which is tolerant to at least one herbicide that inhibits acetyl-Coenzyme A carboxylase activity at levels of herbicide that would normally inhibit the growth of said plant, wherein the herbicide-tolerant plant is produced by: a) obtaining cells from a plant that is not tolerant to the herbicide; b) contacting the cells with a medium comprising one or more acetyl-Coenzyme A carboxylase inhibitors; and c) generating an herbicide-tolerant plant from the cells. Herbicide-tolerant plants produced by methods of the invention include, but are not limited to, herbicide-tolerant plants generated by performing a), b) and c) above and progeny of a plant generated by performing a), b), and c) above. In one embodiment, cells used to practice methods of this type will be in the form of a callus.

[0009] The present invention provides plants expressing acetyl-Coenzyme A carboxylase enzymes comprising defined amino acid sequences. For example, the present invention provides a rice plant, wherein one or more of the genomes of said rice plant encode a protein comprising a modified version of one or both of SEQ ID NOs: 2 and 3, wherein the sequence is modified such that the encoded protein comprises one or more of the following: the amino acid at position 1,781(*Am*) is leucine, threonine, valine, or alanine; the amino acid at position 1,785(*Am*) is glycine; the amino acid at position 1,786(*Am*) is proline; the amino acid at position 1,811(*Am*) is asparagine; the amino acid at position 1,824(*Am*) is proline; the amino acid at position 1,864(*Am*) is phenylalanine; the amino acid at position 1,999(*Am*) is cysteine or glycine; the amino acid at position 2,027(*Am*) is cysteine; the amino acid at position 2,039(*Am*) is glycine; the amino acid at position 2,041(*Am*) is asparagine; the amino acid at position 2049(*Am*) is phenylalanine; the amino acid at position 2,059(*Am*) is valine; the amino acid at position 2,074(*Am*) is leucine; the amino acid at position 2,075(*Am*) is leucine, isoleucine or methionine; the amino acid at position 2,078(*Am*) is glycine, or threonine; the amino acid at position 2,079(*Am*) is phenylalanine; the amino acid at position 2,080(*Am*) is glutamic acid; the amino acid at position 2,080(*Am*) is deleted; the amino acid at position

2,081(*Am*) is deleted; the amino acid at position 2,088(*Am*) is arginine, or tryptophan; the amino acid at position 2,095(*Am*) is glutamic acid; the amino acid at position 2,096(*Am*) is alanine, or serine; or the amino acid at position 2,098(*Am*) is alanine, glycine, proline, histidine, or serine. Figure 19 below provides an alignment of the *Alopecurus myosuroides* acetyl-Coenzyme A carboxylase sequence (SEQ ID NO:1), the *Oryza sativa* Indica1 acetyl-Coenzyme A carboxylase sequence (SEQ ID NO:2) and the *Oryza sativa* Japonica acetyl-Coenzyme A carboxylase sequence (SEQ ID NO:3) with examples of positions where the wild type sequences may differ with sequences of the invention indicated.

[0010] In another embodiment, the present invention comprises seeds deposited in an acceptable depository in accordance with the Budapest Treaty, cells derived from such seeds, plants grown from such seeds and cells derived from such plants, progeny of plants grown from such seed and cells derived from such progeny. The growth of plants produced from deposited seed and progeny of such plants will typically be tolerant to acetyl-Coenzyme A carboxylase-inhibiting herbicides at levels of herbicide that would normally inhibit the growth of a corresponding wild-type plant. In one embodiment, the present invention provides a rice plant grown from a seed produced from a plant of any one of lines OsHPHI2, OsARWI1, OsARWI3, OsARWI8, or OsHPHN1, a representative sample of seed of each line having been deposited with American Type Culture Collection (ATCC) under Patent Deposit Designation Number PTA-10267, PTA-10568, PTA-10569, PTA-10570, or PTA-10571, respectively. The present invention also encompasses mutants, recombinants, and/or genetically engineered derivatives prepared from a plant of any one of lines OsHPHI2, OsARWI1, OsARWI3, OsARWI8, or OsHPHN1, a representative sample of seed of each line having been deposited with ATCC under Patent Deposit Designation Number PTA-10267, PTA-10568, PTA-10569, PTA-10570, or PTA-10571, respectively, as well as any progeny of the plant grown or bred from a plant of any one of lines OsHPHI2, OsARWI1, OsARWI3, OsARWI8, or OsHPHN1, a representative sample of seed of each line having been deposited with ATCC under Patent Deposit Designation Number PTA-10267, PTA-10568, PTA-10569, PTA-10570, or PTA-10571, respectively, so long as such plants or progeny have the herbicide tolerance characteristics of the plant grown from a a plant of any one of lines OsHPHI2, OsARWI1, OsARWI3, OsARWI8, or OsHPHN1, a representative sample of seed of each line having been deposited with ATCC under Patent Deposit

Designation Number PTA-10267, PTA-10568, PTA-10569, PTA-10570, or PTA-10571, respectively. The present invention also encompasses cells cultured from such seeds and plants and their progeny produced from the cultured cells.

[0011] An herbicide-tolerant plant of the invention may be a member of the species *O. sativa*. Herbicide-tolerant plants of the invention are typically tolerant to aryloxyphenoxypropionate herbicides, cyclohexanedione herbicides, phenylpyrazoline herbicides or combinations thereof at levels of herbicide that would normally inhibit the growth of a corresponding wild-type plant, for example, a rice plant. In some embodiments, an herbicide-tolerant plant of the invention is not a GMO-plant. The present invention also provides an herbicide-tolerant plant that is mutagenized, for example, a mutagenized rice plant. The present invention also encompasses cells derived from the plants and seeds of the herbicide-tolerant plants described above.

[0012] The present invention provides methods for controlling growth of weeds. In one embodiment, the present invention provides a method of controlling growth of weeds in vicinity to rice plants. Such methods may comprise applying to the weeds and rice plants an amount of an acetyl-Coenzyme A carboxylase-inhibiting herbicide that inhibits naturally occurring acetyl-Coenzyme A carboxylase activity, wherein said rice plants comprise altered acetyl-Coenzyme A carboxylase activity such that said rice plants are tolerant to the applied amount of herbicide. Methods of the invention may be practiced with any herbicide that interferes with acetyl-Coenzyme A carboxylase activity including, but not limited to, aryloxyphenoxypropionate herbicides, cyclohexanedione herbicides, phenylpyrazoline herbicides or combinations thereof.

[0013] The present invention provides a method for controlling growth of weeds in vicinity to rice plants. One example of such methods may comprise applying one or more herbicides to the weeds and to the rice plants at levels of herbicide that would normally inhibit the growth of a rice plant, wherein at least one herbicide inhibits acetyl-Coenzyme A carboxylase activity. Such methods may be practiced with any herbicide that inhibits acetyl-Coenzyme A carboxylase activity. Suitable examples of herbicides that may be used in the practice of methods of controlling weeds include, but are not limited to,

aryloxyphenoxypropionate herbicides, cyclohexanedione herbicides, phenylpyrazoline herbicides or combinations thereof.

[0014] The present invention encompasses a method for controlling growth of weeds. One example of such methods may comprise (a) crossing an herbicide-tolerant rice plant with other rice germplasm, and harvesting the resulting hybrid rice seed; (b) planting the hybrid rice seed; and (c) applying one or more acetyl-Coenzyme A carboxylase-inhibiting herbicides to the hybrid rice and to the weeds in vicinity to the hybrid rice at levels of herbicide that would normally inhibit the growth of a rice plant. Such methods may be practiced with any herbicide that inhibits acetyl-Coenzyme A carboxylase activity. Suitable examples of herbicides that may be used in the practice of methods of controlling weeds include, but are not limited to, aryloxyphenoxypropionate herbicides, cyclohexanedione herbicides, phenylpyrazoline herbicides or combinations thereof.

[0015] In another embodiment, the present invention includes a method for selecting herbicide-tolerant rice plants. One example of such methods may comprise (a) crossing an herbicide-tolerant rice plant with other rice germplasm, and harvesting the resulting hybrid rice seed; (b) planting the hybrid rice seed; (c) applying one or more herbicides to the hybrid rice at levels of herbicide that would normally inhibit the growth of a rice plant, wherein at least one of the herbicides inhibits acetyl-Coenzyme A carboxylase; and (d) harvesting seeds from the rice plants to which herbicide has been applied. Such methods may be practiced with any herbicide that inhibits acetyl-Coenzyme A carboxylase activity. Suitable examples of herbicides that may be used in the practice of methods of controlling weeds include, but are not limited to, aryloxyphenoxypropionate herbicides, cyclohexanedione herbicides, phenylpyrazoline herbicides or combinations thereof.

[0016] The present invention also encompasses a method for growing herbicide-tolerant rice plants. One example of such a method comprises (a) planting rice seeds; (b) allowing the rice seeds to sprout; (c) applying one or more herbicides to the rice sprouts at levels of herbicide that would normally inhibit the growth of a rice plant, wherein at least one of the herbicides inhibits acetyl-Coenzyme A carboxylase. Such methods may be practiced with any herbicide that inhibits acetyl-Coenzyme A carboxylase activity. Suitable examples of herbicides that may be used in the practice of methods of controlling weeds include, but are

not limited to, aryloxyphenoxypropionate herbicides, cyclohexanedione herbicides, phenylpyrazoline herbicides or combinations thereof.

[0017] In one embodiment, the present invention provides a seed of an herbicide-tolerant rice plant. Such seed may be used to grow herbicide-tolerant rice plants, wherein a plant grown from the seed is tolerant to at least one herbicide that inhibits acetyl-Coenzyme A carboxylase activity at levels of herbicide that would normally inhibit the growth of a rice plant. Examples of herbicides to which plants grown from seeds of the invention would be tolerant include but are not limited to, aryloxyphenoxypropionate herbicides, cyclohexanedione herbicides, phenylpyrazoline herbicides or combinations thereof.

[0018] In another embodiment, the present invention provides a seed of a rice plant, wherein a plant grown from the seed expresses an acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence differs from an amino acid sequence of an acetyl-Coenzyme A carboxylase of a wild-type rice plant at one or more of the following positions: 1,781(*Am*), 1,785(*Am*), 1,786(*Am*), 1,811(*Am*), 1,824(*Am*), 1,864(*Am*), 1,999(*Am*), 2,027(*Am*), 2,039(*Am*), 2,041(*Am*), 2,049(*Am*), 2,059(*Am*), 2,074(*Am*), 2,075(*Am*), 2,078(*Am*), 2,079(*Am*), 2,080(*Am*), 2,081(*Am*), 2,088(*Am*), 2,095(*Am*), 2,096(*Am*), or 2,098(*Am*). Examples of differences at these amino acid positions include, but are not limited to, one or more of the following: the amino acid at position 1,781(*Am*) is other than isoleucine; the amino acid at position 1,785(*Am*) is other than alanine; the amino acid at position 1,786(*Am*) is other than alanine; the amino acid at position 1,811(*Am*) is other than isoleucine; the amino acid position 1,824(*Am*) is other than glutamine; the amino acid position 1,864(*Am*) is other than valine; the amino acid at position 1,999(*Am*) is other than tryptophan; the amino acid at position 2,027(*Am*) is other than tryptophan; the amino acid position 2,039(*Am*) is other than glutamic acid; the amino acid at position 2,041(*Am*) is other than isoleucine; the amino acid at position 2,049(*Am*) is other than valine; the amino acid position 2,059(*Am*) is other than an alanine; the amino acid at position 2,074(*Am*) is other than tryptophan; the amino acid at position 2,075(*Am*) is other than valine; the amino acid at position 2,078(*Am*) is other than aspartate; the amino acid position at position 2,079(*Am*) is other than serine; the amino acid at position 2,080(*Am*) is other than lysine; the amino acid position at position 2,081(*Am*) is other than isoleucine; the amino acid at position 2,088(*Am*)

is other than cysteine; the amino acid at position 2,095(*Am*) is other than lysine; the amino acid at position 2,096(*Am*) is other than glycine; or the amino acid at position 2,098(*Am*) is other than valine. In some embodiments, a plant grown from the seed may express an acetyl-Coenzyme A carboxylase enzyme comprising an amino acid sequence that comprises one or more of the following: the amino acid at position 1,781(*Am*) is leucine, threonine, valine, or alanine; the amino acid at position 1,785(*Am*) is glycine; the amino acid at position 1,786(*Am*) is proline; the amino acid at position 1,811(*Am*) is asparagine; the amino acid at position 1,824(*Am*) is proline; the amino acid at position 1,864(*Am*) is phenylalanine; the amino acid at position 1,999(*Am*) is cysteine or glycine; the amino acid at position 2,027(*Am*) is cysteine; the amino acid at position 2,039(*Am*) is glycine; the amino acid at position 2,041(*Am*) is asparagine; the amino acid at position 2049(*Am*) is phenylalanine; the amino acid at position 2,059(*Am*) is valine; the amino acid at position 2,074(*Am*) is leucine; the amino acid at position 2,075(*Am*) is leucine, isoleucine or methionine; the amino acid at position 2,078(*Am*) is glycine, or threonine; the amino acid at position 2,079(*Am*) is phenylalanine; the amino acid at position 2,080(*Am*) is glutamic acid; the amino acid at position 2,080(*Am*) is deleted; the amino acid at position 2,081(*Am*) is deleted; the amino acid at position 2,088(*Am*) is arginine, or tryptophan; the amino acid at position 2,095(*Am*) is glutamic acid; the amino acid at position 2,096(*Am*) is alanine, or serine; or the amino acid at position 2,098(*Am*) is alanine, glycine, proline, histidine, or serine.

[0019] The present invention encompasses seeds of specific herbicide-tolerant cultivars. One example of such seeds is a seed of rice cultivar Indica1, wherein a representative sample of seed of said cultivar was deposited under ATCC Accession No. PTA-10267, PTA-10568, PTA-10569, or PTA-10570. Another example of such seeds are those of an herbicide-tolerant Nipponbare cultivar, wherein a representative sample of seed of said cultivar was deposited under ATCC Accession No. PTA-10571. The present invention also encompasses a rice plant, or a part thereof, produced by growing the seeds as well as a tissue culture of cells produced from the seed. Tissue cultures of cells may be produced from a seed directly or from a part of a plant grown from a seed, for example, from the leaves, pollen, embryos, cotyledons, hypocotyls, meristematic cells, roots, root tips, pistils, anthers, flowers and/or stems. The present invention also includes plants and their progeny that have been generated

from tissue cultures of cells. Such plants will typically have all the morphological and physiological characteristics of cultivar Indica1.

[0020] The present invention also provides methods for producing rice seed. Such methods may comprise crossing an herbicide-tolerant rice plant with other rice germplasm; and harvesting the resulting hybrid rice seed, wherein the herbicide-tolerant rice plant is tolerant to aryloxyphenoxypropionate herbicides, cyclohexanedione herbicides, phenylpyrazoline herbicides or combinations thereof at levels of herbicide that would normally inhibit the growth of a rice plant.

[0021] The present method also comprises methods of producing F1 hybrid rice seed. Such methods may comprise crossing an herbicide-tolerant rice plant with a different rice plant; and harvesting the resultant F1 hybrid rice seed, wherein the herbicide-tolerant rice plant is tolerant to aryloxyphenoxypropionate herbicides, cyclohexanedione herbicides, phenylpyrazoline herbicides or combinations thereof at levels of herbicide that would normally inhibit the growth of a rice plant.

[0022] The present method also comprises methods of producing F1 hybrid plants. Such methods may comprise crossing an herbicide-tolerant plant with a different plant; and harvesting the resultant F1 hybrid seed and growing the resultant F1 hybrid plant, wherein the herbicide-tolerant plant is tolerant to aryloxyphenoxypropionate herbicides, cyclohexanedione herbicides, phenylpyrazoline herbicides or combinations thereof at levels of herbicide that would normally inhibit the growth of a plant.

[0023] The present invention also provides methods of producing herbicide-tolerant rice plants that may also comprise a transgene. One example of such a method may comprise transforming a cell of a rice plant with a transgene, wherein the transgene encodes an acetyl-Coenzyme A carboxylase enzyme that confers tolerance to at least one herbicide is selected from the group consisting of aryloxyphenoxypropionate herbicides, cyclohexanedione herbicides, phenylpyrazoline herbicides or combinations thereof. Any suitable cell may be used in the practice of the methods of the invention, for example, the cell may be in the form of a callus. In some embodiments, the transgene may comprise a nucleic acid sequence encoding an amino acid sequence comprising a modified version of one or both of SEQ ID NOs: 2 and 3, wherein the sequence is modified such that the encoded protein comprises one

or more of the following: the amino acid at position 1,781(*Am*) is leucine, threonine, valine, or alanine; the amino acid at position 1,785(*Am*) is glycine; the amino acid at position 1,786(*Am*) is proline; the amino acid at position 1,811(*Am*) is asparagine; the amino acid at position 1,824(*Am*) is proline; the amino acid at position 1,864(*Am*) is phenylalanine; the amino acid at position 1,999(*Am*) is cysteine or glycine; the amino acid at position 2,027(*Am*) is cysteine; the amino acid at position 2,039(*Am*) is glycine; the amino acid at position 2,041(*Am*) is asparagine; the amino acid at position 2049(*Am*) is phenylalanine; the amino acid at position 2,059(*Am*) is valine; the amino acid at position 2,074(*Am*) is leucine; the amino acid at position 2,075(*Am*) is leucine, isoleucine or methionine; the amino acid at position 2,078(*Am*) is glycine, or threonine; the amino acid at position 2,079(*Am*) is phenylalanine; the amino acid at position 2,080(*Am*) is glutamic acid; the amino acid at position 2,080(*Am*) is deleted; the amino acid at position 2,081(*Am*) is deleted; the amino acid at position 2,088(*Am*) is arginine, or tryptophan; the amino acid at position 2,095(*Am*) is glutamic acid; the amino acid at position 2,096(*Am*) is alanine, or serine; or the amino acid at position 2,098(*Am*) is alanine, glycine, proline, histidine, or serine. The present invention also encompasses plants produced by such methods. Another example of a method of producing an herbicide-tolerant plant comprising a transgene may comprise transforming a cell of a rice plant with a transgene encoding an enzyme that confers herbicide tolerance, wherein the cell was produced from a rice plant or seed thereof expressing an acetyl-Coenzyme A carboxylase enzyme that confers tolerance to at least one herbicide is selected from the group consisting of aryloxyphenoxypropionate herbicides, cyclohexanedione herbicides, phenylpyrazoline herbicides or combinations thereof. Any suitable cell may be used in the practice of the methods of the invention, for example, the cell may be in the form of a callus. The present invention also encompasses herbicide-tolerant plants produced by such methods.

[0024] In one embodiment, the present invention comprises methods of producing recombinant plants. An example of a method for producing a recombinant rice plant may comprise transforming a cell of a rice plant with a transgene, wherein the cell was produced from a rice plant expressing an acetyl-Coenzyme A carboxylase enzyme that confers tolerance to at least one herbicide is selected from the group consisting of aryloxyphenoxypropionate herbicides, cyclohexanedione herbicides, phenylpyrazoline

herbicides or combinations thereof. Any suitable cell may be used in the practice of the methods of the invention, for example, the cell may be in the form of a callus. A transgene for use in the methods of the invention may comprise any desired nucleic acid sequence, for example, the transgene may encode a protein. In one example, the transgene may encode an enzyme, for example, an enzyme that modifies fatty acid metabolism and/or carbohydrate metabolism. Examples of suitable enzymes include but are not limited to, fructosyltransferase, levansucrase, alpha-amylase, invertase and starch branching enzyme or encoding an antisense of stearyl-ACP desaturase. The present invention also encompasses recombinant plants produced by methods of the invention.

[0025] Methods of the invention may be used to produce a plant, e.g., a rice plant, having any desired traits. An example of such a method may comprise: (a) crossing a rice plant that is tolerant to aryloxyphenoxypropionate herbicides, cyclohexanedione herbicides, phenylpyrazoline herbicides or combinations thereof at levels of herbicide that would normally inhibit the growth of a rice plant with a plant of another rice cultivar that comprises the desired trait to produce progeny plants; (b) selecting one or more progeny plants that have the desired trait to produce selected progeny plants; (c) crossing the selected progeny plants with the herbicide-tolerant plants to produce backcross progeny plants; (d) selecting for backcross progeny plants that have the desired trait and herbicide tolerance; and (e) repeating steps (c) and (d) three or more times in succession to produce selected fourth or higher backcross progeny plants that comprise the desired trait and herbicide tolerance. Any desired trait may be introduced using the methods of the invention. Examples of traits that may be desired include, but are not limited to, male sterility, herbicide tolerance, drought tolerance insect resistance, modified fatty acid metabolism, modified carbohydrate metabolism and resistance to bacterial disease, fungal disease or viral disease. An example of a method for producing a male sterile rice plant may comprise transforming a rice plant tolerant to at least one herbicide that inhibits acetyl-Coenzyme A carboxylase activity at levels of herbicide that would normally inhibit the growth of a rice plant with a nucleic acid molecule that confers male sterility. The present invention also encompasses male sterile plants produced by such methods.

[0026] The present invention provides compositions comprising plant cells, for example, cells from a rice plant. One example of such a composition comprises one or more cells of a rice plant; and an aqueous medium, wherein the medium comprises a compound that inhibits acetyl-Coenzyme A carboxylase activity. In some embodiments, the cells may be derived from a rice plant tolerant to aryloxyphenoxypropionate herbicides, cyclohexanedione herbicides, phenylpyrazoline herbicides or combinations thereof at levels of herbicide that would normally inhibit the growth of a rice plant. Any compound that inhibits acetyl-Coenzyme A carboxylase activity may be used in the compositions of the invention, for example, one or more of aryloxyphenoxypropionate herbicides, cyclohexanedione herbicides, phenylpyrazoline herbicides and combinations thereof.

[0027] The present invention comprises nucleic acid molecules encoding all or a portion of an acetyl-Coenzyme A carboxylase enzyme. In some embodiments, the invention comprises a recombinant, mutagenized, synthetic, and/or isolated nucleic acid molecule encoding a rice acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence differs from an amino acid sequence of an acetyl-Coenzyme A carboxylase of a wild-type rice plant at one or more of the following positions: 1,781(*Am*), 1,785(*Am*), 1,786(*Am*), 1,811(*Am*), 1,824(*Am*), 1,864(*Am*), 1,999(*Am*), 2,027(*Am*), 2,039(*Am*), 2,041(*Am*), 2,049(*Am*), 2,059(*Am*), 2,074(*Am*), 2,075(*Am*), 2,078(*Am*), 2,079(*Am*), 2,080(*Am*), 2,081(*Am*), 2,088(*Am*), 2,095(*Am*), 2,096(*Am*), or 2,098(*Am*). Examples of differences at these amino acid positions include, but are not limited to, one or more of the following: the amino acid at position 1,781(*Am*) is other than isoleucine; the amino acid at position 1,785(*Am*) is other than alanine; the amino acid at position 1,786(*Am*) is other than alanine; the amino acid at position 1,811(*Am*) is other than isoleucine; the amino acid position 1,824(*Am*) is other than glutamine; the amino acid position 1,864(*Am*) is other than valine; the amino acid at position 1,999(*Am*) is other than tryptophan; the amino acid at position 2,027(*Am*) is other than tryptophan; the amino acid position 2,039(*Am*) is other than glutamic acid; the amino acid at position 2,041(*Am*) is other than isoleucine; the amino acid at position 2,049(*Am*) is other than valine; the amino acid position 2,059(*Am*) is other than an alanine; the amino acid at position 2,074(*Am*) is other than tryptophan; the amino acid at position 2,075(*Am*) is other than valine; the amino acid at position 2,078(*Am*) is other than aspartate; the amino acid position at position 2,079(*Am*) is other than serine; the amino acid at position

2,080(*Am*) is other than lysine; the amino acid position at position 2,081(*Am*) is other than isoleucine; the amino acid at position 2,088(*Am*) is other than cysteine; the amino acid at position 2,095(*Am*) is other than lysine; the amino acid at position 2,096(*Am*) is other than glycine; or the amino acid at position 2,098(*Am*) is other than valine. In some embodiments, a nucleic acid molecule of the invention may encode an acetyl-Coenzyme A carboxylase enzyme comprising an amino acid sequence that comprises one or more of the following: the amino acid at position 1,781(*Am*) is leucine, threonine, valine, or alanine; the amino acid at position 1,785(*Am*) is glycine; the amino acid at position 1,786(*Am*) is proline; the amino acid at position 1,811(*Am*) is asparagine; the amino acid at position 1,824(*Am*) is proline; the amino acid at position 1,864(*Am*) is phenylalanine; the amino acid at position 1,999(*Am*) is cysteine or glycine; the amino acid at position 2,027(*Am*) is cysteine; the amino acid at position 2,039(*Am*) is glycine; the amino acid at position 2,041(*Am*) is asparagine; the amino acid at position 2049(*Am*) is phenylalanine; the amino acid at position 2,059(*Am*) is valine; the amino acid at position 2,074(*Am*) is leucine; the amino acid at position 2,075(*Am*) is leucine, isoleucine or methionine; the amino acid at position 2,078(*Am*) is glycine, or threonine; the amino acid at position 2,079(*Am*) is phenylalanine; the amino acid at position 2,080(*Am*) is glutamic acid; the amino acid at position 2,080(*Am*) is deleted; the amino acid at position 2,081(*Am*) is deleted; the amino acid at position 2,088(*Am*) is arginine, or tryptophan; the amino acid at position 2,095(*Am*) is glutamic acid; the amino acid at position 2,096(*Am*) is alanine, or serine; or the amino acid at position 2,098(*Am*) is alanine, glycine, proline, histidine, or serine. In some embodiments, the invention comprises a recombinant, mutagenized, synthetic, and/or isolated nucleic acid encoding a protein comprising all or a portion of a modified version of one or both of SEQ ID NOs: 2 and 3, wherein the sequence is modified such that the encoded protein comprises one or more of the following: the amino acid at position 1,781(*Am*) is leucine, threonine, valine, or alanine; the amino acid at position 1,785(*Am*) is glycine; the amino acid at position 1,786(*Am*) is proline; the amino acid at position 1,811(*Am*) is asparagine; the amino acid at position 1,824(*Am*) is proline; the amino acid at position 1,864(*Am*) is phenylalanine; the amino acid at position 1,999(*Am*) is cysteine or glycine; the amino acid at position 2,027(*Am*) is cysteine; the amino acid at position 2,039(*Am*) is glycine; the amino acid at position 2,041(*Am*) is asparagine; the amino acid at position 2049(*Am*) is phenylalanine; the amino acid at position 2,059(*Am*) is valine; the

amino acid at position 2,074(*Am*) is leucine; the amino acid at position 2,075(*Am*) is leucine, isoleucine or methionine; the amino acid at position 2,078(*Am*) is glycine, or threonine; the amino acid at position 2,079(*Am*) is phenylalanine; the amino acid at position 2,080(*Am*) is glutamic acid; the amino acid at position 2,080(*Am*) is deleted; the amino acid at position 2,081(*Am*) is deleted; the amino acid at position 2,088(*Am*) is Arginine, or tryptophan; the amino acid at position 2,095(*Am*) is glutamic acid; the amino acid at position 2,096(*Am*) is alanine, or serine; or the amino acid at position 2,098(*Am*) is alanine, glycine, proline, histidine, or serine.

[0028] In one embodiment, the present invention provides an herbicide-tolerant, BEP clade plant. Typically such a plant is one having increased tolerance to an ACCase-inhibitor (ACCI) as compared to a wild-type variety of the plant. Such plants may be produced by a process comprising either:

(I) the steps of

- (a) providing BEP clade plant cells having a first, zero or non-zero level of ACCI tolerance;
- (b) growing the cells in contact with a medium to form a cell culture;
- (c) contacting cells of said culture with an ACCI;
- (d) growing ACCI-contacted cells from step (c) to form a culture containing cells having a level of ACCI tolerance greater than the first level of step (a); and
- (e) generating, from ACCI-tolerant cells of step (d), a plant having a level of ACCI tolerance greater than that of a wild-type variety of the plant; or

(II) the steps of

- (f) providing a first, herbicide-tolerant, BEP clade plant having increased tolerance to an ACCase-inhibitor (ACCI) as compared to a wild-type variety of the plant, said herbicide-tolerant plant having been produced by a process comprising steps (a)-(e); and
- (g) producing from the first plant a second, herbicide-tolerant, BEP clade plant that retains the increased herbicide tolerance characteristics of the first plant;

thereby obtaining an herbicide-tolerant, BEP clade plant.

[0029] In one embodiment, an herbicide-tolerant BEP clade plant of the invention is a BET subclade plant.

[0030] In one embodiment, an herbicide-tolerant BET subclade plant of the invention is a BET crop plant.

[0031] In some embodiments, an herbicide-tolerant plant of the invention may be a member of the Bambusoideae - Ehrhartoideae subclade. Any suitable medium for growing plant cells may be used in the practice of the invention. In some embodiments, the medium may comprise a mutagen while in other embodiments the medium does not comprise a mutagen. In some embodiments, an herbicide-tolerant plant of the invention may be a member of the subfamily Ehrhartoideae. Any suitable cells may be used in the practice of the methods of the invention, for example, the cells may be in the form of a callus. In some embodiments, an herbicide-tolerant plant of the invention may be a member of the genus *Oryza*, for example, may be a member of the species *O. sativa*.

[0032] The present invention includes herbicide-tolerant BEP clade plants produced by the above method. Such herbicide-tolerant plants may express an acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence differs from an amino acid sequence of an acetyl-Coenzyme A carboxylase of a corresponding wild-type BEP clade plant at one or more of the following positions: 1,781(*Am*), 1,785(*Am*), 1,786(*Am*), 1,811(*Am*), 1,824(*Am*), 1,864(*Am*), 1,999(*Am*), 2,027(*Am*), 2,039(*Am*), 2,041(*Am*), 2,049(*Am*), 2,059(*Am*), 2,074(*Am*), 2,075(*Am*), 2,078(*Am*), 2,079(*Am*), 2,080(*Am*), 2,081(*Am*), 2,088(*Am*), 2,095(*Am*), 2,096(*Am*), or 2,098(*Am*). Examples of differences at these amino acid positions include, but are not limited to, one or more of the following: the amino acid at position 1,781(*Am*) is other than isoleucine; the amino acid at position 1,785(*Am*) is other than alanine; the amino acid at position 1,786(*Am*) is other than alanine; the amino acid at position 1,811(*Am*) is other than isoleucine; the amino acid position 1,824(*Am*) is other than glutamine; the amino acid position 1,864(*Am*) is other than valine; the amino acid at position 1,999(*Am*) is other than tryptophan; the amino acid at position 2,027(*Am*) is other than tryptophan; the amino acid position 2,039(*Am*) is other than glutamic acid; the amino acid at position 2,041(*Am*) is other than isoleucine; the amino acid at position 2,049(*Am*) is other than valine; the amino acid position 2,059(*Am*) is other than an alanine;

the amino acid at position 2,074(*Am*) is other than tryptophan; the amino acid at position 2,075(*Am*) is other than valine; the amino acid at position 2,078(*Am*) is other than aspartate; the amino acid position at position 2,079(*Am*) is other than serine; the amino acid at position 2,080(*Am*) is other than lysine; the amino acid position at position 2,081(*Am*) is other than isoleucine; the amino acid at position 2,088(*Am*) is other than cysteine; the amino acid at position 2,095(*Am*) is other than lysine; the amino acid at position 2,096(*Am*) is other than glycine; or the amino acid at position 2,098(*Am*) is other than valine. In some embodiments, the an herbicide-tolerant BEP clade plant of the invention may express an acetyl-Coenzyme A carboxylase enzyme comprising an amino acid sequence that comprises one or more of the following: the amino acid at position 1,781(*Am*) is leucine, threonine, valine, or alanine; the amino acid at position 1,785(*Am*) is glycine; the amino acid at position 1,786(*Am*) is proline; the amino acid at position 1,811(*Am*) is asparagine; the amino acid at position 1,824(*Am*) is proline; the amino acid at position 1,864(*Am*) is phenylalanine; the amino acid at position 1,999(*Am*) is cysteine or glycine; the amino acid at position 2,027(*Am*) is cysteine; the amino acid at position 2,039(*Am*) is glycine; the amino acid at position 2,041(*Am*) is asparagine; the amino acid at position 2049(*Am*) is phenylalanine; the amino acid at position 2,059(*Am*) is valine; the amino acid at position 2,074(*Am*) is leucine; the amino acid at position 2,075(*Am*) is leucine, isoleucine or methionine; the amino acid at position 2,078(*Am*) is glycine, or threonine; the amino acid at position 2,079(*Am*) is phenylalanine; the amino acid at position 2,080(*Am*) is glutamic acid; the amino acid at position 2,080(*Am*) is deleted; the amino acid at position 2,081(*Am*) is deleted; the amino acid at position 2,088(*Am*) is Arginine, or tryptophan; the amino acid at position 2,095(*Am*) is glutamic acid; the amino acid at position 2,096(*Am*) is alanine, or serine; or the amino acid at position 2,098(*Am*) is alanine, glycine, proline, histidine, or serine.

[0033] In one embodiment, the present invention also includes rice plants that are tolerant to ACCase inhibitors by virtue of having only one substitution in its plastidic ACCase as compared to the corresponding wild-type ACCase. In yet another embodiment, the invention includes rice plants that are tolerant to ACCase inhibitors by virtue of having two or more substitutions in its plastidic ACCase as compared to the corresponding wild-type ACCase.

[0034] In one embodiment, the present invention provides rice plants that are tolerant to ACCase inhibitors, by virtue of having two or more substitution in its plastidic ACCase as compared to the corresponding wild-type ACCase, wherein the substitutions are at amino acid positions selected from the group consisting of 1,781(*Am*), 1,785(*Am*), 1,786(*Am*), 1,811(*Am*), 1,824(*Am*), 1,864(*Am*), 1,999(*Am*), 2,027(*Am*), 2,039(*Am*), 2,041(*Am*), 2,049(*Am*), 2,059(*Am*), 2,074(*Am*), 2,075(*Am*), 2,078(*Am*), 2,079(*Am*), 2,080(*Am*), 2,081(*Am*), 2,088(*Am*), 2,095(*Am*), 2,096(*Am*), or 2,098(*Am*).

[0035] In one embodiment, the present invention provides rice plants wherein the rice plants comprise plastidic ACCase that is not transgenic. In one embodiment, the present invention provides plants wherein the plants comprise a rice plastidic ACCase that is transgenic.

[0036] In one embodiment, the present invention provides method for controlling growth of weeds within the vicinity of a rice plant as described herein, comprising applying to the weeds and rice plants an amount of an acetyl-Coenzyme A carboxylase-inhibiting herbicide that inhibits naturally occurring acetyl-Coenzyme A carboxylase activity, wherein said rice plants comprise altered acetyl-Coenzyme A carboxylase activity such that said rice plants are tolerant to the applied amount of herbicide.

[0037] In one embodiment, the present invention provides methods for producing seed comprising: (i) planting seed produced from a plant of the invention, (ii) growing plants from the seed and (ii) harvesting seed from the plants.

[0038] The present invention also encompasses herbicide-tolerant BEP clade plants produced by the process of (a) crossing or back-crossing a plant grown from a seed of an herbicide-tolerant BEP clade plant produced as described above with other germplasm; (b) growing the plants resulting from said crossing or back-crossing in the presence of at least one herbicide that normally inhibits acetyl-Coenzyme A carboxylase, at levels of the herbicide that would normally inhibit the growth of a plant; and (c) selecting for further propagation plants resulting from said crossing or back-crossing, wherein the plants selected are plants that grow without significant injury in the presence of the herbicide.

[0039] The present invention also encompasses a recombinant, mutagenized, synthetic, and/or isolated nucleic acid molecule comprising a nucleotide sequence encoding a

mutagenized acetyl-Coenzyme A carboxylase of a plant in the BEP clade of the Family Poaceae, in which the amino acid sequence of the mutagenized acetyl-Coenzyme A carboxylase differs from an amino acid sequence of an acetyl-Coenzyme A carboxylase of the corresponding wild-type plant at one or more of the following positions: 1,781(*Am*), 1,785(*Am*), 1,786(*Am*), 1,811(*Am*), 1,824(*Am*), 1,864(*Am*), 1,999(*Am*), 2,027(*Am*), 2,039(*Am*), 2,041(*Am*), 2,049(*Am*), 2,059(*Am*), 2,074(*Am*), 2,075(*Am*), 2,078(*Am*), 2,079(*Am*), 2,080(*Am*), 2,081(*Am*), 2,088(*Am*), 2,095(*Am*), 2,096(*Am*), or 2,098(*Am*). Such a nucleic acid molecule may be produced by a process comprising either:

(I) the steps of

- (a) providing BEP clade plant cells having a first, zero or non-zero level of ACCase-inhibitor (ACCI) tolerance;
- (b) growing the cells in contact with a medium to form a cell culture;
- (c) contacting cells of said culture with an ACCI;
- (d) growing ACCI-contacted cells from step (c) to form a culture containing cells having a level of ACCI tolerance greater than the first level of step (a); and
- (e) generating, from ACCI-tolerant cells of step (d), a plant having a level of ACCI tolerance greater than that of a wild-type variety of the plant; or

(II) the steps of

- (f) providing a first, herbicide-tolerant, BEP clade plant having increased tolerance to an ACCase-inhibitor (ACCI) as compared to a wild-type variety of the plant, said herbicide-tolerant plant having been produced by a process comprising steps (a)-(e); and
- (g) producing from the first plant a second, herbicide-tolerant, BEP clade plant that retains the increased herbicide tolerance characteristics of the first plant;

thereby obtaining an herbicide-tolerant, BEP clade plant; and isolating a nucleic acid from the herbicide-tolerant BEP clade plant.

[0040] In one embodiment, the invention encompasses methods of screening, isolating, identifying, and/or characterizing herbicide tolerant mutations in monocot plastidic ACCases. In one embodiment, the invention encompasses the use of calli, or plant cell lines. In other

embodiments, the invention encompasses performing the culturing of plant material or cells in a tissue culture environment. In yet other embodiments, the invention encompasses the presence of a nylon membrane in the tissue culture environment. In other embodiments, the tissue culture environment comprises liquid phase media while in other embodiments, the environment comprises semi-solid media. In yet other embodiments, the invention encompasses culturing plant material in the presence of herbicide (e.g., cycloxydim) in liquid media followed by culturing in semi-solid media with herbicide. In yet other embodiments, the invention encompasses culturing plant material in the presence of herbicide in semi-solid media followed by culturing in liquid media with herbicide.

[0041] In some embodiments, the invention encompasses the direct application of a lethal dose of herbicide (e.g., cycloxydim). In other embodiment, the invention encompasses the step-wise increase in herbicide dose, starting with a sub-lethal dose. In other embodiments, the invention encompasses at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, or more herbicides in one step, or concurrently.

[0042] In other embodiments, the mutational frequency is determined by the number of mutant herbicide-tolerant clones as a fraction of the number of the individual calli used in the experiment. In some embodiments, the invention encompasses a mutational frequency of at least 0.03% or higher. In some embodiments, the invention encompasses mutational frequencies of at least 0.03%, at least 0.05%, at least 0.10%, at least 0.15%, at least 0.20%, at least 0.25%, at least 0.30%, at least 0.35%, at least 0.40% or higher. In other embodiments, the invention encompasses mutational frequencies that are at least 2 fold, at least 3 fold, at least 4 fold, at least 5 fold, at least 6 fold, at least 7 fold, at least 8 fold, at least 9 fold, at least 10 fold or higher than other methods of screening, isolating, identifying, and/or characterizing herbicide tolerant mutations in monocot plastidic ACCases.

[0043] In some embodiments, the methods of the invention encompass identifying the herbicide tolerant mutation(s) in the ACCase. In further embodiments, the invention comprises recapitulating the herbicide tolerant mutation(s) in monocot plant cells.

[0044] In some embodiments, the invention encompasses an isolated cell or tissue said cell or tissue of plant origin having: a) a deficiency in ACCase activity derived from a host

ACCCase (i.e., endogenous) gene; and b) an ACCase activity from a monocot-derived plastidic ACCase gene.

[0045] Monocot sources of ACCase

[0046] In other embodiments, the invention encompasses plastidic ACCases or portions thereof from the monocot family of plants as described herein.

[0047] In other embodiments, the invention encompasses screening for herbicide-tolerant mutants of monocot plastidic ACCase in host plant cells.

[0048] In other embodiments, the invention encompasses the use of prepared host cells to screen for herbicide-tolerant mutants of monocot plastidic ACCase. In some embodiments, the invention provides a host cell which is devoid of plastidic ACCase activity. In other embodiments, the host cells of the invention express a monocot plastidic ACCase which is herbicide sensitive.

[0049] In other embodiments, methods of the invention comprise host cells deficient in ACCase activity due to a mutation of the genomic plastidic ACCase gene which include a single point mutation, multiple point mutations, a partial deletion, a partial knockout, a complete deletion and a complete knockout. In another embodiment, genomic plastidic ACCase activity is reduced or ablated using other molecular biology techniques such as RNAi, siRNA or antisense RNA. Such molecular biology techniques are well known in the art. In yet other embodiments, genomic ACCase derived activity may be reduced or ablated by a metabolic inhibitor of ACCase.

[0050] In some embodiments, the host cell is a monocot plant host cell.

[0051] In yet other embodiments, the invention encompasses a method of making a transgenic plant cell comprising: a) isolating a cell having a monocot plant origin; b) inactivating at least one copy of a genomic ACCase gene; c) providing a monocot-derived plastidic ACCase gene to said cell; d) isolating the cell comprising the monocot-derived plastidic ACCase gene; and optionally; e) inactivating at least additional copy of a genomic ACCase gene and wherein said cell is deficient in ACCase activity provided by the genomic ACCase gene.

- [0052] In one embodiment, the the cycloxydim-tolerant mutational frequency is greater than 0.03 %.
- [0053] In one embodiment, the present invention provides a method for screening, wherein cycloxydim-tolerant plant cells or tissues are also tolerant to other ACCase inhibitors.
- [0054] In one embodiment, the present invention provides a method for screening, wherein the cycloxydim-tolerant plant cells or tissues comprise only one mutation not present in the monocot plastidic ACCase prior to culturing in the presence of the herbicide.
- [0055] In one embodiment, the present invention provides a method for screening, wherein the cycloxydim-tolerant plant cells or tissues comprise two or more mutations not present in the monocot plastidic ACCase prior to culturing in the presence of the herbicide.
- [0056] In one embodiment, the present invention provides a method for screening, wherein the cycloxydim is present at a sub-lethal dose.
- [0057] In one embodiment, the present invention provides a method for screening, wherein the culturing in the presence of cycloxydim is performed in step-wise or gradual increase in cycloxydim concentrations.
- [0058] In one embodiment, the present invention provides a method for screening, wherein the method comprises culturing of cells on a membrane. In a preferred embodiment, the present invention provides a method for screening comprises culturing of cells on a nylon membrane.
- [0059] In one embodiment, the present invention provides a method for screening cycloxydim-tolerant plant cells, wherein the culturing of cells is in liquid media or semi-solid media.
- [0060] In one embodiment, the present invention provides a method for screening, wherein the method further comprises identification of the at least one mutation not present in the exogenous monocot plastidic ACCase prior to culturing in the presence of the cycloxydim.

[0061] In one embodiment, the present invention provides a method for screening, wherein said monocot is rice.

[0062] In one embodiment, the present invention provides a method for screening, wherein said exogenous monocot plastidic ACCase is from rice.

BRIEF DESCRIPTION OF THE DRAWINGS

[0063] Figure 1 is a bar graph showing relative growth rice calli derived from *Oryza sativa* subsp. *indica* grown in the presence of difference selection levels of herbicide. Figure 1A shows the results obtained with tepraloxym, Figure 1B shows the results obtained with sethoxydim, and Figure 1C shows the results obtained with cycloxydim.

[0064] Figure 2 is a diagram of the selection process used to produce herbicide-tolerant rice plants.

[0065] Figure 3 shows photographs of plants taken one week after treatment with herbicide.

[0066] Figure 4 shows photographs of plants taken two weeks after treatment with herbicide.

[0067] Figure 5 provides the amino acid sequence of acetyl-coenzyme A carboxylase from *Alopecurus myosuroides* (GenBank accession number CAC84161).

[0068] Figure 6 provides the mRNA encoding acetyl-coenzyme A carboxylase from *Alopecurus myosuroides* (GenBank accession number AJ310767 region: 157..7119) (SEQ ID NO:4).

[0069] Figure 7A provides the genomic nucleotide sequence for *Oryza sativa* Indica & Japonica acetyl-Coenzyme A carboxylase gene (SEQ ID NO:5).

[0070] Figure 7B provides the nucleotide sequence encoding *Oryza sativa* Indica & Japonica acetyl-Coenzyme A carboxylase (SEQ ID NO:6).

[0071] Figure 7C provides the amino acid sequence of *Oryza sativa* Indica acetyl-Coenzyme A carboxylase (SEQ ID NO:3).

[0072] Figure 8A provides the nucleotide sequence encoding *Zea mays* acetyl-Coenzyme A carboxylase (SEQ ID NO:11).

- [0073] Figure 8B provides the amino acid sequence of *Zea mays* acetyl-Coenzyme A carboxylase (SEQ ID NO:12).
- [0074] Figure 9A provides the nucleotide sequence encoding *Zea mays* acetyl-Coenzyme A carboxylase (SEQ ID NO:13).
- [0075] Figure 9B provides the amino acid sequence of *Zea mays* acetyl-Coenzyme A carboxylase (SEQ ID NO:14).
- [0076] Figure 10A provides the nucleotide sequence encoding *Triticum aestivum* acetyl-Coenzyme A carboxylase (SEQ ID NO:15).
- [0077] Figure 10B provides the amino acid sequence of *Triticum aestivum* acetyl-Coenzyme A carboxylase (SEQ ID NO:16).
- [0078] Figure 11A provides the nucleotide sequence encoding *Setaria italica* acetyl-Coenzyme A carboxylase (SEQ ID NO:17).
- [0079] Figure 11B provides the amino acid sequence of *Setaria italica* acetyl-Coenzyme A carboxylase (SEQ ID NO:18).
- [0080] Figure 12A provides the nucleotide sequence encoding *Setaria italica* acetyl-Coenzyme A carboxylase (SEQ ID NO:19).
- [0081] Figure 12B provides the amino acid sequence of *Setaria italica* acetyl-Coenzyme A carboxylase (SEQ ID NO:20).
- [0082] Figure 13A provides the nucleotide sequence encoding *Setaria italica* acetyl-Coenzyme A carboxylase (SEQ ID NO:21).
- [0083] Figure 13B provides the amino acid sequence of *Setaria italica* acetyl-Coenzyme A carboxylase (SEQ ID NO:22).
- [0084] Figure 14A provides the nucleotide sequence encoding *Alopecurus myosuroides* acetyl-Coenzyme A carboxylase (SEQ ID NO:23).
- [0085] Figure 14B provides the amino acid sequence of *Alopecurus myosuroides* acetyl-Coenzyme A carboxylase (SEQ ID NO:24).

[0086] Figure 15A provides the nucleotide sequence encoding *Aegilops tauschii* acetyl-Coenzyme A carboxylase (SEQ ID NO:25).

[0087] Figure 15B provides the amino acid sequence of *Aegilops tauschii* acetyl-Coenzyme A carboxylase (SEQ ID NO:26).

[0088] Figure 16 provides a comparison of single and double mutants.

[0089] Figure 17 provides a graph showing results for mutant rice versus various ACCase inhibitors.

[0090] Figure 18 provides *Alopecurus myosuroides* acetyl-Coenzyme A carboxylase amino acid sequence (GenBank accession no. CAC84161). Amino acids that may be altered in the acetyl-Coenzyme A carboxylase enzymes of the invention are indicated in bold double underline.

[0091] Figure 19 provides amino acid sequence of wild-type *Oryza sativa* acetyl-Coenzyme A carboxylases aligned with *Alopecurus myosuroides* acetyl-Coenzyme A carboxylase with some critical residues denoted.

DETAILED DESCRIPTION OF THE INVENTION

[0092] Definitions

[0093] As used herein, “tolerant” or “herbicide-tolerant” indicates a plant or portion thereof capable of growing in the presence of an amount of herbicide that normally causes growth inhibition in a non-tolerant (e.g., a wild-type) plant or portion thereof. Levels of herbicide that normally inhibit growth of a non-tolerant plant are known and readily determined by those skilled in the art. Examples include the amounts recommended by manufacturers for application. The maximum rate is an example of an amount of herbicide that would normally inhibit growth of a non-tolerant plant.

[0094] As used herein, “recombinant” refers to an organism having genetic material from different sources.

[0095] As used herein, “mutagenized” refers to an organism having an altered genetic material as compared to the genetic material of a corresponding wild-type organism, wherein the alterations in genetic material were induced and/or selected by human action. Examples

of human action that can be used to produce a mutagenized organism include, but are not limited to, tissue culture of plant cells (e.g., calli) in sub-lethal concentrations of herbicides (e.g., acetyl-Coenzyme A carboxylase inhibitors such as cycloxydim or sethoxydim), treatment of plant cells with a chemical mutagen and subsequent selection with herbicides (e.g., acetyl-Coenzyme A carboxylase inhibitors such as cycloxydim or sethoxydim); or by treatment of plant cells with x-rays and subsequent selection with herbicides (e.g., acetyl-Coenzyme A carboxylase inhibitors such as cycloxydim or sethoxydim). Any method known in the art may be used to induce mutations. Methods of inducing mutations may induce mutations in random positions in the genetic material or may induce mutations in specific locations in the genetic material (i.e., may be directed mutagenesis techniques).

[0096] As used herein, a “genetically modified organism” (GMO) is an organism whose genetic characteristics have been altered by insertion of genetic material from another source organism or progeny thereof that retain the inserted genetic material. The source organism may be of a different type of organism (e.g., a GMO plant may contain bacterial genetic material) or from the same type of organism (e.g., a GMO plant may contain genetic material from another plant). As used herein, recombinant and GMO are considered synonyms and indicate the presence of genetic material from a different source whereas mutagenized indicates altered genetic material from a corresponding wild-type organism but no genetic material from another source organism.

[0097] As used herein, “wild-type” or “corresponding wild-type plant” means the typical form of an organism or its genetic material, as it normally occurs, as distinguished from mutagenized and/or recombinant forms.

[0098] For the present invention, the terms “herbicide-tolerant” and “herbicide-resistant” are used interchangeably and are intended to have an equivalent meaning and an equivalent scope. Similarly, the terms “herbicide-tolerance” and “herbicide-resistance” are used interchangeably and are intended to have an equivalent meaning and an equivalent scope. Similarly, the terms “tolerant” and “resistant” are used interchangeably and are intended to have an equivalent meaning and an equivalent scope.

[0099] As used herein in regard to herbicides useful in various embodiments hereof, terms such as auxinic herbicide, AHAS inhibitor, acetyl-Coenzyme A carboxylase (ACCase)

inhibitor, PPO inhibitor, EPSPS inhibitor, imidazolinone, sulfonylurea, and the like, refer to those agronomically acceptable herbicide active ingredients (A.I.) recognized in the art. Similarly, terms such as fungicide, nematicide, pesticide, and the like, refer to other agronomically acceptable active ingredients recognized in the art.

[0100] When used in reference to a particular mutant enzyme or polypeptide, terms such as herbicide tolerant (HT) and herbicide tolerance refer to the ability of such enzyme or polypeptide to perform its physiological activity in the presence of an amount of an herbicide A.I. that would normally inactivate or inhibit the activity of the wild-type (non-mutant) version of said enzyme or polypeptide. For example, when used specifically in regard to an AHAS enzyme, or AHASL polypeptide, it refers specifically to the ability to tolerate an AHAS-inhibitor. Classes of AHAS-inhibitors include sulfonylureas, imidazolinones, triazolopyrimidines, sulfonylaminocarbonyltriazolinones, and pyrimidinyloxy[thio]benzoates.

[0101] As used herein, “descendant” refers to any generation plant.

[0102] As used herein, “progeny” refers to a first generation plant.

[0103] Plants

[0104] The present invention provides herbicide-tolerant monocotyledonous plants of the grass family Poaceae. The family Poaceae may be divided into two major clades, the clade containing the subfamilies Bambusoideae, Ehrhartoideae, and Pooideae (the BEP clade) and the clade containing the subfamilies Panicoideae, Arundinoideae, Chloridoideae, Centothecoideae, Micrairoideae, Aristidoideae, and Danthonioideae (the PACCMAD clade). The subfamily Bambusoideae includes tribe *Oryzeae*. The present invention relates to plants of the BEP clade, in particular plants of the subfamilies Bambusoideae and Ehrhartoideae. Plants of the invention are typically tolerant to at least one herbicide that inhibits acetyl-Coenzyme A carboxylase activity as a result of expressing an acetyl-Coenzyme A carboxylase enzyme of the invention as described below. The BET clade includes subfamilies Bambusoideae, Ehrhartoideae, and group Triticoideae and no other subfamily Pooideae groups. BET crop plants are plants grown for food or forage that are members of BET subclade, for example barley, corn, etc.

- [0105] The present invention also provides commercially important herbicide-tolerant monocots, including Sugarcane (*Saccharum* spp.), as well as Turfgrasses, e.g., *Poa pratensis* (Bluegrass), *Agrostis* spp. (Bentgrass), *Lolium* spp. (Ryegrasses), *Festuca* spp. (Fescues), *Zoysia* spp. (*Zoysia* grass), *Cynodon* spp. (Bermudagrass), *Stenotaphrum secundatum* (St. Augustine grass), *Paspalum* spp. (Bahia grass), *Eremochloa ophiuroides* (Centipedegrass), *Axonopus* spp. (Carpetgrass), *Bouteloua dactyloides* (Buffalograss), and *Bouteloua* var. spp. (Grama grass).
- [0106] In one embodiment, the present invention provides herbicide-tolerant plants of the Bambusoideae subfamily. Such plants are typically tolerant to one or more herbicides that inhibit acetyl-Coenzyme A carboxylase activity. Examples of herbicide-tolerant plants of the subfamily Bambusoideae include, but are not limited to, those of the genera *Arundinaria*, *Bambusa*, *Chusquea*, *Guadua*, and *Shibataea*.
- [0107] In one embodiment, the present invention provides herbicide-tolerant plants of the Ehrhartoideae subfamily. Such plants are typically tolerant to one or more herbicides that inhibit acetyl-Coenzyme A carboxylase activity. Examples of herbicide-tolerant plants of the subfamily Ehrhartoideae include, but are not limited to, those of the genera *Erharta*, *Leersia*, *Microlaena*, *Oryza*, and *Zizania*.
- [0108] In one embodiment, the present invention provides herbicide-tolerant plants of the Pooideae subfamily. Such plants are typically tolerant to one or more herbicides that inhibit acetyl-Coenzyme A carboxylase activity. Examples of herbicide-tolerant plants of the subfamily Ehrhartoideae include, but are not limited to, those of the genera *Triticeae*, *Aveneae*, and *Poeae*.
- [0109] In one embodiment, herbicide-tolerant plants of the invention are rice plants. Two species of rice are most frequently cultivated, *Oryza sativa* and *Oryza glaberrima*. Numerous subspecies of *Oryza sativa* are commercially important including *Oryza sativa* subsp. *indica*, *Oryza sativa* subsp. *japonica*, *Oryza sativa* subsp. *javanica*, *Oryza sativa* subsp. *glutinosa* (glutinous rice), *Oryza sativa* Aromatica group (e.g., basmati), and *Oryza sativa* (Floating rice group). The present invention encompasses herbicide-tolerant plants in all of the aforementioned species and subspecies.

[0110] In one embodiment, herbicide-tolerant plants of the invention are wheat plants. Two species of wheat are most frequently cultivated, *Triticum aestivum*, and *Triticum turgidum*. Numerous other species are commercially important including, but not limited to, *Triticum timopheevii*, *Triticum monococcum*, *Triticum zhukovskyi* and *Triticum urartu* and hybrids thereof. The present invention encompasses herbicide-tolerant plants in all of the aforementioned species and subspecies. Examples of *T. aestivum* subspecies included within the present invention are *aestivum* (common wheat), *compactum* (club wheat), *macha* (macha wheat), *vavilovi* (vavilovi wheat), *spelta* and *sphaerococcum* (shot wheat). Examples of *T. turgidum* subspecies included within the present invention are *turgidum*, *carthlicum*, *dicoccon*, *durum*, *paleocolchicum*, *polonicum*, *turanicum* and *dicoccoides*. Examples of *T. monococcum* subspecies included within the present invention are *monococcum* (einkorn) and *aegilopoides*. In one embodiment of the present invention, the wheat plant is a member of the *Triticum aestivum* species, and more particularly, the CDC Teal cultivar.

[0111] In one embodiment, herbicide-tolerant plants of the invention are barley plants. Two species of barley are most frequently cultivated, *Hordeum vulgare* and *Hordeum arizonicum*. Numerous other species are commercially important including, but not limited, *Hordeum bogdanii*, *Hordeum brachyantherum*, *Hordeum brevisubulatum*, *Hordeum bulbosum*, *Hordeum comosum*, *Hordeum depressum*, *Hordeum intercedens*, *Hordeum jubatum*, *Hordeum marinum*, *Hordeum marinum*, *Hordeum parodii*, *Hordeum pusillum*, *Hordeum secalinum*, and *Hordeum spontaneum*. The present invention encompasses herbicide-tolerant plants in all of the aforementioned species and subspecies.

[0112] In one embodiment, herbicide-tolerant plants of the invention are rye plants. Commercially important species include, but are not limited to, *Secale sylvestre*, *Secale strictum*, *Secale cereale*, *Secale vavilovii*, *Secale africanum*, *Secale ciliatoglume*, *Secale ancestrale*, and *Secale montanum*. The present invention encompasses herbicide-tolerant plants in all of the aforementioned species and subspecies.

[0113] In one embodiment, herbicide-tolerant plants of the invention are turf plants. Numerous commercially important species of Turf grass include *Zoysia japonica*, *Agrostis palustris*, *Poa pratensis*, *Poa annua*, *Digitaria sanguinalis*, *Cyperus rotundus*, *Kyllinga*

brevifolia, *Cyperus amuricus*, *Erigeron canadensis*, *Hydrocotyle sibthorpioides*, *Kummerowia striata*, *Euphorbia humifusa*, and *Viola arvensis*. The present invention encompasses herbicide-tolerant plants in all of the aforementioned species and subspecies.

[0114] In addition to being able to tolerate herbicides that inhibit acetyl-Coenzyme A carboxylase activity, plants of the invention may also be able to tolerate herbicides that work on other physiological processes. For example, plants of the invention may be tolerant to acetyl-Coenzyme A carboxylase inhibitors and also tolerant to other herbicides, for example, enzyme inhibitors. Examples of other enzyme inhibitors to which plants of the invention may be tolerant include, but are not limited to, inhibitors of 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS) such as glyphosate, inhibitors of acetohydroxyacid synthase (AHAS) such as imidazolinones, sulfonyleureas and sulfonamide herbicides, and inhibitors of glutamine synthase such as glufosinate. In addition to enzyme inhibitors, plants of the invention may also be tolerant of herbicides having other modes of action, for example, auxinic herbicides such as 2,4-D or dicamba, chlorophyll/carotenoid pigment inhibitors such as hydroxyphenylpyruvate dioxygenase (HPPD) inhibitors or phytoene desaturase (PDS) inhibitors, protoporphyrinogen-IX oxidase inhibitors, cell membrane destroyers, photosynthetic inhibitors such as bromoxynil or ioxynil, cell division inhibitors, root inhibitors, shoot inhibitors, and combinations thereof. Thus, plants of the invention tolerant to acetyl-Coenzyme A carboxylase inhibitors can be made resistant to multiple classes of herbicides.

[0115] For example, plants of the invention tolerant to acetyl-Coenzyme A carboxylase inhibitors, such as “dims” (e.g., cycloxydim, sethoxydim, clethodim, or tepraloxydim), “fops” (e.g., clodinafop, diclofop, fluazifop, haloxyfop, or quizalofop), and “dens” (such as pinoxaden), in some embodiments, may be auxinic-herbicide tolerant, tolerant to EPSPS inhibitors, such as glyphosate; to PPO inhibitors, such as pyrimidinedione, such as saflufenacil, triazolinone, such as sulfentrazone, carfentrazone, flumioxazin, diphenylethers, such as acifluorfen, fomesafen, lactofen, oxyfluorfen, N-phenylphthalamides, such as flumiclorac, CGA-248757, and/or to GS inhibitors, such as glufosinate. In addition to these classes of inhibitors, plants of the invention tolerant to acetyl-Coenzyme A carboxylase inhibitors may also be tolerant to herbicides having other modes of action, for example,

chlorophyll/carotenoid pigment inhibitors, cell membrane disruptors, photosynthesis inhibitors, cell division inhibitors, root inhibitors, shoot inhibitors, and combinations thereof. Such tolerance traits may be expressed, *e.g.*, as mutant EPSPS proteins, or mutant glutamine synthetase proteins; or as mutant native, inbred, or transgenic aryloxyalkanoate dioxygenase (AAD or DHT), haloarylnitrilase (BXN), 2,2-dichloropropionic acid dehalogenase (DEH), glyphosate-N-acetyltransferase (GAT), glyphosate decarboxylase (GDC), glyphosate oxidoreductase (GOX), glutathione-S-transferase (GST), phosphinothricin acetyltransferase (PAT or bar), or cytochrome P450 (CYP450) proteins having an herbicide-degrading activity. Plants tolerant to acetyl-Coenzyme A carboxylase inhibitors hereof can also be stacked with other traits including, but not limited to, pesticidal traits such as *Bt* Cry and other proteins having pesticidal activity toward coleopteran, lepidopteran, nematode, or other pests; nutrition or nutraceutical traits such as modified oil content or oil profile traits, high protein or high amino acid concentration traits, and other trait types known in the art.

[0116] Furthermore, plants are also covered that, in addition to being able to tolerate herbicides that inhibit acetyl-Coenzyme A carboxylase activity, are by the use of recombinant DNA techniques capable to synthesize one or more insecticidal proteins, especially those known from the bacterial genus *Bacillus*, particularly from *Bacillus thuringiensis*, such as δ -endotoxins, *e.g.* CryIA(b), CryIA(c), CryIF, CryIF(a2), CryIIA(b), CryIIIA, CryIIIB(b1) or Cry9c; vegetative insecticidal proteins (VIP), *e.g.* VIP1, VIP2, VIP3 or VIP3A; insecticidal proteins of bacteria colonizing nematodes, *e.g.* *Photorhabdus* spp. or *Xenorhabdus* spp.; toxins produced by animals, such as scorpion toxins, arachnid toxins, wasp toxins, or other insect-specific neurotoxins; toxins produced by fungi, such as Streptomycetes toxins, plant lectins, such as pea or barley lectins; agglutinins; proteinase inhibitors, such as trypsin inhibitors, serine protease inhibitors, patatin, cystatin or papain inhibitors; ribosome-inactivating proteins (RIP), such as ricin, maize-RIP, abrin, luffin, saporin or bryodin; steroid metabolism enzymes, such as 3-hydroxy-steroid oxidase, ecdysteroid-IDP-glycosyl-transferase, cholesterol oxidases, ecdysone inhibitors or HMG-CoA-reductase; ion channel blockers, such as blockers of sodium or calcium channels; juvenile hormone esterase; diuretic hormone receptors (helicokinin receptors); stilben synthase, bibenzyl synthase, chitinases or glucanases. In the context of the present invention

these insecticidal proteins or toxins are to be understood expressly also as pre-toxins, hybrid proteins, truncated or otherwise modified proteins. Hybrid proteins are characterized by a new combination of protein domains, (see, e. g. WO 02/015701). Further examples of such toxins or genetically modified plants capable of synthesizing such toxins are disclosed, e. g., in EP-A 374 753, WO 93/007278, WO 95/34656, EP-A 427 529, EP-A 451 878, WO 03/18810 und WO 03/52073. The methods for producing such genetically modified plants are generally known to the person skilled in the art and are described, e. g. in the publications mentioned above. These insecticidal proteins contained in the genetically modified plants impart to the plants producing these proteins tolerance to harmful pests from all taxonomic groups of arthropods, especially to beetles (Coleoptera), two-winged insects (Diptera), and moths (Lepidoptera) and to nematodes (Nematoda).

[0117] Furthermore, in one embodiment, plants are also covered that are, e.g., by the use of recombinant DNA techniques and/or by breeding and/or otherwise selected for such traits, able to synthesize one or more proteins to increase the resistance or tolerance of those plants to bacterial, viral or fungal pathogens. The methods for producing such genetically modified plants are generally known to the person skilled in the art. The plants produced as described herein can also be stacked with other traits including, but not limited to, disease resistance, enhanced mineral profile, enhanced vitamin profile, enhanced oil profile (e.g., high oleic acid content), amino acid profile (e.g. high lysine corn), and other trait types known in the art.

[0118] Furthermore, in one embodiment, plants are also covered that are, e.g., by the use of recombinant DNA techniques and/or by breeding and/or by other means of selection, able to synthesize one or more proteins to increase the productivity (e.g. bio mass production, grain yield, starch content, oil content or protein content), tolerance to drought, salinity or other growth-limiting environmental factors or tolerance to pests and fungal, bacterial or viral pathogens of those plants.

[0119] Furthermore, in one embodiment, plants are also covered that contain, e.g., by the use of recombinant DNA techniques and/or by breeding and/or by other means of selection, a modified amount of substances of content or new substances of content, specifically to improve human or animal nutrition. Furthermore, plants are also covered that contain by the

use of recombinant DNA techniques a modified amount of substances of content or new substances of content, specifically to improve raw material production.

[0120] Furthermore, in some embodiments, plants of the instant invention are also covered which are, *e.g.* by the use of recombinant DNA techniques and/or by breeding and/or otherwise selected for such traits, altered to contain increased amounts of vitamins and/or minerals, and/or improved profiles of nutraceutical compounds.

[0121] In one embodiment, plants of the invention tolerant to acetyl-Coenzyme A carboxylase inhibitors, relative to a wild-type plant, comprise an increased amount of, or an improved profile of, a compound selected from the group consisting of: glucosinolates (*e.g.*, glucoraphanin (4-methylsulfinylbutyl-glucosinolate), sulforaphane, 3-indolylmethyl-glucosinolate (glucobrassicin), 1-methoxy-3-indolylmethyl-glucosinolate (neoglucobrassicin)); phenolics (*e.g.*, flavonoids (*e.g.*, quercetin, kaempferol), hydroxycinnamoyl derivatives (*e.g.*, 1,2,2'-trisinapoylgentiobiose, 1,2-diferuloylgentiobiose, 1,2'-disinapoyl-2-feruloylgentiobiose, 3-O-caffeoyl-quinic (neochlorogenic acid)); and vitamins and minerals (*e.g.*, vitamin C, vitamin E, carotene, folic acid, niacin, riboflavin, thiamine, calcium, iron, magnesium, potassium, selenium, and zinc).

[0122] In another embodiment, plants of the invention tolerant to acetyl-Coenzyme A carboxylase inhibitors, relative to a wild-type plant, comprise an increased amount of, or an improved profile of, a compound selected from the group consisting of: progoitrin; isothiocyanates; indoles (products of glucosinolate hydrolysis); glutathione; carotenoids such as beta-carotene, lycopene, and the xanthophyll carotenoids such as lutein and zeaxanthin; phenolics comprising the flavonoids such as the flavonols (*e.g.* quercetin, rutin), the flavans/tannins (such as the procyanidins comprising coumarin, proanthocyanidins, catechins, and anthocyanins); flavones; phytoestrogens such as coumestans, lignans, resveratrol, isoflavones *e.g.*, genistein, daidzein, and glycitein; resorcylic acid lactones; organosulphur compounds; phytosterols; terpenoids such as carnosol, rosmarinic acid, glycyrrhizin and saponins; chlorophyll; chlorophyllin, sugars, anthocyanins, and vanilla.

[0123] In other embodiments, plants of the invention tolerant to acetyl-Coenzyme A carboxylase inhibitors, relative to a wild-type plant, comprise an increased amount of, or an improved profile of, a compound selected from the group consisting of: vincristine,

vinblastine, taxanes (e.g., taxol (paclitaxel), baccatin III, 10-desacetylbaccatin III, 10-desacetyl taxol, xylosyl taxol, 7-epitaxol, 7-epibaccatin III, 10-desacetylcephalomannine, 7-epicephalomannine, taxotere, cephalomannine, xylosyl cephalomannine, taxagifine, 8-benxoyloxy taxagifine, 9-acetyloxy taxusin, 9-hydroxy taxusin, taiwanxam, taxane Ia, taxane Ib, taxane Ic, taxane Id, GMP paclitaxel, 9-dihydro 13-acetylbaccatin III, 10-desacetyl-7-epitaxol, tetrahydrocannabinol (THC), cannabidiol (CBD), genistein, diadzein, codeine, morphine, quinine, shikonin, ajmalacine, serpentine, and the like.

[0124] The present invention also encompasses progeny of the plants of the invention as well as seeds derived from the herbicide-tolerant plants of the invention and cells derived from the herbicide-tolerant plants of the invention.

[0125] In various embodiments, plants hereof can be used to produce plant products. Thus, a method for preparing a descendant seed comprises planting a seed of a capable of producing a plant hereof, growing the resulting plant, and harvesting descendant seed thereof. In some embodiments, such a method can further comprise applying an ACCase-inhibiting herbicide composition to the resulting plant. Similarly, a method for producing a derived product from a plant hereof can comprise processing a plant part thereof to obtain a derived product. In some embodiments, such a method can be used to obtain a derived product that is any of, e.g., fodder, feed, seed meal, oil, or seed-treatment-coated seeds. Seeds, treated seeds, and other plant products obtained by such methods are useful products that can be commercialized.

[0126] In various embodiment, the present invention provides production of food products, consumer products, industrial products, and veterinary products from any of the plants described herein.

[0127] Acetyl-Coenzyme A carboxylase Enzymes

[0128] The present invention provides plants expressing acetyl-Coenzyme A carboxylase enzymes with amino acid sequences that differ from the amino acid sequence of the acetyl-Coenzyme A carboxylase enzyme found in the corresponding wild-type plant. For ease of understanding, the amino acid numbering system used herein will be the numbering system used for the acetyl-Coenzyme A carboxylase from *Alopecurus myosuroides* [Huds.] (also referred to as black grass). The mRNA sequence encoding the *A. myosuroides* acetyl-

Coenzyme A carboxylase is available at GenBank accession number AJ310767 and the protein sequence is available at GenBank accession no. CAC84161 both of which are specifically incorporated herein by reference. The number of the amino acid referred to will be followed with (*Am*) to indicate the amino acid in the *Alopecurus myosuroides* sequence to which the amino acid corresponds. Figure 18 provides *Alopecurus myosuroides* acetyl-Coenzyme A carboxylase amino acid sequence (GenBank accession no. CAC84161). Amino acids that may be altered in the acetyl-Coenzyme A carboxylase enzymes of the invention are indicated in bold double underline, and Figure 19 depicts the amino acid sequence of wild-type *Oryza sativa* acetyl-Coenzyme A carboxylases aligned with *Alopecurus myosuroides* acetyl-Coenzyme A carboxylase with some critical residues denoted.

[0129] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 1,781(*Am*). Wild-type *A. myosuroides* acetyl-Coenzyme A carboxylase has an isoleucine at position 1,781(*Am*) (I1781). The 1,781(*Am*) ACCase mutants of the invention will have an amino acid other than isoleucine at this position. Suitable examples of amino acids that may be found at this position in the acetyl-Coenzyme A carboxylase enzymes of the invention include, but are not limited to, leucine (I1781L), valine (I1781V), threonine (I1781T) and alanine (I1781A). In one embodiment, an acetyl-Coenzyme A carboxylase enzyme of the invention will have a leucine at position 1,781(*Am*).

[0130] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 1,785(*Am*). Wild-type *A. myosuroides* acetyl-Coenzyme A carboxylase has an alanine at position 1,785(*Am*) (A1785). The 1,785(*Am*) ACCase mutants of the invention will have an amino acid other than alanine at this position. Suitable examples of amino acids that may be found at this position in the acetyl-Coenzyme A carboxylase enzymes of the invention include, but are not limited to, glycine (A1785G). In one embodiment, an acetyl-Coenzyme A carboxylase enzyme of the invention will have a glycine at position 1,785(*Am*).

[0131] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 1,786(*Am*). Wild-type *A. myosuroides* acetyl-Coenzyme A carboxylase has an alanine at

position 1,786(*Am*) (A1786). The 1,786(*Am*) ACCase mutants of the invention will have an amino acid other than alanine at this position. Suitable examples of amino acids that may be found at this position in the acetyl-Coenzyme A carboxylase enzymes of the invention include, but are not limited to, proline (A1786P). In one embodiment, an acetyl-Coenzyme A carboxylase enzyme of the invention will have a proline at position 1,786(*Am*).

[0132] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 1,811(*Am*). Wild-type *A. myosuroides* acetyl-Coenzyme A carboxylase has an isoleucine at position 1,811(*Am*) (I1811). The 1,811(*Am*) ACCase mutants of the invention will have an amino acid other than isoleucine at this position. Suitable examples of amino acids that may be found at this position in the acetyl-Coenzyme A carboxylase enzymes of the invention include, but are not limited to, asparagine (I1811N). In one embodiment, an acetyl-Coenzyme A carboxylase enzyme of the invention will have an asparagine at position 1,811(*Am*).

[0133] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 1,824(*Am*). Wild-type *A. myosuroides* acetyl-Coenzyme A carboxylase has a glutamine at position 1,824(*Am*) (Q1824). The 1,824(*Am*) ACCase mutants of the invention will have an amino acid other than glutamine at this position. Suitable examples of amino acids that may be found at this position in the acetyl-Coenzyme A carboxylase enzymes of the invention include, but are not limited to, proline (Q1824P). In one embodiment, an acetyl-Coenzyme A carboxylase enzyme of the invention will have a proline at position 1,824(*Am*).

[0134] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 1,864(*Am*). Wild-type *A. myosuroides* acetyl-Coenzyme A carboxylase has a valine at position 1,864(*Am*) (V1864). The 1,864(*Am*) ACCase mutants of the invention will have an amino acid other than valine at this position. Suitable examples of amino acids that may be found at this position in the acetyl-Coenzyme A carboxylase enzymes of the invention include, but are not limited to, phenylalanine (V1864F). In one embodiment, an acetyl-

Coenzyme A carboxylase enzyme of the invention will have a phenylalanine at position 1,864(*Am*).

[0135] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 1,999(*Am*). Wild-type *A. myosuroides* acetyl-Coenzyme A carboxylase has a tryptophan at position 1,999(*Am*) (W1999). The 1,999(*Am*) ACCase mutants of the invention will have an amino acid other than tryptophan at this position. Suitable examples of amino acids that may be found at this position in the acetyl-Coenzyme A carboxylase enzymes of the invention include, but are not limited to, cysteine (W1999C) and glycine (W1999G). In one embodiment, an acetyl-Coenzyme A carboxylase enzyme of the invention will have a glycine at position 1,999(*Am*).

[0136] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,027(*Am*). Wild-type *A. myosuroides* acetyl-Coenzyme A carboxylase has a tryptophan at position 2,027(*Am*)(W2027). The 2,027(*Am*) ACCase mutants of the invention will have an amino acid other than tryptophan at this position. Suitable examples of amino acids that may be found at this position in the acetyl-Coenzyme A carboxylase enzymes of the invention include, but are not limited to, cysteine (W2027C) and arginine (W2027R). In one embodiment, an acetyl-Coenzyme A carboxylase enzyme of the invention will have a cysteine at position 2,027(*Am*).

[0137] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,039(*Am*). Wild-type *A. myosuroides* acetyl-Coenzyme A carboxylase has a glutamic acid at position 2,039(*Am*) (E2039). The 2,039(*Am*) ACCase mutants of the invention will have an amino acid other than glutamic acid at this position. Suitable examples of amino acids that may be found at this position in the acetyl-Coenzyme A carboxylase enzymes of the invention include, but are not limited to, glycine (E2039G). In one embodiment, an acetyl-Coenzyme A carboxylase enzyme of the invention will have an glycine at position 2,039(*Am*).

[0138] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,041(*Am*). Wild-type *A. myosuroides* acetyl-Coenzyme A carboxylase has an isoleucine at position 2,041(*Am*) (I2041). The 2,041(*Am*) ACCase mutants of the invention will have an amino acid other than isoleucine at this position. Suitable examples of amino acids that may be found at this position in the acetyl-Coenzyme A carboxylase enzymes of the invention include, but are not limited to, asparagine (I2041N), or valine (I2041V). In one embodiment, an acetyl-Coenzyme A carboxylase enzyme of the invention will have an asparagine at position 2,041(*Am*).

[0139] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,049(*Am*). Wild-type *A. myosuroides* acetyl-Coenzyme A carboxylase has a valine at position 2,049(*Am*) (V2049). The 2,049(*Am*) ACCase mutants of the invention will have an amino acid other than valine at this position. Suitable examples of amino acids that may be found at this position in the acetyl-Coenzyme A carboxylase enzymes of the invention include, but are not limited to, phenylalanine (V2049F), isoleucine (V2049I) and leucine (V2049L). In one embodiment, an acetyl-Coenzyme A carboxylase enzyme of the invention will have a phenylalanine at position 2,049(*Am*).

[0140] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,059(*Am*). Wild-type *A. myosuroides* acetyl-Coenzyme A carboxylase has an alanine at position 2,059(*Am*) (A2059). The 2,059(*Am*) ACCase mutants of the invention will have an amino acid other than an alanine at this position. Suitable examples of amino acids that may be found at this position in the acetyl-Coenzyme A carboxylase enzymes of the invention include, but are not limited to, valine (A2059V). In one embodiment, an acetyl-Coenzyme A carboxylase enzyme of the invention will have a valine at position 2,059(*Am*).

[0141] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2074(*Am*). Wild-type *A. myosuroides* acetyl-Coenzyme A carboxylase has a tryptophan at position 2074(*Am*) (W2074). The 2,074(*Am*) ACCase mutants of the invention will have an

amino acid other than tryptophan at this position. Suitable examples of amino acids that may be found at this position in the acetyl-Coenzyme A carboxylase enzymes of the invention include, but are not limited to, leucine (W2074L). In one embodiment, an acetyl-Coenzyme A carboxylase enzyme of the invention will have a leucine at 2074(*Am*).

[0142] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,075(*Am*). Wild-type *A. myosuroides* acetyl-Coenzyme A carboxylase has a valine at position 2,075(*Am*) (V2075). The 2,075(*Am*) ACCase mutants of the invention will have an amino acid other than valine at this position. Suitable examples of amino acids that may be found at this position in the acetyl-Coenzyme A carboxylase enzymes of the invention include, but are not limited to, methionine (V2075M), leucine (V2075L) and isoleucine (V2075I). In one embodiment, an acetyl-Coenzyme A carboxylase enzyme of the invention will have a leucine at position 2,075(*Am*). In some embodiments, an acetyl-Coenzyme A carboxylase enzyme of the invention will have a valine at position 2075(*Am*) and an additional valine immediately after position 2075(*Am*) and before the valine at position 2076(*Am*), i.e., may have three consecutive valines where the wild-type enzyme has two.

[0143] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,078(*Am*). Wild-type *A. myosuroides* acetyl-Coenzyme A carboxylase has an aspartate at position 2,078(*Am*) (D2078). The 2,078(*Am*) ACCase mutants of the invention will have an amino acid other than aspartate at this position. Suitable examples of amino acids that may be found at this position in the acetyl-Coenzyme A carboxylase enzymes of the invention include, but are not limited to, lysine (D2,078K), glycine (D2078G), or threonine (D2078T). In one embodiment, an acetyl-Coenzyme A carboxylase enzyme of the invention will have a glycine at position 2,078(*Am*).

[0144] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,079(*Am*). Wild-type *A. myosuroides* acetyl-Coenzyme A carboxylase has a serine at position 2,079(*Am*) (S2079). The 2,079(*Am*) ACCase mutants of the invention will have an amino acid other than serine at this position. Suitable examples of amino acids that may be

found at this position in the acetyl-Coenzyme A carboxylase enzymes of the invention include, but are not limited to, phenylalanine (S2079F). In one embodiment, an acetyl-Coenzyme A carboxylase enzyme of the invention will have a phenylalanine at position 2,079(*Am*).

[0145] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,080(*Am*). Wild-type *A. myosuroides* acetyl-Coenzyme A carboxylase has a lysine at position 2,080(*Am*) (K2080). The 2,080(*Am*) ACCase mutants of the invention will have an amino acid other than lysine at this position. Suitable examples of amino acids that may be found at this position in the acetyl-Coenzyme A carboxylase enzymes of the invention include, but are not limited to, glutamic acid (K2080E). In one embodiment, an acetyl-Coenzyme A carboxylase enzyme of the invention will have a glutamic acid at position 2,080(*Am*). In another embodiment, acetyl-Coenzyme A carboxylase enzymes of the invention will typically have a deletion of this position (Δ 2080).

[0146] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,081(*Am*). Wild-type *A. myosuroides* acetyl-Coenzyme A carboxylase has a isoleucine at position 2,081(*Am*) (I2081). The 2,081(*Am*) ACCase mutants of the invention will have an amino acid other than isoleucine at this position. In one embodiment, acetyl-Coenzyme A carboxylase enzymes of the invention will typically have a deletion of this position (Δ 2081).

[0147] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,088(*Am*). Wild-type *A. myosuroides* acetyl-Coenzyme A carboxylase has a cysteine at position 2,088(*Am*) (C2088). The 2,088(*Am*) ACCase mutants of the invention will have an amino acid other than cysteine at this position. Suitable examples of amino acids that may be found at this position in the acetyl-Coenzyme A carboxylase enzymes of the invention include, but are not limited to, arginine (C2088R), tryptophan (C2088W), phenylalanine (C2088F), glycine (C2088G), histidine (C2088H), lysine (C2088K), serine (C2088S), threonine (C2088T), leucine (C2088L) or valine (C2088V). In one embodiment, an acetyl-

Coenzyme A carboxylase enzyme of the invention will have an arginine at position 2,088(*Am*).

[0148] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,095(*Am*). Wild-type *A. myosuroides* acetyl-Coenzyme A carboxylase has a lysine at position 2,095(*Am*) (K2095). The 2,095(*Am*) ACCase mutants of the invention will have an amino acid other than lysine at this position. Suitable examples of amino acids that may be found at this position in the acetyl-Coenzyme A carboxylase enzymes of the invention include, but are not limited to, glutamic acid (K2095E). In one embodiment, an acetyl-Coenzyme A carboxylase enzyme of the invention will have a glutamic acid at position 2,095(*Am*).

[0149] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,096(*Am*). Wild-type *A. myosuroides* acetyl-Coenzyme A carboxylase has a glycine at position 2,096(*Am*) (G2096). The 2,096(*Am*) ACCase mutants of the invention will have an amino acid other than glycine at this position. Suitable examples of amino acids that may be found at this position in the acetyl-Coenzyme A carboxylase enzymes of the invention include, but are not limited to, alanine (G2096A), or serine (G2096S). In one embodiment, an acetyl-Coenzyme A carboxylase enzyme of the invention will have an alanine at position 2,096(*Am*).

[0150] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,098(*Am*). Wild-type *A. myosuroides* acetyl-Coenzyme A carboxylase has a valine at position 2,098(*Am*) (V2098). The 2,098(*Am*) ACCase mutants of the invention will have an amino acid other than valine at this position. Suitable examples of amino acids that may be found at this position in the acetyl-Coenzyme A carboxylase enzymes of the invention include, but are not limited to, alanine (V2098A), glycine (V2098G), proline (V2098P), histidine (V2098H), serine (V2098S) or cysteine (V2098C). In one embodiment, an acetyl-Coenzyme A carboxylase enzyme of the invention will have an alanine at position 2,098(*Am*).

[0151] In one embodiment, the present invention encompasses acetyl-Coenzyme A carboxylase of an herbicide-tolerant plant of the invention which differs from the acetyl-Coenzyme A carboxylase of the corresponding wild-type plant at only one of the following positions: 1,781(*Am*), 1,785(*Am*), 1,786(*Am*), 1,811(*Am*), 1,824(*Am*), 1,864(*Am*), 1,999(*Am*), 2,027(*Am*), 2,039(*Am*), 2,041(*Am*), 2,049(*Am*), 2,059(*Am*), 2,074(*Am*), 2,075(*Am*), 2,078(*Am*), 2,079(*Am*), 2,080(*Am*), 2,081(*Am*), 2,088(*Am*), 2,095(*Am*), 2,096(*Am*), or 2,098(*Am*). In one embodiment the acetyl-Coenzyme A carboxylase of an herbicide-tolerant plant of the invention will differ at only one of the following positions: 2,078(*Am*), 2,088(*Am*), or 2,075(*Am*). In a preferred embodiment the acetyl-Coenzyme A carboxylase of an herbicide-tolerant plant of the invention will differ at only one of the following positions: 2,039(*Am*), 2,059(*Am*), 2,080(*Am*), or 2,095(*Am*). In a more preferred embodiment the acetyl-Coenzyme A carboxylase of a herbicide-tolerant plant of the invention will differ at only one of the following positions: 1,785(*Am*), 1,786(*Am*), 1,811(*Am*), 1,824(*Am*), 1,864(*Am*), 2,041(*Am*), 2,049(*Am*), 2,074(*Am*), 2,079(*Am*), 2,081(*Am*), 2,096(*Am*), or 2,098(*Am*). In a most preferred embodiment the acetyl-Coenzyme A carboxylase of an herbicide-tolerant plant of the invention will differ at only one of the following positions: 1,781(*Am*), 1,999(*Am*), 2,027(*Am*), 2,041(*Am*), or 2,096(*Am*).

[0152] In one embodiment, Acetyl-Coenzyme A carboxylase enzymes of the invention will have only one of the following substitutions: an isoleucine at position 2,075(*Am*), glycine at position 2,078(*Am*), or arginine at position 2,088(*Am*). In a preferred embodiment, Acetyl-Coenzyme A carboxylase enzymes of the invention will have only one of the following substitutions: a glycine at position 2,039(*Am*), valine at position 2,059(*Am*), methionine at position 2,075(*Am*), duplication of position 2,075(*Am*) (i.e., an insertion of valine between 2,074(*Am*) and 2,075(*Am*), or an insertion of valine between position 2,075(*Am*) and 2,076(*Am*)), deletion of amino acid position 2,080(*Am*), glutamic acid at position 2,080(*Am*), deletion of position 2,081(*Am*), or glutamic acid at position 2,095(*Am*). In a more preferred embodiment, Acetyl-Coenzyme A carboxylase enzymes of the invention will have only one of the following substitutions: a glycine at position 1,785(*Am*), a proline at position 1,786(*Am*), an asparagine at position 1,811(*Am*), a leucine at position 2,075(*Am*), a methionine at position 2,075(*Am*), a threonine at position 2,078(*Am*), a deletion at position 2,080(*Am*), a deletion at position 2,081(*Am*), a tryptophan, phenylalanine, glycine, histidine,

lysine, leucine, serine, threonine, or valine at position 2,088(*Am*), a serine at position 2,096(*Am*), an alanine at position 2,096(*Am*), an alanine at position 2,098(*Am*), a glycine at position 2,098(*Am*), an histidine at position 2,098(*Am*), a proline at position 2,098(*Am*), or a serine at position 2,098(*Am*). In a most preferred embodiment, Acetyl-Coenzyme A carboxylase enzymes of the invention will have only one of the following substitutions: a leucine at position 1,781(*Am*), a threonine at position 1,781(*Am*), a valine at position 1,781(*Am*), an alanine at position 1,781(*Am*), a glycine at position 1,999(*Am*), a cysteine or arginine at position 2,027(*Am*), an arginine at position 2,027(*Am*), an asparagine at position 2,041(*Am*), a valine at position 2,041(*Am*), an alanine at position 2,096(*Am*), and a serine at position 2,096(*Am*).

[0153] In one embodiment, nucleic acids encoding Acetyl-Coenzyme A carboxylase polypeptide having only one of the following substitutions: isoleucine at position 2,075(*Am*), glycine at position 2,078(*Am*), or arginine at position 2,088(*Am*) are used transgenically. In another embodiment, a monocot plant cell is transformed with an expression vector construct comprising the nucleic acid encoding Acetyl-Coenzyme A carboxylase polypeptide having only one of the following substitutions: isoleucine at position 2,075(*Am*), glycine at position 2,078(*Am*), or arginine at position 2,088(*Am*).

[0154] In one embodiment, the invention provides rice plants comprising nucleic acids encoding Acetyl-Coenzyme A carboxylase polypeptides having a substitution at only one amino acid position as described above.

[0155] In one embodiment, the invention provides BEP clade plants comprising nucleic acids encoding Acetyl-Coenzyme A carboxylase polypeptides having a substitution at only one amino acid position as described above.

[0156] In one embodiment, the invention provides BET subclade plants comprising nucleic acids encoding Acetyl-Coenzyme A carboxylase polypeptides having a substitution at only one amino acid position as described above.

[0157] In one embodiment, the invention provides BET crop plants comprising nucleic acids encoding Acetyl-Coenzyme A carboxylase polypeptides having a substitution at only one amino acid position as described above.

- [0158] In one embodiment, the invention provides monocot plants comprising nucleic acids encoding Acetyl-Coenzyme A carboxylase polypeptides having a substitution at only one amino acid position as described above.
- [0159] In one embodiment, the invention provides monocot plants comprising nucleic acids encoding Acetyl-Coenzyme A carboxylase polypeptides having a substitution at amino acid position 1,781(*Am*), wherein the amino acid at position 1,781(*Am*) differs from that of wild type and is not leucine.
- [0160] In one embodiment, the invention provides monocot plants comprising nucleic acids encoding Acetyl-Coenzyme A carboxylase polypeptides having a substitution at amino acid position 1,999(*Am*), wherein the amino acid at position 1,999(*Am*) differs from that of wild type and is not cysteine.
- [0161] In one embodiment, the invention provides monocot plants comprising nucleic acids encoding Acetyl-Coenzyme A carboxylase polypeptides having a substitution at amino acid position 2,027 (*Am*), wherein the amino acid at position 2,027(*Am*) differs from that of wild type and is not cysteine.
- [0162] In one embodiment, the invention provides monocot plants comprising nucleic acids encoding Acetyl-Coenzyme A carboxylase polypeptides having a substitution at amino acid position 2,041(*Am*), wherein the amino acid at position 2,041(*Am*) differs from that of wild type and is not valine or asparagine.
- [0163] In one embodiment, the invention provides monocot plants comprising nucleic acids encoding Acetyl-Coenzyme A carboxylase polypeptides having a substitution at amino acid position 2,096(*Am*), wherein the amino acid at position 2,096(*Am*) differs from that of wild type and is not alanine.
- [0164] The present invention also encompasses acetyl-Coenzyme A carboxylase enzymes with an amino acid sequence that differs in more than one amino acid position from that of the acetyl-Coenzyme A carboxylase enzyme found in the corresponding wild-type plant. For example, an acetyl-Coenzyme A carboxylase of the invention may differ in 2, 3, 4, 5, 6, or 7 positions from that of the acetyl-Coenzyme A carboxylase enzyme found in the corresponding wild-type plant.

[0165] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 1,781(*Am*) and at one or more additional amino acid positions. Acetyl-Coenzyme A carboxylase enzymes of the invention will typically have a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*). In addition, enzymes of this embodiment will also comprise one or more of a glycine at position 1,785(*Am*), a proline at position 1,786(*Am*), an asparagine at position 1,811(*Am*), a proline at position 1,824(*Am*), a phenylalanine at position 1,864(*Am*), a cysteine or glycine at position 1,999(*Am*), a cysteine or arginine at position 2,027(*Am*), a glycine at position 2,039(*Am*), an asparagine at position 2,041(*Am*), a phenylalanine, isoleucine or leucine at position 2,049(*Am*), a valine at position 2,059(*Am*), a leucine at position 2,074(*Am*), a leucine, isoleucine, methionine, or an additional valine at position 2,075(*Am*), a glycine or threonine at position 2,078(*Am*), a phenylalanine at position 2,079(*Am*), a glutamic acid at position 2,080(*Am*), a deletion at position 2,080(*Am*), a deletion at position 2,081(*Am*), an arginine tryptophan, phenylalanine, glycine, histidine, lysine, serine, threonine, or valine at position 2,088(*Am*), a glutamic acid at position 2,095(*Am*), an alanine or serine at position 2,096(*Am*), and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*) and a glycine at position 1,785(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*) and a proline at position 1,786(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*) and an asparagine at position 1,811(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*) and a proline at position 1824(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*) and a phenylalanine at position 1864(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*) and a cysteine or glycine at position 1,999(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*)

and a cysteine or an arginine at position 2,027(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*) and a glycine at position 2039(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*) and an asparagine at position 2,041(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*) and a phenylalanine, leucine or isoleucine at position 2,049(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*) and a valine at position 2059(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*) and a leucine at position 2,074(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*) and a leucine, isoleucine methionine, or additional valine at position 2,075(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*) and a glycine or threonine at position 2,078(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*) and a phenylalanine at position 2079(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*) and a glutamic acid or a deletion at position 2080(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*) and a deletion at position 2081(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*) and an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, serine, threonine, or valine at position 2,088(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*) and a glutamic acid at position 2,095(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*) and an alanine or serine at position 2,096(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will

have a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*) and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*), a cysteine or arginine at position 2,027(*Am*), and an asparagine at position 2,041(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*), a cysteine or arginine at position 2,027(*Am*), an asparagine at position 2,041(*Am*), and an alanine at position 2,096(*Am*).

[0166] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 1,785(*Am*) and at one or more additional amino acid positions. Acetyl-Coenzyme A carboxylase enzymes of the invention will typically have an glycine at position 1,785(*Am*). In addition, enzymes of this embodiment will also comprise one or more of a leucine, threonine, a valine, or alanine at position 1,781(*Am*), a proline at position 1,786(*Am*), an asparagine at position 1,811(*Am*), a proline at position 1,824(*Am*), a phenylalanine at position 1,864(*Am*), a cysteine or glycine at position 1,999(*Am*), a cysteine or arginine at position 2,027(*Am*), a glycine at position 2,039(*Am*), an asparagine at position 2,041(*Am*), a phenylalanine, isoleucine or leucine at position 2,049(*Am*), a valine at position 2,059(*Am*), a leucine at position 2,074(*Am*), a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*), a glycine or threonine at position 2,078(*Am*), a phenylalanine at position 2,079(*Am*), a glutamic acid at position 2,080(*Am*), a deletion at position 2,080(*Am*), a deletion at position 2,081(*Am*), an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*), a glutamic acid at position 2,095(*Am*), an alanine or serine at position 2,096(*Am*), and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine at position 1,785(*Am*) and a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine at position 1,785(*Am*) and a proline at position 1,786(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine at position 1,785(*Am*) and an asparagine at position 1,811(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will

have a glycine at position 1,785(*Am*) and a proline at position 1,824(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine at position 1,785(*Am*) and a phenylalanine at position 1,864(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine at position 1,785(*Am*) and a cysteine or glycine at position 1,999(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine at position 1,785(*Am*) and a cysteine or an arginine at position 2,027(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine at position 1,785(*Am*) and a glycine at position 2,039(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine at position 1,785(*Am*) and an asparagine at position 2,041(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine at position 1,785(*Am*) and a phenylalanine, isoleucine or leucine at position 2,049(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine at position 1,785(*Am*) and a valine at position 2,059(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine at position 1,785(*Am*) and a leucine at position 2,074(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine at position 1,785(*Am*) and a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine at position 1,785(*Am*) and a glycine or threonine at position 2,078(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine at position 1,785(*Am*) and a phenylalanine at position 2,079(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine at position 1,785(*Am*) and a glutamic acid or deletion at position 2,080(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine at position 1,785(*Am*) and a deletion at position 2,081(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine at position 1,785(*Am*) and an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine at position 1,785(*Am*) and a glutamic acid at position 2,095(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine at position 1,785(*Am*) and an alanine or serine at position 2,096(*Am*). In one

embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine at position 1,785(*Am*) and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*).

[0167] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 1,786(*Am*) and at one or more additional amino acid positions. Acetyl-Coenzyme A carboxylase enzymes of the invention will typically have a proline at position 1,786(*Am*). In addition, enzymes of this embodiment will also comprise one or more of a leucine, threonine, a valine, or alanine at position 1,781(*Am*), a glycine at position 1,785(*Am*), an asparagine at position 1,811(*Am*), a proline at position 1,824(*Am*), a phenylalanine at position 1,864(*Am*), a cysteine or glycine at position 1,999(*Am*), a cysteine or arginine at position 2,027(*Am*), a glycine at position 2,039(*Am*), an asparagine at position 2,041(*Am*), a phenylalanine, isoleucine or leucine at position 2,049(*Am*), a valine at position 2,059(*Am*), a leucine at position 2,074(*Am*), a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*), a glycine or threonine at position 2,078(*Am*), a phenylalanine at position 2,079(*Am*), a glutamic acid or deletion at position 2,080(*Am*), a deletion at position 2,081(*Am*), an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*), a glutamic acid at position 2,095(*Am*), an alanine or serine at position 2,096(*Am*), and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a proline at position 1,786(*Am*) and a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a proline at position 1,786(*Am*) and a glycine at position 1,785(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a proline at position 1,786(*Am*) and an asparagine at position 1,811(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a proline at position 1,786(*Am*) and a proline at position 1,824(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a proline at position 1,786(*Am*) and phenylalanine at position 1,864(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a proline at position 1,786(*Am*) and a cysteine or glycine at position 1,999(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a proline at

position 1,786(*Am*) and a cysteine or an arginine at position 2,027(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a proline at position 1,786(*Am*) and a glycine at position 2,039(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a proline at position 1,786(*Am*) and an asparagine at position 2,041(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a proline at position 1,786(*Am*) and phenylalanine, isoleucine or leucine at position 2,049(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a proline at position 1,786(*Am*) and a valine at position 2,059(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a proline at position 1,786(*Am*) and a leucine at position 2,074(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a proline at position 1,786(*Am*) and a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a proline at position 1,786(*Am*) and a glycine or threonine at position 2,078(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a proline at position 1,786(*Am*) and a phenylalanine at position 2,079(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a proline at position 1,786(*Am*) and a glutamic acid or deletion at position 2,080(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a proline at position 1,786(*Am*) and a deletion at position 2,081(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a proline at position 1,786(*Am*) and an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a proline at position 1,786(*Am*) and a glutamic acid at position 2,095(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a proline at position 1,786(*Am*) and an alanine or serine at position 2,096(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a proline at position 1,786(*Am*) and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*).

[0168] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 1,811(*Am*) and at one or more additional amino acid positions. Acetyl-Coenzyme A

carboxylase enzymes of the invention will typically have an asparagine at position 1,811(*Am*). In addition, enzymes of this embodiment will also comprise one or more of a leucine, threonine, a valine, or alanine at position 1,781(*Am*), a glycine at position 1,785(*Am*), a proline at position 1,786(*Am*), a proline at position 1,824(*Am*), a phenylalanine at position 1,864(*Am*), a cysteine or glycine at position 1,999(*Am*), a cysteine or arginine at position 2,027(*Am*), a glycine at position 2,039(*Am*), an asparagine at position 2,041(*Am*), a phenylalanine, isoleucine or leucine at position 2,049(*Am*), a valine at position 2,059(*Am*), a leucine at position 2,074(*Am*), a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*), a glycine or threonine at position 2,078(*Am*), a phenylalanine at position 2,079(*Am*), a glutamic acid at position 2,080(*Am*), a deletion at position 2,080(*Am*), a deletion at position 2,081(*Am*), an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*), a glutamic acid at position 2,095(*Am*), an alanine or serine at position 2,096(*Am*), and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 1,811(*Am*) and a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 1,811(*Am*) and a glycine at position 1,785(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 1,811(*Am*) and a proline at position 1,786(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 1,811(*Am*) and a proline at position 1,824(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 1,811(*Am*) and phenylalanine at position 1,864(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 1,811(*Am*) and a cysteine or glycine at position 1,999(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 1,811(*Am*) and a cysteine or an arginine at position 2,027(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 1,811(*Am*) and a glycine at position 2,039(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 1,811(*Am*) and an asparagine at position 2,041(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at

position 1,811(*Am*) and phenylalanine, isoleucine or leucine at position 2,049(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 1,811(*Am*) and a valine at position 2,059(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 1,811(*Am*) and a leucine at position 2,074(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 1,811(*Am*) and a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 1,811(*Am*) and a glycine or threonine at position 2,078(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 1,811(*Am*) and a phenylalanine at position 2,079(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 1,811(*Am*) and a glutamic acid or deletion at position 2,080(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 1,811(*Am*) and a deletion at position 2,081(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 1,811(*Am*) and an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 1,811(*Am*) and a glutamic acid at position 2,095(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 1,811(*Am*) and an alanine or serine at position 2,096(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 1,811(*Am*) and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*).

[0169] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 1,824(*Am*) and at one or more additional amino acid positions. Acetyl-Coenzyme A carboxylase enzymes of the invention will typically have a proline at position 1,824(*Am*). In addition, enzymes of this embodiment will also comprise one or more of a leucine, threonine, a valine, or alanine at position 1,781(*Am*), a glycine at position 1,785(*Am*), a proline at position 1,786(*Am*), an asparagine at position 1,811(*Am*), a phenylalanine at position

1,864(*Am*), a cysteine or glycine at position 1,999(*Am*), a cysteine or arginine at position 2,027(*Am*), a glycine at position 2,039(*Am*), an asparagine at position 2,041(*Am*), a phenylalanine, isoleucine or leucine at position 2,049(*Am*), a valine at position 2,059(*Am*), a leucine at position 2,074(*Am*), a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*), a glycine or threonine at position 2,078(*Am*), a phenylalanine at position 2,079(*Am*), a glutamic acid at position 2,080(*Am*), a deletion at position 2,080(*Am*), a deletion at position 2,081(*Am*), an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*), a glutamic acid at position 2,095(*Am*), an alanine or serine at position 2,096(*Am*), and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*).

[0170] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 1,864(*Am*) and at one or more additional amino acid positions. Acetyl-Coenzyme A carboxylase enzymes of the invention will typically have a phenylalanine at position 1,864(*Am*). In addition, enzymes of this embodiment will also comprise one or more of a leucine, threonine, a valine, or alanine at position 1,781(*Am*), a glycine at position 1,785(*Am*), a proline at position 1,786(*Am*), an asparagine at position 1,811(*Am*), a proline at position 1,824(*Am*), a cysteine or glycine at position 1,999(*Am*), a cysteine or arginine at position 2,027(*Am*), a glycine at position 2,039(*Am*), an asparagine at position 2,041(*Am*), a phenylalanine, isoleucine or leucine at position 2,049(*Am*), a valine at position 2,059(*Am*), a leucine at position 2,074(*Am*), a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*), a glycine or threonine at position 2,078(*Am*), a phenylalanine at position 2,079(*Am*), a glutamic acid at position 2,080(*Am*), a deletion at position 2,080(*Am*), a deletion at position 2,081(*Am*), an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*), a glutamic acid at position 2,095(*Am*), an alanine or serine at position 2,096(*Am*), and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*).

[0171] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 1,999(*Am*) and at one or more additional amino acid positions. Acetyl-Coenzyme A

carboxylase enzymes of the invention will typically have a cysteine or glycine at position 1,999(*Am*). In addition, enzymes of this embodiment will also comprise one or more of a leucine, threonine, valine, or alanine at position 1,781(*Am*), a glycine at position 1,785(*Am*), a proline at position 1,786(*Am*), an asparagine at position 1,811(*Am*), a proline at position 1,824(*Am*), a phenylalanine at position 1,864(*Am*), a cysteine or arginine at position 2,027(*Am*), a glycine at position 2,039(*Am*), an asparagine at position 2,041(*Am*), a phenylalanine, isoleucine or leucine at position 2,049(*Am*), a valine at position 2,059(*Am*), a leucine at position 2,074(*Am*), a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*), a glycine or threonine at position 2,078(*Am*), a phenylalanine at position 2,079(*Am*), a glutamic acid at position 2,080(*Am*), a deletion at position 2,080(*Am*), a deletion at position 2,081(*Am*), an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*), a glutamic acid at position 2,095(*Am*), an alanine or serine at position 2,096(*Am*), and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or glycine at position 1,999(*Am*) and a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or glycine at position 1,999(*Am*) and a glycine at position 1,785(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or glycine at position 1,999(*Am*) and a proline at position 1,786(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or glycine at position 1,999(*Am*) and have an asparagine at position 1,811(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or glycine at position 1,999(*Am*) and a proline at position 1,824(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or glycine at position 1,999(*Am*) and phenylalanine at position 1,864(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or glycine at position 1,999(*Am*) and a cysteine or an arginine at position 2,027(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or glycine at position 1,999(*Am*) and a glycine at position 2,039(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or glycine at position 1,999(*Am*) and an asparagine at position 2,041(*Am*). In one embodiment, an acetyl-

Coenzyme A carboxylase of the invention will have a cysteine or glycine at position 1,999(*Am*) and a phenylalanine, isoleucine or leucine at position 2,049(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or glycine at position 1,999(*Am*) and a cysteine or a valine at position 2,059(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or glycine at position 1,999(*Am*) and a leucine at position 2,074(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or glycine at position 1,999(*Am*) and a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or glycine at position 1,999(*Am*) and a glycine or threonine at position 2,078(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or glycine at position 1,999(*Am*) and a phenylalanine at position 2,079(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or glycine at position 1,999(*Am*) and a glutamic acid or deletion at position 2,080(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or glycine at position 1,999(*Am*) and a deletion at position 2,081(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or glycine at position 1,999(*Am*) and an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or glycine at position 1,999(*Am*) and a glutamic acid at position 2,095(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or glycine at position 1,999(*Am*) and an alanine or serine at position 2,096(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or glycine at position 1,999(*Am*) and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*).

[0172] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,027(*Am*) and at one or more additional amino acid positions. Acetyl-Coenzyme A carboxylase enzymes of the invention will typically have a cysteine or arginine at position 2,027(*Am*). In addition, enzymes of this embodiment will also comprise one or more of a leucine, threonine, a valine, or alanine at position 1,781(*Am*), a glycine at position

1,785(*Am*), a proline at position 1,786(*Am*), an asparagine at position 1,811(*Am*), a proline at position 1,824(*Am*), a phenylalanine at position 1,864(*Am*), a cysteine or glycine at position 1,999(*Am*), a glycine at position 2,039(*Am*), an asparagine at position 2,041(*Am*), a phenylalanine, isoleucine or leucine at position 2,049(*Am*), a valine at position 2,059(*Am*), a leucine at position 2,074(*Am*), a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*), a glycine or threonine at position 2,078(*Am*), a phenylalanine at position 2,079(*Am*), a glutamic acid at position 2,080(*Am*), a deletion at position 2,080(*Am*), a deletion at position 2,081(*Am*), an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*), a glutamic acid at position 2,095(*Am*), an alanine or serine at position 2,096(*Am*), and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or arginine at position 2,027(*Am*) and a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or arginine at position 2,027(*Am*) and a glycine at position 1,785(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or arginine at position 2,027(*Am*) and a proline at position 1,786(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or arginine at position 2,027(*Am*) and have an asparagine at position 1,811(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or arginine at position 2,027(*Am*) and have a proline at position 1,824(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or arginine at position 2,027(*Am*) and have a phenylalanine at position 1,864(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or arginine at position 2,027(*Am*) and a cysteine or glycine at position 1,999(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or arginine at position 2,027(*Am*) and have a glycine at position 2,039(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or arginine at position 2,027(*Am*) and an asparagine at position 2,041(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or arginine at position 2,027(*Am*) and a phenylalanine, isoleucine or leucine at position 2,049(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the

invention will have a cysteine or arginine at position 2,027(*Am*) and have a valine at position 2,059(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or arginine at position 2,027(*Am*) and a leucine at position 2,074(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or arginine at position 2,027(*Am*) and a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or arginine at position 2,027(*Am*) and a glycine or threonine at position 2,078(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or arginine at position 2,027(*Am*) and a phenylalanine at position 2,079(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or arginine at position 2,027(*Am*) and a glutamic acid or deletion at position 2,080(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or arginine at position 2,027(*Am*) and a deletion at position 2,081(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or arginine at position 2,027(*Am*) and an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or arginine at position 2,027(*Am*) and a glutamic acid at position 2,095(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or arginine at position 2,027(*Am*) and an alanine or serine at position 2,096(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a cysteine or arginine at position 2,027(*Am*) and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*).

[0173] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,039(*Am*) and at one or more additional amino acid positions. Acetyl-Coenzyme A carboxylase enzymes of the invention will typically have a glycine at position 2,039(*Am*). In addition, enzymes of this embodiment will also comprise one or more of a leucine, threonine, a valine, or alanine at position 1,781(*Am*), a glycine at position 1,785(*Am*), a proline at position 1,786(*Am*), an asparagine at position 1,811(*Am*), a proline at position 1,824(*Am*), a phenylalanine at position 1,864(*Am*), a cysteine or glycine at position 1,999(*Am*), a cysteine

or arginine at position 2,027(*Am*), an asparagine at position 2,041(*Am*), a phenylalanine, isoleucine or leucine at position 2,049(*Am*), a valine at position 2,059(*Am*), a leucine at position 2,074(*Am*), a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*), a glycine or threonine at position 2,078(*Am*), a phenylalanine at position 2,079(*Am*), a glutamic acid at position 2,080(*Am*), a deletion at position 2,080(*Am*), a deletion at position 2,081(*Am*), an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*), a glutamic acid at position 2,095(*Am*), an alanine or serine at position 2,096(*Am*), and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*).

[0174] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,041(*Am*) and at one or more additional amino acid positions. Acetyl-Coenzyme A carboxylase enzymes of the invention will typically have an asparagine at position 2,041(*Am*). In addition, enzymes of this embodiment will also comprise one or more of a leucine, threonine, a valine, or alanine at position 1,781(*Am*), a glycine at position 1,785(*Am*), a proline at position 1,786(*Am*), an asparagine at position 1,811(*Am*), a proline at position 1,824(*Am*), a phenylalanine at position 1,864(*Am*), a cysteine or glycine at position 1,999(*Am*), a cysteine or arginine at position 2,027(*Am*), a glycine at position 2,039(*Am*), an asparagine at position 2041(*Am*), a phenylalanine, isoleucine or leucine at position 2,049(*Am*), a valine at position 2,059(*Am*), a leucine at position 2,074(*Am*), a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*), a glycine or threonine at position 2,078(*Am*), a phenylalanine at position 2,079(*Am*), a glutamic acid at position 2,080(*Am*), a deletion at position 2,080(*Am*), a deletion at position 2,081(*Am*), an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*), a glutamic acid at position 2,095(*Am*), an alanine or serine at position 2,096(*Am*), and an alanine, glycine, proline, histidine, cysteine or serine at position 2,098(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 2,041(*Am*) and a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 2,041(*Am*) and a glycine at position 1,785(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an

asparagine at position 2,041(*Am*) and a proline at position 1,786(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 2,041(*Am*) and have an asparagine at position 1,811(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 2,041(*Am*) and a proline at position 1824(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 2,041(*Am*) and a phenylalanine at position 1864(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 2,041(*Am*) and a cysteine or glycine at position 1,999(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 2,041(*Am*) and a cysteine or arginine at position 2,027(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 2,041(*Am*) and a glycine at position 2039(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 2,041(*Am*) and an asparagine at position 2,041(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 2,041(*Am*) and a phenylalanine, isoleucine or leucine at position 2,049(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 2,041(*Am*) and a valine at position 2,059(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 2,041(*Am*) and a leucine at position 2,074(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 2,041(*Am*) and a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 2,041(*Am*) and a glycine or threonine at position 2,078(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 2,041(*Am*) and a phenylalanine at position 2079(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 2,041(*Am*) and a glutamic acid or a deletion at position 2080(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an asparagine at position 2,041(*Am*) and a deletion at position 2081(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an isoleucine at position 2,041(*Am*) and an arginine, tryptophan, phenylalanine, glycine, histidine, lysine,

leucine, serine, threonine, or valine at position 2,088(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an isoleucine at position 2,041(*Am*) and a glutamic acid at position 2,095(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an isoleucine at position 2,041(*Am*) and an alanine or serine at position 2,096(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an isoleucine at position 2,041(*Am*) and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*).

[0175] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,049(*Am*) and at one or more additional amino acid positions. Acetyl-Coenzyme A carboxylase enzymes of the invention will typically have a phenylalanine, isoleucine or leucine at position 2,049(*Am*). In addition, enzymes of this embodiment will also comprise one or more of a leucine, threonine, a valine, or alanine at position 1,781(*Am*), a glycine at position 1,785(*Am*), a proline at position 1,786(*Am*), an asparagine at position 1,811(*Am*), a proline at position 1,824(*Am*), a phenylalanine at position 1,864(*Am*), a cysteine or glycine at position 1,999(*Am*), a cysteine or arginine at position 2,027(*Am*), a glycine at position 2,039(*Am*), an asparagine at position 2,041(*Am*), a valine at position 2,059(*Am*), a leucine at position 2,074(*Am*), a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*), a glycine or threonine at position 2,078(*Am*), a phenylalanine at position 2,079(*Am*), a glutamic acid at position 2,080(*Am*), a deletion at position 2,080(*Am*), a deletion at position 2,081(*Am*), an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*), a glutamic acid at position 2,095(*Am*), an alanine or serine at position 2,096(*Am*), and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a phenylalanine, isoleucine or leucine at position 2,049(*Am*) and a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a phenylalanine, isoleucine or leucine at position 2,049(*Am*) and a glycine at position 1,785(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a phenylalanine, isoleucine or leucine at position 2,049(*Am*) and a proline at position 1,786(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a phenylalanine,

isoleucine or leucine at position 2,049(*Am*) and have an asparagine at position 1,811(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a phenylalanine, isoleucine or leucine at position 2,049(*Am*) and a proline at position 1824(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a phenylalanine, isoleucine or leucine at position 2,049(*Am*) and a phenylalanine at position 1864(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a phenylalanine, isoleucine or leucine at position 2,049(*Am*) and a cysteine or glycine at position 1,999(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a phenylalanine, isoleucine or leucine at position 2,049(*Am*) and a cysteine or an arginine at position 2,027(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a phenylalanine, isoleucine or leucine at position 2,049(*Am*) and a glycine at position 2039(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a phenylalanine, isoleucine or leucine at position 2,049(*Am*) and an asparagine at position 2,041(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a phenylalanine, isoleucine or leucine at position 2,049(*Am*) and a valine at position 2059(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a phenylalanine, isoleucine or leucine at position 2,049(*Am*) and a leucine at position 2,074(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a phenylalanine, isoleucine or leucine at position 2,049(*Am*) and a leucine, isoleucine methionine, or additional valine at position 2,075(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a phenylalanine, isoleucine or leucine at position 2,049(*Am*) and a glycine or threonine at position 2,078(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a phenylalanine, isoleucine or leucine at position 2,049(*Am*) and a phenylalanine at position 2079(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a phenylalanine, isoleucine or leucine at position 2,049(*Am*) and a glutamic acid or a deletion at position 2080(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a phenylalanine, isoleucine or leucine at position 2,049(*Am*) and a deletion at position 2081(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a phenylalanine, isoleucine or leucine at position 2,049(*Am*) and an arginine, tryptophan, phenylalanine, glycine, histidine,

lysine, serine, threonine, or valine at position 2,088(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a phenylalanine, isoleucine or leucine at position 2,049(*Am*) and a glutamic acid at position 2,095(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a phenylalanine, isoleucine or leucine at position 2,049(*Am*) and an alanine or serine at position 2,096(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a phenylalanine, isoleucine or leucine at position 2,049(*Am*) and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*).

[0176] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,059(*Am*) and at one or more additional amino acid positions. Acetyl-Coenzyme A carboxylase enzymes of the invention will typically have a valine at position 2,059(*Am*). In addition, enzymes of this embodiment will also comprise one or more of a leucine, threonine, a valine, or alanine at position 1,781(*Am*), a glycine at position 1,785(*Am*), a proline at position 1,786(*Am*), an asparagine at position 1,811(*Am*), a proline at position 1,824(*Am*), a phenylalanine at position 1,864(*Am*), a cysteine or glycine at position 1,999(*Am*), a cysteine or arginine at position 2,027(*Am*), a glycine at position 2,039(*Am*), an asparagine at position 2,041(*Am*), a phenylalanine, isoleucine or leucine at position 2,049(*Am*), a leucine at position 2,074(*Am*), a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*), a glycine or threonine at position 2,078(*Am*), a phenylalanine at position 2,079(*Am*), a glutamic acid at position 2,080(*Am*), a deletion at position 2,080(*Am*), a deletion at position 2,081(*Am*), an arginine or tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*), a glutamic acid at position 2,095(*Am*), an alanine or serine at position 2,096(*Am*), and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*).

[0177] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,074(*Am*) and at one or more additional amino acid positions. Acetyl-Coenzyme A carboxylase enzymes of the invention will typically have a leucine at position 2,074(*Am*). In addition, enzymes of this embodiment will also comprise one or more of a leucine, threonine,

a valine, or alanine at position 1,781(*Am*), a glycine at position 1,785(*Am*), a proline at position 1,786(*Am*), an asparagine at position 1,811(*Am*), a proline at position 1,824(*Am*), a phenylalanine at position 1,864(*Am*), a cysteine or glycine at position 1,999(*Am*), a cysteine or arginine at position 2,027(*Am*), a glycine at position 2,039(*Am*), an asparagine at position 2,041(*Am*), a phenylalanine, isoleucine or leucine at position 2,049(*Am*), a valine at position 2,059(*Am*), a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*), a glycine or threonine at position 2,078(*Am*), a phenylalanine at position 2,079(*Am*), a glutamic acid at position 2,080(*Am*), a deletion at position 2,080(*Am*), a deletion at position 2,081(*Am*), an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*), a glutamic acid at position 2,095(*Am*), an alanine or serine at position 2,096(*Am*), and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine at position 2,074(*Am*) and a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine at position 2,074(*Am*) and a glycine at position 1,785(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine at position 2,074(*Am*) and a proline at position 1,786(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine at position 2,074(*Am*) and have an asparagine at position 1,811(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine at position 2,074(*Am*) and a proline at position 1824(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine at position 2,074(*Am*) and a phenylalanine at position 1864(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine at position 2,074(*Am*) and a cysteine or glycine at position 1,999(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine at position 2,074(*Am*) and a cysteine or an arginine at position 2,027(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine at position 2,074(*Am*) and a glycine at position 2039(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine at position 2,074(*Am*) and an asparagine at position 2,041(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine at position 2,074(*Am*) and a phenylalanine, leucine or isoleucine at position 2,049(*Am*). In

one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine at position 2,074(*Am*) and a valine at position 2059(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine at position 2,074(*Am*) and a leucine, isoleucine methionine, or additional valine at position 2,075(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine at position 2,074(*Am*) and a glycine or threonine at position 2,078(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine at position 2,074(*Am*) and a phenylalanine at position 2079(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine at position 2,074(*Am*) and a glutamic acid or a deletion at position 2080(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine at position 2,074(*Am*) and a deletion at position 2081(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine at position 2,074(*Am*) and an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, serine, threonine, or valine at position 2,088(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine at position 2,074(*Am*) and a glutamic acid at position 2,095(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine at position 2,074(*Am*) and an alanine or serine at position 2,096(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine at position 2,074(*Am*) and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*).

[0178] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,075(*Am*) and at one or more additional amino acid positions. Acetyl-Coenzyme A carboxylase enzymes of the invention will typically have a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*). In addition, enzymes of this embodiment will also comprise one or more of a leucine, threonine, or alanine at position 1,781(*Am*), a glycine at position 1,785(*Am*), a proline at position 1,786(*Am*), an asparagine at position 1,811(*Am*), a proline at position 1,824(*Am*), a phenylalanine at position 1,864(*Am*), a cysteine or glycine at position 1,999(*Am*), a cysteine or arginine at position 2,027(*Am*), a glycine at position 2,039(*Am*), an asparagine at position 2,041(*Am*), a phenylalanine, isoleucine or leucine at position 2,049(*Am*), a valine at position 2,059(*Am*), a leucine at position 2,074(*Am*), a glycine

or threonine at position 2,078(*Am*), a phenylalanine at position 2,079(*Am*), a glutamic acid at position 2,080(*Am*), a deletion at position 2,080(*Am*), a deletion at position 2,081(*Am*), an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*), a glutamic acid at position 2,095(*Am*), an alanine or serine at position 2,096(*Am*), and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*) and a leucine, a threonine, a valine, or an alanine at position 1,781(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*) and a glycine at position 1,785(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*) and a proline at position 1,786(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*) and have an asparagine at position 1,811(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*) and a cysteine or glycine at position 1,999(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*) and a cysteine or arginine at position 2,027(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*) and an isoleucine at position 2,041(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*) and a phenylalanine, isoleucine or leucine at position 2,049(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*) and a leucine at position 2,074(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*) and a glycine or threonine at position 2,078(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*) and an arginine or tryptophan, phenylalanine, glycine, histidine, lysine,

leucine, serine, threonine, or valine at position 2,088(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*) and an alanine or serine at position 2,096(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*) and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*).

[0179] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,078(*Am*) and at one or more additional amino acid positions. Acetyl-Coenzyme A carboxylase enzymes of the invention will typically have a glycine or threonine at position 2,078(*Am*). In addition, enzymes of this embodiment will also comprise one or more of a leucine, threonine, a valine, or alanine at position 1,781(*Am*), a glycine at position 1,785(*Am*), a proline at position 1,786(*Am*), an asparagine at position 1,811(*Am*), a proline at position 1,824(*Am*), a phenylalanine at position 1,864(*Am*), a cysteine or glycine at position 1,999(*Am*), a cysteine or arginine at position 2,027(*Am*), a glycine at position 2,039(*Am*), an asparagine at position 2,041(*Am*), a phenylalanine, isoleucine or leucine at position 2,049(*Am*), a valine at position 2,059(*Am*), a leucine at position 2,074(*Am*), a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*), a phenylalanine at position 2,079(*Am*), a glutamic acid at position 2,080(*Am*), a deletion at position 2,080(*Am*), a deletion at position 2,081(*Am*), an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*), a glutamic acid at position 2,095(*Am*), an alanine or serine at position 2,096(*Am*), and an alanine, glycine, proline, histidine, cysteine or serine at position 2,098(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine or threonine at position 2,078(*Am*) and a leucine, a threonine or an alanine at position 1,781(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine or threonine at position 2,078(*Am*) and a glycine at position 1,785(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine or threonine at position 2,078(*Am*) and a proline at position 1,786(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine or threonine at position 2,078(*Am*) and an asparagine at position 1,811(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the

invention will have a glycine or threonine at position 2,078(*Am*) and a cysteine or glycine at position 1,999(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine or threonine at position 2,078(*Am*) and a cysteine or arginine at position 2,027(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine or threonine at position 2,078(*Am*) and an isoleucine at position 2,041(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine or threonine at position 2,078(*Am*) and a phenylalanine, isoleucine or leucine at position 2,049(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine or threonine at position 2,078(*Am*) and a leucine at position 2,074(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine or threonine at position 2,078(*Am*) and a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine or threonine at position 2,078(*Am*) and an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine or threonine at position 2,078(*Am*) and an alanine or serine at position 2,096(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have a glycine or threonine at position 2,078(*Am*) and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*).

[0180] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,079(*Am*) and at one or more additional amino acid positions. Acetyl-Coenzyme A carboxylase enzymes of the invention will typically have a phenylalanine at position 2,079(*Am*). In addition, enzymes of this embodiment will also comprise one or more of a leucine, threonine, valine, or alanine at position 1,781(*Am*), a glycine at position 1,785(*Am*), a proline at position 1,786(*Am*), an asparagine at position 1,811(*Am*), a proline at position 1,824(*Am*), a phenylalanine at position 1,864(*Am*), a cysteine or glycine at position 1,999(*Am*), a cysteine or arginine at position 2,027(*Am*), a glycine at position 2,039(*Am*), an asparagine at position 2,041(*Am*), a phenylalanine, isoleucine or leucine at position 2,049(*Am*), a valine at position 2,059(*Am*), a leucine at position 2,074(*Am*), a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*), a glycine or threonine at

position 2,078(*Am*), a glutamic acid at position 2,080(*Am*), a deletion at position 2,080(*Am*), a deletion at position 2,081(*Am*), an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*), a glutamic acid at position 2,095(*Am*), an alanine or serine at position 2,096(*Am*), and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*).

[0181] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,080(*Am*) and at one or more additional amino acid positions. Acetyl-Coenzyme A carboxylase enzymes of the invention will typically have a glutamic acid or a deletion at position 2,080(*Am*). In addition, enzymes of this embodiment will also comprise one or more of a leucine, threonine, valine, or alanine at position 1,781(*Am*), a glycine at position 1,785(*Am*), a proline at position 1,786(*Am*), an asparagine at position 1,811(*Am*), a proline at position 1,824(*Am*), a phenylalanine at position 1,864(*Am*), a cysteine or glycine at position 1,999(*Am*), a cysteine or arginine at position 2,027(*Am*), a glycine at position 2,039(*Am*), an asparagine at position 2,041(*Am*), a phenylalanine, isoleucine or leucine at position 2,049(*Am*), a valine at position 2,059(*Am*), a leucine at position 2,074(*Am*), a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*), a glycine or threonine at position 2,078(*Am*), a phenylalanine at position 2,079(*Am*), a deletion at position 2,081(*Am*), an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*), a glutamic acid at position 2,095(*Am*), an alanine or serine at position 2,096(*Am*), and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*).

[0182] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,081(*Am*) and at one or more additional amino acid positions. Acetyl-Coenzyme A carboxylase enzymes of the invention will typically have a deletion at position 2,081(*Am*),. In addition, enzymes of this embodiment will also comprise one or more of a leucine, threonine, valine, or alanine at position 1,781(*Am*), a glycine at position 1,785(*Am*), a proline at position 1,786(*Am*), an asparagine at position 1,811(*Am*), a proline at position 1,824(*Am*), a phenylalanine at position 1,864(*Am*), a cysteine or glycine at position 1,999(*Am*), a cysteine

or arginine at position 2,027(*Am*), a glycine at position 2,039(*Am*), an asparagine at position 2,041(*Am*), a phenylalanine, isoleucine or leucine at position 2,049(*Am*), a valine at position 2,059(*Am*), a leucine at position 2,074(*Am*), a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*), a glycine or threonine at position 2,078(*Am*), a phenylalanine at position 2,079(*Am*), a glutamic acid at position 2,080(*Am*), a deletion at position 2,080(*Am*), an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*), a glutamic acid at position 2,095(*Am*), an alanine or serine at position 2,096(*Am*), and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*).

[0183] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,088(*Am*) and at one or more additional amino acid positions. Acetyl-Coenzyme A carboxylase enzymes of the invention will typically have an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*). In addition, enzymes of this embodiment will also comprise one or more of a leucine, threonine, valine, or alanine at position 1,781(*Am*), a glycine at position 1,785(*Am*), a proline at position 1,786(*Am*), an asparagine at position 1,811(*Am*), a proline at position 1,824(*Am*), a phenylalanine at position 1,864(*Am*), a cysteine or glycine at position 1,999(*Am*), a cysteine or arginine at position 2,027(*Am*), a glycine at position 2,039(*Am*), an asparagine at position 2,041(*Am*), a phenylalanine, isoleucine or leucine at position 2,049(*Am*), a valine at position 2,059(*Am*), a leucine at position 2,074(*Am*), a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*), a glycine or threonine at position 2,078(*Am*), a phenylalanine at position 2,079(*Am*), a glutamic acid at position 2,080(*Am*), a deletion at position 2,080(*Am*), a deletion at position 2,081(*Am*), a glutamic acid at position 2,095(*Am*), an alanine or serine at position 2,096(*Am*), and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*) and a leucine, a threonine, valine, or an alanine at position 1,781(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at

position 2,088(*Am*) and a glycine at position 1,785(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*) and a proline at position 1,786(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*) and an asparagine at position 1,811(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*) and a cysteine or glycine at position 1,999(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an arginine or tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*) and a cysteine or arginine at position 2,027(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*) and an isoleucine at position 2,041(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*) and a phenylalanine, isoleucine or leucine at position 2,049(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*) and a leucine at position 2,074(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*) and a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*) and a glycine or threonine at position 2,078(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*) and an alanine or serine at position 2,096(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine,

serine, threonine, or valine at position 2,088(*Am*) and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*).

[0184] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,095(*Am*) and at one or more additional amino acid positions. Acetyl-Coenzyme A carboxylase enzymes of the invention will typically have a glutamic acid at position 2,095(*Am*). In addition, enzymes of this embodiment will also comprise one or more of a leucine, threonine, valine, or alanine at position 1,781(*Am*), a glycine at position 1,785(*Am*), a proline at position 1,786(*Am*), an asparagine at position 1,811(*Am*), a proline at position 1,824(*Am*), a phenylalanine at position 1,864(*Am*), a cysteine or glycine at position 1,999(*Am*), a cysteine or arginine at position 2,027(*Am*), a glycine at position 2,039(*Am*), an asparagine at position 2,041(*Am*), a phenylalanine, isoleucine or leucine at position 2,049(*Am*), a valine at position 2,059(*Am*), a leucine at position 2,074(*Am*), a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*), a glycine or threonine at position 2,078(*Am*), a phenylalanine at position 2,079(*Am*), a glutamic acid at position 2,080(*Am*), a deletion at position 2,080(*Am*), a deletion at position 2,081(*Am*), an arginine or tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*), an alanine or serine at position 2,096(*Am*), and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*).

[0185] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,096(*Am*) and at one or more additional amino acid positions. Acetyl-Coenzyme A carboxylase enzymes of the invention will typically have an alanine or serine at position 2,096(*Am*). In addition, enzymes of this embodiment will also comprise one or more of a leucine, threonine, valine, or alanine at position 1,781(*Am*), a glycine at position 1,785(*Am*), a proline at position 1,786(*Am*), an asparagine at position 1,811(*Am*), a proline at position 1,824(*Am*), a phenylalanine at position 1,864(*Am*), a cysteine or glycine at position 1,999(*Am*), a cysteine or arginine at position 2,027(*Am*), a glycine at position 2,039(*Am*), an asparagine at position 2,041(*Am*), a phenylalanine, isoleucine or leucine at position 2,049(*Am*), a valine at position 2,059(*Am*), a leucine at position 2,074(*Am*), a leucine,

isoleucine, methionine or additional valine at position 2,075(*Am*), a glycine or threonine at position 2,078(*Am*), a phenylalanine at position 2,079(*Am*), a glutamic acid at position 2,080(*Am*), a deletion at position 2,080(*Am*), a deletion at position 2,081(*Am*), an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*), a glutamic acid at position 2,095(*Am*), and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an alanine or serine at position 2,096(*Am*) and a leucine, a threonine or an alanine at position 1,781(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an alanine or serine at position 2,096(*Am*) and a glycine at position 1,785(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an alanine or serine at position 2,096(*Am*) and a proline at position 1,786(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an alanine or serine at position 2,096(*Am*) and an asparagine at position 1,811(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an alanine or serine at position 2,096(*Am*) and a cysteine or glycine at position 1,999(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an alanine or serine at position 2,096(*Am*) and a cysteine or arginine at position 2,027(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an alanine or serine at position 2,096(*Am*) and an isoleucine at position 2,041(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an alanine or serine at position 2,096(*Am*) and a phenylalanine, isoleucine or leucine at position 2,049(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an alanine or serine at position 2,096(*Am*) and a leucine at position 2,074(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an alanine or serine at position 2,096(*Am*) and a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an alanine or serine at position 2,096(*Am*) and a glycine or threonine at position 2,078(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an alanine or serine at position 2,096(*Am*) and an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the

invention will have an alanine or serine at position 2,096(*Am*) and an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*).

[0186] In one embodiment, an acetyl-Coenzyme A carboxylase of the invention differs from the corresponding wild-type acetyl-Coenzyme A carboxylase at amino acid position 2,098(*Am*) and at one or more additional amino acid positions. Acetyl-Coenzyme A carboxylase enzymes of the invention will typically have an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*). In addition, enzymes of this embodiment will also comprise one or more of a leucine, threonine, valine, or alanine at position 1,781(*Am*), a glycine at position 1,785(*Am*), a proline at position 1,786(*Am*), an asparagine at position 1,811(*Am*), a proline at position 1,824(*Am*), a phenylalanine at position 1,864(*Am*), a cysteine or glycine at position 1,999(*Am*), a cysteine or arginine at position 2,027(*Am*), a glycine at position 2,039(*Am*), an asparagine at position 2,041(*Am*), a phenylalanine, isoleucine or leucine at position 2,049(*Am*), a valine at position 2,059(*Am*), a leucine at position 2,074(*Am*), a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*), a glycine or threonine at position 2,078(*Am*), a phenylalanine at position 2,079(*Am*), a glutamic acid at position 2,080(*Am*), a deletion at position 2,080(*Am*), a deletion at position 2,081(*Am*), an arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*), a glutamic acid at position 2,095(*Am*), and an alanine or serine at position 2,096(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*) and a leucine, a threonine, valine, or an alanine at position 1,781(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*) and a glycine at position 1,785(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*) and a proline at position 1,786(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*) and an asparagine at position 1,811(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*) and a cysteine or glycine at position 1,999(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of

the invention will have an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*) and a cysteine or arginine at position 2,027(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*) and an isoleucine at position 2,041(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*) and a phenylalanine, isoleucine or leucine at position 2,049(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*) and a leucine at position 2,074(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*) and a leucine, isoleucine, methionine or additional valine at position 2,075(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*) and a glycine or threonine at position 2,078(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*) and an arginine or tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at position 2,088(*Am*). In one embodiment, an acetyl-Coenzyme A carboxylase of the invention will have an alanine, glycine, proline, histidine, cysteine, or serine at position 2,098(*Am*) and an alanine or serine at position 2,096(*Am*).

[0187] In one embodiment, the invention includes acetyl-Coenzyme A carboxylases having an isoleucine at position 2,075(*Am*) and a glycine at position 1,999(*Am*); acetyl-Coenzyme A carboxylases having a methionine at position 2,075(*Am*) and a glutamic acid at position 2,080(*Am*); acetyl-Coenzyme A carboxylases having a methionine at position 2,075(*Am*) and a glutamic acid at position 2,095(*Am*); acetyl-Coenzyme A carboxylases having a glycine at position 2,078(*Am*) and a valine at position 2,041(*Am*); acetyl-Coenzyme A carboxylases having a glycine at position 2,078(*Am*) and a glycine at position 2,039(*Am*); acetyl-Coenzyme A carboxylases having a glycine at position 2,078(*Am*) and an alanine at position 2,049(*Am*); acetyl-Coenzyme A carboxylases having a glycine at position 2,078(*Am*) and a cysteine at position 2,049(*Am*); acetyl-Coenzyme A carboxylases having a glycine at position 2,078(*Am*) and a serine at position 2,049(*Am*); acetyl-Coenzyme A carboxylases

having a glycine at position 2,078(*Am*) and a threonine at position 2,049(*Am*); acetyl-Coenzyme A carboxylases having a glycine at position 2,078(*Am*) and a valine at position 2,059(*Am*); acetyl-Coenzyme A carboxylases having a glycine at position 2,078(*Am*) and a phenylalanine at position 2,079(*Am*); acetyl-Coenzyme A carboxylases having a glycine at position 2,078(*Am*) and a proline at position at position 2,079(*Am*); and acetyl-Coenzyme A carboxylases having a glycine at position 2,078(*Am*) and a glycine at position 2,088(*Am*).

[0188] In a preferred embodiment, the invention includes acetyl-Coenzyme A carboxylases having a leucine at position 1,781(*Am*) and a proline at position 1,824(*Am*); acetyl-Coenzyme A carboxylases having a leucine at position 1,781(*Am*) and an arginine at position 2027(*Am*); and acetyl-Coenzyme A carboxylases having a glycine at position 2,078(*Am*) and a proline at position 1,824(*Am*).

[0189] In a more preferred embodiment, the invention includes, acetyl-Coenzyme A carboxylases having a leucine at position 1,781(*Am*) and a phenylalanine at position 2,049(*Am*); acetyl-Coenzyme A carboxylases having an alanine at position 2,098(*Am*) and a leucine at position 2,049(*Am*); acetyl-Coenzyme A carboxylases having an alanine at position 2,098(*Am*) and a histidine at position 2088(*Am*); acetyl-Coenzyme A carboxylases having an alanine at position 2,098(*Am*) and a phenylalanine at position 2,088(*Am*); acetyl-Coenzyme A carboxylases having an alanine at position 2,098(*Am*) and a lysine at position 2,088(*Am*); acetyl-Coenzyme A carboxylases having an alanine at position 2,098(*Am*) and a leucine at position 2,088(*Am*); acetyl-Coenzyme A carboxylases having an alanine at position 2,098(*Am*) and a threonine at position 2,088(*Am*); acetyl-Coenzyme A carboxylases having a glycine at position 2,098(*Am*) and a glycine at position 2,088(*Am*); acetyl-Coenzyme A carboxylases having a glycine at position 2,098(*Am*) and a histidine at position 2,088(*Am*); acetyl-Coenzyme A carboxylases having a glycine at position 2,098(*Am*) and leucine at position 2,088(*Am*); acetyl-Coenzyme A carboxylases having a glycine at position 2,098(*Am*) and a serine at position 2,088(*Am*); acetyl-Coenzyme A carboxylases having a glycine at position 2,098(*Am*) and threonine at position 2,088(*Am*); acetyl-Coenzyme A carboxylases having a glycine at position 2,098(*Am*) and a valine at position 2,088(*Am*); acetyl-Coenzyme A carboxylases having a cysteine at position 2,098(*Am*) and a tryptophan at position 2088(*Am*); acetyl-Coenzyme A carboxylases having a serine at position 2,098(*Am*) and a

tryptophan at position 2088(*Am*); and acetyl-Coenzyme A carboxylases having a deletion at position 2,080(*Am*) and a deletion at position 2081(*Am*).

[0190] In a most preferred embodiment, the invention includes acetyl-Coenzyme A carboxylases having a leucine at position 1,781(*Am*) and a asparagine at position 2,041(*Am*); acetyl-Coenzyme A carboxylases having a leucine at position 1,781(*Am*) and a cysteine at position 2,027(*Am*); acetyl-Coenzyme A carboxylases having a leucine at position 1,781(*Am*) and a leucine at position 2,075(*Am*); acetyl-Coenzyme A carboxylases having a leucine at position 1,781(*Am*) and a phenylalanine at position 1,864(*Am*); acetyl-Coenzyme A carboxylases having a leucine at position 1,781(*Am*) and an alanine at position 2098(*Am*); acetyl-Coenzyme A carboxylases having a leucine at position 1,781(*Am*) and a glycine at position 2,098(*Am*); acetyl-Coenzyme A carboxylases having a leucine at position 1,781(*Am*) and a duplication 2,075(*Am*); acetyl-Coenzyme A carboxylases having a glycine at position 1,999(*Am*) and a phenylalanine at position 1,864(*Am*); acetyl-Coenzyme A carboxylases having a glycine at position 1,999(*Am*) and isoleucine at position 2,049(*Am*); acetyl-Coenzyme A carboxylases having a glycine at position 1,999(*Am*) and leucine at position 2,075(*Am*); and acetyl-Coenzyme A carboxylases having a glycine at position 1,999(*Am*) and alanine at position 2,098(*Am*).

[0191] Nucleic acid molecules:

[0192] The present invention also encompasses nucleic acid molecules that encode all or a portion of the acetyl-Coenzyme A carboxylase enzymes described above. Nucleic acid molecules of the invention may comprise a nucleic acid sequence encoding an amino acid sequence comprising a modified version of one or both of SEQ ID NOs: 2 and 3, wherein the sequence is modified such that the encoded protein comprises one or more of the following: the amino acid at position 1,781(*Am*) is leucine, threonine, valine, or alanine; the amino acid at position 1,785(*Am*) is glycine; the amino acid at position 1,786(*Am*) is proline; the amino acid at position 1,811(*Am*) is asparagine; the amino acid at position 1,824(*Am*) is proline; the amino acid at position 1,864(*Am*) is phenylalanine; the amino acid at position 1,999(*Am*) is cysteine or glycine; the amino acid at position 2,027(*Am*) is cysteine or arginine; the amino acid at position 2,039(*Am*) is glycine; the amino acid at position 2,041(*Am*) is asparagine; the amino acid at position 2049(*Am*) is phenylalanine, isoleucine or leucine; the amino acid at

position 2,059(*Am*) is valine; the amino acid at position 2,074(*Am*) is leucine; the amino acid at position 2,075(*Am*) is leucine, isoleucine, methionine or additional valine; the amino acid at position 2,078(*Am*) is glycine, or threonine; the amino acid at position 2,079(*Am*) is phenylalanine; the amino acid at position 2,080(*Am*) is glutamic acid; the amino acid at position 2,080(*Am*) is deleted; the amino acid at position 2,081(*Am*) is deleted; the amino acid at position 2,088(*Am*) is arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine; the amino acid at position 2,095(*Am*) is glutamic acid; the amino acid at position 2,096(*Am*) is alanine, or serine; or the amino acid at position 2,098(*Am*) is alanine, glycine, proline, histidine, or serine, as well as nucleic acid molecules complementary to all or a portion of the coding sequences. In some embodiments, a nucleic acid molecule of the invention may encode an acetyl-Coenzyme A carboxylase having multiple differences from the wild type acetyl-Coenzyme A carboxylase as described above.

[0193] In one embodiment, the present invention encompasses a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase which differs from the acetyl-Coenzyme A carboxylase of the corresponding wild-type plant at only one of the following positions: 1,781(*Am*), 1,785(*Am*), 1,786(*Am*), 1,811(*Am*), 1,824(*Am*), 1,864(*Am*), 1,999(*Am*), 2,027(*Am*), 2,039(*Am*), 2,041(*Am*), 2,049(*Am*), 2,059(*Am*), 2,074(*Am*), 2,075(*Am*), 2,078(*Am*), 2,079(*Am*), 2,080(*Am*), 2,081(*Am*), 2,088(*Am*), 2,095(*Am*), 2,096(*Am*), or 2,098(*Am*). In one embodiment the acetyl-Coenzyme A carboxylase of an herbicide-tolerant plant of the invention will differ at only one of the following positions: 2,078(*Am*), 2,088(*Am*), or 2,075(*Am*). In a preferred embodiment the acetyl-Coenzyme A carboxylase of an herbicide-tolerant plant of the invention will differ at only one of the following positions: 2,039(*Am*), 2,059(*Am*), 2,080(*Am*), or 2,095(*Am*). In a more preferred embodiment the acetyl-Coenzyme A carboxylase of an herbicide-tolerant plant of the invention will differ at only one of the following positions: 1,785(*Am*), 1,786(*Am*), 1,811(*Am*), 1,824(*Am*), 1,864(*Am*), 2,041(*Am*), 2,049(*Am*), 2,074(*Am*), 2,079(*Am*), 2,081(*Am*), 2,096(*Am*), or 2,098(*Am*). In a most preferred embodiment the acetyl-Coenzyme A carboxylase of an herbicide-tolerant plant of the invention will differ at only one of the following positions: 1,781(*Am*), 1,999(*Am*), 2,027(*Am*), 2,041(*Am*), or 2,096(*Am*).

[0194] In one embodiment, the present invention encompasses a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having only one of the following substitutions: isoleucine at position 2,075(*Am*), glycine at position 2,078(*Am*), or arginine at position 2,088(*Am*). In a preferred embodiment, the present invention encompasses a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having only one of the following substitutions: glycine at position 2,039(*Am*), valine at position 2,059(*Am*), methionine at position 2,075(*Am*), duplication of position 2,075(*Am*) (i.e., an insertion of valine between 2,074(*Am*) and 2,075(*Am*), or an insertion of valine between position 2,075(*Am*) and 2,076(*Am*), deletion of amino acid position 2,088(*Am*), glutamic acid at position 2,080(*Am*), deletion of position 2,088(*Am*), or glutamic acid at position 2,095(*Am*). In a more preferred embodiment, the present invention encompasses a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having only one of the following substitutions: a glycine at position 1,785(*Am*), a proline at position 1,786(*Am*), an asparagine at position 1,811(*Am*), a leucine at position 2,075(*Am*), a methionine at position 2,075(*Am*), a threonine at position 2,078(*Am*), a deletion at position 2,080(*Am*), a deletion at position 2,081(*Am*), a tryptophan at position 2,088(*Am*), a serine at position 2,096(*Am*), an alanine at position 2,096(*Am*), an alanine at position 2,098(*Am*), a glycine at position 2,098(*Am*), an histidine at position 2,098(*Am*), a proline at position 2,098(*Am*), or a serine at position 2,098(*Am*). In a most preferred embodiment, the present invention encompasses a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having only one of the following substitutions: a leucine at position 1,781(*Am*), a threonine at position 1,781(*Am*), a valine at position 1,781(*Am*), an alanine at position 1,781(*Am*), a glycine at position 1,999(*Am*), a cysteine at position 2,027(*Am*), an arginine at position 2,027(*Am*), an asparagine at position 2,041(*Am*), a valine at position 2,041(*Am*), an alanine at position 2,096(*Am*), and a serine at position 2,096(*Am*).

[0195] In one embodiment, a nucleic acid molecule of the invention may encode an acetyl-Coenzyme A carboxylase comprising a leucine, threonine, valine, or an alanine at position 1,781(*Am*) and a cysteine or glycine at position 1,999(*Am*). In one embodiment, a nucleic acid molecule of the invention may encode an acetyl-Coenzyme A carboxylase comprising a leucine, threonine, valine, or an alanine at position 1,781(*Am*) and a cysteine or arginine at position 2,027(*Am*). In one embodiment, a nucleic acid molecule of the invention may encode an acetyl-Coenzyme A carboxylase comprising a leucine, threonine, valine, or

an alanine at position 1,781(*Am*) and an asparagine at position 2,041(*Am*). In one embodiment, a nucleic acid molecule of the invention may encode an acetyl-Coenzyme A carboxylase comprising a leucine, threonine, valine, or an alanine at position 1,781(*Am*) and a phenylalanine, isoleucine or leucine at position 2,049(*Am*). In one embodiment, a nucleic acid molecule of the invention may encode an acetyl-Coenzyme A carboxylase comprising a leucine, threonine, valine, or an alanine at position 1,781(*Am*) and a leucine or isoleucine at position 2,075(*Am*). In one embodiment, a nucleic acid molecule of the invention may encode an acetyl-Coenzyme A carboxylase comprising a leucine, threonine, valine, or an alanine at position 1,781(*Am*) and a glycine at position 2,078(*Am*). In one embodiment, a nucleic acid molecule of the invention may encode an acetyl-Coenzyme A carboxylase comprising a leucine, threonine, valine, or an alanine at position 1,781(*Am*) and an arginine at position 2,088(*Am*). In one embodiment, a nucleic acid molecule of the invention may encode an acetyl-Coenzyme A carboxylase comprising a leucine, threonine, valine, or an alanine at position 1,781(*Am*) and an alanine at position 2,096(*Am*). In one embodiment, a nucleic acid molecule of the invention may encode an acetyl-Coenzyme A carboxylase comprising a leucine, threonine, valine, or an alanine at position 1,781(*Am*) and an alanine at position 2,098(*Am*). In one embodiment, a nucleic acid molecule of the invention may encode an acetyl-Coenzyme A carboxylase comprising a leucine, threonine, valine, or an alanine at position 1,781(*Am*), a cysteine at position 2,027(*Am*), and an asparagine at position 2,041(*Am*). In one embodiment, a nucleic acid molecule of the invention may encode an acetyl-Coenzyme A carboxylase comprising a leucine, threonine, valine, or an alanine at position 1,781(*Am*), a cysteine at position 2,027(*Am*), an asparagine at position 2,041(*Am*), and an alanine at position 2,096(*Am*).

[0196] In one embodiment, the invention includes, a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having an isoleucine at position 2,075(*Am*) and a glycine at position 1,999(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a methionine at position 2,075(*Am*) and a glutamic acid at position 2,080(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a methionine at position 2,075(*Am*) and a glutamic acid at position 2,095(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a glycine at position 2,078(*Am*) and a valine at position 2,041(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A

carboxylase having a glycine at position 2,078(*Am*) and a glycine at position 2,039(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a glycine at position 2,078(*Am*) and an alanine at position 2,049(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a glycine at position 2,078(*Am*) and a cysteine at position 2,049(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a glycine at position 2,078(*Am*) and a serine at position 2,049(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a glycine at position 2,078(*Am*) and a threonine at position 2,049(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a glycine at position 2,078(*Am*) and a valine at position 2,059(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a glycine at position 2,078(*Am*) and a phenylalanine at position 2,079(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a glycine at position 2,078(*Am*) and a proline at position 2,079(*Am*); or a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a glycine at position 2,078(*Am*) and a glycine at position 2,088(*Am*).

[0197] In a preferred embodiment, the invention includes a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a leucine at position 1,781(*Am*) and a proline at position 1,824(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a leucine at position 1,781(*Am*) and an arginine at position 2027(*Am*); or a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a glycine at position 2,078(*Am*) and a proline at position 1,824(*Am*).

[0198] In a more preferred embodiment, the invention includes a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a leucine at position 1,781(*Am*) and a phenylalanine at position 2,049(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having an alanine at position 2,098(*Am*) and a leucine at position 2,049(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having an alanine at position 2,098(*Am*) and a histidine at position 2088(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having an alanine at position 2,098(*Am*) and a phenylalanine at position 2,088(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having an alanine at position 2,098(*Am*) and a lysine at position 2,088(*Am*); a

nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having an alanine at position 2,098(*Am*) and a leucine at position 2,088(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having an alanine at position 2,098(*Am*) and a threonine at position 2,088(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a glycine at position 2,098(*Am*) and a glycine at position 2,088(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a glycine at position 2,098(*Am*) and a histidine at position 2,088(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a glycine at position 2,098(*Am*) and leucine at position 2,088(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a glycine at position 2,098(*Am*) and a serine at position 2,088(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a glycine at position 2,098(*Am*) and threonine at position 2,088(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a glycine at position 2,098(*Am*) and a valine at position 2,088(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a cysteine at position 2,098(*Am*) and a tryptophan at position 2088(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a serine at position 2,098(*Am*) and a tryptophan at position 2088(*Am*); or a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a deletion at position 2,080(*Am*) and a deletion at position 2081(*Am*).

[0199] In a most preferred embodiment, the invention includes, a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a leucine at position 1,781(*Am*) and a asparagine at position 2,041(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a leucine at position 1,781(*Am*) and a cysteine at position 2,027(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a leucine at position 1,781(*Am*) and a leucine at position 2,075(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a leucine at position 1,781(*Am*) and a phenylalanine at position 1,864(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a leucine at position 1,781(*Am*) and an alanine at position 2098(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a leucine at position 1,781(*Am*) and a glycine at position 2,098(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a leucine at position 1,781(*Am*) and a duplication 2,075(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a

glycine at position 1,999(*Am*) and a phenylalanine at position 1,864(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a glycine at position 1,999(*Am*) and isoleucine at position 2,049(*Am*); a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a glycine at position 1,999(*Am*) and leucine at position 2,075(*Am*); or a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase having a glycine at position 1,999(*Am*) and alanine at position 2,098(*Am*).

[0200] In one embodiment, the invention provides rice plants comprising nucleic acids encoding Acetyl-Coenzyme A carboxylase polypeptide having one or more substitutions as described above.

[0201] In one embodiment, the invention provides BEP clade plants comprising nucleic acids encoding Acetyl-Coenzyme A carboxylase polypeptide having one or more substitutions as described above.

[0202] In one embodiment, the invention provides BET subclade plant comprising nucleic acids encoding Acetyl-Coenzyme A carboxylase polypeptide having one or more substitutions as described above.

[0203] In one embodiment, the invention provides BET crop plants comprising nucleic acids encoding Acetyl-Coenzyme A carboxylase polypeptide having one or more substitutions as described above.

[0204] In one embodiment, the invention provides monocot plants comprising nucleic acids encoding Acetyl-Coenzyme A carboxylase polypeptide having one or more substitutions as described above.

[0205] A nucleic acid molecule of the invention may be DNA, derived from genomic DNA or cDNA, or RNA. A nucleic acid molecule of the invention may be naturally occurring or may be synthetic. A nucleic acid molecule of the invention may be isolated, recombinant and/or mutagenized.

[0206] In one embodiment, a nucleic acid molecule of the invention encodes an acetyl-Coenzyme A carboxylase enzyme in which the amino acid at position 1,781(*Am*) is leucine or alanine or is complementary to such a nucleic acid molecule. Such nucleic acid molecules include, but are not limited to, genomic DNA that serves as a template for a primary RNA

transcription, a plasmid molecule encoding the acetyl-Coenzyme A carboxylase, as well as an mRNA encoding such an acetyl-Coenzyme A carboxylase.

[0207] Nucleic acid molecules of the invention may comprise non-coding sequences, which may or may not be transcribed. Non-coding sequences that may be included in the nucleic acid molecules of the invention include, but are not limited to, 5' and 3' UTRs, polyadenylation signals and regulatory sequences that control gene expression (e.g., promoters). Nucleic acid molecules of the invention may also comprise sequences encoding transit peptides, protease cleavage sites, covalent modification sites and the like. In one embodiment, nucleic acid molecules of the invention encode a chloroplast transit peptide sequence in addition to a sequence encoding an acetyl-Coenzyme A carboxylase enzyme.

[0208] In another embodiment, nucleic acid molecules of the invention may encode an acetyl-Coenzyme A carboxylase enzyme having at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or more sequence identity to a modified version of one or both of SEQ ID NOs: 2 and 3, wherein the sequence is modified such that the encoded protein comprises one or more of the following: the amino acid at position 1,781(*Am*) is leucine, threonine, valine, or alanine; the amino acid at position 1,785(*Am*) is glycine; the amino acid at position 1,786(*Am*) is proline; the amino acid at position 1,811(*Am*) is asparagine; the amino acid at position 1,824(*Am*) is proline; the amino acid at position 1,864(*Am*) is phenylalanine; the amino acid at position 1,999(*Am*) is cysteine or glycine; the amino acid at position 2,027(*Am*) is cysteine or arginine; the amino acid at position 2,039(*Am*) is glycine; the amino acid at position 2,041(*Am*) is asparagine; the amino acid at position 2049(*Am*) is phenylalanine, leucine or isoleucine; the amino acid at position 2,059(*Am*) is valine; the amino acid at position 2,074(*Am*) is leucine; the amino acid at position 2,075(*Am*) is leucine, isoleucine or methionine or an additional valine; the amino acid at position 2,078(*Am*) is glycine, or threonine; the amino acid at position 2,079(*Am*) is phenylalanine; the amino acid at position 2,080(*Am*) is glutamic acid; the amino acid at position 2,080(*Am*) is deleted; the amino acid at position 2,081(*Am*) is deleted; the amino acid at position 2,088(*Am*) is arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine; the amino acid at position 2,095(*Am*) is glutamic acid; the amino acid at position 2,096(*Am*) is alanine, or serine; or the amino acid at position 2,098(*Am*) is alanine, glycine, proline,

histidine, or serine, as well as nucleic acid molecules complementary to all or a portion of the coding sequences.

[0209] As used herein, "percent (%) sequence identity" is defined as the percentage of nucleotides or amino acids in the candidate derivative sequence identical with the nucleotides or amino acids in the subject sequence (or specified portion thereof), after aligning the sequences and introducing gaps, if necessary to achieve the maximum percent sequence identity, as generated by the program BLAST available at <http://blast.ncbi.nlm.nih.gov/Blast.cgi> with search parameters set to default values.

[0210] The present invention also encompasses nucleic acid molecules that hybridize to nucleic acid molecules encoding acetyl-Coenzyme A carboxylase of the invention as well as nucleic acid molecules that hybridize to the reverse complement of nucleic acid molecules encoding an acetyl-Coenzyme A carboxylase of the invention. In one embodiment, nucleic acid molecules of the invention comprise nucleic acid molecules that hybridize to a nucleic acid molecule encoding one or more of a modified version of one or both of SEQ ID NOs: 2 and 3, wherein the sequence is modified such that the encoded protein comprises one or more of the following: the amino acid at position 1,781(*Am*) is leucine, threonine, valine, or alanine; the amino acid at position 1,785(*Am*) is glycine; the amino acid at position 1,786(*Am*) is proline; the amino acid at position 1,811(*Am*) is asparagine; the amino acid at position 1,824(*Am*) is proline; the amino acid at position 1,864(*Am*) is phenylalanine; the amino acid at position 1,999(*Am*) is cysteine or glycine; the amino acid at position 2,027(*Am*) is cysteine or arginine; the amino acid at position 2,039(*Am*) is glycine; the amino acid at position 2,041(*Am*) is asparagine; the amino acid at position 2049(*Am*) is phenylalanine, isoleucine or leucine; the amino acid at position 2,059(*Am*) is valine; the amino acid at position 2,074(*Am*) is leucine; the amino acid at position 2,075(*Am*) is leucine, isoleucine or methionine or an additional valine; the amino acid at position 2,078(*Am*) is glycine, or threonine; the amino acid at position 2,079(*Am*) is phenylalanine; the amino acid at position 2,080(*Am*) is glutamic acid; the amino acid at position 2,080(*Am*) is deleted; the amino acid at position 2,081(*Am*) is deleted; the amino acid at position 2,088(*Am*) is arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine; the amino acid at position 2,095(*Am*) is glutamic acid; the amino acid at position 2,096(*Am*) is

alanine, or serine; or the amino acid at position 2,098(*Am*) is alanine, glycine, proline, histidine, or serine, as well as nucleic acid molecules complementary to all or a portion of the coding sequences, or the reverse complement of such nucleic acid molecules under stringent conditions. The stringency of hybridization can be controlled by temperature, ionic strength, pH, and the presence of denaturing agents such as formamide during hybridization and washing. Stringent conditions that may be used include those defined in *Current Protocols in Molecular Biology*, Vol. 1, Chap. 2.10, John Wiley & Sons, Publishers (1994) and Sambrook et al., *Molecular Cloning*, Cold Spring Harbor (1989) which are specifically incorporated herein as they relate to teaching stringent conditions.

[0211] Any of the mutants described above in a plasmid with a combination of the gene of interest can be used in transformation.

[0212] In one embodiment, the present invention provides expression vectors comprising nucleic acid molecules encoding any of the ACCase mutants described above.

[0213] In one embodiment, the present invention provides for the use of mutant ACCase nucleic acids and proteins encoded by such mutant ACCase nucleic acids as described above as selectable markers.

[0214] In one embodiment, nucleic acid molecules invention encompasses oligonucleotides that may be used as hybridization probes, sequencing primers, and/or PCR primers. Such oligonucleotides may be used, for example, to determine a codon sequence at a particular position in a nucleic acid molecule encoding an acetyl-Coenzyme A carboxylase, for example, by allele specific PCR. Such oligonucleotides may be from about 15 to about 30, from about 20 to about 30, or from about 20-25 nucleotides in length.

[0215] Test for double mutant ACCase genes "DBLM Assay":

[0216] (1) In a test population (of, e.g., at least 12 and preferably at least 20) whole rice plants containing 1 or 2 copies of a transgenic ACCase gene encoding an at-least-double-mutant ACCase (i.e. 1 min. and 2 max. chromosomal insertions of the transgenic ACCase gene to be tested),

wherein the rice plants are T0 ("T-zero") regenerants

and in parallel with a control population of such plants to be used as untreated check plants;

(2) Application to the test population at 200 L / ha spray volume of a composition comprising Tepraloxym (AI) and 1% Crop Oil Concentrate (COC), to provide an AI application rate equivalent to 50 g/ha of Tepraloxym (AI);

(3) Determining a phytotoxicity score for each test and check plant, based on a traditional plant injury rating system (e.g., evaluating visual evidence of herbicide burn, leaf morphology changes, wilt, yellowing, and other morphological characteristics, preferably according to a typical, at least-5-level injury rating scale);

(4) Analyzing the collected data to determine whether at least 75% of the plants in the test population exhibit an average phytotoxicity, i.e. increase in injury relative to check plants, of less than 10%; and

(5) Identifying a positive result so determined as demonstrating that the double-mutant ACCase provides an acceptable AIT.

[0217] Herbicides

[0218] The present invention provides plants, e.g., rice plants, that are tolerant of concentrations of herbicide that normally inhibit the growth of wild-type plants. The plants are typically resistant to herbicides that interfere with acetyl-Coenzyme A carboxylase activity. Any herbicide that inhibits acetyl-Coenzyme A carboxylase activity can be used in conjunction with the plants of the invention. Suitable examples include, but are not limited to, cyclohexanedione herbicides, aryloxyphenoxy propionate herbicides, and phenylpyrazole herbicides. In some methods of controlling weeds and/or growing herbicide-tolerant plants, at least one herbicide is selected from the group consisting of sethoxydim, cycloxydim, tepraloxym, haloxyfop, haloxyfop-P or a derivative of any of these herbicides.

Table 1 provides a list of cyclohexanedione herbicides (DIMs, also referred to as: cyclohexene oxime cyclohexanedione oxime; and CHD) that interfere with acetyl-Coenzyme A carboxylase activity and may be used in conjunction with the herbicide-tolerant plants of the invention. One skilled in the art will recognize that other herbicides in this class exist and may be used in conjunction with the herbicide-tolerant plants of the invention. Also included

in Table 1 is a list of aryloxyphenoxy propionate herbicides (also referred to as aryloxyphenoxy propanoate; aryloxyphenoxyalkanoate; oxyphenoxy; APP; AOPP; APA; APPA; FOP, note that these are sometime written with the suffix '-oic') that interfere with acetyl-Coenzyme A carboxylase activity and may be used in conjunction with the herbicide-tolerant plants of the invention. One skilled in the art will recognize that other herbicides in this class exist and may be used in conjunction with the herbicide-tolerant plants of the invention.

[0219] Table 1

ACC	Case Inhibitor	Class	Company	Examples of Synonyms and Trade Names
	alloxydim	DIM	BASF	Fervin, Kusagard, NP-48Na, BAS 9021H, Carbodimedon, Zizalon
	butroxydim	DIM	Syngenta	Falcon, ICI-A0500, Butroxydim
	clethodim	DIM	Valent	Select, Prism, Centurion, RE-45601, Motsa
	Clodinafop-propargyl	FOP	Syngenta	Discover, Topik, CGA 184 927
	clofop	FOP		Fenofibric Acid, Alopex
	cloproxydim	FOP		
	chlorazifop	FOP		
	cycloxydim	DIM	BASF	Focus, Laser, Stratos, BAS 517H
	cyhalofop-butyl	FOP	Dow	Clincher, XDE 537, DEH 112, Barnstorm
	diclofop-methyl	FOP	Bayer	Hoegrass, Hoelon, Illoxan, HOE 23408, Dichlorfop, Illoxan
	fenoxaprop-P-ethyl	FOP	Bayer	Super Whip, Option Super, Exel Super, HOE-46360, Aclain, Puma S, Fusion
	fenthiaprop	FOP		Taifun; Joker
	fluazifop-P-butyl	FOP	Syngenta	Fusilade, Fusilade 2000, Fusilade DX, ICI-A 0009, ICI-A 0005, SL-236, IH-773B, TF-1169, Fusion
	haloxyfop-etotyl	FOP	Dow	Gallant, DOWCO 453EE
	haloxyfop-methyl	FOP	Dow	Verdict, DOWCO 453ME
	haloxyfop-P-methyl	FOP	Dow	Edge, DE 535
	isoxapyrifop	FOP		
	Metamifop	FOP	Dongbu	NA
	pinoxaden	DEN	Syngenta	Axial
	profoxydim	DIM	BASF	Aura, Tetris, BAS 625H, Clefoxydim
	propaquizafop	FOP	Syngenta	Agil, Shogun, Ro 17-3664, Correct
	quizalofop-P-ethyl	FOP	DuPont	Assure, Assure II, DPX-Y6202-3, Targa Super, NC-302, Quizafop
	quizalofop-P-tefuryl	FOP	Uniroyal	Pantera, UBI C4874
	sethoxydim	DIM	BASF	Poast, Poast Plus, NABU, Fervinal, NP-55, Sertin, BAS 562H, Cyethoxydim, Rezult
	tepraloxym	DIM	BASF	BAS 620H, Aramo, Caloxydim
	tralkoxydim	DIM	Syngenta	Achieve, Splendor, ICI-A0604, Tralkoxydime, Tralkoxidym
	trifop	FOP		

[0220] In addition to the herbicides listed above, other ACCase-inhibitors can be used in conjunction with the herbicide-tolerant plants of the invention. For example, ACCase-inhibiting herbicides of the phenylpyrazole class, also known as DENs, can be used. An exemplary DEN is pinoxaden, which is a phenylpyrazoline-type member of this class. Herbicide compositions containing pinoxaden are sold under the brands Axial and Traxos.

[0221] The herbicidal compositions hereof comprising one or more acetyl-Coenzyme A carboxylase-inhibiting herbicides, and optionally other agronomic A.I.(s), *e.g.*, one or more sulfonylureas (SUs) selected from the group consisting of amidosulfuron, flupyralsulfuron, foramsulfuron, imazosulfuron, iodosulfuron, mesosulfuron, nicosulfuron, thifensulfuron, and tribenuron, agronomically acceptable salts and esters thereof, or one or more imidazolinones selected from the group of imazamox, imazethapyr, imazapyr, imazapic, combinations thereof, and their agriculturally suitable salts and esters, can be used in any agronomically acceptable format. For example, these can be formulated as ready-to-spray aqueous solutions, powders, suspensions; as concentrated or highly concentrated aqueous, oily or other solutions, suspensions or dispersions; as emulsions, oil dispersions, pastes, dusts, granules, or other broadcastable formats. The herbicide compositions can be applied by any means known in the art, including, for example, spraying, atomizing, dusting, spreading, watering, seed treatment, or co-planting in admixture with the seed. The use forms depend on the intended purpose; in any case, they should ensure the finest possible distribution of the active ingredients according to the invention.

[0222] In other embodiments, where the optional A.I. includes an herbicide from a different class to which the plant(s) hereof would normally be susceptible, the plant to be used is selected from among those that further comprise a trait of tolerance to such herbicide. Such further tolerance traits can be provided to the plant by any method known in the art, *e.g.*, including techniques of traditional breeding to obtain a tolerance trait gene by hybridization or introgression, of mutagenesis, and/or of transformation. Such plants can be described as having “stacked” traits.

[0223] In addition, any of the above acetyl-Coenzyme A carboxylase-inhibiting herbicides can be combined with one or more herbicides of another class, for example, any of the acetohydroxyacid synthase-inhibiting herbicides, EPSP synthase-inhibiting herbicides,

glutamine synthase-inhibiting herbicides, lipid- or pigment-biosynthesis inhibitor herbicides, cell-membrane disruptor herbicides, photosynthesis or respiration inhibitor herbicides, or growth regulator or growth inhibitor herbicides known in the art. Non-limiting examples include those recited in Weed Science Society of America's *Herbicide Handbook*, 9th Edition edited by S.A. Senseman, copy right 2007. An herbicidal composition herein can contain one or more agricultural active ingredient(s) selected from the agriculturally-acceptable fungicides, strobilurin fungicides, insecticides (including nematicides), miticides, and molluscicides. Non-limiting examples include those recited in 2009 Crop Protection Reference (www.greenbook.net), Vance Publications.

[0224] In one embodiment of the invention, any of the above acetyl-Coenzyme A carboxylase-inhibiting herbicides are combined with herbicides which exhibit low damage to rice, whereby the rice tolerance to such herbicides may optionally be a result of genetic modifications of the crop plants. Examples of such herbicides are the acetohydroxyacid synthase-inhibiting herbicides imazamethabenz, imazamox, imazapic, imazapyr, imazaquin, imazethapyr, azimsulfuron, bensulfuron, chlorimuron, cyclosulfamuron, ethoxysulfuron, flucetosulfuron, halosulfuron, imazosulfuron, metsulfuron, orthosulfamuron, propyrisulfuron, pyrazosulfuron, bispyribac, pyrimisulfan or penoxsulam, the EPSP synthase-inhibiting herbicides glyphosate or sulfosate, the glutamine synthase-inhibiting herbicides glufosinate, glufosinate-P or bialaphos, the lipid biosynthesis inhibitor herbicides benfuresate, molinate or thiobencarb, the photosynthesis inhibitor herbicides bentazon, paraquat, prometryn or propanil, the bleacher herbicides benzobicyclone, clomazone or tefuryltrione, the auxin herbicides 2,4-D, fluroxypyr, MCPA, quinclorac, quinmerac or triclopyr, the microtubule inhibitor herbicide pendimethalin, the VLCFA inhibitor herbicides anilofos, butachlor, fentrazamide, ipfencarbazone, mefenacet, pretilachlor, acetochlor, metolachlor or S-metolachlor or the protoporphyrinogen-IX-oxidase inhibitor herbicides carfentrazone, oxadiazon, oxyfluorfen, pyraclonil or saflufenacil.

[0225] In one embodiment of the invention, any of the above acetyl-Coenzyme A carboxylase-inhibiting herbicides are combined with herbicides which exhibit low damage to cereals such as wheat, barley or rye, whereby the cereals tolerance to such herbicides may optionally be a result of genetic modifications of the crop plants. Examples of such

herbicides are the acetohydroxyacid synthase-inhibiting herbicides imazamethabenz, imazamox, imazapic, imazapyr, imazaquin, imazethapyr, amidosulfuron, chlorsulfuron, flucetosulfuron, flupyralsulfuron, iodosulfuron, mesosulfuron, metsulfuron, sulfosulfuron, thifensulfuron, triasulfuron, tribenuron, tritosulfuron, florasulam, pyroxsulam, pyrimisulfan, flucarbazone, propoxycarbazon or thien carbazon, the EPSP synthase-inhibiting herbicides glyphosate or sulfosate, the glutamine synthase-inhibiting herbicides glufosinate, glufosinate-P or bialaphos, the lipid biosynthesis inhibitor herbicides prosulfocarb, the photosynthesis inhibitor herbicides bentazon, chlorotoluron, isoproturon, ioxynil, bromoxynil, the bleacher herbicides diflufenican, flurtamone, picolinafen or pyrasulfotole, the auxin herbicides aminocyclopyrachlor, aminopyralid, 2,4-D, dicamba, fluroxypyr, MCPA, clopyralid, MCPP, or MCPP-P, the microtubule inhibitor herbicides pendimethalin or trifluralin, the VLCFA inhibitor herbicide flufenacet, or the protoporphyrinogen-IX-oxidase inhibitor herbicides bencarbazon, carfentrazone or saflufenacil, or the herbicide difenzoquat.

[0226] In one embodiment of the invention, any of the above acetyl-Coenzyme A carboxylase-inhibiting herbicides are combined with herbicides which exhibit low damage to turf, whereby the turf tolerance to such herbicides may optionally be a result of genetic modifications of the crop plants. Examples of such herbicides are the acetohydroxyacid synthase-inhibiting herbicides imazamethabenz, imazamox, imazapic, imazapyr, imazaquin, imazethapyr, flazasulfuron, foramsulfuron, halosulfuron, trifloxysulfuron, bispyribac or thien carbazon, the EPSP synthase-inhibiting herbicides glyphosate or sulfosate, the glutamine synthase-inhibiting herbicides glufosinate, glufosinate-P or bialaphos, the photosynthesis inhibitor herbicides atrazine or bentazon, the bleacher herbicides mesotrione, picolinafen, pyrasulfotole or topramezone, the auxin herbicides aminocyclopyrachlor, aminopyralid, 2,4-D, 2,4-DB, clopyralid, dicamba, dichlorprop, dichlorprop-P, fluroxypyr, MCPA, MCPB, MCPP, MCPP-P, quinclorac, quinmerac or trichlopyr, the microtubule inhibitor herbicide pendimethalin, the VLCFA inhibitor herbicides dimethenamide, dimethenamide-P or ipfencarbazon, the protoporphyrinogen-IX-oxidase inhibitor herbicides saflufenacil or sulfentrazone, or the herbicide indaziflam.

[0227] Furthermore, any of the above acetyl-Coenzyme A carboxylase-inhibiting herbicides can be combined with safeners. Safeners are chemical compounds which prevent

or reduce damage on useful plants without having a major impact on the herbicidal action of the herbicides towards unwanted plants. They can be applied either before sowings (e. g. on seed treatments, shoots or seedlings) or in the pre-emergence application or post-emergence application of the useful plant. The safeners and the aforementioned herbicides can be applied simultaneously or in succession. Suitable safeners are e. g. (quinolin-8-oxy)acetic acids, 1-phenyl-5-haloalkyl-1H-1,2,4-triazol-3-carboxylic acids, 1-phenyl-4,5-dihydro-5-alkyl-1H-pyrazol-3,5-dicarboxylic acids, 4,5-dihydro-5,5-diaryl-3-isoxazol carboxylic acids, dichloroacetamides, alpha-oximinophenylacetoneitriles, acetophenonoximes, 4,6-dihalo-2-phenylpyrimidines, N-[[4-(aminocarbonyl)phenyl]sulfonyl]-2-benzoic amides, 1,8-naphthalic anhydride, 2-halo-4-(haloalkyl)-5-thiazol carboxylic acids, phosphorothiolates and N-alkyl-O-phenylcarbamates. Examples of safeners are benoxacor, cloquintocet, cyometrinil, cyprosulfamide, dichlormid, dicyclonon, dietholate, fenchlorazole, fenclorim, flurazole, fluxofenim, furilazole, isoxadifen, mefenpyr, mephenate, naphthalic anhydride, oxabetrinil, 4-(dichloroacetyl)-1-oxa-4-azaspiro[4.5]decane (MON4660, CAS 71526-07-3) and 2,2,5-trimethyl-3-(dichloroacetyl)-1,3-oxazolidine (R-29148, CAS 52836-31-4).

[0228] In some embodiments, an herbicidal composition hereof can comprise, e.g., a combination of: auxinic herbicide(s), e.g., dicamba; AHAS-inhibitor(s), e.g., imidazolinone(s) and/or sulfonylurea(s); ACCase-inhibitor(s); EPSPS inhibitor(s), e.g., glyphosate; glutamine synthetase inhibitor(s), e.g., glufosinate; protoporphyrinogen-IX oxidase (PPO) inhibitor(s), e.g., saflufenacil; fungicide(s), e.g., strobilurin fungicide(s) such as pyraclostrobin; and the like. In some embodiments, an herbicidal composition hereof can comprise, e.g., a combination of auxinic herbicide(s), e.g., dicamba; a microtubule inhibitor herbicide, e.g., pendimethalin and strobilurin fungicide(s) such as pyraclostrobin(s). An herbicidal composition will be selected according to the tolerances of a plant hereof, and the plant can be selected from among those having stacked tolerance traits.

[0229] The herbicides individually and/or in combination as described in the present invention can be used as pre-mixes or tank mixes. Such herbicides can also be incorporated into an agronomically acceptable compositions.

[0230] Those skilled in the art will recognize that some of the above mentioned herbicides and/or safeners are capable of forming geometrical isomers, for example E/Z

isomers. It is possible to use both, the pure isomers and mixtures thereof, in the compositions according to the invention. Furthermore, some of the above mentioned herbicides and/or safeners have one or more centers of chirality and, as a consequence, are present as enantiomers or diastereomers. It is possible to use both, the pure enantiomers and diastereomers and their mixtures, in the compositions according to the invention. In particular, some of the aryloxyphenoxy propionate herbicides are chiral, and some of them are commonly used in enantiomerically enriched or enantiopure form, e. g. clodinafop, cyhalofop, fenoxaprop-P, fluazifop-P, haloxyfop-P, metamifop, propaquizafop or quizalofop-P. As a further example, glufosinate may be used in enantiomerically enriched or enantiopure form, also known as glufosinate-P.

[0231] Those skilled in the art will recognize that any derivative of the above mentioned herbicides and/or safeners can be used in the practice of the invention, for example agriculturally suitable salts and esters.

[0232] The herbicides and/or safeners, or the herbicidal compositions comprising them, can be used, for example, in the form of ready-to-spray aqueous solutions, powders, suspensions, also highly concentrated aqueous, oily or other suspensions or dispersions, emulsions, oil dispersions, pastes, dusts, materials for broadcasting, or granules, by means of spraying, atomizing, dusting, spreading, watering or treatment of the seed or mixing with the seed. The use forms depend on the intended purpose; in any case, they should ensure the finest possible distribution of the active ingredients according to the invention.

[0233] The herbicidal compositions comprise an herbicidal effective amount of at least one of the acetyl-Coenzyme A carboxylase-inhibiting herbicides and potentially other herbicides and/or safeners and auxiliaries which are customary for the formulation of crop protection agents.

[0234] Examples of auxiliaries customary for the formulation of crop protection agents are inert auxiliaries, solid carriers, surfactants (such as dispersants, protective colloids, emulsifiers, wetting agents and tackifiers), organic and inorganic thickeners, bactericides, antifreeze agents, antifoams, optionally colorants and, for seed formulations, adhesives. The person skilled in the art is sufficiently familiar with the recipes for such formulations.

- [0235] Examples of thickeners (i.e. compounds which impart to the formulation modified flow properties, i.e. high viscosity in the state of rest and low viscosity in motion) are polysaccharides, such as xanthan gum (Kelzan® from Kelco), Rhodopol® 23 (Rhône Poulenc) or Veegum® (from R.T. Vanderbilt), and also organic and inorganic sheet minerals, such as Attaclay® (from Engelhardt).
- [0236] Examples of antifoams are silicone emulsions (such as, for example, Silikon® SRE, Wacker or Rhodorsil® from Rhodia), long-chain alcohols, fatty acids, salts of fatty acids, organofluorine compounds and mixtures thereof.
- [0237] Bactericides can be added for stabilizing the aqueous herbicidal formulations. Examples of bactericides are bactericides based on diclorophen and benzyl alcohol hemiformal (Proxel® from ICI or Acticide® RS from Thor Chemie and Kathon® MK from Rohm & Haas), and also isothiazolinone derivatives, such as alkylisothiazolinones and benzisothiazolinones (Acticide MBS from Thor Chemie).
- [0238] Examples of antifreeze agents are ethylene glycol, propylene glycol, urea or glycerol.
- [0239] Examples of colorants are both sparingly water-soluble pigments and water-soluble dyes. Examples which may be mentioned are the dyes known under the names Rhodamin B, C.I. Pigment Red 112 and C.I. Solvent Red 1, and also pigment blue 15:4, pigment blue 15:3, pigment blue 15:2, pigment blue 15:1, pigment blue 80, pigment yellow 1, pigment yellow 13, pigment red 112, pigment red 48:2, pigment red 48:1, pigment red 57:1, pigment red 53:1, pigment orange 43, pigment orange 34, pigment orange 5, pigment green 36, pigment green 7, pigment white 6, pigment brown 25, basic violet 10, basic violet 49, acid red 51, acid red 52, acid red 14, acid blue 9, acid yellow 23, basic red 10, basic red 108.
- [0240] Examples of adhesives are polyvinylpyrrolidone, polyvinyl acetate, polyvinyl alcohol and tylose.
- [0241] Suitable inert auxiliaries are, for example, the following: mineral oil fractions of medium to high boiling point, such as kerosene and diesel oil, furthermore coal tar oils and oils of vegetable or animal origin, aliphatic, cyclic and aromatic hydrocarbons, for example

paraffin, tetrahydronaphthalene, alkylated naphthalenes and their derivatives, alkylated benzenes and their derivatives, alcohols such as methanol, ethanol, propanol, butanol and cyclohexanol, ketones such as cyclohexanone or strongly polar solvents, for example amines such as N-methylpyrrolidone, and water.

[0242] Suitable carriers include liquid and solid carriers. Liquid carriers include e.g. non-aqueous solvents such as cyclic and aromatic hydrocarbons, e.g. paraffins, tetrahydronaphthalene, alkylated naphthalenes and their derivatives, alkylated benzenes and their derivatives, alcohols such as methanol, ethanol, propanol, butanol and cyclohexanol, ketones such as cyclohexanone, strongly polar solvents, e.g. amines such as N-methylpyrrolidone, and water as well as mixtures thereof. Solid carriers include e.g. mineral earths such as silicas, silica gels, silicates, talc, kaolin, limestone, lime, chalk, bole, loess, clay, dolomite, diatomaceous earth, calcium sulfate, magnesium sulfate and magnesium oxide, ground synthetic materials, fertilizers such as ammonium sulfate, ammonium phosphate, ammonium nitrate and ureas, and products of vegetable origin, such as cereal meal, tree bark meal, wood meal and nutshell meal, cellulose powders, or other solid carriers.

[0243] Suitable surfactants (adjuvants, wetting agents, tackifiers, dispersants and also emulsifiers) are the alkali metal salts, alkaline earth metal salts and ammonium salts of aromatic sulfonic acids, for example lignosulfonic acids (e.g. Borrespers-types, Borregaard), phenolsulfonic acids, naphthalenesulfonic acids (Morwet types, Akzo Nobel) and dibutyl naphthalenesulfonic acid (Nekal types, BASF AG), and of fatty acids, alkyl- and alkylarylsulfonates, alkyl sulfates, lauryl ether sulfates and fatty alcohol sulfates, and salts of sulfated hexa-, hepta- and octadecanols, and also of fatty alcohol glycol ethers, condensates of sulfonated naphthalene and its derivatives with formaldehyde, condensates of naphthalene or of the naphthalenesulfonic acids with phenol and formaldehyde, polyoxyethylene octylphenol ether, ethoxylated isooctyl-, octyl- or nonylphenol, alkylphenyl or tributylphenyl polyglycol ether, alkylaryl polyether alcohols, isotridecyl alcohol, fatty alcohol/ethylene oxide condensates, ethoxylated castor oil, polyoxyethylene alkyl ethers or polyoxypropylene alkyl ethers, lauryl alcohol polyglycol ether acetate, sorbitol esters, lignosulfite waste liquors and proteins, denaturated proteins, polysaccharides (e.g. methylcellulose), hydrophobically modified starches, polyvinyl alcohol (Mowiol types Clariant), polycarboxylates (BASF AG,

Sokalan types), polyalkoxylates, polyvinylamine (BASF AG, Lupamine types), polyethyleneimine (BASF AG, Lupasol types), polyvinylpyrrolidone and copolymers thereof.

[0244] Powders, materials for broadcasting and dusts can be prepared by mixing or concomitant grinding the active ingredients together with a solid carrier.

[0245] Granules, for example coated granules, impregnated granules and homogeneous granules, can be prepared by binding the active ingredients to solid carriers.

[0246] Aqueous use forms can be prepared from emulsion concentrates, suspensions, pastes, wettable powders or water-dispersible granules by adding water. To prepare emulsions, pastes or oil dispersions, the herbicidal compositions, either as such or dissolved in an oil or solvent, can be homogenized in water by means of a wetting agent, tackifier, dispersant or emulsifier. Alternatively, it is also possible to prepare concentrates comprising active compound, wetting agent, tackifier, dispersant or emulsifier and, if desired, solvent or oil, which are suitable for dilution with water.

[0247] Methods of controlling weeds

[0248] Herbicide-tolerant plants of the invention may be used in conjunction with an herbicide to which they are tolerant. Herbicides may be applied to the plants of the invention using any techniques known to those skilled in the art. Herbicides may be applied at any point in the plant cultivation process. For example, herbicides may be applied pre-planting, at planting, pre-emergence, post-emergence or combinations thereof.

[0249] Herbicide compositions hereof can be applied, e.g., as foliar treatments, soil treatments, seed treatments, or soil drenches. Application can be made, e.g., by spraying, dusting, broadcasting, or any other mode known useful in the art.

[0250] In one embodiment, herbicides may be used to control the growth of weeds that may be found growing in the vicinity of the herbicide-tolerant plants invention. In embodiments of this type, an herbicide may be applied to a plot in which herbicide-tolerant plants of the invention are growing in vicinity to weeds. An herbicide to which the herbicide-tolerant plant of the invention is tolerant may then be applied to the plot at a

concentration sufficient to kill or inhibit the growth of the weed. Concentrations of herbicide sufficient to kill or inhibit the growth of weeds are known in the art.

[0251] It will be readily apparent to one of ordinary skill in the relevant arts that other suitable modifications and adaptations to the methods and applications described herein are obvious and may be made without departing from the scope of the invention or any embodiment thereof. Having now described the present invention in detail, the same will be more clearly understood by reference to the following examples, which are included herewith for purposes of illustration only and are not intended to be limiting of the invention.

[0252] Use of Tissue Culture for Selection of Herbicide

[0253] Herbicide tolerant crops offer farmers additional options for weed management. Currently, there are genetically modified (GMO) solutions available in some crop systems. Additional, mutational techniques have been used to select for altered enzyme, activities or structures that confer herbicide resistance such as the current CLEARFIELD[®] solutions from BASF. In the US, CLEARFIELD Rice is the premier tool for managing red rice in infested areas (USDA-ARS, 2006); however, gene flow between red rice and CLEARFIELD Rice represents a considerable risk for the AHAS tolerance since out-crossing, has been reported at up to 170 F1 hybrids/ha (Shivrain et al, 2007). Stewardship guidelines including, amongst many other aspects, alternation non CLEARFIELD Rice can limit CLEARFIELD Rice market penetration. The generation of cultivated rice with tolerance to a different mode of action (MOA) graminicides would reduce these risks and provide more tools for weed management.

[0254] One enzyme that is already a target for many different graminaceous herbicides is acetyl CoA carboxylase (ACCase, EC 6.4.1.2), which catalyzes the first committed step in fatty acid (FA) biosynthesis. Aryloxyphenoxypropionate (APP or FOP) and cyclohexanedione (CHD or DIM) type herbicides are used post-emergence in dicot crops, with the exception of cyhalofop-butyl which is selective in rice to control grass weeds. Furthermore, most of these herbicides have relatively low persistence in soil and provide growers with flexibility for weed control and crop rotation. Mutations in this enzyme are known that confer tolerance to specific sets of FOPS and/or DIMS (Liu et al, 2007; Delye et al, 2003, 2005).

- [0255] Tissue culture offers an alternative approach in that single clumps of callus represent hundreds or even thousands of cells, each of which can be selected for a novel trait such as herbicide resistance (Jain, 2001). Mutations arising spontaneously in tissue culture or upon some kind of induction can be directly selected in culture and mutated events selected.
- [0256] The exploitation of somaclonal variation that is inherent to *in vitro* tissue culture techniques has been a successful approach to selectively generate mutations that confer DIM and FOP tolerance in corn (Somers, 1996; Somers et al., 1994; Marshal et al., 1992; Parker et al., 1990) and in seashore paspalum (Heckart et al, 2009). In the case of maize, the efficiencies of producing regenerable events can be calculated. In Somers et al, 1994, sethoxydim resistant maize plants were obtained using tissue culture selection. They utilized 100 g of callus and obtained 2 tolerant lines following stepwise selection at 0.5, 1.0, 2.0, 5.0 and 10 μ M sethoxydim. A calculated mutation rate in their protocol would be 2 lines/100 g of callus or 0.02 lines/g.
- [0257] In the case of seashore paspalum, Heckert directly utilized a high level of sethoxydim and recovered 3 regenerable lines in approx 10,000 callus pieces or, essentially, a 0.03 % rate. While not comparable, these numbers will be later used for comparison with rice tissue culture mutagenesis. In the maize work, calli were constantly culled at each selection stage with only growing callus being transferred; however, in the case of seashore paspalum, all calli were transferred at each subculture. ACCase genes as selectable markers:
- [0258] Plant transformation involves the use of selectable marker genes to identify the few transformed cells or individuals from the larger group of non-transformed cells or individuals. Selectable marker genes exist, but they are limited in number and availability. Alternative marker genes are required for stacking traits. In addition, the use of a selectable marker gene that confers an agronomic trait (i.e. herbicide resistance) is often desirable. The present invention discloses ACCase genes as selectable markers that can be added to the current limited suite of available selectable marker genes. Any of the mutants described herein can be introduced into a plasmid with a gene of interest and transformed into the whole plant, plant tissue or plant cell for use as selectable markers. A detailed method is outlined in example 7 below. The selectable markers of the inventions may be utilized to produce events

that confer field tolerance to a given group of herbicides and other where cross protection has been shown (i.e., FOP's).

[0259] Modern, high throughput plant transformation systems require an effective selectable marker system; however, there is a limited number available that are acceptable in the market. Therefore, selection systems which also convey a commercial trait are always valuable. The system described herein is an effective selection system in/for plant cells which also encode for an herbicide tolerance trait suitable for use in any monocotyledonous crop.

[0260] In one embodiment, the present invention provides a method for selecting a tranformed plant comprising introducing a nucleic acid molecule encoding a gene of interest into a plant cell, wherein the nucleic acid molecule further encodes a mutant acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence differs from an amino acid sequence of an ACCase of a corresponding wild-type rice plant at one amino acid position; and contacting the plant cells with an ACCase inhibitor to obtain the transformed plant, wherein said mutant ACCase confers upon the transformed plant increased herbicide tolerance as compared to the corresponding wild-type variety of the plant when expressed therein.

[0261] In one embodiment, the present invention provides a method of marker-assisted breeding, the method comprising breeding any plant of the invention with a second plant; and contacting progeny of the breeding step with an ACCase inhibitor to obtain the progeny comprising said mutant ACCase; wherein said mutant ACCase confers upon the progeny plant increased herbicide tolerance as compared to the second plant.

[0262] In one embodiment, a single ACCase gene is linked to a single gene of interest. The ACCase gene may be linked upstream or downstream of the gene of interest.

[0263] In one embodiment, the present invention provides for the use of ACCase nucleic acid and protein as described above in diagnostic assays. The diagnostic uses for selectable markers described herein can be employed to identify ACCase gene. Diagnostic methods can include PCR methodologies, proteins assays, labeled probes, and any other standard diagnostic methods known in the art.

EXAMPLES

EXAMPLE 1

[0264] Tissue culture conditions

[0265] An *in vitro* tissue culture mutagenesis assay has been developed to isolate and characterize plant tissue (e.g., rice tissue) that is tolerant to acetyl-Coenzyme A carboxylase inhibiting herbicides, e.g., tepraloxym, cycloxydim, and sethoxydim. The assay utilizes the somaclonal variation that is found in *in vitro* tissue culture. Spontaneous mutations derived from somaclonal variation can be enhanced by chemical mutagenesis and subsequent selection in a stepwise manner, on increasing concentrations of herbicide.

[0266] The present invention provides tissue culture conditions for encouraging growth of friable, embryogenic rice callus that is regenerable. Calli were initiated from 4 different rice cultivars encompassing both Japonica (Taipei 309, Nipponbare, Koshihikari) and Indica (Indica 1) varieties. Dehusked seed were surface sterilized in 70% ethanol for approximately 1 min followed by 20% commercial Clorox bleach for 20 minutes. Seeds were rinsed with sterile water and plated on callus induction media. Various callus induction media were tested. The ingredient lists for the media tested are presented in Table 2.

[0267] Table 2

Ingredient	Supplier	R001M	R025M	R026M	R327M	R008M	MS711R
B5 Vitamins	Sigma					1.0 X	
MS salts	Sigma			1.0 X	1.0 X	1.0 X	1.0 X
MS Vitamins	Sigma			1.0 X	1.0 X		
N6 salts	Phytotech	4.0 g/L	4.0g/L				
N6 vitamins	Phytotech	1.0 X	1.0 X				
L-Proline	Sigma	2.9 g/L	0.5 g/L				1.2 g/L
Casamino Acids	BD	0.3 g/L	0.3 g/L	2 g/L			
Casein Hydrolysate	Sigma						1.0 g/L
L-Asp Monohydrate	Phytotech						150 mg/L
Nicotinic Acid	Sigma						0.5 mg/L
Pyridoxine HCl	Sigma						0.5 mg/L
Thiamine HCl	Sigma						1.0 mg/L
Myo-inositol	Sigma						100 mg/L
MES	Sigma	500 mg/L	500 mg/L	500 mg/L	500 mg/L	500 mg/L	500 mg/L
Maltose	VWR	30 g/L	30 g/L	30 g/L	30 g/L		
Sorbitol	Duchefa			30 g/L			
Sucrose	VWR					10 g/L	30 g/L
NAA	Duchefa					50 µg/L	
2,4-D	Sigma	2.0 mg/L					1.0 mg/L
MgCl ₂ ·6H ₂ O	VWR					750 mg/L	
→pH		5.8	5.8	5.8	5.8	5.8	5.7
Gelrite	Duchefa	4.0 g/L				2.5 g/L	
Agarose Type1	Sigma		7.0 g/L	10 g/L	10 g/L		
→Autoclave		15 min	15 min	15 min	15 min	15 min	20 min
Kinetin	Sigma		2.0 mg/L	2.0 mg/L			
NAA	Duchefa		1.0 mg/L	1.0 mg/L			
ABA	Sigma		5.0 mg/L				
Cefotaxime	Duchefa		0.1 g/L	0.1 g/L	0.1 g/L		
Vancomycin	Duchefa		0.1 g/L	0.1 g/L	0.1 g/L		
G418 Disulfate	Sigma		20 mg/L	20 mg/L	20 mg/L		

[0268] R001M callus induction media was selected after testing numerous variations.

Cultures were kept in the dark at 30°C. Embryogenic callus was subcultured to fresh media after 10-14 days.

EXAMPLE 2

[0269] Selection of herbicide-tolerant calli

[0270] Once tissue culture conditions were determined, further establishment of selection conditions were established through the analysis of tissue survival in kill curves with cycloxydim, tepraloxym, sethoxydim (Figure 1) or haloxyfop (not shown). Careful consideration of accumulation of the herbicide in the tissue, as well as its persistence and

stability in the cells and the culture media was performed. Through these experiments, a sub-lethal dose has been established for the initial selection of mutated material.

[0271] After the establishment of the starting dose of sethoxydim, cycloxydim, tepraloxym, and haloxyfop in selection media, the tissues were selected in a step-wise fashion by increasing the concentration of the ACCase inhibitor with each transfer until cells are recovered that grew vigorously in the presence of toxic doses (see Figure 2). The resulting calli were further subcultured every 3-4 weeks to R001M with selective agent. Over 26,000 calli were subjected to selection for 4-5 subcultures until the selective pressure was above toxic levels as determined by kill curves and observations of continued culture. Toxic levels were determined to be 50 μ M sethoxydim, 20 μ M cycloxydim, 2.5 μ M tepraloxym (Figure 1) and 10 μ M haloxyfop (not shown).

[0272] Alternatively, liquid cultures initiated from calli in MS711R (Table 2) with slow shaking and weekly subcultures. Once liquid cultures were established, selection agent was added directly to the flask at each subculture. Following 2-4 rounds of liquid selection, cultures were transferred to filters on solid R001M media for further growth.

EXAMPLE 3

[0273] Regeneration of plants

[0274] Tolerant tissue was regenerated and characterized molecularly for ACCase gene sequence mutations and/or biochemically for altered ACCase activity in the presence of the selective agent.

[0275] Following herbicide selection, calli were regenerated using a media regime of R025M for 10 – 14 days, R026M for ca. 2 weeks, R327M until well formed shoots were developed, and R008S until shoots were well rooted for transfer to the greenhouse (Table 2). Regeneration was carried out in the light. No selection agent was included during regeneration.

[0276] Once strong roots were established, M0 regenerants were transplant to the greenhouse in 4" square pots in a mixture of sand, NC Sandhills loamy soil, and Redi-earth (2:4:6) supplemented with gypsum. Transplants were maintained under a clear plastic cup until they were adapted to greenhouse conditions (ca. 1 week). The greenhouse was set to a

day/night cycle of 27°C/21°C (80°F/70°F) with 600W high pressure sodium lights supplementing light to maintain a 14 hour day length. Plants were watered 2-3 times a day depending in the weather and fertilized daily. Rice plants selected for seed increase were transplanted into one gallon pots. As plants approached maturity and prepared to bolt, the pots were placed in small flood flats to better maintain water and nutrient delivery. Plants were monitored for insects and plant health and managed under standard Integrated Pest Management practices.

EXAMPLE 4

[0277] Sequence analysis

[0278] Leaf tissue was collected from clonal plants separated for transplanting and analyzed as individuals. Genomic DNA was extracted using a Wizard® 96 Magnetic DNA Plant System kit (Promega, US Patent Nos. 6,027,945 & 6,368,800) as directed by the manufacturer. Isolated DNA was PCR amplified using one forward and one reverse primer.

[0279] Forward Primers:

[0280] OsACCpU5142: 5'-GCAAATGATATTACGTTTCAGAGCTG-3' (SEQ ID NO:7)

[0281] OsACCpU5205: 5'-GTTACCAACCTAGCCTGTGAGAAG-3' (SEQ ID NO: 8)

[0282] Reverse Primers:

[0283] OsACCpL7100: 5'-GATTTCTTCAACAAGTTGAGCTCTTC-3' (SEQ ID NO: 9)

[0284] OsACCpL7054: 5'-AGTAACATGGAAAGACCCTGTGGC-3' (SEQ ID NO: 10)

[0285] PCR amplification was performed using Hotstar Taq DNA Polymerase (Qiagen) using touchdown thermocycling program as follows: 96°C for 15 min, followed by 35 cycles (96°C, 30 sec; 58°C – 0.2 °C per cycle, 30 sec; 72°C, 3 min and 30 sec), 10 min at 72°C.

[0286] PCR products were verified for concentration and fragment size via agarose gel electrophoresis. Dephosphorylated PCR products were analyzed by direct sequence using the PCR primers (DNA Landmarks). Chromatogram trace files (.scf) were analyzed for mutation relative to Os05g0295300 using Vector NTI Advance 10™ (Invitrogen). Based on

sequence information, two mutations were identified in several individuals. I1,781(*Am*)L and D2,078(*Am*)G were present in the heterozygous state. Sequence analysis was performed on the representative chromatograms and corresponding AlignX alignment with default settings and edited to call secondary peaks.

[0287] Samples inconsistent with an ACCase mutation were spray tested for tolerance and discarded as escapes. Surprisingly, most of the recovered lines were heterozygous for the I1,781(*Am*)L mutation and resistant events were generated in all tested genotypes using cycloxydim or sethoxydim: Indica1 (≥ 18 lines), Taipei 309 (≥ 14 lines), Nipponbare (≥ 3 lines), and Koshihikari (≥ 6 lines). One line was heterozygous for a D2,078(*Am*)G mutation. The D2,078(*Am*)G heterozygote line appeared stunted with narrow leaves, while the I1,781(*Am*)L heterozygotes varied in appearance, but most looked normal relative to their parental genotype. Several escapes were recovered and confirmed by sequencing and spray testing; however, sequencing results of the herbicide sensitive region of ACCase revealed that most tolerant mutants were heterozygous for an I1,781(*Am*)L, A to T mutation (See Table 3). One line, OsARWI010, was heterozygous for a D2,078(*Am*)G, A to G mutation. To date, all recovered plants lacking an ACCase mutation have been sensitive to herbicide application in the greenhouse.

[0288] Table 3: Genotype of Rice Lines Recovered via Tissue Culture Selection

Line	Parental Genotype	Rice Type	Mutation Identified	ATCC® Patent Deposit Designation
OsARWI1	Indica 1	<i>indica</i>	I1781(<i>Am</i>)L	PTA-10568
OsARWI3	Indica 1	<i>indica</i>	I1781(<i>Am</i>)L	PTA-10569
OsARWI8	Indica 1	<i>indica</i>	I1781(<i>Am</i>)L	PTA-10570
OsARWI10	Indica 1	<i>indica</i>	D2078(<i>Am</i>)G	NA, sterile
OsARWI15	Indica 1	<i>indica</i>	I1781(<i>Am</i>)L	NA
OsHPHI2	Indica 1	<i>indica</i>	I1781(<i>Am</i>)L	PTA-10267
OsHPHI3	Indica 1	<i>indica</i>	I1781(<i>Am</i>)L	NA
OsHPHI4	Indica 1	<i>indica</i>	I1781(<i>Am</i>)L	NA
OsHPHK1	Koshihikari	<i>japonica</i>	I1781(<i>Am</i>)L	NA
OsHPHK2	Koshihikari	<i>japonica</i>	I1781(<i>Am</i>)L	NA
OsHPHK3	Koshihikari	<i>japonica</i>	I1781(<i>Am</i>)L	NA
OsHPHK4	Koshihikari	<i>japonica</i>	I1781(<i>Am</i>)L	NA
OsHPHK6	Koshihikari	<i>japonica</i>	I1781(<i>Am</i>)L	NA
OsHPHN1	Nipponbare	<i>japonica</i>	I1781(<i>Am</i>)L	PTA-10571
OsHPHT1	Taipei 309	<i>japonica</i>	I1781(<i>Am</i>)L	NA

OsHPHT4	Taipei 309	<i>japonica</i>	I1781(<i>Am</i>)L	NA
OsHPHT6	Taipei 309	<i>japonica</i>	I1781(<i>Am</i>)L	NA

EXAMPLE 5

[0289] Demonstration of herbicide-tolerance

[0290] Selected mutants and escapes were transferred to small pots. Wild-type cultivars and 3 biovars of red rice were germinated from seed to serve as controls.

[0291] After ca. 3 weeks post-transplant, M0 regenerants were sprayed using a track sprayer with 400-1600 g ai/ha cycloxydim (BAS 517H) supplemented with 0.1% methylated seed oil. After the plants had adapted to greenhouse conditions, a subset were sprayed with 800 g ai/ha cycloxydim. Once sprayed, plants were kept on drought conditions for 24 hours before being watered and fertilized again. Sprayed plants were photographed and rated for herbicide injury at 1 (Figure 3) and 2 weeks after treatment (Figure 4). No injury was observed on plants containing the I1,781(*Am*)L heterozygous mutation while control plants and tissue culture escapes (regenerated plants negative for the sequenced mutations) were heavily damaged after treatment (Figures 3 & 4). Figures 5-15 provide nucleic acid and/or amino acid sequences of acetyl-Coenzyme A carboxylase enzymes from various plants. Figure 17 provides a graph showing results for mutant rice versus various ACCase inhibitors.

EXAMPLE 6

[0292] Herbicide selection using tissue Culture

[0293] Media was selected for use and kill curves developed as specified above. For selection, different techniques were utilized. Either a step wise selection was applied, or an immediate lethal level of herbicide was applied. In either case, all of the calli were transferred for each new round of selection. Selection was 4-5 cycles of culture with 3-5 weeks for each cycle. Cali were placed onto nylon membranes to: facilitate transfer (200 micron pore sheets, Biodesign, Saco, Maine). Membranes were cut to fit 100x20 mm Petri dishes and were autoclaved prior to use 25-35 calli (average weight/calli being 22mg) were utilized in every plate. In addition, one set of calli were subjected to selection in liquid culture media with weekly subcultures followed by further selection on semi-solid media.

[0294] Mutant lines were selected using cycloxydim or sethoxydim in 4 different rice genotypes. Efficiencies of obtaining mutants was high either based on a percentage of calli that gave rise to a regenerable, mutant line or the number of lines as determined by the gram of tissue utilized. Overall, the mutation frequency compared to seashore paspalum is 5 fold and compared to maize is 2 fold. In some cases, this difference is much higher (>10 fold) as shown in Table 4 below.

[0295] Table 4

Genotype	# Calli	Selection	Mutants	Rate	Weight (g)	# / gm callus
Indica 1	1865	Cycloxydim	3	0.161%	41.04	0.07
Indica 1	2640	Sethoxydim	3	0.114%	58.08	0.05
Koshi	1800	Cycloxydim	6	0.333%	39.6	0.15
NB	3400	Cycloxydim	1	0.029%	74.8	0.01
NB	725	Sethoxydim	0	0.000%	15.95	0.00
T309	1800	Cycloxydim	8	0.444%	36.9	0.20
T309	1015	Sethoxydim	0	0.000%	22.33	0.00
Total	13245		21	0.159%	291.39	0.07

[0296] If the data is analyzed using the criteria of selection, it is possible to see that cycloxydim selection contributes to a higher rate of mutants isolated than sethoxydim, as shown in Table 5.

[0297] Table 5

Genotype	# Calli	Selection	Mutants	Rate	Weight (g)	# / gm callus
Indica 1	1865	Cycloxydim	3	0.161%	41.03	0.07
Koshi	1800	Cycloxydim	6	0.333%	39.6	0.15
NB	3400	Cycloxydim	1	0.029%	74.8	0.01
T309	1800	Cycloxydim	8	0.444%	39.6	0.20
Total	8865		18	0.203%	195.03	0.09

Indica 1	2640	Sethoxydim	3	0.114%	58.08	0.05
NB	725	Sethoxydim	0	0.000%	15.95	0.00
T309	1015	Sethoxydim	0	0.000%	22.33	0.00
Total	4380		3	0.068%	96.36	0.03

[0298] Using this analysis, the rate for cycloxydim is almost 10 fold higher than either of the previous reports using sethoxydim selection, whereas rates using sethoxydim selection are similar to those previously reported. Further, 68% of the lines were confirmed as mutants when selection was on cycloxydim compared to 21% of the lines when selection was on sethoxydim. Increases seem to come from using cycloxydim instead of sethoxydim as a selection agent. Further, the use of membranes made transfer of callus significantly easier than moving each piece individually during subcultures. Over 20 mutants were obtained. Fertility appears to be high with the exception of one mutant that has a mutation known to cause a fitness penalty (D2,078(*Am*)G).

EXAMPLE 7

[0299] Use of mutant ACCase genes as selectable markers in plant transformation

[0300] Methods:

[0301] Indica1 and Nipponbare rice callus transformation was carried out essentially as described in Hiei and Komari (2008) with the exception of media substitutions as specified (see attached media table for details). Callus was induced on R001M media for 4-8 weeks prior to use in transformation. Agrobacterium utilized was LBA4404(pSB1) (Ishida et al. 1996) transformed with RLM185 (L. Mankin, unpublished: contains DsRed and a mutant AHAS for selection), ACC gene containing I1781(*Am*)L, ACC gene containing I1781(*Am*)L and W2027C, ACC gene containing I1781(*Am*)L and I2041(*Am*)N, or ACC gene containing I1781(*Am*)A or wild type which also contains a mutant AHAS gene for selection. Agrobacterium grown for 1-3 days on solid media was suspended in M-LS-002 medium and the OD₆₆₀ adjusted to approximately 0.1. Callus was immersed in the Agrobacterium solution for approximately 30 minutes. Liquid was removed, and then callus was moved to filter paper for co-culture on semi-solid rice cc media. Co-culture was for 3 days in the dark at 24°C. Filters containing rice callus were directly transferred to R001M media containing Timentin for 1-2 weeks for recovery and cultured in the dark at 30°C. Callus was subdivided onto fresh R001M media with Timentin and supplemented with 100µM Imazethapyr, 10µM Cycloxydim or 2.5µM Tepraloxym. After 3-4 weeks, callus was transferred to fresh selection media. Following another 3-4 weeks, growing callus was transferred to fresh media and allowed to grow prior to Taqman analysis. Taqman analysis was for the Nos terminator

and was conducted to provide for a molecular confirmation of the transgenic nature of the selected calli. Growth of transgenic calli was measured with various selection agents by subculturing calli on media containing either 10 μ M Cycloxydim or Haloxyfop, 2.5 μ M Tepraloxymid or 100 μ M Imazethapyr. Calli size was measured from scanned images following initial subculture and then after approximately 1 month of growth.

[0302] Transformation of maize immature embryos was carried out essentially as described by Lai et al (submitted). Briefly, immature embryos were co-cultured with the same *Agrobacterium* strains utilized for rice transformation suspended in M-LS-002 medium to an OD₆₆₀ of 1.0. Co-culture was on Maize CC medium for 3 days in the dark at 22°C. Embryos were removed from co-culture and transferred to M-MS-101 medium for 4-7 days at 27°C. Responding embryos were transferred to M-LS-202 medium for Imazethapyr selection or M-LS-213 media supplemented with either 1 μ M Cycloxydim or 0.75 μ M Tepraloxymid. Embryos were cultured for 2 weeks and growing callus was transferred to a second round of selection using the same media as previous except that Cycloxydim selection was increased to 5 μ M. Selected calli were transferred to M-LS-504 or M-LS-513 media supplemented with either 5 μ M Cycloxydim or 0.75 μ M of Tepraloxymid for and moved to the light (16hr/8hr day/night) for regeneration. Shoots appeared between 2-3 weeks and were transferred to plantcon boxes containing either M-LS-618 or M-LS-613 supplemented with either 5 μ M Cycloxydim or 0.75 μ M of Tepraloxymid for further shoot development and rooting. Leaf samples were submitted for Taqman analysis. Positive plants were transferred to soil for growth and seed generation. In the second set of experiments, conditions were identical except that Tepraloxymid selection was decreased to 0.5 μ M during regeneration and shoot and root formation. In the third set of experiments, Haloxyfop was also tested as a selection agent. In these experiments, 1 μ M was used throughout for selection

[0303] Results and Discussion:

[0304] Transgenic calli were obtained from Indica1 rice transformation experiments using ACC gene containing I1781(*Am*)L and W2027(*Am*)C, and ACC gene containing I1781(*Am*)L and I2041(*Am*)N. One callus was obtained from ACC gene containing I1781(*Am*)L and W2027(*Am*)C following Tepraloxymid selection and 3 calli were obtained from ACC gene containing I1781(*Am*)L and I2041(*Am*)N. One callus was obtained from

ACC gene containing I1781(*Am*)L and I2041(*Am*)N using Cycloxydim selection. Nos Taqman showed that all of these calli were transgenic. Calli were screened for growth under various selection agents including Imazethapy (Pursuit – P) for the mutant AHAS selectable marker.

[0305] As can be observed in Table 6, the double mutant constructs allowed for growth on both Cycloxydim and Tepraloxym in addition to Haloxyp. The levels utilized in these growth experiments are inhibitory for wild type material.

[0306] Table 6: Growth of transgenic Indica1 callus on various selection media. Growth was measured as a % change in size following 1 month of culture on the selection media.

Selection μ M				
Construct	H10	C10	T2.5	P100
I1781(<i>Am</i>)L, W2027(<i>Am</i>)C	1669%	867%	1416%	739%
I1781(<i>Am</i>)L, I2041(<i>Am</i>)N	1613%	884%	1360%	634%

[0307] Results from the first set of maize experiments reveal that both the single of the double mutant can be used to select for Cycloxydim resistance or both Cycloxydim or Tepraloxym resistance at a relatively high efficiency (Figure 16).

[0308] Efficiencies between selection agents was relatively comparable in these experiments with maybe a slight decrease in the overall efficiency with the single mutant on Cycloxydim compared to Pursuit selection. However, the double mutant may have a slight increased efficiency. The escape rate – the percentage of non-confirmed putative events – was lower for Cycloxydim or Tepraloxym. Further, under the conditions described, it was possible to differentiate between the single and double mutants using Tepraloxym selection.

[0309] Similar results have been obtained in the second set of experiments (not shown). In the third set of experiments, Haloxyp is also an efficient selectable marker for use in transformation with either the single or the double mutant (not shown).

[0310] The single mutant is useful for high efficiency transformation using Cycloxydim or Haloxyp selection. It should also be useful for other related compounds such as

Sethoxydim. The double mutant is useful for these selection agents with the addition that Tepraloxym can be used. The single and the double mutant can be used in a two stage transformation in that the single mutant can be differentiated from the double with Tepraloxym selection. In combination with other current BASF selection markers, these give two more options for high efficiency transformations of monocots and maize in particular.

[0311] Herbicide tolerance phenotypes as described herein have also been exhibited by ACCase-inhibitor tolerant rice plants hereof, in the field under 600 g/ha cycloxydim treatment (data not shown).

[0312] While the foregoing invention has been described in some detail for purposes of clarity and understanding, it will be appreciated by one skilled in the art from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention and appended claims. All patents and publications cited herein are entirely incorporated herein by reference.

What is claimed is:

1. A rice plant that expresses a mutagenized or recombinant acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence differs from an amino acid sequence of an acetyl-Coenzyme A carboxylase of a corresponding wild-type rice plant at amino acid position 1,781(*Am*), wherein said ACCase confers upon the plant increased herbicide tolerance as compared to the corresponding wild-type variety of the plant when expressed therein.

2. The plant of claim 1, wherein the amino acid at position at 1,781(*Am*) is leucine.

3. The plant of claim 1, wherein the amino acid position at 1,781(*Am*) is alanine.

4. The plant of claim 1, wherein the amino acid at position at 1,781(*Am*) is valine.

5. The plant of claim 1, wherein the amino acid at position at 1,781(*Am*) is threonine.

6. A rice plant that expresses a mutagenized or recombinant acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence differs from an amino acid sequence of an acetyl-Coenzyme A carboxylase of a corresponding wild-type rice plant at amino acid position 1,999(*Am*), wherein said ACCase confers upon the plant increased herbicide tolerance as compared to a wild-type variety of the plant when expressed therein.

7. The plant of claim 6, wherein the amino acid at position at 1,999(*Am*) is glycine.

8. The plant of claim 6, wherein the amino acid at position at 1,999(*Am*) is cysteine.

9. A rice plant that expresses a mutagenized or recombinant acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence differs from an amino acid sequence of an acetyl-Coenzyme A carboxylase of a corresponding wild-type rice plant at amino acid position 2,027(*Am*), wherein said ACCase confers upon the plant increased herbicide tolerance as compared to a wild-type variety of the plant when expressed therein.

10. The plant of claim 9, wherein the amino acid at position at 2,027(*Am*) is cysteine.

11. The plant of claim 9, wherein the amino acid at position at 2,027(*Am*) is arginine.

12. A rice plant that expresses a mutagenized or recombinant acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence differs from an amino acid sequence of an acetyl-Coenzyme A carboxylase of a corresponding wild-type rice plant at amino acid

position 2,041(*Am*), wherein said ACCase confers upon the plant increased herbicide tolerance as compared to a wild-type variety of the plant when expressed therein.

13. The plant of claim 12, wherein the amino acid at position at 2,041(*Am*) is asparagine.

14. The plant of claim 12, wherein the amino acid at position 2,041(*Am*) is valine.

15. A rice plant that expresses a mutagenized or recombinant acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence differs from an amino acid sequence of an acetyl-Coenzyme A carboxylase of a corresponding wild-type rice plant at amino acid position 2,096(*Am*), wherein said ACCase confers upon the plant increased herbicide tolerance as compared to a wild-type variety of the plant when expressed therein.

16. The plant of claim 15, wherein the amino acid at position at 2,096(*Am*) is alanine.

17. The plant of claim 15, wherein the amino acid at position at 2,096(*Am*) is serine.

18. A rice plant that expresses a mutagenized or recombinant acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence differs from an amino acid sequence of an acetyl-Coenzyme A carboxylase of a corresponding wild-type rice plant at only one of the following positions: 1,785(*Am*); 1,786(*Am*); 1,811(*Am*); 2,049(*Am*); 2,074(*Am*); 2,075(*Am*), 2,078(*Am*); deletion at 2,080(*Am*); 2,088(*Am*); and 2,098(*Am*), wherein said ACCase confers upon the plant increased herbicide tolerance as compared to a wild-type variety of the plant when expressed therein.

19. The plant of claim 18, wherein the plant expresses a mutagenized or recombinant acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence comprises only one substitution selected from the group consisting of isoleucine, leucine, or phenylalanine at 2,049(*Am*); leucine at position 2,074(*Am*); leucine, isoleucine, or methionine at position 2,075(*Am*), or duplication of position 2,075(*Am*); threonine, glycine or lysine at position 2,078(*Am*); arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at 2,088(*Am*); and alanine, histidine, proline, serine, or glycine at 2,098(*Am*).

20. The plant of claim 18, wherein the plant expresses a mutagenized or recombinant acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence comprises only

one substitution selected from the group consisting of glycine at position 1,785(*Am*); proline at position 1,786(*Am*); and asparagine at position 1,811(*Am*).

21. A rice plant that expresses a mutagenized or recombinant acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence differs from an amino acid sequence of an acetyl-Coenzyme A carboxylase of a corresponding wild-type rice plant at only one of the following positions: 2,039(*Am*); 2,059(*Am*); 2,080(*Am*); and 2,095(*Am*), wherein said ACCase confers upon the plant increased herbicide tolerance as compared to the corresponding wild-type variety of the plant when expressed therein.

22. The plant of claim 21, wherein the plant expresses a mutagenized or recombinant acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence comprises only one substitution selected from the group consisting of glycine at position 2,039(*Am*); valine at position 2,059(*Am*); glutamic acid at position 2,080(*Am*); and glutamic acid at position 2,095(*Am*).

23. A rice plant expressing a mutagenized or recombinant plastidic acetyl-Coenzyme A carboxylase (ACCase), wherein a mutation at only one amino acid position in the plastidic ACCase confers upon the plant increased herbicide tolerance as compared to a corresponding wild-type variety of the rice plant when expressed therein.

24. The plant of claim 23, wherein the amino acid position is selected from the group consisting of 1,785(*Am*), 1,786(*Am*), 1,811(*Am*), 1,824(*Am*), 1,864(*Am*), 2,039(*Am*), 2,049(*Am*), 2,059(*Am*), 2,074(*Am*), 2,075(*Am*), 2,078(*Am*), 2,079(*Am*), 2,080(*Am*), 2,081(*Am*), 2,088(*Am*), 2,095(*Am*), and 2,098(*Am*).

25. The plant of claim 23, wherein the mutant ACCase is not transgenic.

26. The plant of any one of claims 1 to 22, wherein said plants are not transgenic

27. A plant according to any one claims 1 to 25, wherein said ACCase is encoded by a genomic nucleic acid, and comprises as its amino acid sequence a modified SEQ ID NO:2, wherein the modified sequences comprise said modification.

28. A method for controlling growth of weeds within the vicinity of a plant of any one of claims 1 to 25, comprising applying to the weeds and plants an amount of an acetyl-Coenzyme A carboxylase-inhibiting herbicide that inhibits growth of a wild type plant.

29. The method according to claim 28, wherein at least one herbicide is selected from the group consisting of alloxymid, butoxydim, clethodim, cloproxydim, cycloxydim, sethoxydim, tepraloxymid, tralkoxydim, chlorazifop, clodinafop, clofop, diclofop, fenoxaprop, fenoxaprop-P, fenthiaprop, fluazifop, fluazifop-P, haloxyfop, haloxyfop-P, isoxapyrifop, propaquizafop, quizalofop, quizalofop-P, trifop, and pinoxaden or agronomically acceptable salts or esters of any of these herbicides at levels of herbicide that would normally inhibit the growth of a wild type plant.

30. A method for controlling growth of weeds, comprising:

- a. crossing a plant of any one of claims 1 to 25 with other plant germplasm, and harvesting the resulting hybrid seed;
- b. planting the hybrid seed; and
- c. applying one or more acetyl-Coenzyme A carboxylase-inhibiting herbicides to the hybrid plant and to the weeds in vicinity to the hybrid plant at levels of herbicide that would normally inhibit the growth of a wild type plant.

31. A plant cell of the plant of any one of claims 1 to 25.

32. A plant part of the plant of any one of claims 1 to 25.

33. A seed produced by the plant of any one of claims 1 to 25.

34. A method of producing a hybrid plant, comprising breeding the plant of any one claims 1 to 25 with a second plant, wherein the hybrid plant exhibits increased herbicide tolerance as compared to the second plant.

35. A food product prepared from the plant of any one of claims 1 to 25.

36. A consumer product prepared from the plant of any one of claims 1 to 25.

37. An industrial product prepared from the plant of any one of claims 1 to 25.

38. A veterinary product prepared from the plant of any one of claims 1 to 25.

39. As isolated, recombinant, or mutagenized nucleic acid molecule encoding the ACCase as described in any one claims 1 to 25.

40. Use of nucleic acid molecule according to claim 39 as a selectable marker.

41. A method of treating the plant of any one of claims 1 to 25, comprising contacting said plant with an agronomically acceptable composition.

42. A BEP clade plant that expresses a mutagenized or recombinant acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence differs from an amino acid sequence of an acetyl-Coenzyme A carboxylase of a corresponding wild-type BEP clade plant at amino acid position 1,781(*Am*), wherein said ACCase confers upon the plant increased herbicide tolerance as compared to the corresponding wild-type variety of the plant when expressed therein.

43. The plant of claim 42, wherein the amino acid at position at 1,781(*Am*) is leucine.

44. The plant of claim 42, wherein the amino acid position at 1,781(*Am*) is alanine.

45. The plant of claim 42, wherein the amino acid at position at 1,781(*Am*) is valine.

46. The plant of claim 42, wherein the amino acid at position at 1,781(*Am*) is threonine.

47. A BEP clade plant that expresses a mutagenized or recombinant acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence differs from an amino acid sequence of an acetyl-Coenzyme A carboxylase of a corresponding wild-type BEP clade plant at amino acid position 1,999(*Am*), wherein said ACCase confers upon the plant increased herbicide tolerance as compared to a wild-type variety of the plant when expressed therein.

48. The plant of claim 47, wherein the amino acid at position at 1,999(*Am*) is glycine.

49. The plant of claim 47, wherein the amino acid at position at 1,999(*Am*) is cysteine.

50. A BEP clade plant that expresses a mutagenized or recombinant acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence differs from an amino acid sequence of an acetyl-Coenzyme A carboxylase of a corresponding wild-type BEP clade plant at amino acid position 2,027(*Am*), wherein said ACCase confers upon the plant increased herbicide tolerance as compared to a wild-type variety of the plant when expressed therein.

51. The plant of claim 50, wherein the amino acid at position at 2,027(*Am*) is cysteine.

52. The plant of claim 50, wherein the amino acid at position at 2,027(*Am*) is arginine.

53. A BEP clade plant that expresses a mutagenized or recombinant acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence differs from an amino acid sequence of an acetyl-Coenzyme A carboxylase of a corresponding wild-type BEP clade plant at amino acid position 2,041(*Am*), wherein said ACCase confers upon the plant increased herbicide tolerance as compared to a wild-type variety of the plant when expressed therein.

54. The plant of claim 53, wherein the amino acid at position at 2,041(*Am*) is asparagine.

55. The plant of claim 53, wherein the amino acid at position 2,041(*Am*) is valine.

56. A BEP clade plant that expresses a mutagenized or recombinant acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence differs from an amino acid sequence of an acetyl-Coenzyme A carboxylase of a corresponding wild-type BEP clade plant at amino acid position 2,096(*Am*), wherein said ACCase confers upon the plant increased herbicide tolerance as compared to a wild-type variety of the plant when expressed therein.

57. The plant of claim 56, wherein the amino acid at position at 2,096(*Am*) is alanine.

58. The plant of claim 56, wherein the amino acid at position at 2,096(*Am*) is serine.

59. A BEP clade plant that expresses a mutagenized or recombinant acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence differs from an amino acid sequence of an acetyl-Coenzyme A carboxylase of a corresponding wild-type BEP clade plant at only one of the following positions: 1,785(*Am*); 1,786(*Am*); 1,811(*Am*); 2049(*Am*); 2,074(*Am*); 2,075(*Am*), 2,078(*Am*); 2,080(*Am*); 2,088(*Am*); and 2,098(*Am*), wherein said ACCase confers upon the plant increased herbicide tolerance as compared to a wild-type variety of the plant when expressed therein.

60. The plant of claim 59, wherein the plant expresses a mutagenized or recombinant acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence comprises only one substitution selected from the group consisting of isoleucine, leucine, or phenylalanine at 2,049(*Am*); leucine at position 2,074(*Am*); leucine, isoleucine, or methionine at position 2,075(*Am*), or duplication of position 2,075(*Am*); threonine, glycine or lysine at position

2,078(*Am*); arginine, tryptophan, phenylalanine, glycine, histidine, lysine, leucine, serine, threonine, or valine at 2,088(*Am*); and alanine, histidine, proline, serine, or glycine at 2,098(*Am*).

61. The plant of claim 59, wherein the plant expresses a mutagenized or recombinant acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence comprises only one substitution selected from the group consisting of glycine at position 1,785(*Am*); proline at position 1,786(*Am*); and asparagine at position 1,811(*Am*).

62. A BEP clade plant that expresses a mutagenized or recombinant acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence differs from an amino acid sequence of an acetyl-Coenzyme A carboxylase of a corresponding wild-type rice BEP clade at only one of the following positions: 2,039(*Am*); 2,059(*Am*); 2,080(*Am*); and 2,095(*Am*).

63. The plant of claim 62, wherein the plant expresses a mutagenized or recombinant acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence comprises only one substitution selected from the group consisting of glycine at position 2,039(*Am*); valine at position 2,059(*Am*); glutamic acid at position 2,080(*Am*); and glutamic acid at position 2,095(*Am*).

64. The plant of any one of claims 42 to 63, wherein said plants are not transgenic.

65. The plant of any one of claims 42 to 63, wherein the BEP clade plant is a BET subclade plant.

66. The plant of claim 65, wherein the BET subclade plant is a BET crop plant.

67. A method for controlling growth of weeds within the vicinity of a plant of any one of claims 42 to 63, comprising applying to the weeds and monocot plants an amount of an acetyl-Coenzyme A carboxylase-inhibiting herbicide that inhibits growth of a wild type plant.

68. The method according to claim 67, wherein at least one herbicide is selected from the group consisting of alloxymid, butoxydim, clethodim, cloproxydim, cycloxydim, sethoxydim, tepraloxymid, tralkoxydim, chlorazifop, clodinafop, clofop, diclofop, fenoxaprop, fenoxaprop-P, fenthiaprop, fluazifop, fluazifop-P, haloxyfop, haloxyfop-P, isoxapyrifop, propaquizafop, quizalofop, quizalofop-P, trifop, and pinoxaden or agronomically acceptable salts or esters of any of these herbicides at levels of herbicide that would normally inhibit the growth of a wild type plant.

69. A method for controlling growth of weeds, comprising:
 - a. crossing a plant of any one of claims 42 to 63 with other plant germplasm, and harvesting the resulting hybrid seed;
 - b. planting the hybrid seed; and
 - c. applying one or more acetyl-Coenzyme A carboxylase-inhibiting herbicides to the hybrid plant and to the weeds in vicinity to the hybrid plant at levels of herbicide that would normally inhibit the growth of a wild type plant.
70. A plant cell of the plant of any one of claims 42 to 63.
71. A plant part of the plant of any one of claim 42 to 63.
72. A seed produced by the rice plant of any one of claims 42 to 63.
73. A method of producing a hybrid plant, comprising breeding the plant of any one claims 42 to 63 with a second plant, wherein the hybrid plant exhibits increased herbicide tolerance as compared to the second plant.
74. A food product prepared from the plant of any one of claims 42 to 63.
75. A consumer product prepared from the plant of any one of claims 42 to 63.
76. An industrial product prepared from the plant of any one of claims 42 to 63.
77. A veterinary product prepared from the plant of any one of claims 42 to 63.
78. As isolated, recombinant, or mutagenized nucleic acid molecule encoding the ACCase as described in any one claims 42 to 63.
79. Use of nucleic acid molecule according to claim 78 as a selectable marker.
80. A method of treating the plant of any one of claims 42 to 63, comprising contacting said plant with an agronomically acceptable composition.
81. A monocot plant that expresses a mutagenized or recombinant acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence differs from an amino acid sequence of an acetyl-Coenzyme A carboxylase of a corresponding wild-type monocot plant at only one amino acid position selected from the group consisting of:

- a. amino acid at position 1,781(*Am*), wherein the amino acid at position 1,781(*Am*) is not leucine, and not a wild type amino acid;
- b. amino acid at position 1,999(*Am*), wherein the amino acid at position 1,999(*Am*) is not cysteine, and not a wild type amino acid;
- c. amino acid at position 2,027(*Am*), wherein the amino acid at position 2,027(*Am*) is not cysteine, and not a wild type amino acid;
- d. amino acid at position 2,041(*Am*), wherein the amino acid at position 2,041(*Am*) is not valine or asparagine, and not a wild type amino acid; and
- e. amino acid at position 2,096(*Am*), wherein the amino acid at position 2,096(*Am*) is not alanine, and not a wild type amino acid;

wherein said ACCase confers upon the plant increased herbicide tolerance as compared to a wild-type variety of the plant when expressed therein.

82. The plant of claim 81, wherein:

the difference at 1,781(*Am*) is a substitution with alanine, valine, threonine; the difference at 1,999(*Am*) is a substitution with glycine; the difference at 2,027(*Am*) is arginine; and the difference at 2,096(*Am*) is a substitution with serine.

83. A monocot plant that expresses a mutagenized or recombinant acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence differs from an amino acid sequence of an acetyl-Coenzyme A carboxylase of a corresponding wild-type monocot plant at only one amino acid position:

- a. selected from the group consisting of 1,785(*Am*); 1,786(*Am*); 1,811(*Am*); 2049(*Am*); 2,074(*Am*); 2,075(*Am*), 2,078(*Am*); 2,081(*Am*); 2,088(*Am*); and 2,098(*Am*); or
- b. selected from the group consisting of 2,039(*Am*); 2,059(*Am*); 2,080(*Am*); and 2,095(*Am*).

84. The plant of claim 83, wherein:

- a. the difference at position 1,785(*Am*) is a substitution with glycine; the difference at position 1,786(*Am*) is a substitution with proline; the difference at position

1,811(*Am*) is a substitution with asparagine, the difference at position 2049(*Am*) is a substitution with phenylalanine, isoleucine, or leucine; wherein the difference at position 2,074(*Am*) is a substitution with leucine; wherein the difference at position 2,075(*Am*) is methionine, leucine, isoleucine, or a duplication of 2,075(*Am*); wherein the difference at position 2,078(*Am*) is lysine, glycine, or threonine; wherein the substitution at position 2,098(*Am*) is alanine, glycine, proline, histidine, serine or cysteine; or

- b. the difference at position 2,039(*Am*) is a substitution with glycine; the difference at position 2,059(*Am*) is a substitution with valine; the difference at position 2,080(*Am*) is a substitution with glutamic acid, or a deletion of 2,080(*Am*); and the difference at position 2,095(*Am*) is a substitution with glutamic acid.

85. A method for controlling growth of weeds within the vicinity of a plant of any one of claims 81 to 84, comprising applying to the weeds and monocot plants an amount of an acetyl-Coenzyme A carboxylase-inhibiting herbicide that inhibits growth of a wild type plant.

86. The method according to claim 85, wherein at least one herbicide is selected from the group consisting of alloxymid, butoxydim, clethodim, cloproxydim, cycloxydim, sethoxydim, tepraloxymid, tralkoxydim, chlorazifop, clodinafop, clofop, diclofop, fenoxaprop, fenoxaprop-P, fenthiaprop, fluazifop, fluazifop-P, haloxyfop, haloxyfop-P, isoxapyrifop, propaquizafop, quizalofop, quizalofop-P, trifop, and pinoxaden or agronomically acceptable salts or esters of any of these herbicides at levels of herbicide that would normally inhibit the growth of a wild type plant.

87. A method for controlling growth of weeds, comprising:

- a. crossing a plant of any one of claims 81 to 84 with other plant germplasm, and harvesting the resulting hybrid seed;
- b. planting the hybrid seed; and
- c. applying one or more acetyl-Coenzyme A carboxylase-inhibiting herbicides to the hybrid plant and to the weeds in vicinity to the hybrid plant at levels of herbicide that would normally inhibit the growth of a wild type plant.

88. A plant cell of the plant of any one of claims 81 to 84.

89. A plant part of the plant of any one of claims 81 to 84.
90. A seed produced by the plant of any one of claims 81 to 84.
91. A method of producing a hybrid plant, comprising breeding the plant of any one claims 81 to 84 with a second plant, wherein the hybrid plant exhibits increased herbicide tolerance as compared to the second plant.
92. A food product prepared from the plant of any one of claims 81 to 84.
93. A consumer product prepared from the plant of any one of claim 81 to 84.
94. An industrial product prepared from the plant of any one of claim 81 to 84.
95. A veterinary product prepared from the plant of any one of claim 81 to 84.
96. As isolated, recombinant, or mutagenized nucleic acid molecule encoding the ACCase as described in any one of claims 81 to 84.
97. Use of the nucleic acid according to claim 96 as a selectable marker.
98. A method of treating the rice plant of any one of claims 81 to 84, contacting said plant with an agronomically acceptable composition.
99. A method for selecting a transformed plant cell, the method comprising:
 - a. introducing a nucleic acid molecule encoding a gene of interest into a plant cell, wherein the nucleic acid molecule further encodes a mutant acetyl-Coenzyme A carboxylase (ACCase) in which the amino acid sequence differs from an amino acid sequence of an ACCase of a corresponding wild-type plant at one amino acid position; and
 - b. contacting the plant cell with an ACCase inhibitor to identify the transformed plant cell, wherein said mutant ACCase exhibits increased herbicide tolerance to said ACCase inhibitor as compared to the corresponding wild-type ACCase.
100. A method of breeding, the method comprising:
 - a. breeding a plant comprising the cell of claim 99 with a second plant to obtain a progeny plant; and
 - b. determining whether said progeny plant expresses said mutant ACCase;

wherein said mutant ACCase confers upon the progeny plant increased herbicide tolerance as compared to the second plant.

101. The method of any one of claims 99 and 100, wherein the mutant ACCase comprises a substitution at only one amino acid position selected from the group consisting of: 1,781(*Am*), 1,785(*Am*), 1,786(*Am*), 1,811(*Am*), 1,824(*Am*), 1,864(*Am*), 1,999(*Am*), 2,027(*Am*), 2,039(*Am*), 2,041(*Am*), 2,049(*Am*), 2,059(*Am*), 2,074(*Am*), 2,075(*Am*), 2,078(*Am*), 2,079(*Am*), 2,080(*Am*), 2,081(*Am*), 2,088(*Am*), 2,095(*Am*), 2,096(*Am*), and 2,098(*Am*).

102. A rice plant wherein:

- a. growth of said plant is tolerant to acetyl-Coenzyme A carboxylase-inhibiting herbicides at levels of herbicide that would normally inhibit the growth of a rice plant;
- b. said plant is a plant of any one of lines OsHPHI2, OsARWI1, OsARWI3, OsARWI8, or OsHPHN1, a representative sample of seed of each line having been deposited with American Type Culture Collection (ATCC) under Patent Deposit Designation Number PTA-10267, PTA-10568, PTA-10569, PTA-10570, or PTA-10571, respectively; or is a mutant, recombinant, or genetically engineered derivative of a plant of any one of lines OsHPHI2, OsARWI1, OsARWI3, OsARWI8, or OsHPHN1, a representative sample of seed of each line having been deposited with American Type Culture Collection (ATCC) under Patent Deposit Designation Number PTA-10267, PTA-10568, PTA-10569, PTA-10570, or PTA-10571, respectively; or is a plant which is the progeny of any of these plants; and
- c. said plant has the herbicide tolerance characteristics of a plant of any one of lines OsHPHI2, OsARWI1, OsARWI3, OsARWI8, or OsHPHN1, a representative sample of seed of each line having been deposited with American Type Culture Collection (ATCC) under Patent Deposit Designation Number PTA-10267, PTA-10568, PTA-10569, PTA-10570, or PTA-10571, respectively.

FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5

1 MGSTHLPVIG FNASTTPSLS TLRQINSAAA AFQSSSPSRs SKKKSRRVKS IRDDGDGSVP
61 DPAGHGQSIR QGLAGIIDLP KEGASAPDND ISHGSEDHKA SYQMNGILNE SHNGRHSLS
121 KVEYFCTELG GKTPHISVLV ANNGMAAAKF MRSVRTWAND TFGSEKAIQL IAMATPEDMR
181 INAEHIRIAD QFVEVPGGTN NNNYANVQLI VEIAERTGVS AVWPGWGHAS ENPELPDALT
241 AKGIVFLCPP ASSMNALGDK VGSALIAQAA GVPTLAWSGS HVEIPLELCL DSIPEEMYRK
301 ACVTTADEAV ASCQMIGYPA MIKASWGGGG KGIRKVNND D EVKALFKQVQ GEVPGSPIFI
361 MRLASQSRHL EVQLLCDEYG NVAALHSRDC SVQRRHQKII EEGPVTVAPR ETVKELEQAA
421 RRLAKAVGYV GAATVEYLYS METGEYYFLE LNPRLQVEHP VTESIAEVNL PAAQVAVGMG
481 IPLWQIPEIR RFYGMNDGGG YDIWRKTAAL ATPFNDFEVD SQWPKGHCVV VRITSENPD
541 GFKPTGGKVK EISFKSKPNV WGYFSVKS GG GIHEFADSQF GHVFAYGETR SAAITSM SLA
601 LKEIQIRGEI HTNVDYTVDL LNPDFRENT IHTGWLDTRI AMRVQAE RPP WYISVVG GAL
661 YKTITNAET VSEYVSYLIK QQIPPKHISL VHSTISLNIE ESKYTIEIVR SGQGSYRLRL
721 NGSLIEANVQ TLCDGGLLMQ LDGNSHVIYA EEEAGGTRLL IDGKTCLLQN DHDP SRL LAE
781 TPCKLLRFLI ADGAHV DADV PYAEVEVMKM CMLLSPAAG VINVLLSEGG AMQAGDLIAR
841 LDLD DDP SAVK RAEPFEGSFP EMSLP IAAAG QVHKRCAASL NAARMVL AGY DHAANKV VQD
901 LVWCLDTPAL PFLQWHEELMS VLATRLPRRL KSELEGKYNE YKLNVDHVKI KDFPT EMLRE
961 TIEENLACVS EKEMVTIERL VDLMSLLKS YEGGRESHAH FIVKSLFEEY LSVEELFSDG
1021 IQSDVIERLR LQYSKDLQKV VDIVLSHQGV RNKTKLILAL MEKLVYPNPA AYR DQLIRFS
1081 SLNHKRY YKL ALKASELLEQ TKLSELRTSI ARNLSALDMF TEEKADFSLO DRKLAINESM
1141 GDLVTAPLPV EDALVSLFDC TDQTLQQRVI QTYISRLYQP QLVKDSIQLK YQDSGVIALW
1201 EFTEGNHEKR LGAMVILKSL ESVSTAIGAA LKDASHYASS AGNTVHIALL DADTQLNTE
1261 DSGDNDQAQD KMDKLSFVLK QDVVMADLRA ADVKVVSCIV QRDGAIMP MR RTFLLSEEKL
1321 CYEEEPILRH VEPPLSALLE LDKLKVKGYN EMKYTPSRDR QWHIYTLRNT ENPKMLHRVF
1381 FRTLVRQPSA GNRFTSDHIT DVEVGHAEEP LSFTSSSILK SLKIAKEELE LHAIR TGHSH
1441 MYLCILKEQK LLDLVPVSGN TVVDVGQDEA TACSLLKEMA LKIH ELVGAR MHL SVCQWE
1501 VKLKLVS DGP ASGSRVVT T NVTGHTCTVD IYREVEDTES QKL VYHSTAL SSGPLHGVAL
1561 NTSYQPLSVI DLKRC SARNN KTTYCYDFPL TFEAAVQKSW SNISSENNQC YVKATELVFA
1621 EKNGSWGTP I IPMQRAAGLN DIGMVAWILD MSTPEFP SGR QIIIVANDIT FRAGSFGPRE
1681 DAFFEAVTNL ACEKKLPIY LAANS GARIG IADEVKSCFR VGWTD DSSPE RGFRIYMTD
1741 EDHDRIGSSV IAHKMQLDSG EIRWVIDSVV GKEDGLGVEN IHGSAAIASA YSRAYEETFT
1801 LTFVTGRTVG IGAYLARLGI RCIQRIDQPI ILTGFSALNK LLGREVYSSH MQLGGPKIMA
1861 TNGVVHLTVP DDLEGVSNIL RWLSYVPANI GGPLPITKSL DPIDRPVAYI PENTCDPRAA
1921 ISGIDDSQ GK WLGGMFDKDS FVETFE GWAK TVVTGRALG GIPVGVI AVE TQTMMLVPA
1981 DPGQPD SHER SVPRAGQWVF PDSATKTAQA MLDFNREGLF LFILANWRGF SGGQRDLFEG
2041 ILQAGSTIVE NLRTYNQPAF VYIPKAE LR GGAWVVIDSK INPDRIECYA ERTAKGNVLE
2101 PQGLIEIKFR SEELKECMGR LDP ELIDLKA RLQ GANGSLS DGESLQKSIE ARKKQLLPLY
2161 TQIAVRFAEL HDTSLRMAAK GVIRKVV DWE DSR SFFYKRL RRR LSEDVLA KEIRGVIGEK
2221 FPHKSAIELI KKWYLASEAA AAGSTDWDDD DAFVAWRENP ENYKEYIKEL RAQRVSRLLS
2281 DVAGSSSDLQ ALPQGLSMLL DKMDPSKRAQ FIEEVMKVLK

FIGURE 6

```

1  ATGGGATCCA CACATCTGCC CATTGTCGGG TTTAATGCAT CCACAACACC ATCGCTATCC
61  ACTCTTCGCC AGATAAACTC AGCTGCTGCT GCATTCCAAT CTTCGTCCCC TTCAAGGTCA
121  TCCAAGAAGA AAAGCCGACG TGTTAAGTCA ATAAGGGATG ATGGCGATGG AAGCGTGCCA
181  GACCCCTGCAG GCCATGGCCA GTCTATTTCG CAAGGTCTCG CTGGCATCAT CGACCTCCCA
241  AAGGAGGGCG CATCAGCTCC AGATGTGGAC ATTTACATG GGTCTGAAGA CCACAAGGCC
301  TCCTACCAA TGAATGGGAT ACTGAATGAA TCACATAACG GGAGGCACGC CTCTCTGTCT
361  AAAGTTTATG AATTTTGCAC GGAATTGGGT GGAAAAACAC CAATTACAG TGTATTAGTC
421  GCCAACAAATG GAATGGCAGC AGCTAAGTTC ATGCGGAGTG TCCGGACATG GGCTAATGAT
481  ACATTTGGGT CAGAGAAGGC GATTCAAGTTG ATAGCTATGG CAACTCCGGA AGACATGAGA
541  ATAAATGCAG AGCACATTAG AATTGCTGAT CAGTTTGTG AAGTACCTGG TGGAAACAAAC
601  AATAACAAC ATGCAAATGT CCAACTCATA GTGGAGATAG CAGAGAGAAC TGGTGTCTCC
661  GCCGTTTGGC CTGGTTGGGG CCATGCATCT GAGAATCCTG AACTTCCAGA TGCACTAACT
721  GCAAAAGGAA TTGTTTTTCT TGGGCCACCA GCATCATCAA TGAACGCACT AGGCGACAAG
781  GTTGGTTCAG CTCTCATTGC TCAAGCAGCA GGGGTTCCCA CTCTTGCTTG GAGTGGATCA
841  CATGTGGAAA TTCCATTAGA ACTTTGTTTG GACTCGATAC CTGAGGAGAT GTATAGGAAA
901  GCCTGTGTTA CAACCGCTGA TGAAGCAGTT GCAAGTTGTC AGATGATTGG TTACCCTGCC
961  ATGATCAAGG CATCCTGGGG TGGTGGTGGT AAAGGGATTA GAAAGGTTAA TAATGATGAC
1021  GAGGTGAAAG CACTGTTTAA GCAAGTACAG GGTGAAGTTC CTGGCTCCCC GATATTTATC
1081  ATGAGACTTG CATCTCAGAG TCGTCATCTT GAAGTCCAGC TGCTTTGTGA TGAATATGGC
1141  AATGTAGCAG CACTTCACAG TCGTGATTGC AGTGTGCAAC GACGACACCA AAAGATTATC
1201  GAGGAAGGAC CAGTTACTGT TGCTCCTCGT GAAACAGTGA AAGAGCTAGA GCAAGCAGCA
1261  AGGAGGCTTG CTAAGGCCGT GGGTTACGTC GGTGCTGCTA CTGTTGAATA TCTCTACAGC
1321  ATGGAGACTG GTGAATACTA TTTTCTGGAG CTTAATCCAC GGTTGCAGGT TGAGCACCCA
1381  GTCACCGAGT CGATAGCTGA AGTAAATTTG CCTGCAGCCC AAGTTGCAGT TGGGATGGGT
1441  ATACCCCTTT GGCAGATTCC AGAGATCAGA CGTTTCTACG GAATGGACAA TGGAGGAGGC
1501  TATGATATTT GGAGGAAAAC AGCAGCTCTC GCTACTCCAT TCAACTTTGA TGAAGTAGAT
1561  TCTCAATGGC CGAAGGGTCA TTGTGTGGCA GTTAGGATAA CCAGTGAGAA TCCAGATGAT
1621  GGATTCAAGC CTACTGTTGG AAAAGTAAAG GAGATAAGTT TAAAAAGTAA GCCAAATGTC
1681  TGGGATATTT TCTCAGTTAA GTCTGGTGGA GGCATTCTAG AATTTGCGGA TTCTCAGTTT
1741  GGACACGTTT TTGCCATATG AGAGACTAGA TCAGCAGCAA TAACCAGCAT GTCTCTTGCA
1801  CTAAAAGAGA TTCAAATTCG TGGAGAAATT CATACAAACG TTGATTACAC GGTGATTATC
1861  TTGAATGCCC CAGACTTCAG AGAAAAACAG ATCCATACCG GTTGGCTGGA TACCAGAATA
1921  GCTATGCGTG TTCAAGCTGA GAGGCCTCCC TGGTATATTT CAGTGGTTGG AGGAGCTCTA
1981  TATAAAACAA TAACCACCAA TGCGGAGACC GTTTCTGAAT ATGTTAGCTA TCTCATCAAG
2041  GGTCAGATTC CACCAAAGCA CATATCCCTT GTCCATTCAA CTATTTCTTT GAATATAGAG
2101  GAAAGCAAAT ATACAATTGA GATTGTGAGG AGTGGACAGG GTAGCTACAG ATTGAGACTG
2161  AATGGATCAC TTATTGAAGC CAATGTACAA ACATTATGTG ATGGAGGCCT TTTAATGCAG
2221  CTGGATGGAA ATAGCCATGT TATTTATGCT GAAGAAGAAG CGGGTGGTAC ACGGCTTCTT
2281  ATTGATGGAA AAACATGCTT GCTACAGAAT GACCATGATC CGTCAAGGTT ATTAGCTGAG
2341  ACACCTGCTC AACTTCTTCG TTTCTTGATT GCCGATGGTG CTCATGTTGA TGCTGATGTA
2401  CCATACGCGG AAGTTGAGGT TATGAAGATG TGCATGCCCC TCTTGTCGCC TGCTGCTGGT
2461  GTCATTAATG TTTTGTTGTC TGAGGGCCAG GCGATGCAGG CTGGTGATCT TATAGCGAGA
2521  CTTGATCTCG ATGACCCTTC TGCTGTGAAG AGAGCCGAGC CATTTGAAGG ATCTTTTCCA
2581  GAAATGAGCC TTCCTATTGC TGCTTCTGGC CAAGTTCACA AAAGATGTGC TGCAAGTTTG
2641  AACGCTGCTC GAATGGTCCT TGCAGGATAT GACCATGCGG CCAACAAAGT TGTGCAAGAT
2701  TTGGTATGGT GCCTTGATAC ACCTGCTCTT CCTTTCCTAC AATGGGAAGA GCTTATGTCT
2761  GTTTTAGCAA CTAGACTTCC AAGACGTCTT AAGAGCGAGT TGGAGGGCAA ATACAATGAA
2821  TACAAGTTAA ATGTTGACCA TGTGAAGATC AAGGATTTC CTACCGAGAT GCTTAGAGAG
2881  ACAATCGAGG AAAATCTTGC ATGTGTTTCC GAGAAGGAAA TGGTGACAA TGAAGGCTT
2941  GTTGACCTC TGATGAGCCT GCTGAAGTCA TACGAGGGTG GGAGAGAAAG CCAATGCCAC

```

3001 TTTATTGTCA AGTCCCTTTT TGAGGAGTAT CTCTCGGTTG AGGAAGTATT CAGTGATGGC
3061 ATTCAGTCTG ACGTGATTGA ACGCCTGCGC CTACAATATA GTAAAGACCT CCAGAAGGTT
3121 GTAGACATTG TTTTGTCTCA CCAGGGTGTG AGAAACAAAA CAAAGCTGAT ACTCGCGCTC
3181 ATGGAGAAAC TGGTCTATCC AAACCTTGCT GCCTACAGAG ATCAGTTGAT TCGCTTTTCT
3241 TCCCTCAACC ATAAAAGATA TTATAAGTTG GCTCTTAAAG CTAGTGAAC TCTTGAACAA
3301 ACCAAGCTCA GCGAAGTCCG CACAAGCATT GCAAGGAAAC TTTGAGCGCT GGATATGTTT
3361 ACCGAGGAAA AGGCAGATTT CTCCTTGCAA GACAGAAAA TGGCCATTAA TGAGAGCATG
3421 GGAGATTTAG TCACTGCCCC ACTGCCAGTT GAAGATGCAC TTGTTTCTTT GTTTGATTGT
3481 ACTGATCAAA CTCTTCAGCA GAGAGTGATT CAGACATACA TATCTCGATT ATACCAGCCT
3541 CAACTTGTGA AGGATAGCAT CCAGCTGAAA TATCAGGATT CTGGTGTAT TGCTTTATGG
3601 GAATTCACATG AAGGAAATCA TGAGAAGAGA TTGGGTGCTA TGGTTATCCT GAAGTCACTA
3661 GAATCTGTGT CAACAGCCAT TGGAGCTGCT CTAAAGGATG CATCACATTA TGCAAGCTCT
3721 GCGGGCAACA CCGTGATAT TGCTTTGTG GATGCTGATA CCCAACTGAA TACAACGTAA
3781 GATAGTGGTG ATAATGACCA AGCTCAAGAC AAGATGGATA AACTTTCTTT TGTACTGAAA
3841 CAAGATGTTG TCATGGCTGA TCTACGTGCT GCTGATGTCA AGGTTGTTAG TTGCATTGTT
3901 CAAAGAGATG GAGCAATCAT GCCTATGCGC CGTACCTTCC TCTTGTGAGA GGAAGAACTT
3961 TGTTACGAGG AAGAGCCGAT TCTTCGGCAT GTGGAGCCTC CACTTTCTGC ACTTCTTGAG
4021 TTGGATAAAAT TGAAAGTGAA AGGATACAAT GAGATGAAGT ATACACCGTC ACGTGATCGT
4081 CAGTGGCATA TATACACACT TAGAAATACT GAAAATCCAA AAATGCTGCA CAGGGTATTT
4141 TTCCGAACAC TTGTTCAGACA ACCCAGTGCA GGCAACAGGT TTACATCAGA CCATATCACT
4201 GATGTTGAAG TAGGACACGC AGAGGAACCT CTTTCATTTA CTTCAAGCAG CATATTAATA
4261 TCGTTGAAGA TTGCTAAAGA AGAATTGGAG CTTACGCGCA TCAGGACTGG CCATTCTCAT
4321 ATGTACTTGT GCATATTGAA AGAGCAAAAG CTTCTTGACC TTGTTCTGT TTCAGGGAAC
4381 ACTGTTGTGG ATGTTGGTCA AGATGAAGCT ACTGCATGCT CTCTTTTGAA AGAAATGGCT
4441 TTAAAGATAC ATGAACTTGT TGGTGCAAGA ATGCATCATC TTTCTGTATG CCAGTGGGAA
4501 GTGAACTTA AGTTGGTGAG CGATGGGCCT GCCAGTGGTA GCTGGAGAGT TGTAACAACC
4561 AATGTTACTG GTCACACCTG CACTGTGGAT ATCTACCGGG AGGTGCAAGA TACAGAATCA
4621 CAGAACTAG TATACCACTC CACCGCATTG TCATCTGGTC CTTTGCATGG TGTGCACTG
4681 AATACTTCGT ATCAGCCTTT GAGTGTATT GATTTAAAC GTTGCTCTGC CAGGAACAAC
4741 AAAACTACAT ACTGCTATGA TTTTCCATTG ACATTTGAAG CTGCAGTGCA GAAGTCGTGG
4801 TCTAACATTT CCAGTGAAAA CAACCAATGT TATGTTAAAG CGACAGAGCT TGTGTTTGCT
4861 GAAAAGAATG GGTCTGGGG CACTCCTATA ATTCCTATGC AGCGTGCTGC TGGGCTGAAT
4921 GACATTGGTA TGGTAGCCTG GATCTTGGAC ATGTCCACTC CTGAATTTCC CAGCGGCAGA
4981 CAGATCATTTG TTATCGCAAA TGATATTACA TTTAGAGCTG GATCATTTGG CCCAAGGGAA
5041 GATGCATTTT TCGAAGCTGT AACCAACCTG GCTTGTGAGA AGAAGCTTCC ACTTATCTAC
5101 TTGGCTGCAA ACTCTGGTGC TCGGATTGGC ATTGCTGATG AAGTAAAAATC TTGCTTCCGT
5161 GTTGGATGGA CTGATGATAG CAGCCCTGAA CGTGGATTTA GGTACATTTA TATGACTGAC
5221 GAAGACCATG ATCGTATTGG CTCTTCAGTT ATAGCACACA AGATGCAGCT AGATAGTGGC
5281 GAGATCAGGT GGGTTATTGA TTCTGTTGTG GGAAAAGAGG ATGGACTAGG TGTGGAGAAC
5341 ATACATGGAA GTGCTGCTAT TGCCAGTGCC TATTCTAGGG CGTACGAGGA GACATTTACA
5401 CTTACATTCG TTAGTGGAC AACTGTTGGA ATCGGAGCCT ATCTTGCTCG ACTTGGCATA
5461 CGGTGATAC AGCGTATTGA CCAGCCCAT ATTGTTGACCG GGTGTTCTGC CCTGAACAAG
5521 CTTCTTGGGC GGGAGGTGTA CAGCTCCAC ATGCAGTTGG GTGGTCCCAA AATCATGGCG
5581 ACGAATGGTG TTGTCCATCT GACTGTTCCA GATGACCTTG AAGGTGTTTC TAATATATTG
5641 AGGTGGCTCA GCTATGTTCC TGCAAACATT GGTGGACCTC TTCCTATTAC AAAATCTTTG
5701 GACCCAATAG ACAGACCCGT TGCAATACAT CCTGAGAATA CATGTGATCC TCGTGCAGCC
5761 ATCAGTGGCA TTGATGACAG CCAAGGGAAG TGGTTGGGTG GCATGTTTGA CAAAGACAGT
5821 TTTGTGGAGA CATTGGAAG ATGGGCGAAG ACAGTAGTTA CTGGCAGAGC AAAACTTGGA
5881 GGGATTCCTG TTGGTGTAT AGCTGTGGAG ACACAGACCA TGATGCAGCT CGTCCCCGCT
5941 GATCCAGGCC AGCCTGATTC CCACGAGCGG TCTGTTCTCT GTGCTGGGCA AGTTTGGTTT
6001 CCAGATTCTG CTACCAAGAC AGCGCAGGCG ATGTTGGACT TCAACCGTGA AGGATTACCT
6061 CTGTTTCATC TTGCTAACTG GAGAGGCTTC TCTGGAGGGC AAAGAGATCT TTTTGAAGGA
6121 ATTCTGCAGG CTGGGTCAAC AATTGTTGAG AACCTTAGGA CATACAATCA GCCTGCCTTT
6181 GTATATATCC CCAAGGCTGC AGAGCTACGT GGAGGAGCCT GGGTCTGTAT TGATAGCAAG

6241 ATAAACCCAG ATCGCATCGA GTGCTATGCT GAGAGGACTG CAAAGGGTAA TGTTCCTCGAA
6301 CCTCAAGGGT TGATTGAGAT CAAGTTCAGG TCAGAGGAAC TCAAAGAATG CATGGGTAGG
6361 CTTGATCCAG AATTGATAGA TCTGAAAGCA AGACTCCAGG GAGCAAATGG AAGCCTATCT
6421 GATGGAGAAT CCCTTCAGAA GAGCATAGAA GCTCGGAAGA AACAGTTGCT GCCTCTGTAC
6481 ACCCAAATCG CGGTACGTTT TGC GGAATTG CACGACACTT CCCTTAGAAT GGCTGCTAAA
6541 GGTGTGATCA GGAAAGTTGT AGACTGGGAA GACTCTCGGT CTTTCTTCTA CAAGAGATTA
6601 CGGAGGAGGC TATCCGAGGA CGTTCTGGCA AAGGAGATTA GAGGTGTAAT TGGTGAGAAG
6661 TTCCTCACA AATCAGCGAT CGAGCTGATC AAGAAATGGT ACTTGGCTTC TGAGGCAGCT
6721 GCAGCAGGAA GCACCGACTG GGATGACGAC GATGCTTTTG TCGCCTGGAG GGAGAACCCT
6781 GAAAACTATA AGGAGIATAT CAAAGAGCTT AGGGCTCAAA GGGTATCTCG GTTGCTCTCA
6841 GATGTTGCAG GCTCCAGTTC GGATTTACAA GCCTTGCCGC AGGGTCTTTC CATGCTACTA
6901 GATAAGATGG ATCCCTCTAA GAGAGCACAG TTTATCGAGG AGGTCATGAA GGTCTTGAAA
6961 TGA

FIGURE 7A**>Oryza sativa Plastidic ACCase genomic sequence**

ATGACATCCACACATGTGGCGACATTGGGAGTTGGTGCCACGGCACCTCCTCGTCACCAGAAAAAGTCAGCTGG
CACTGCAATTTGTATCATCTGGGTCATCAAGACCCTCATACCGAAAAGAAATGGTCAGCGTACTCGGTCACTTAGGG
AAGAAAGCAATGGAGGAGTGTCTGATTCCAAAAAGCTTAACCACTCTATTGCCCAAGGTGACCACTAGCTACTT
TACATATGCTATAATTTGTGCCAAACATAAACATGCAATGGCTGCTATTATTTAAACGTTAATGTTGAAATAGC
TGCTATAGGATACAGCAAAAATATATAAATTGACTGGGCAAGATGCAACAATTGTTTTCTACTAAAGTTAGTTAT
CTTTTGCTGTAAAAGACAACCTGTTTTTACATAAAATGGTATTAATAACCTTGTAATATTCAATGCAACATGTT
CTCAAGTAAAAAAAACATTGCCTGGTTGTATAAGCAAATGTGTCGTTGTAGACATCTTATTAAACCTTTTTGT
GATATCTATTACCGTAGGGAACAGGGGAGCTGTTAAATCTGTTATCATAGAGTAATATGAGAAAAGTGGATTG
TGCGACTTTGGCATGTATACCTGCTCAATTTCAAATATATGTCTATGTGCAGGTCTTGCTGGCATCATTGACCT
CCCAAATGACGCAGCTTCAGAAGTTGATATTACAGTAAGGACTTATATTTTATAATAATTATTATATAAATT
TTCTGACATGTTTTGAGAACCCTCAAAACATGTGATTGCACCTTCCTTTTTTATGTCTGGTTGAGAACTGATAA
GTTTTGACAGTGTTTAGGATGGATCTTTGATGCGCACAGTGCTTTCTAATGTTTTCAATTTTTGAAAGTAATGTT
TTAGGAAGAAATATCTGATTAAATTTATACCTTTATCTTTACAAAAGTCAAATGCGTCTGTATCAATTGCGGTT
TGTAATATGGCAAGAACATGCTTTTCAGAATTTGTTTCATACAATGCTTTCTTTCTATTATTATGTAGAACAATA
CCTAATACTTTGTTACCTTTTATAGTGGACACCTCTCACAGCTTTTTCAGTAAGTGATGCAATTTTGTACATT
TGTAAGATGTGTTCCAGAAAACCTTTTCTCCTGCAATTTCTAATGTACCCACTCAAACCTGGTATCACCAAAGATCT
CCATCTGATTGAAAAAAGCTGCGTGAAGTATGCTTATTTATGCTAACCATACATGATTTATACTGTTTTATAG
TACAATGCTTATTTATGCTAACCATACATAAATTTTATCTGTTTTCTAGTACATTATTTGTGCCCTGACCATA
AATGATCCTTTTCTTTTACAGTGGTTCCGAAGATCCCAGGGGGCCTACGGTCCCAGGTTCTTACCAAATGAATGG
GATTATCAATGAAACACATAATGGGAGGCATGCTTCAGTCTCCAAGGTTGTTGAGTTTTGTACGGCACTTGCTG
GCAAAACACCAATTCACAGTGTTATTAGTGGCCAACAATGGAATGGCAGCAGTAAGTTCATGCGGAGTGTCCGA
ACATGGGCTAATGATACTTTTGATCAGAGAGGCAATTCAGCTGATAGCTATGGCAACTCCGAGGATCTGAG
GATAAATGCAGAGCACATCAGAATTGCCGATCAATTTGTAGAGGTACCTGGTGGAAACAAACAACAACATATG
CAAATGTCCAACCTCATAGTGGAGGTAGTTTCAGCTCATCCCTCAACACAACATTTTCGTTTCTATTTAAGTTAG
GGAAAAATCTCTACGACCCTCCAATTTCTGAACATCCAATTTTACCATCAACTGCAATCAGATAGCAGAGA
GAACAGGTGTTTCTGCTGTTTGGCCTGGTTGGGGTCATGCATCTGAGAATCCTGAACTTCCAGATGCGCTGACT
GCAAAAGGAATTTGTTTTTCTTGGGCCACCAGCATCATCAATGCATGCATTAGGAGACAAGGTTGGCTCAGCTCT
CATTGCTCAAGCAGCTGGAGTTCCAACACTTGCTTGGAGTGGATCACATGTGAGCCTTGTCTTCTTTTTTAG
CTTATCATCTTATCTTTTTCGGTGATGCATTATCCCAATGACACTAAACCATAGGTGGAAGTTCCTCTGGAGTGT
TGCTTGGACTCAATACCTGATGAGATGTATAGAAAAGCTTGTGTTACTACCACAGAGGAAGCAGTTGCAAGTTG
TCAGGTPGGTTGGTTATCCTGCCATGATTAAGGCATCTTGGGGTGGTGGTAAAGGAATAAGGAAGGTTTGTT
CTTCTTGTAGTTATCAAGAGATTGTTGGATTGCAAGTGTTTAGTGCCCATAGTTAACTCTGGTCTTTCTAACA
TGAGTAAGTCAACTTTCTTGCAGGTTCATAATGATGATGAGGTTAGGACATTATTTAAGCAAGTTCAAGGCCAA
GTACCTGGTTCCCCAATAATTTATCATGAGGCTAGCTGCTCAGGTGGGGCCTTTTATGGAAGTTACACCTTTTCC
CTTAATGTTGAGTTATTCGGAGTTATTATGGTTATGTTCTGTATGTTTGATCTGTAAATTATGAAATTCACC
TCCATTGGTTCTCCAGATTAGCAGACCTACAATCTACATATGGTTTATACTTTATAAATACTAGGATTTAGGG
ATCTTCATATAGTTTATACATGGTATTTAGATTTTCAATTTGTAACCTATTGAAGACATCCTGATTGTTGTCTTA
TGTAAGTTCGACATCTTGAAGTTCAGTTGCTTTGTGATCAATATGGCAACGTAGCAGCACTTCACAGTCGAGAT
TGCAGTGTAACGGCGACACCAAAAGGTCTGCTGTCTCAGTTAAATCACCCCTCTGAATGATCTACTTCTTGC
CTGCTGCGTTGGTCAGAGGAATAATGGTTGTATTCTACTGAACAGATAATCGAGGAAGGACCAGTTACTGTTGC
TCCTCGTGAGACTGTGAAAGAGCTTGAGCAGGCAGCACGGAGGCTTGCTAAAGCTGTGGGTTATGTTGGTGCTG
CTACTGTTGAATACCTTTACAGCATGGAACTGGTGAATATTATTTCTGGAACCTAATCCACGGCTACAGGTC
GGCTCCTTTGACATTCCTCAGGAATTAATTTCTGTTGACCACATGATTTACATTGTCAAATGGTCTCACAGGTT
GAGCATCCTGTCACTGAGTGGATAGCTGAAGTAAATTTGCTGCGGCTCAAGTTGCTGTTGGAATGGGTATACC
CCTTTGGCAGATTCCAGGTAATGCTTCTTCATTTAGTTCCTGCTCTTTGTTAATTGAATGAGCTCTTATACAGA
CCATGAGACACATCTACTGTTAATTCATAGTATCCCTGACTTGTTAGTGTAGAGATACAGAGATGTATCAC

AAATTCATTGTATCTCCTCAAGGACTGTAAAAATCCTATAATTAATTTCTGAAAAATTTGTTCTTTTAAGCAGA
AAAAAAATCTCTAAATATCTCCCTGTATACAGAGATCAGGCGCTTCTACGGAATGAACCATGGAGGAGGCTAT
GACCTTTGGAGGAAAACAGCAGCTCTAGCGACTCCATTTAACTTTGATGAAGTAGATTCTAAATGGCCAAAAGG
CCACTGCGTAGCTGTTAGAATAACTAGCGAGGATCCAGATGATGGGTTTAAGCCTACTGGTGGAAAAGTAAAGG
TGCGGTTTTCTGATGTAGGTGTATGAATTGAACACATTGCTATATTGCAGCTAGTGAAATGACTGGATCATGG
TTCTCTTATTTTCAGGAGATAAGTTTCAAGAGTAAACCAATGTTTGGGCCTATTTCTCAGTAAAGGTAGTCCT
CAATATTGTTGCACTGCCACATTATTTGAGTTGTCCTAACAAATTGTGCTGCAATTGTTAGTTTCAACTATTTG
TTGTTCTGTTTGGTTGACTGGTACCCTCTCTTGCAGTCTGGTGGAGGCATCCATGAATTCGCTGATTCTCAGT
TCGGTATGTAAAGTTAAAAGAGTAATATTGTCTTGTCTATTTATGTTTGTCTCACTTTTAAAGCATATTGCCT
TCCATTACAGGACATGTTTTGCGTATGGAACACTAGATCGGCAGCAATAACTACCATGGCTCTTGCCTAAA
AGAGGTTCAAATTCGTGGAGAAATTCATTCAACGTAGACTACACAGTTGACCTATTAAATGTAAAGGACTAAAT
ATCTGCTTATTGAACCTTGCTTTTTGGTTCCCTAATGCCATTTTAGTCTGGCTACTGAAGAACTTATCCATCAT
GCCATTTCTGTTATCTTAAATTCAGGCCTCAGATTTTAGAGAAAATAAGATTCACTAGTTGGCTGGGATACCA
GGATAGCCATGCGTGTTCAGCTGAGAGGCCCTCCATGGTATATTTCAGTCTGGTGGAGGGGCTTTATATGTAAGA
CAAACATATGCCACTCATTAGCATTATGTGAAGCAAATGCGGAAAACATGATCAATATGTCGTCTATTTAAAT
TTATTTATTTTTGTGCTGCAGAAAACAGTAACTGCCAACACGGCCACTGTTTCTGATTATGTTGGTTATCTTAC
CAAGGGCCAGATTCCACCAAAGGTACTATTCTGTTTTTTCAGGATATGAATGCTGTTTGAATGTGAAAACCAT
GACCATAAATCCTTGTGTTGCAGCATATATCCCTTGTCTATACGACTGTTGCTTTGAATATAGATGGGAAAAAT
ATACAGTAAGTGTGACATTCTTAATGGGAAAACCTTAATTTGTTGTAATAATCAATATCATATTGACTCGTGTA
TGCTGCATCATAGATCGATACTGTGAGGAGTGGACATGGTAGCTACAGATTGCGAATGAATGGATCAACGGTTG
ACGCAAATGTACAAATATTATGTGATGGTGGGCTTTTAAATGCAGGTAATATCTTCTCCTAGTTAAAGAAGATA
TATCTTGTTCAAAGAAATCTGATTATTGATCTTTTAAATGTTTCAGCTGGATGGAAACAGCCATGTAATTTATG
CTGAAGAAGAGGGCCAGTGGTACACGACTTCTTATTGATGGAAAGACATGCATGTTACAGGTAAATGATAGCCTTG
TTCTTTTGTAGTTCTAGTCACGGTGTGTTGCTTGTCTATTTGTTGATCTATTTAATGCATTCACTAATTACTATAT
TAGTTTTGCATCATCAAGTTAAAATGGAACCTTCTTCTTGCAGAAATGACCATGACCCATCAAAGTTATTAGCTGA
GACCCATGCAAACCTTCTTCTGTTTCTTGGTTGCTGATGGTGTCTCATGTTGATGCTGATGTACCATATGCGGAAG
TTGAGGTTATGAAGATGTGCATGCCCTCTTATCACCCGCTTCTGGTGTCTATACATGTTGTAATGTCTGAGGGC
CAAGCAATGCAGGTACATTCCCTACATTCCATTGCTGTGCTGACATGAACATTTCAAGTAAATACCTGT
AACTTGTTTATTATCTAGGCTGGTGATCTTATAGCTAGGCTGGATCTTGTATGACCCTTCTGCTGTTAAGAGAG
CTGAGCCGTTTGAAGATACTTTTCCACAAATGGGTCTCCCTATTGCTGCTTCTGGCCAAAGTTCACAAATTATGT
GCTGCAATCTGAATGCTTGTGCAATGATCCTTGCGGGGTATGAGCATGATATTGACAAGGTAACATCATGTC
CTCTTGTTTTTCTTTTGTGTTTATCATGCATTCTTATGTTTCATCATGTCTCTGGCAAATCTAGATTCCGCTGTC
GTTTCACACAGATTTTCTCATTCTCATAATGGTGCCAAACATAAAATATGCTGCTATATTATCAATGTTTTCA
CTCGATTTCTAATTTTGCTTTTGTGTTTAACTTTAGTACAATCCATATCTAATCTCCTTTGGCAACAGTGAA
TCCATTATATATATTTTATTAACCTGCTTTCTTTTCAGGTTGTGCCAGAGTTGGTATACTGCCTAGACACTC
CGGAGCTTCTTTTCCCTGCAGTGGGAGGAGCTTATGCTGCTTTTAGCAACTAGACTTCCAAGAAATCTTAAAGT
GAGGTATATTATGGTTGACAAGATAGCTAGTCTCATGCTCTAAGGACTTGTAACATTTGCCACATAGGTTAAT
TTCCATATCAAGTTCTAATGTACGATATAAAAGTAGTACTGGCCTAAACAGTATTGGTGGTTGACTATCTTTG
TTGTGTAAGATCAAGTATTTCTTTTTCATGCTTAGTTTGTCAATACTTCACATTTATCACTGACTTGTGCGAGCT
AAATGAGATTTTATTGATTTCTGTGCTCCATTATTTTGTATATATATATATATTTAACTATGACTATATG
TTATGCCCTCAAACGTTTCAAACCTTTTCAGTTGGAGGGCAAAATATGAGGAATACAAAGTAAATTTGACTCTGG
GATAATCAATGATTTCCCTGCCAATATGCTACGAGTGATAATTGAGGTGAGTTATTCAATTTGTTGTGATAATC
ACTGCCTTAACTGTTGCTTCTTTTAAACAGCGGTTTTATAGGAAAATCTTGCATGTGGTTCTGAGAAGGAGAAG
GCTACAAATGAGAGGCTTGTGAGCCTCTTATGAGCCTACTGAAGTCATATGAGGTGGGAGAGAAAGTCATGC
TCACTTTGTTGTCAAGTCCCTTTTTGAGGAGTATCTCTATGTTGAAGAATTGTTCACTGATGGAATTCAGGTTA
ACTTACCTATTTCGCATTAAACAAATCATCAGTTGTTTTATGATAAAGTCAAAATGTTTATATTTCCCATCTTC
TGTGGATCAAATATATCACGGACATGATATAGTTTCTTAGGCTATATAATGGTTCTTCATCAAATAATATTGC
AGGAAACAGTATAGCAAACATTTGTATATACTCGAGATGGAAATTTGTAGAAACATCATTGACTAAATCTGTC
CTTTGTTACGCTGTTTTGTAGTCTGATGTGATTGAGCGTCTGCGCCTTCAACATAGTAAAGACCTACAGAAGG
TCGTAGACATTGTGTTGTCCCACAGGTAAATTTCTTCATGGTCTGATGACTTCACTGCGAATGGTTACTGAAC
TGTCTTCTGTTCTGACAAATGTGACTTTTCTTTGTAGAGTGTAGAAATAAACTAAGCTGATACTAAAACCTCA
TGGAGAGTCTGGTCTATCCAAATCCTGCTGCCTACAGGATCAATTGATTGCTTTTCTTCCCTAATCACAAA
GCGTATTACAAGGTGACCAGGATAAACATAAAATAACGTGAATTTTTCAATGACCTTTTCTTCTGACATCTGAA
TCTGATGAATTTCTTGCAATTAATAACAGTTGGCACTTAAAGCTAGTGAACCTTCTGAACAAACAAAACCTTAGT

GAGCTCCGTGCAAGAATAGCAAGGAGCCTTTTCAGAGCTGGAGATGTTTACTGAGGAAAGCAAGGGTCTCTCCAT
GCATAAGCGAGAAATGCCATTAAGGAGAGCATGGAAGATTTAGTCACTGCTCCACTGCCAGTTGAAGATGCGC
TCATTTCTTTATTTGATTGTAGTGATACAACCTGTTCAACAGAGAGTGATTGAGACTTATATAGCTCGATTATAC
CAGGTATGAGAAGAAAGACCTTTTGAAATTATTTATATTAACATATCCTAGTAAAAAGCATGCTCATCATTTTC
TTAAAAAAGTTTACAGCACCTGATGTTTGGTACTGACCGCATCATTAATAAAGTTACTTGTGTGGAGAG
ATGTATTTTGAACTTGTGGCAGATGCAGTAACATGCTACTGCTCGATATGTTTGCTAACTTGACAACAATATT
TTTCAGCTCATCTTGTAAGGACAGTATCAAAATGAAATGGATAGAATCGGGTGTTATTGCTTTATGGGAATT
TCCTGAAGGGCATTGTGATGCAAGAAATGGAGGAGCGTTCTTGGTGACAAAAGATGGGGTGCCATGGTCATTG
TCAAGTCTCTTGAATCACTTTCAATGGCCATTAGATTTGCACTAAAGGAGACATCACACTACACTAGCTCTGAG
GGCAATATGATGCATATTGCTTTGTTGGGTGCTGATAATAAGATGCATATAATTCAAGAAAGGTATGTTTCATAT
GCTATGTTGGTGCTGAAATAGTTATATATGTAGTTAGCTGGTGGAGTTCTGGTAATTAACCTATCCCATTGTTC
AGTGGTGATGATGCTGCAGAAATAGCCAACTTCCCTTGATACTAAAGGATAATGTAACCGATCTGCATGCCCTC
TGGTGTGAAAACAATAAGTTTCATTGTTCAAAGAGATGAAGCACGGATGACAATGCGTCGTACCTTCCCTTTGGT
CTGATGAAAAGCTTTCTTATGAGGAAGAGCCAATTCTCCGGCATGTGGAACCTCTCTTTCTGCACCTCTTGAG
TTGGTACGTGATATCATCAAAATGATAATGTTTGGTATGGCATTGATTATCTTCTATGCTCTTTGTATTATTTATT
CAGCCTATTGTGGATACAGGACAAGTTGAAAGTGAAAGGATACAATGAAATGAAGTATACCCCATCACGGGATC
GTCAATGGCATATCTACACACTTAGAAATACTGAAAACCCCAAAATGTGACCGGGTATTTTCCGAACCTT
GTCAGGCAACCCAGTGTATCCAACAAGTTTTCTCGGGCCAGATTGGTGACATGGAAGTTGGGAGTGTGAAGA
ACCTCTGTCAATTTACATCAACCAGCATATTAAGATCTTTGATGACTGCTATAGAGGAATTGGAGCTTCACGCAA
TTAGAACTGGCCATTACACATGTATTTGTCATGTATTGAAAAGAACAAAAGCTTCTTGATCTTGTTCAGTTTCA
GGGTAAAGTGCGCATATTTCTTTTGGGAACATATGCTTGCTTATGAGGTTGGTCTTCTCAATGATCTTCTTATC
TTACTCAGGAATACAGTTTTTGGATGTTGGTCAAGATGAAGCTACTGCATATTCATTTTTAAAGAAATGGCTAT
GAAGATACATGAACCTTGTGGTGCAAGAATGCACCATCTTCTGTATGCCAATGGGAAGTGAACTTAAGTTGG
ACTGCGATGGTCCCGCAGTGGTACCTGGAGGATTGTAACAACCAATGTTACTAGTCACACTTGCAGTGTGGAT
GTAAGTTTAAAGCTTGTAGCATTTTGTCTTTGTTGAAAAGCATGTGATTTTAAAGCCGGCTGTCCTCATACCCA
GACCTAGTGATCTTTATATAGTGATAGACATTTTTCTAACTGCTTTTAATTGTTTTAGATCTACCGTGAGATGGA
AGATAAAGAATCACGGAAGTTAGTATACCATCCCGCCACTCCGGCGGCTGGTCTCTGCATGGTGTGGCACTGA
ATAATCCATATCAGCCTTTGAGTGTATTGATCTCAACGCTGTTCTGCTAGGAATAATAGAACTACATACTGC
TATGATTTTCCACTGGTGAGTTGACTGCTCCCTTATATTCAATGCATTACCATAGCAAATTCATATTCGTTTCAT
GTTGTCAAATAAAGCCGATGAAAATTCAAACCTGTAGGCAATTTGAACTGCAGTGAGGAAGTCATGGTCTCTTA
GTACCTCTGGTGCTTCTAAAGGTGTTGAAAATGCCAATGTTATGTTAAAGCTACAGAGTTGGTATTTGCGGAC
AAACATGGGTGATGGGGCACTCCTTTAGTTCAAATGGACCGGCTGCTGGGCTCAATGACATTGGTATGGTAGC
TTGGACCTTGAAGATGTCCACTCCTGAATTTCTAGTGGTAGGGAGATTATTGTTGTTGCAATGATATTACGT
TCAGAGCTGGATCATTTGGCCCAAGGGAAGATGCATTTTTTGAAGCTGTTACCAACCTAGCTGTGAGAAAGAAA
CTTCTCTTATTTATTTGGCAGCAAATTCGGTGCTCGAATTGGCATAGCAGATGAAGTGAATCTTGCTTCCG
TGTTGGGTGGTCTGATGATGGCAGCCCTGAACGTGGGTTTCAGTACATTTATCTAAGCGAAGAAGACTATGCTC
GTATTGGCACTTCTGTCATAGCACATAAGATGCAGCTAGACAGTGGTGAAATTAGGTGGGTATTGATTCTGTT
GTGGGCAAGGAAGATGGACTTGGTGTTGAGAATATACATGGAAGTGTGCTATTGCCAGTGCTTATTCTAGGGC
ATATAAGGAGACATTTACACTTACATTTGTGACTGGAAGAACTGTTGGAATAGGAGCTTATCTTGCTCGACTTG
GCATCCGGTGCCATACAGCGTCTTGACCAGCCTATTATCTTACAGGCTATTCTGCACTGAACAAGCTTCTTGGG
CGGGAAGTGATACAGCTCCACATGCAGTTGGGTGGTCCCAAAATCATGGCAACTAATGGTGTTGTCCATCTTAC
TGTTTTCAAGATGACCTTGAAGGCGTTTCTAATATATTGAGGTGGCTCAGTTATGTTCTGCTTACATTGGTGGAC
CACTTCCAGTAACAACACCGTTGGACCCACCGGACAGACCTGTTGCATACATTCTGAGAACTCGTGTGATCCT
CGAGCGGCTATCCGTGGTGTTGATGACAGCCAAGGGAATGGTTAGGTGGTATGTTTGATAAGACAGCTTGTG
GGAAACATTTGAAGGTGGGCTAAGACAGTGGTTACTGGCAGAGCAAAGCTTGGTGGAATTCAGTGGGTGTGA
TAGCTGTGGAGACTCAGACCATGATGCAAACTATCCCTGCTGACCTGGTCAGCTTGATTCCCGTGAGCAATCT
GTTCTCGTGCTGGACAAGTGTGGTTTCCAGATTCTGCAACCAAGACTGCGCAGGCATTGCTGGACTTCAACCG
TGAAGGATTACCTCTGTTTATCCTCGCTAACTGGAGAGGCTTCTCTGGTGGACAAAAGAGATCTTTTTGAAGGAA
TTCTTCAGGCTGGCTCGACTATTGTTGAGAACCTTAGGACATACAATCAGCCTGCCTTTGTCTACATTCCCATG
GCTGCAAGACTACAGGAGGGGCTTGGGTGTGGTTGTAGCAAGATAAACCCAGACCGCATTTGAGTGCTATGC
TGAGAGGACTGCAAAAGGCAATGTTCTGGAACCGCAAGGGTTAATTGAGATCAAGTTTCAAGGTCAGAGGAACTCC
AGGATTGCATGAGTCGGCTTGACCCAACATTAATTGATCTGAAAGCAAACTCGAAGTAGCAAATAAAAAAGGA
AGTGCTGACACAAAATCGCTTCAAGAAAATATAGAAGCTCGAACAAAACAGTTGATGCCTCTATATACTCAGAT
TGCGATACGGTTTGTGAATTGCATGATACATCCCTCAGAATGGCTGCGAAAGGTGTGATTAAGAAAGTTGTGG

ACTGGGAAGAATCAGGATCTTTCTTCTATAAGAGATTACGGAGGAGGATCTCTGAGGATGTTCTTGCAAAAGAA
ATTAGAGCTGTAGCAGGTGAGCAGTTTTCCCAACCAACCAGCAATCGAGCTGATCAAGAAATGGTATTCAGCTTC
ACATGCAGCTGAATGGGATGATGACGATGCTTTTGTTGCTTGGATGGATAACCCTGAAAACTACAAGGATTATA
TTCAATATCTTAAGGCTCAAAGAGTATCCCAATCCCTCTCAAGTCTTTCAGATTCCAGCTCAGATTGCAAGCC
CTGCCACAGGGTCTTCCATGTTACTAGATAAGGTAATTAGCTTACTGATGCTTATATAAATTCTTTTCATT
CATATGGCTGGAGAACTATCTAATCAAATAATGATTATAATTCCAATCGTTCCTTTTATGCCATTATGATCTTC
TGAAATTTCTTCTTTGGACACTTATTCAGATGGATCCCTCTAGAAGAGCTCAACTTGTTGAAGAAATCAGGAA
GGTCCTTGGTTGA

FIGURE 7B**>Orzya sativa Plastidic ACCase protein coding sequence**

ATGACATCCACACATGTGGCGACATTGGGAGTTGGTGCCAGGCACCTCCTCGTCACCAGAAAAAGTCAGCTGG
CACTGCATTTGTATCATCTGGGTCATCAAGACCCTCATACCGAAAGAAATGGTCAGCGTACTCGGTCACTTAGGG
AAGAAAGCAATGGAGGAGTGTCTGATTCCAAAAAGCTTAACCACTCTATTTCGCCAAGGTCTTGCTGGCATCAT
GACCTCCCAAATGACGCAGCTTCAGAAAGTTGATATTTCACATGGTTCCGAAGATCCAGGGGGCTACGGTCCC
AGGTTCCCTACCAAATGAATGGGATTATCAATGAAACACATAATGGGAGGCATGCTTCAGTCTCCAAGTTGTG
AGTTTTGTACGGCACTTGGTGGCAAAACACCAATTCACAGTGTATTAGTGGCCAACAATGGAATGGCAGCAGCT
AAGTTCATGCGGAGTGTCCGAACATGGGCTAATGATACCTTTGGATCAGAGAAGGCAATTCAGCTGATAGCTAT
GGCAACTCCGAGGATCTGAGGATAAATGCAGAGCACATCAGAATTGCCGATCAATTTGTAGAGGTACCTGGTG
GAACAAACAACAACAACTATGCAATGTCCAACCTCATAGTGGAGATAGCAGAGAGAACAGGTGTTCTGCTGTT
TGGCCTGGTTGGGGTCATGCATCTGAGAACTCTGAACCTCCAGATGCGCTGACTGCAAAAGGAATGTTTTTCT
TGGGCCACCAGCATCATCAATGCATGCATTAGGAGACAAGGTTGGCTCAGCTCTCATTGCTCAAGCAGCTGGAG
TTCCAACACTTGCTTGGAGTGGATCAGATGTGGAAGTCTCTGGAGTGTGCTTGGACTCAATACCTGATGAG
ATGTATAGAAAAGCTTGTGTTACTACCACAGAGGAAGCAGTTGCAAGTTGTCAGGTGGTTGGTTATCCTGCCAT
GATTAAGGCATCTTGGGGTGGTGGTGGTAAAGGAATAAGGAAGGTTTCATAATGATGATGAGGTTAGGACATTAT
TTAAGCAAGTTCAAGGCGAAGTACCTGGTTCCCAATATTTATCATGAGGCTAGCTGCTCAGAGTCGACATCTT
GAAGTTCAGTTGCTTTGTGATCAATATGGCAACGTAGCAGCACTTCACAGTCGAGATTGCAAGTGTACAACGGCG
ACACAAAAGATAATCGAGGAAGGACCAGTTACTGTTGCTCCTCGTGAGACTGTGAAAGAGCTTGAGCAGGCAG
CACGGAGGCTTGCTAAAGCTGIGGGTTATGTTGGTGTGCTACTGTTGAATACCTTTACAGCATGGAACTGGT
GAATATATATTTCTGGAACTTAATCCACGGCTACAGGTTGAGCATCCTGTCACTGAGTGGATAGCTGAAGTAAA
TTTGCTCGCGCTCAAGTTGCTGTTGGAATGGGTATACCCCTTTGGCAGATTCCAGAGATCAGGCGCTTCTACG
GAATGAACCATGGAGGAGGCTATGACCTTTGGAGGAAAACAGCAGCTCTAGCGACTCCATTAACTTTGATGAA
GTAGATTCTAAATGGCCAAAAGGCCACTGCGTAGCTGTTAGAAATAACTAGCGAGGATCCAGATGATGGGTTTAA
GCCTACTGGTGGAAAAGTAAAGGAGATAAGTTTCAAGAGTAAACCAATGTTTGGGCCTATTTCTCAGTAAAGT
CTGGTGGAGGCATCCATGAATTCGCTGATTCTCAGTTCGGACATGTTTTTGGCTATGGAACCTACTAGATCGGCA
GCAATACTACCATGGCTCTTGCACTAAAAGAGGTTCAATTCGTGGAGAAATTCATTCAAACGTAGACTACAC
AGTTGACCTATTAATGCCTCAGATTTTAGAGAAAAATAAGATTCACTGTTGGTGGCTGGATACCAGGATAGCCA
TGCGTGTTCAGGCTGAGAGGCCCTCCATGGTATATTTTCAGTCGTTGGAGGGGCTTTATATAAAACAGTAACGGC
AACACGGCCACTGTTTCTGATTATGTTGGTTATCTTACCAAGGGCCAGATTCCACCAAAGCATATATCCCTTGT
CTATACGACTGTTGCTTTGAATATAGATGGGAAAAAATATACAATCGATACTGTGAGGAGTGGACATGGTAGCT
ACAGATTGCGAATGAATGGATCAACGGTTGACGCAAAATGTACAAATATTAATGATGGTGGGCTTTTAAATGCAG
CTGGATGGAAACAGCCATGTAATTTATGCTGAAGAAGAGGCCAGTGGTACACGACTTCTTATGATGGAAAGAC
ATGCATGTTACAGAAATGACCATGACCCATCAAAGTTATAGCTGAGACACCATGCAAACCTTCTCGTTTCTTGG
TTGCTGATGGTGCTCATGTTGATGCTGATGTACCATATGCGGAAGTTGAGGTTATGAAGATGTGCATGCCCTC
TTATACCCGCTTCTGGTGTACATACATGTTGTAATGTCTGAGGGCCAAGCAATGCAGGCTGGTGTATATAGC
TAGGCTGGATCTTGATGACCTTCTGCTGTTAAGAGAGCTGAGCCGTTTCAAGATACTTTTCCACAAATGGGTC
TCCCTATGCTGCTTCTGGCCAAGTTCACAAATATGTTGCTGCAAGTCTGAATGCTTGTGCAATGATCCTTGCG
GGGTATGAGCATGATATTGACAAGGTTGTGCCAGAGTTGGTATACCTGCTAGACACTCCGGAGCTTCCTTTCT
GCAGTGGGAGGAGCTTATGCTGTTTTAGCACTAGACTTCCAAGAAATCTTAAAGTGAGTTGGAGGGCAAT
ATGAGGAATACAAAGTAAATTTGACTCTGGGATAATCAATGATTTCCCTGCCAATATGCTACGAGTGATAATT
GAGGAAAACTTGCATGTGGTCTGAGAAGGAGAAGGCTACAAATGAGAGGCTTGTGAGCCTCTTATGAGCCT
ACTGAAGTCATATGAGGGTGGGAGAGAAAGTCATGCTCACTTTGTTGTCAAGTCCCTTTTGGAGGAGTATCTCT
ATGTTGAAGAATTGTTCAAGTGTGAATTCAGTCTGATGTGATTGAGCGTCTGCGCCTTCAACATAGTAAAGAC
CTACAGAAGGTCGTAGACATTGTTGTGTCACCAAGAGTGTAGAAATAAACTAAGCTGATACTAAACCTCAT
GGAGAGTCTGGTCTATCCAAATCCTGTGCTACAGGGATCAATGATTTCGCTTTCTTCCCTTAATCACAAAG
CGTATTACAAGTTGGCACTTAAAGCTAGTGAACCTTCTGAACAAACAAAACCTTAGTGAGCTCCGTGCAAGAATA
GCAAGGAGCCTTTACAGAGCTGGAGATGTTTACTGAGGAAAGCAAGGTTCTCTCCATGCATAAGCGAGAAATGC

CATTAAGGAGAGCATGGAAGATTTAGTCACTGCTCCACTGCCAGTTGAAGATGCGCTCATTCTTTATTTGATT
GTAGTGATACAACATGTTCAACAGAGAGTGATTGAGACTTATATAGCTCGATTATACCAGCCTCATCTTGTAAAG
GACAGTATCAAAATGAAATGGATAGAATCGGGTGTTATGCTTTATGGGAATTCCTGAAGGGCATTCTTGATGC
AAGAAATGGAGGAGCGGTTCTTGGTGACAAAAGATGGGGTGCCATGGTCATTGTCAAGTCTCTGAATCACTTT
CAATGGCCATTAGATTGCACTAAAGGAGACATCACACTACACTAGCTCTGAGGGCAATATGATGCATATGCT
TTGTTGGGTGCTGATAATAAGATGCATATAATTCAAGAAAGTGGTGATGATGCTGACAGAAATAGCCAAACCTCC
CTTGATACTAAAGGATAATGTAACCGATCTGCATGCCCTCTGGTGTGAAAACAATAAGTTTCATTGTTCAAAGAG
ATGAAGCACGGATGACAATGCGTCGTACCTTCCTTTGGTCTGATGAAAAGCTTCTTATGAGGAAGAGCCAATT
CTCCGGCATGTGGAACCTCCTCTTTCTGCACTTCTTGAGTTGGACAAGTTGAAAGTGAAAGGATACAATGAAAT
GAAGTATACCCCATCACGGGATCGTCAATGGCATATCTACACACTTAGAAATACTGAAAACCCCAAAATGTTGC
ACCGGGTATTTTTCCGAACCCCTGTGTCAGGCAACCCAGTGTATCCAACAAGTTTCTTCCGGCCAGATTGGTGAC
ATGGAAGTTGGGAGTGCTGAAGAACCTCTGTCAATTTACATCAACCAGCATATTAAGATCTTTGATGACTGCTAT
AGAGGAATTGGAGCTTCACGCAATTAGAACTGGCCATTACACATGTATTTGTCATGTATTGAAAGAACAAAAGC
TTCTTGATCTTTGTTCCAGTTTTCAGGGAATACAGTTTGGATGTTGGTCAAGATGAAGCTACGTCAATTTCACTT
TTAAAGAAATGGCTATGAAGATACATGAACCTGTTGGTGCAAGAATGCACCATCTTTCTGTATGCCAATGGGA
AGTGAAACTTAAAGTTGGACTGCGATGGTCTGCCAGTGGTACCTGGAGGATTGTAACAACCAATGTTACTAGTC
ACACTTGCACCTGTGGATATCTACCGTGAGATGGAAGATAAAGAATCACGGAAGTTAGTATACCATCCCGCCACT
CCGGCGGCTGGTCTCTGTCATGGTGTGGCACTGAATAATCCATATCAGCCTTTGAGTGTCAATTGATCTCAAACG
CTGTTCTGCTAGGAATAATAGAACTACATACTGCTATGATTTTCCACTGGCATTGAAACTGCAGTGAGGAAGT
CATGGTCCCTCTAGTACCTCTGGTGCTTCTAAAGGTGTTGAAAATGCCCAATGTTATGTTAAAGCTACAGAGTTG
GTATTTGCGGACAAACATGGGTCATGGGGCACTCCTTTAGTTCAAATGGACCGGCTGCTGGGCTCAATGACAT
TGGTATGGTAGCTTGGACCTTGAAGATGTCCACTCCTGAATTTCTAGTGGTAGGGAGATTATTGTTGTTGCAA
ATGATATTACGTTTCAAGAGCTGGATCATTTGGCCCAAGGGAAGATGCATTTTTTGAAGCTGTACCAACCTAGCC
TGTGAGAAGAACTTCCTCTTATTTATTTGGCAGCAAAATCTGGTGTCTGAATTGGCATAGCAGATGAAGTGAA
ATCTTGCTTCCGTGTTGGGTGGTCTGATGTGGCAGCCCTGAACCTGGGTTTCAGTACATTTATCTAAGCGAAG
AAGACTATGCTCGTATTGGCACTTCTGTATAGCACATAAGATGCAGCTAGACAGTGGTGAATTAGGTGGGTT
ATTGATTCTGTTTGGGCAAGGAAGATGGACTTGGTGTGGAGAATATACATGGAAGTGCTGCTATTGCCAGTGC
TTATTTAGGGCATATAAGGAGACATTTACACTTACATTTGTGACTGGAAGAACTGTTGGAATAGGAGCTTATC
TTGCTCGACTTGGCATCCGGTGCATACAGCGTCTTGACCAGCCTATTATTCTTACAGGCTATTTCTGCACCTGAAC
AAGCTTCTTGGGCGGAAGTGTACAGCTCCCACATGCAGTTGGGTGGTCCCAAAATCATGGCAACTAATGGTGT
TGTCCATCTTACTTTTCAGATGACCTTGAAGGCGTTTCTAATATATTGAGGTGGCTCAGTTATGTTCCCTGCCCT
ACATTGGTGGACCACTTCCAGTAACAACACCGTTGGACCCACCGGACAGACCTGTTGCATACATTCTTGAGAAC
TCGTGTGATCCTCGAGCGGCTATCCGTGGTGTGATGACAGCCAAGGGAATGTTAGGTGGTATGTTTGATAA
AGACAGCTTTGTGGAACATTTGAAGGTTGGGCTAAGACAGTGGTTACTGGCAGAGCAAAGCTTGGTGGAAATTC
CAGTGGGTGTGATAGCTGTGGAGACTCAGACCATGATGCAAACTATCCCTGCTGACCCTGGTCAGCTTGATTCC
CGTGAGCAATCTGTTCCCTCGTGTGGACAAGTGTGGTTTCCAGATTCTGCAACCAAGACTGCGCAGGCATGCT
GGACTTCAACCGTGAAGGATTACCTCTGTTTCATCCTCGCTAACTGGAGAGGCTTCTCTGGTGGACAAAGAGATC
TTTTTGAAGGAATTTCTCAGGCTGGCTCGACTATTGTTGAGAACCCTTAGGACATACAATCAGCCTGCCTTTGTC
TACATTTCCCATGGCTGCAGAGCTACGAGGAGGGGCTTGGGTTGTGGTTGATAGCAAGATAAACCAGACCGCAT
TGAGTGCTATGCTGAGAGGACTGCAAAAGGCAATGTTCTGGAACCGCAAGGGTTAATTGAGATCAAGTTCAAGG
CAGAGGAACTCCAGGATTGCATGAGTCGGCTTGACCAACATTAATGATCTGAAAGCAAACTCGAAGTAGCA
AATAAAAATGGAAGTGCTGACACAAAATCGCTTCAAGAAAATATAGAAGCTCGAACAAAACAGTTGATGCCTCT
ATATACTCAGATTGCGATACGGTTTGGTGAATTGCATGATACATCCCTCAGAATGGCTGCGAAAGGTGTGATTA
AGAAAGTTGTGGACTGGGAAGAATCACGATCTTTCTTCTATAAGAGATTACGGAGGAGGATCTCTGAGGATGTT
CTTGCAAAAAGAAATTAGAGCTGTAGCAGGTGAGCAGTTTTCCACCAACAGCAATCGAGCTGATCAAGAAATG
GTATTCAGCTTCACATGCAGCTGAATGGGATGATGACGATGCTTTTGTGCTTGGATGGATAACCCCTGAAAAC
ACAAGGATTATATTCAATATCTTAAGGCTCAAAGAGTATCCCAATCCCTCTCAAGTCTTTCAGATTCCAGCTCA
GATTTGCAAGCCCTGCCACAGGTCTTTCCATGTTACTAGATAAGATGGATCCCTCTAGAAGAGCTCAACTGTG
TGAAGAAATCAGGAAGGTCCTTGGTTGA

FIGURE 7C

>*Oryza sativa* Plastidic ACCase protein

MTSTHVATLGVGAQAPPRHQKKSAGTAFVSSGSSRPSYRKNQQRTRSLREESNGGVSDSKKLNHSIRQGLAGII
 DLPNDAAASEVDISHGSEDPRGPTVPGSYQMNGIINETHNGRHASVSKVVEFCTALGGKTPIHSVLVANNGMAAA
 KFMRSVRTWANDTFGSEKAIQLIAMATPEDLRINAEHIRIADQFVEVPGGTNNNNYANVQLIVEIAERTGVSAAV
 WPGWGHASENPELDPALTAKGIVFLGPPASSMHALGDKVGSALIAQAAGVPTLAWSGSHVEVPLECCLD SIPDE
 MYRKACVTTTTEEAVASCQVVGYPAMIKASWGGGGKGIRKVNNDDEVRTLKQVQGEVPGSPIFIMRLAAQSRHL
 EVQLLCQYGNVAALHSRDCSVQRRHQKIIIEEGPVTVAPRETVKELEQAARRLAKAVGYVGAATVEYLYSMETG
 EYFFLELNPRLOVEHPVTEWIAEVNLPAAQVAVGMGIPLWQIPEIRRFYGMNHGGGYDLWRKTAALATPFNFDE
 VDSKWPKGHCVAVRITSEDPDDGKPTGGKVKEISFKSKPNVWAYFSVKSGGGIHEFADSQFGHVFAYGTTTSA
 AITTMALALKEVQIRGEIHSNVDTVDLLNASDFRENKIHTGWLDTRIAMRVQAERPPWYISVVGALYKTVTA
 NTATVSDYVGYLTGQIPPKHISLVYTTVALNIDGKKYITDTVRSGHGSYRLRMNGSTVDANVQILCDGGLMQ
 LDGNSHYIYAEEEASGTRLLIDGKTCMLQNDHDP SKLLAETPCKLLRFLVADGAHVDAVPAEVEVMKCMPL
 LSPASGVHIVVMSEGAQAGDLIARLDLDDPSAVKRAEPFEDTFPQMGLPIAASGQVHKLCAASLNACRMILA
 GYEHDIKVVPELVYCLDTPPELPELQWEELMSVLATRLPRNLKSELEGKYEEYKVKFDSGIINDFPANMLRVI
 EENLACGSEKEKATNERLVEPLMSLLKSYEGGRESHAHFVVKSLFEEYLYVEELFSDGIQSDVIERLRLQHSKD
 LQKVVDIVLSHQSVRNKTKLILKLMSLVYPNPAAYRDQLIRFSSLNHKAYYKLALKASELLEQTKLSELRARI
 ARSLSELEMFTEESKGLSMHKREIAIKESMEDLVTAPLPVEDALISLFDSDTTVQQRVIETYIARLYQPHLVK
 DSIKMKWIESGVIALWEFPEGHFDARNGGAVLGDKRWGAMVIVKSLESLSMAIRFALKETSHYTSSEGNMMHIA
 LLGADNKMHI IQESGDDADRIAKLPLILKDNVTDLHASGVKTIISFIVQDEARMTRRTFLWSDEKLSYEEFPI
 LRHVEPPLSALLELDKLKVKGYNEMKYTPSRDRQWHIYTLRNTENPKMLHRVFFRTLVRQPSVSNKFSSGQIGD
 MEVGSAAEPLSFTSTSILRSLMTAIEELELHAIRTGHSMYLHVLKEQKLLDLVPVSGNTVLDVGQDEATAYSL
 LKEMAMKIHVLGARMHHL SVCQWEVKLKLDCDG PASGTWRIVTTNVT SHTCTVDIYREME DKESRKL VYHPAT
 PAAGPLHGVALLNNPYQPLSVI DLKRC SARNNRTTYCYDFLAFETA VRKSWSSSTSGASKGVENAQC YVKATEL
 VFADKHGSGWGTPLVQMDR PAGLNDIGMVAWTLK MSTPEFPGREIIVVANDITFRAGSFGPREDAFFEAVTNLA
 CEKKLPLIYLAANS GARI GIAD EVKSCFRV GWSDDGSPERG FQYIYLSEEDYARIGTSVIAHKMLDSDGEIRWV
 IDS VVGKEDGLGVENIHGSAIASAYSRAYKETFTLTFTVTGRTVGIGAYLARLGIRCIQRLDQPIILTGYSALN
 KLLGREVYSSHMQLG GPKIMATNGVVHLTVSDDLEGVSNILRWLSYVPAYIGGPLVTTPLDPPDRPVAYIPEN
 SCDPRAAIRGVDDSQGKWLGGMPDKDSFVETFE GWAKTVVTGRAKLGGIPVGVIAVETQTMMQTI PADPGQLDS
 REQSVPRAGQVWFPDSATKTAQALLDFNREG LPLFILANWRGFSGGQ RDLFE GILQAGSTIVENLRTYNQPAFV
 YIPMAAELRGGA WVVVDSKINPDRIECYAERTAKGNVLEPQGLIEIKFRSEELQDCMSRLDPTLIDLKAKLEVA
 NKNGSADTKSLQENIEARTKQIMPLYTQIAIRFAELHDTSLRMAAKGVIKKVV DWEESRSFFYKRLRRRI SEDV
 LAKEIRAVAGEQF SHQPAIELIKKWYSASHAAEWDDDDAFVAMMDN PENYKDYIQYLKAQRVSQSLSSLS DSSS
 DLQALPQGLSMLLDKMDPSRRAQLVEEIRKVLG*

FIGURE 8A

>AY312172_Zea mays

ATGTCACAGCTTGGATTAGCCGAGCTGCCTCAAAGGCCTTGCCACTACTCCCTAATCGCCAGAGAAGTTCAGCTGG
GACTACATTCTCATCATCTTTCATTATCGAGGCCCTTAAACAGAAAGGAAAGCCGTACTCGTTCCTCCGTGATGGCG
GAGATGGGGTATCAGATGCCAAAAGCAGCCAGTCTGTTCGTCAAGGTCTTGCTGGCATTATCGACCTCCCAAGT
GAGGCACCTTCCGAAGTGGATATTTACATGGATCTGAGGATCCTAGGGGGCCAAACAGATTCTTATCAAATGAATGG
GATTATCAATGAAACACATAATGGAAGACATGCCCTCAGTGTCCAAGGTGTGTGAATTTTGTGCGGCACTAGGTGGCA
AAACACCAATTCACAGTATATTTAGTGGCCAACAATGGAATGGCAGCAGCAAAATTTATGAGGAGTGTCCGGACATGG
GCTAATGATACTTTTGGATCTGAGAAGGCAATTCAACTCATAGCTATGGCAACTCCGGAAGACATGAGGATAAATGC
AGAACACATTAGAATTGCTGACCAATTCGTAGAGGTGCCTGGTGGAAACAAACAATAAATACTACGCCAATGTTCAAC
TCATAGTGGAGATGGCACAATACTAGTGTCTTCTGCTGTTTGGCCTGGTTGGGGTCATGCTTCTGAGAATCCTGAA
CTGCCAGATGCATTGACCGCAAAAGGGATCGTTTTCTTGGCCACCTGCATCATCAATGAATGCTTTGGGAGATAA
GGTCGGCTCAGCTCTCATTTGCTCAAGCAGCCGGGGTCCCACCTCTTGCTCGGAGTGGATCACATGTTGAAGTTCAT
TAGAGTGTCTGTAGACGCGATACCTGAGGAGATGTATAGAAAAGCTTGCCTTACTACCACAGAGGAAGCAGTTGCA
AGTTGTCAAGTGGTTGGTTATCTGCCATGATTAAGGCATCCTGGGAGGTGGTGGTAAAGGAATAAGAAAGGTTCA
TAATGATGATGAGGTTAGAGCGCTGTTTAAAGCAAGTACAAGGTGAAGTCCCTGGCTCCCAATATTTGTGATGAGGC
TTGCATCCAGAGTCGGCATCTTGAAGTTCAGTTGCTTTGTGATCAATATGGTAATGTAGCAGCACTTCACAGTCGT
GATTGCAGTGTGCAACGGCGACACCAGAAGATTATTGAAGAAGGTCCAGTTACTGTTGCTCCTCGTGAGACAGTTAA
AGCACTTGAGCAGGCAGCAAGGAGGCTTGCTAAGGCTGTGGGTTATGTTGGTGTCTACTGTTGAGTATCTTTACA
GCATGGAAACTGGAGACTACTATTTCTGGAACCTAATCCCCGACTACAGGTTGAGCATCCAGTCACCGAGTGGATA
GCTGAAGTAAATCTGCCTGCAGCTCAAGTTGCTGTTGGAATGGGCATACCTCTTGGCAGATTCAGAAATCAGACG
TTTCTATGGAATGGACTATGGAGGAGGTATGACATTTGGAGGAAAACAGCAGCTCTTGCTACACCATTTAATTTTG
ATGAAGTAGATTCTCAATGGCCAAAGGGCCATTGTGTAGCAGTTAGAATTACTAGTGAGGACCCAGATGATGGTTTC
AAACCTACTGGTGGGAAAGTGAAGGAGATAAGTTTAAAGCAAGCCTAATGTTTGGGCCTACTTCTCAGTAAAGTC
TGGTGGAGGCATTCATGAATTTGCTGATTCCTCAGTTCGGACATGTTTTCATATATGGGCTCTCTAGATCAGCAGCAA
TAACAAACATGACTCTTGCATTAAAAGAGATTCAATTCGTGGAGAAATTCATTCAATGTTGATTACACAGTTGAC
CTCTTAAATGCTTCAGACTTTTAGAGAAAACAAGATTCACTGTTGGCTCGACACCAGAATAGCTATGCGTGTTC
AGCTGAGAGGCCCCCATGGTATATTTTCAAGTGGTGGAGGTGCTTTATATAAAACAGTAACCACCAATGCAGCCACTG
TTTCTGAATATGTTAGTTATCTCACCAAGGGCCAGATTCACCAAAAGCATATATCCCTTGTCAATTCACAGTTAAT
TTGAATATAGAAGGGAGCAAAATACACAATGAAACTGTAAGGACTGGACATGGTAGCTACAGTTGAGAATGAATGA
TTCAACAGTTGAAGCGAATGTACAATCTTTATGTGATGGTGGCCCTCTAATGCAGTTGGATGGAAACAGCCATGTAA
TTTTATGCAGAAGAAGAAGCTGGTGGTACACGGCTTCAGATTGATGGAAGACATGTTTATTGCAGAATGACCATGAT
CCATCAAAGTTATTAGCTGAGACACCTGCAAACCTCTTCGTTTCTTGGTTGCTGATGGTGTCTCATGTTGATGCGGA
TGTACCATACGCGGAAGTTGAGGTTATGAAGATGTGCATGCCTCTCTGTGCACTGCTCTGTTGTCTATTGTTA
TGATGTCTGAGGGCCAGGCATTGCAGGCTGGTGATCTTATAGCAAGGTTGGATCTTGATGACCTTCTGCTGTGAAA
AGAGCTGAGCCATTTGATGGAATATTTCCACAAATGGAGCTCCCTGTGCTGTCTCTAGTCAAGTACACAAAAGATA
TGCTGCAAGTTTGAATGCTGCTCGAATGGTCTTGCAGGATATGAGCACAATATTAATGAAGTCGTTCAAGATTTGG
TATGCTGCCTGGACAACCTGAGCTTCCTTTCCCTACAGTGGGATGAACCTTATGTCTGTCTAGCAACGAGGCTTCCA
AGAAATCTCAAGAGTGAGTTAGAGGATAAATACAGGAATACAAGTTGAATTTTACCATGGAATAAACGAGGACTT
TCCATCCAAGTTGCTAAGAGACATCATTTAGGAAAATCTTTCTTATGGTTTACAGAGAAGGAAAAGGCTACAAATGAGA
GGCTGTTTGGAGCTCTTATGAACCTACTGAAGTCATATGAGGGTGGGAGAGAGAGCCATGCACATTTTGTGTCAAG
TCTCTTTTCGAGGAGTATCTTACAGTGAAGAATCTTTTAGTGATGGCATTCACTGACGTGATTGAAACATTGCG
GCATCAGCACAGTAAAGACCTGCAGAAGGTTGTAGACATTGTGTTGCTCACCAGGGTGTGAGGAAACAAAGCTAAGC
TTGTAACGGCACTTATGGAAGGCTGGTTTATCCAATCCTGGTGGTTACAGGGATCTGTTAGTTTCGCTTTTCTTCC
CTCAATCATAAAAGATATTATAAGTTGGCCCTTAAAGCAAGTGAACCTCTTGAACAAACCAAATAAGTGAACCTCCG
TGCAAGCGTTGCAAGAAGCCTTTTCGGATCTGGGGATGCATAAGGGAGAAATGAGTATTAAGGATAACATGGAAGATT
TAGTCTCTGCCCCATTACCTGTGAAGATGCTCTGATTTCTTGTGTTGATTACAGTGTATCGAATGTTTACAGAGAAA
GTGATTGAGACATACATATCACGATTGTACCAGCCTCATCTGTAAAGGATAGCATCCAATGAAATTCAGGAATC
TGGTGCTATTACTTTTGGGAATTTATGAAGGCATGTTGATACAGAAATGGACATGGGGCTATTATGGTGGGA
AGCGATGGGGTGCCATGGTCTCTCAATCACTGAAATCTGCGTCAACAGCCATTGTGGCTGCATTAAGGATTGCG
GCACAGTTCAACAGCTCTGAGGGCAACATGATGCACATTGCATTATTGAGTGTGAAAATGAAAGTAATATAAGTGG
AATAAGCAGTGATGATCAAGCTCAACATAAGATGGAAGGCTTAGCAAGATACTGAAGGATACTAGCGTTGCAAGTG
ATCTCCAAGCTGCTGGTTTGAAGGTTATAAGTTGCATTGTTCAAAGAGATGAAGCTCGCATGCCAATGCGCCACACA

TTCTCTGGTTGGATGACAAGAGTTGTTATGAAGAAGAGCAGATTCTCCGGCATGTGGAGCCTCCCCCTCTCTACACT
TCTTGAATTGGATAAGTTGAAGGTGAAAGGATACAATGAAATGAAGTATACTCCTTCGCGTGACCGCCAATGGCATA
TCTACACACTAAGAAATCTGAAAACCCCAAATGTTGCATAGGGTGTTCCTCGAATATTGTGAGGCAACCCAAT
GCAGGCAACAAGTTTACATCGGCTCAGATCAGCGACGCTGAAGTAGGATGTCCCGAAGAATCTCTTTTATTACATC
AAATAGCATCTTAAGATCATTGATGACTGCTATTGAAGAATTAGAGCTTCATGCAATTAGGACAGGTCAATTCTCACA
TGTATTTGTGCATACTGAAAGAGCAAAAGCTTCTTGACCTCATTCCATTTTCAGGGAGTACAATTGTGATGTTGGC
CAAGATGAAGCTACCGCTTGTTCACTTTTAAATCAATGGCTTTGAAGATACATGAGCTTGTTGGTGCAAGGATGCA
TCATCTGTCTGTATGCCAGTGGGAGGTGAAACTCAAGTTGGACTGTGATGGCCCTGCAAGTGGTACCTGGAGAGTTG
TAACTACAAATGTTACTGGTCACACCTGCACCATTGATATATACCGAGAAGTGGAGGAAATAGAATCGCAGAAGTTA
GTGTACCATTACGCCACTTCGTGAGCTGGACCATTCATGGTGTGCTGACTGAATAATCCATATCAACCTTTGAGTGT
GATTGATCTAAAGCGCTGCTCTGTCTAGGAACAACAGAACACATATTGCTATGATTTTCGCGTGGCTTTTGAACTG
CACTGCAGAAGTCATGGCAGTCCAATGGCTCTACTGTTTCTGAAGGCAATGAAAATAGTAAATCCTACGTGAAGGCA
ACTGAGCTAGTGTGTTGCTGAAAAACATGGGTCTGGGGCCTCCTATAATTCGATGGAACGCCCTGCTGGGCTCAA
CGACATTGGTATGGTTCGCTTGGATCATGGAGATGTCAACACCTGAATTTCCCAATGGCAGGCAGATTATTGTTGTAG
CAAATGATACTACTTTAGAGCTGGATCATTGGGCCAAGGGAAGATGCATTTTGAAGTGTCACTAACCTGGCT
TGCGAAAGGAACTTCCCTCTATATACCTGGCAGCAAACTCTGGTGCTAGGATTGGCATAGCTGATGAAGTAAATC
TTGCTTCCGTGTTGGATGGTCTGACGAAGGCAGTCTGAACGAGGGTTTCAGTACATCTATCTGACTGAAGAAGACT
ATGCTCGCATTAGCTCTTCTGTATAGCACATAAGCTGGAGCTAGATAGTGGTGAATAGGTTGATTATTGACTCT
GTTGTGGGCAAGGAGGATGGGCTTGGTGTGCGAGAACATACATGGAAGTGTGCTATTGCCAGTGGTTATTCTAGGGC
ATATGAGGAGACATTTACACTTACATTTGTGACTGGGCGGACTGTAGGAATAGGAGCTTATCTTGCTCGACTTGGTA
TACGGTGCTATACAGCGTCTTGACAGCCTATTATTTTAACAGGGTTTCTGCGCTGAACAAGCTCTTGGGCGGGAA
GTGTACAGCTCCACATGCAGCTTGGTGGTCTAAGATCATGGCGACTAATGGTGTGTCACCTCACTGTTCCAGA
TGACCTTGAAGGTGTTTCCAATATATTGAGGTGGCTCAGCTATGTTCTGCAACATTGGTGGACCTCTTCTCTATTA
CCAAACCTCTGGACCTCCAGACAGACCTGTTGCTTACATCCCTGAGAACACATGCGATCCACGTGCAGCTATCTGT
GGTGTAGATGACAGCCAGGGAAATGGTTGGGTGGTATGTTTGACAAAGACAGCTTTGTGGAGACATTTGAAGGATG
GGCAAAACAGTGGTTACTGGCAGAGCAAAGCTTGGAGGAATTCCTGTGGGCGTCATAGCTGTGGAGACACAGACCA
TGATGCAGATCATCCCTGCTGATCCAGGTGAGCTTGATTCCCATGAGCGATCTGTCCCTCGTGTGGACAAGTGTGG
TTCCAGATTCTGCAACCAAGACCGCTCAGGCAATTATTAGACTTCAACCGTGAAGGATTGCCTCTGTTCTATCTGGC
TAATTGGAGAGGCTTCTCTGGTGGACAAAGAGATCTCTTTGAAGGAATCTTTCAGGCTGGGTCAACAATTGTCGAGA
ACCTTAGGACATCTAATCAGCCTGCTTTTGTGTACATTCCTATGGCTGGAGAGCTTCGTGGAGGAGCTTGGGTGTG
GTGATAGCAAAATAAATCAGACCGCATTGAGTGTATGCTGAAAGGACTGCCAAAGTAATGTTCTCGAACCTCA
AGGGTTAATTGAAATCAAGTTCAGGTGAGGGAATCCAAAGACTGTATGGGTAGGCTTGACCCAGAGTTGATAAATC
TGAAAGCAAACTCCAAGATGTAAATCATGGAATGGAAGTCTACCAGACATAGAAGGGATTCCGAAGAGTATAGAA
GCACGTACGAAACAGTTGCTGCCTTTATATACCCAGATTGCAATACGGTTTGCTGAATGCGATGATACTTCCCTAAG
AATGGCAGCTAAAGGTGTGATTAAGAAAGTGTAGACTGGGAAGAATCACGCTCGTTCCTCTATAAAAGGCTACGGA
GGAGGATCGCAGAAGATGTTCTTGCAAAAGAAATAAGGCAGATAGTCGGTGATAAATTTACGCACCAATTAGCAATG
GAGCTCATCAAGGAATGGTACCTTGCTTCTCAGGCCACAACAGGAAGCACTGGATGGGATGACGATGATGCTTTTGT
TGCTTGAAGGACAGTCTGAAACTACAAGGGGCATATCCAAAAGCTTAGGGCTCAAAAAGTGTCTCATTCGCTCT
CTGATCTTGCTGACTCCAGTTCAGATCTGCAAGCATCTCGCAGGGTCTTTCTACGCTATTAGATAAGATGGATCCC
TCTCAGAGAGCGAAGTTTGTTCAGGAAGTCAAGAAGTCTTGATTGA

FIGURE 8B

>AAP78897_Zea Mays

MSQLGLAAAASKALPELLPNRQRSSAGTTFFSSSSLSRPLNRRKSRTRSLRDGGDGVSDAKKHSQSVRQGLAGIID
LPSEAPSEVDISHGSEDPRGPTDSYQMNGIINETHNGRHASVSKVVEFCAALGGKTPIHSLVANNGMAAAKFM
RSVRTWANDTFGSEKAIQLIAMATPEDMRINAHERIADQFVEVPGGTNNNNYANVQLIVEMAQKLGVS AVWPG
WGHASENPELPDALTAKGIVFLGPPASSMNALGDKVGSALIAQAAGVPTLARSGSHVEVPLECCLDAIPEEMYR
KACVTTTEEAVASCQVVGYPAMIKASWGGGKGIRKVNHDDEVRALEFKQVQGEVPGSPIFVMRLASQSRHLEVQ
LLCDQYGNVAALHSRDCSVQRRHQKIIIEEGFVTVAPRETVKALEQAARRLAKAVGYVGAATVEYLYSMETGDYY
FLELNPRLOVEHPVTEWIAEVLNLPAAQVAVGMGIPLWQIPEIRRFYGM DYGGGYDIWRKTAALATPFNFDEVDS
QWPKGHCVAVRITSEDPDDGFKPTGGKVKEISFKSKPNVWAYFSVKSGGGIHEFADSQFGHVFAAYGLSRSAIT
NMTLALKEIQIRGEIHSNVDTVDLLNASDFRENKIHTGWLDTRIAMRVQAERPPWYISVVGALYKTVTTNAA
TVSEYVSYLTKGQIPPKHISLVNSTVNLNIEGSKYTIETVRTGHGSYRLRMNDSTVEANVQSLCDGGLLMQLDQ
NSHVIYABEEAGGTRLQIDGKTCLLQNDHDFSKLLAETPCKLLRFLVADGAHVADVPYAEVEVMKMCMLLSP
ASGVIHCCMSEGQALQAGDLIARLDLDDPSAVKRAEPFDGIFPQMELPVAVSSQVHKRYAASLNAARMVLAGE
HNINEVVQDLVCCLDNPELPLFLQWDELMSVLATRLPRNLKSELEDKYKEYKLN FYHGKNE DFP SKLLRDIIEEN
LSYGSEKEKATNERLVEPLMNLKSYEGGRE SHAHFVVKSLFEEYLTVEELFSDGIQSDVIETLRHQH SKDLQK
VVDIVLSHQGVNRNKA KLVTALMEKLVYPNPGGYRDLVRFSSLNHKRYK LALKASELLEQTKLSELRASVARS
LSDLGMHKGEMSIKDNMEDLVSAPLPVEDALISLFDYSRDTVQKVIETYISRLYQPHLVKDSIQMKFKESGAI
TFWEFYE GHVDTRNGHGAII GGKRWGAMVVLKSLESASTAIVAALKDSAQFNSSEGNMMHIALLSAENESNIG
ISSDDQAQHKMEKLSKILKDTSVASDLQAAGLKVISCIQVRDEARMFMRHTFLWLDDKSCYEEEQILRHVEPPL
STLLELDKLVKGYNEMKYTPSRDRQWHIYTLRNTENPKMLHRVFFRTIVRQPNAGNKFTSAQISDAEVGCPPE
SLSFTSNSILRSLMTAIEEELHAI RTGHSHMYLCILKEQKLLDLIPFSGSTIVDVGQDEATACSLKSMALKI
HELVGARMHHL SVCQWEVKLKLDCGPASGTWRVVTNTVGTCTIDIYREVEEIESQKLVYHSATSSAGPLHG
VALNNPYQPLSVI DLKRC SARNNRTTYCYDFPLAFETALQKSWQNGSTVSEGNENSKSYVKATELVFAEKHGS
WGTPPIIPMER PAGLNDIGMVAWIMEMSTPEFPNGRQIIIVVANDITFRAGSFGPREDAFFETVTNLACERKLPLI
YLAANS GARIGIAD EVKSCFRV GWSDEGSPERGFQYIYLTEEDYARISSSVIAHKELD SGEIRWIIDSVVGKE
DGLGVENIHGSAAIASAYS RAYEETFTLTFTVGTGRTVGIGAYLARLGIRCIQRLDQPIILTGFSA LNKLLGREVY
SSHMQLGGPKIMATNGVVH LTVDDLEGVSNILRWLSYVPANIGGPLPITKPLDPPDRPVAYIPENTCDPRAAI
CGVDDSQGKWLGGMF DKDSFVETFE GWAKTVVTGR AKLGGIPVGVI AVETQTMQIIPADPGQLDSHERSVPR
AQVWFPSATKTAQALLDFNREGLPLFILANWRGFSGGQRDLFEGILQAGSTIVENLR TSNQPAFVYI PMAGEL
RGGAWVVVDSKINPDRIECYAERTAKGNVLEPQGLIEIKFRSEELQDCMGRLDPELINLKAKLQDVNHGNGSLP
DIEGIRKSIEARTKQLLPLYTQIAIRFAELHDTSLRMAAGVVIKKVVDWEESRSFFYKRLRRRIAEDVLAKAIR
QIVGDKFTHQLAMELIK EWYLASQATTGSTGWDDDDAFVAWKDSPENYKGHIQKLRAQKVSHSLSDLADSSSDL
QAFSQGLSTLLDKMDPSQRAK FVQEVKKVLD

FIGURE 9A

>AY312171 Zea mays

ATGTCACAGCTTGGATTAGCCGAGCTGCTCAAAGGCCTTGCCACTACTCCCTAATCGCCAGAGAAGTTAGCTGG
GACTACATTCTCATCATCTTCATTATCGAGGCCCTTAAACAGAAGGAAAAGCCGTACTCGTTCACTCCGTGATGGCG
GAGATGGGGTATCAGATGCCAAAAGCAGCCAGTCTGTTTCGTCAAGGTCTTGCTGGCATTATCGACCTCCCAAGT
GAGGCACCTTCCGAAGTGGATATTTACATGGATCTGAGGATCCTAGGGGGCCAAAGATTCTTATCAAATGAATGG
GATTATCAATGAAACACATAATGGAAGACATGCCTCAGTGTCCAAGGTTGTTGAATTTTGTGCGGCACTAGGTGGCA
AAACACCAATTACAGTATATTAGTGGCCAAACAATGGAATGGCAGCAGCAAAATTTATGAGGAGTGTCCGGACATGG
GCTAATGATACTTTTGGATCTGAGAAGGCAATCAACTCATAGCTATGGCAACTCCGGAAGACATGAGGATAAATGC
AGAACACATTAGAATTGCTGACCAATTCGTAGAGGTGCCTGGTGGAAACAACAATAAATACTACGCCAATGTTCAAC
TCATAGTGGAGATGGCACAAAACCTAGGTGTTTCTGCTGTTTGGCCTGGTTGGGGTCATGCTTCTGAGAATCCTGAA
CTGCCAGATGCATTGACCGCAAAGGGATCGTTTTTCTTGGCCCACCTGCATCATCAATGAATGCTTTGGGAGATAA
GGTCGGCTCAGCTCTCATTGCTCAAGCAGCCGGGTCCCAACTCTTGCTTGGAGTGGATCACATGTTGAAGTTCCTAT
TAGAGTGTCTGCTTAGACGCGATACCTGAGGAGATGTATAGAAAAGCTTGCGTTACTACCACAGAGGAAGCAGTTGCA
AGTTGTCAAGTGGTTGTTATCTGCTGCCATGATTAAGGCATCTGCGGAGGTGCTGGGAGGTGTTGGTAAAGGAATAAGAAAGTTCA
TAATCATGATGAGGTTAGAGCGCTGTTTAAAGCAAGTACAAGTGAAGTCCCTGGCTCCCCAATATTTGTTCATGAGGC
TTGCATCCAGAGTCGGCATCTTGAAGTTCAGTTGCTTTGTGATCAATATGGTAATGTAGCAGACTTCACAGTCCGT
GATTGCAAGTGTGCAACGGCGACACCAGAGATTATGAAGAAGGTCCAGTTACTGTTGCTCCTCGTGAGACAGTTAA
AGCACTTGAGCAGGCAGCAAGGAGGCTTGCTAAGGCTGTGGGTTATGTTGGTGCTGCTACTGTTGAGTATCTTTACA
GCATGGAAACTGGAGACTACTATTTTCTGGAACCTAATCCCGACTACAGGTGAGCATCCAGTCAACCGAGTGGATA
GCTGAAGTAAATCTGCCTGCAGCTCAAGTTGCTGTTGGAATGGGCATACCTCTTTGGCAGATTCCAGAAATCAGACG
TTTCTATGGAATGGACTATGGAGGAGGTATGACATTGGAGGAAAACAGCAGCTCTGCTACACCATTAAATTTTG
ATGAAGTAGATTCTCAATGGCCAAAGGGCCATTGTGTAGCAGTTAGAATTACTAGTGAGGACCCAGATGATGGTTTC
AAACCTACTGGTGGGAAAGTGAAGGAGATAAGTTTAAAGCAAGCCTAATGTTTGGGCTACTCTCAGTAAAGTC
TGGTGGAGGCATTATGAATTTGCTGATTCTCAGTTGCGGACATGTTTTCATATGGGCTCTCTAGATCAGCAGCAA
TAACAAACATGACTCTTGCATTAAAAGAGATTCAAATTCGTGGAGAAATTCATTCAAATGTTGATTACACAGTTGAC
CTCTTAAATGCTTCAGACTTTAGAGAAAACAAGATTCACTACTGGTTGGCTCGACACCAGAATAGCTATGCGTGTTC
AGCTGAGAGGCCCCATGGTATATTTTCAAGTGGTTGGGGTCTTTATATAAAACAGTAACCACCAATGCAGCCACTG
TTTTCTGAATATGTTAGTTATCTCACCAGGGCCAGATTCCACCAAAGCATATATCCCTGTCAATTTCTACAGTTAAT
TTGAATATAGAAGGGAGCAAATACACAATTGAAACTGTAAGGACTGGACATGGTAGCTACAGGTTGAGAATGAATGA
TTCAACAGTTGAAGCGAATGTACAATCTTTATGTGATGTTGGCCTCTAATGCAAGTTGGATGGAAACAGCCATGTAA
TTTTATGCAAGAAGAAGCTGGTGGTACACGGCTTCAGATTGATGGAAAGACATGTTTATGCAAGATGACCATGAT
CCATCAAAGTTATTAGTGTAGACACCCCTGCAAACTTCTTCGTTTCTGTTGCTGATGGTGTCTGTTGATGCGGA
TGTACCATACGCGAAGTTGAGGTTATGAAGATGTGCATGCCTCTCTGTGCGCTGCTCTGGTGTCTATTCATTGTA
TGATGTCTGAGGGCCAGGCATTGCAGGCTGGTGTATCTTATAGCAAGGTTGGATCTTGATGACCTTCTGCTGTGAAA
AGAGCTGAGCCATTTGATGGAATATTTCCACAAATGGAGCTCCCTGTTGCTGTCTCTAGTCAAGTACACAAAAGATA
TGCTGCAAGTTGAATGCTGCTCGAATGGTCTTGCAGGATATGAGCACAAATATTAATGAAGTCGTTCAAGATTTGG
TATGCTGCTGGACAACCTGAGCTTCCCTTCTACAGTGGGATGAACCTTATGTCTGTCTAGCAACGAGGCTTCCA
AGAAATCTCAAGAGTGAGTTAGAGGATAAATACAAGGAATACAAGTTGAATTTTACCATGGAAAAACGAGGACTT
TCCATCCAAGTTGCTAAGAGACATCATTGAGGAAAATCTTTCTTATGGTTTCAGAGAAGGAAAAGGCTACAAATGAGA
GGCTTGTGAGCCTCTTATGAACCTACTGAAGTCAATGAGGGTGGGAGAGAGCCATGCACATTTTGTGTCAAG
TCTCTTTTCGAGGAGTATCTTACAGTGAAGAACCTTTTGTGATGGCATTCTGCTGACGTGATTGAAACATTGGC
GCATCAGCACAGTAAAGACCTGCAGAAGGTTGTAGACATTGTGTTGTCTCAGCAGGGTGTGAGGAAACAAGCTAAGC
TTGTAAACGGCACTTATGGAAGCTGGTTTATCCAAATCCTGGTGGTTACAGGGATCTGTTAGTTGCTTTCTTCC
CTCAATCATAAAAGATATTATAAGTTGGCCCTTAAAGCAAGTGAACCTCTTGAACAAACCAACTAAGTGAACCTCG
TGCAAGCGTTGCAAGAAGCCTTTCGGATCTGGGATGCATAAGGGAGAAATGAGTATTAAGGATAACATGGAAGATT
TAGTCTCTGCCCCATTACCTGTTGAAGATGCTCTGATTTCTTGTGTTGATTACAGTGATCGAAGTGTTCAGCAGAAA
GTGATTGAGACATACATATCAGGATTGTACCAGCTCATCTGTAAAGGATAGCATCCAATGAAATTCAGGAATC
TGGTGTCTATTACTTTTGGGAATTTTATGAAGGCATGTTGATACTAGAAATGGACATGGGGCTATTATTGGTGGGA
AGCGATGGGGTGCCATGGTCGTTCTCAATCACTTGAATCTGCGTCAACAGCCATTGTGGCTGCATTAAAGGATTCC
GCACAGTTCAACAGCTCTGAGGCAACATGATGCACATTGCAATTATGAGTGTGAAAATGAAAGTAAATATAAGTGG
AATAAGTGTGATCAAGCTCAACATAAGATGGAAGGCTTAGCAAGATACTGAAGGATACTAGCGTTGCAAGTGATC
TCCAAGCTGCTGGTTTGAAGTTATAAGTTGATTGTTCAAAGAGATGAAGCTCGCATGCCAATGCGCCACACATTC
CTCTGGTTGGATGACAAGAGTTGTTATGAAGAAGAGCAGATTCTCCGGCATGTGGAGCCTCCCTCTCTACACTTCT
TGAATTGGATAAGTTGAAGGTGAAAGGATACAATGAAATGAAGTATACTCCTTCGCGTGACCGCAATGGCATATCT
ACACACTAAGAAATACTGAAAACCCCAAAATGTTGCATAGGGTGTTTTCCGAACATATGTGTCAGGCAACCCAATGCA

GGCAACAAGTTTACATCGGCTCAGATCAGCGACGCTGAAGTAGGATGTCCCGAAGAATCTCTTTCAATTTACATCAAA
TAGCATCTTAAGATCATTGATGACTGCTATTGAAGAATTAGAGCTTCATGCCAATTAGGACAGGTCAATCTCACATGT
ATTTGTGCATACTGAAAGAGCAAAAGCTTCTTGACCTCATTCATTTTCAGGGAGTACAATTGTTGATGTTGGCCAA
GATGAAGCTACCCGCTTGTTCACCTTTAAAATCAATGGCTTTGAAGATACATGAGCTTGTGGTGCAAGGATGCATCA
TCTGTCTGTATGCCAGTGGGAGGTGAAACTCAAGTTGGACTGTGATGGCCCTGCAAGTGGTACCTGGAGAGTTGTAA
CTACAAATGTTACTGGTCACACCTGCACCATTGATATATACCGAGAAGTGGAGGAAATAGAATCGCAGAAGTTAGTG
TACCATTGAGCCACTTCGTGAGCTGGACCATTGCATGGTGTGCACTGAATAATCCATATCAACCTTTGAGTGTGAT
TGATCTAAAGCGCTGCTCTGCTAGGAACAACAGAACACATATTGCTATGATTTTCCGCTGGCCTTTGAACTGCAC
TGCAGAAGTCATGGCAGACCAATGGCTCTACTGTTTCTGAAGGCAATGAAATAGTAAATCCTACGTGAAGGCAACT
GAGCTAGTGTTTGGCTGAAAAACATGGGTCTGGGGCACTCCTATAATTCCGATGGAACGCCCTGCTGGGCTCAACGA
CATTGGTATGGTCGCTTGGATCATGGAGATGTCAACACCTGAATTTCCCAATGGCAGGCAGATTATTGTTGTAGCAA
ATGATATCACTTTCAGAGCTGGATCATTGGCCCCAAGGGAGATGCATTTTTTGAAACTGTCACTAACCTGGCTTGC
GAAAGGAACTTCTCTTATATACTTGGCAGCAAACTCTGGTGTAGGATTGGCATAGCTGATGAAGTAAATCTTG
CTTCCGTGTTGGATGGTCTGACGAAGGCAGTCTGAACGAGGGTTTCAGTACATCTATCTGACTGAAGAAGACTATG
CTCGCATTAGCTCTTCTGTTATAGCACATAAGCTGGAGCTAGATAGTGGTGAATTAGTGGATTATTGACTCTGTT
GTGGGCAAGGAGGATGGCTTGGTGTGCGAACAATACATGGAAGTGTGCTATTGCCAGTGCTTATTCTAGGGCATA
TGAGGAGACATTTACACTTACATTTGTGACTGGGCGACTGTAGGAATAGGAGCTTATCTTGCTCGACTTGGTATAC
GGTGATACAGCGTCTTGACCAGCCTATTATTTTAAACAGGGTTTTCTGCCCTGAACAAGCTCCTGGGCGGGAAGTG
TACAGCTCCCACATGCAGCTTGGTGGTCTTAAGATCATGGCGACTAATGGTGTGTCCACCTCACTGTTCCAGATGA
CCTTGAAGGTGTTTCCAATATATTGAGGTGGCTCAGCTATGTTCTGCAAACATTGGTGGACCTCTTCTTATTACCA
AACCTCTGGACCTCCAGACAGACCTGTTGCTTACATCCCTGAGAACACATGCGATCCACGTGCAGCTATCTGTGGT
GTAGATGACAGCCAAGGGAATGGTGGGTGGTATGTTTGACAAAGACAGCTTGTGGGAGACATTTGAAGGATGGG
AAAAACAGTGGTACTGCGAGAGCAAGCTTGGAGGAATTCCTGTGGGCGTCATAGCTGTGGAGACACAGACCATGA
TGCAGATCATCCCTGCTGATCCAGGTGACGCTTGATTCCCATGAGCGATCTGTCCCTCGTGTGGACAAGTGTGGTTC
CCAGATTCTGCAACCAAGACCGCTCAGGCATTATTAGACTTCAACCGTGAAGGATTGCCTCTGTTCATCTGGCTAA
TTGGAGAGGCTTCTCTGGTGGACAAAGATCTCTTTGAAGGAATTCCTCAGGCTGGGTCAACAATTGTGCGAGAACC
TTAGGACATATAATCAGCCTGCTTTTGTGTACATTCCTATGGCTGGAGAGCTTCGTGGAGGAGCTTGGGTTGTGGT
GATAGCAAAATAAATCCAGACCGCATTGAGTGTTATGCTGAAAGGACTGCCAAAGGTAAATGTTCTCGAACCTCAAGG
GTTAATTGAAATCAAGTTCAGGTCAGAGGAACCTCAAGACTGTATGGGTAGGCTTGACCCAGAGTTGATAAATCTGA
AAGCAAAACTCCAAGATGTAATCATGGAATGGAAGTCTACCAAGACATAGAAGGGATTGGAAGAGTATAGAAGCA
CGTACGAAACAGTTGCTGCTTTATATACCCAGATTGCAATACGGTTTGCTGAATTGCATGATACTTCCCTAAGAAT
GGCAGCTAAAGGTGTGATTAAGAAAGTTGTAGACTGGGAAGAATCACGCTCGTTCCTTATAAAAGGCTACGGAGGA
GGATCGCAGAAGATGTTCTTGCAAAAGAAATAAGGCAGATAGTCGGTGATAAATTTACGCACCAATTAGCAATGGAG
CTCATCAAGGAATGGTACCTTGCTTCTCAGGCCACAACAGGAAGCACTGGATGGGATGACGATGATGCTTTTGTGTC
CTGGAAGGACACTCCTGAAACTACAAGGGGCATATCCAAAGCTTAGGGCTCAAAAAGTGTCTCATTGCTCTCTG
ATCTTGCTGACTCCAGTTCAGATCTGCAAGCATTCTCGCAGGCTCTTCTACGCTATTAGATAAGATGGATCCCTCT
CAGAGAGCGAAGTTTGTTCAGGAAGTCAAGAAGTCCCTTGATTGA

FIGURE 9B

>AAP78896_Zea mays

MSQLGLAAAAASKALPLLPNRQRSSAGTTFFSSSSLSRPLNRRKSRTRSLRDGGDGVSDAKKHSQSVRQGLAGIID
LPSEAPSEVDISHGSEDPGPTDSYQMNIGIINETHNGRHASVSKVVEFCAALGGKTPIHSLVANNGMAAAKFM
RSVRTWANDTFGSEKAIQLIAMATPEDMRINAEHRIADQFVEVPGGTNNNNYANVQLIVEMAQKLGVS AVWPG
WGHASENPELPDALTAKGIVFLGFPASSMNALGDKVGSALIAQAAGVPTLAWSGSHVEVPLECCLDAIPEEMYR
KACVTTTEEAVASCQVVGYPAMIKASWGGGGKGIRKVHNDDEVRALEFKQVQGEVPGSPIFVMRLASQSRHLEVQ
LLCDQYGNVAALHSRDCSVQRRHQKII EEGFVT VAPRET VKALEQAARRLAKAVGYVGAATVEYLYSMETGDYY
FLELNPRLQVEHPVTEWIAEVLNLPAAQVAVGMGIPLWQIPEIRRFYGM DYGGGYDIWRKTAALATPFNFDEVDS
QWPKGHC VAVRITSEDPDDGFKPTGGKVKEISFKSKPNVWAYFSVKSGGGIHEFADSQFGHV FAYGLSRSAIT
NMTLALKEIQIRGEIHSNVDYTVDLLNASDFRENKIHTGWLDTRIAMRVQAERP PWYISVVGALYKTVTNA
TVSEYVSYLTKGQIPPKHISLVNSTVNLNIEGSKYTIETVRTGHGSYRLRMNDSTVEANVQSLCDGGLLMQLD
NSHVIYAE EEEAGGTRLQIDGKTCLLQNDHDFSKLLAETPCKLLRFLVADGAHV DADVPYAEVEVMKMCMLLSP
ASGVIHCCMMSEGQALQAGDLIARLDLDDPSAVKRAEPFDGIFPQMELPVAVSSQVHKRYAASLNAARMVLAGYE
HNINEVVQDLVCCLDNPPELPFLQWDELMSVLATRLPRNLKSELEDKYKEYKLN FYHGKNE DFP SKLLRDI I EEN
LSYGSEKEKATNERLVEPLMNLKSYEGGRESHAFVVKSLFEEYLTVEELFSDGI QSDVIETLRHQH SKDLQK
VVDIVLSHQGV RNKAKLV TALMEKLVYPNPGGYRDL LVRFSSLNHKRYYKLALKASELLEQTKLSELRASVARS
LSDLGMHKGEMSIKDNMEDLVSAFLPVEDALISLFDYSDRTVQQKVIETIYISRLYQPHLVKDSIQMKFKESGAI
TFWEFYEGHVDTRNGHGAII GGKRWGAMVVLKSLESASTAIVAALKDSAQFNSSEGNNMHIALLSAENESNISG
ISDDQAQHKMEKLSKILKDTSVASDLQAAGLKVISCIVQRDEARMPMRHTFLWLDDKSCYEEEQILRHVEPPLS
TLEELD KLVKGYNEMKYTPSRDRQWHIYTLRNTENPKMLHRVFFRTIVRQPNAGNKFTSAQISDAEVCPEES
LSFTSNSILRSLMTAIEEELHAIRTGHS HMYLCILKEQKLLDLIPFSGSTIVDVGQDEATACSLKSMALKIH
ELVGARMHHL SVCQWEVKLKLDCGPASGTWRVVTNVTGHTCTIDIYREVEEIESQKLVYHSATSSAGPLHGV
ALNNPYQPLSVIDLKRC SARNNRTTYCYDFLAFETALQKSWQTNGSTVSEGNENSKSYVKATELVFAEKHGSW
GTPIIPMERPAGLNDIGMVAWIMEMSTPEFENGRIIVVANDITFRAGSFGPREDAFFETVTNLACERKPLIY
LAANS GARIGIAD EVKSCFRVGSDEGSPERGFQYIYLTEEDYARISSSVIAHKLELDSGEIRWIIDS VVGKED
GLGVENIHGSAATASAYSRA YEETFTLTFTVGTGRTVGIGAYIARLGIRCIQRLDQPIILTGFSALNKL LGREYVS
SHMQLGGPKIMATNGVVHLTVPDDLEGVSNILRWLSYVPANIGGPLPITKPLDPPDRPVAYIPENTCDPRAAIC
GVDDSQGKWLGGMFDKDSFVETFEGWAKTVVTGRAKLG GIPVGVI AVETQTMQIIPADPGQLDSHERSVPRAG
QVWFPSATKTAQALLDFNREGLELFI LANWRGFSGGQRLDFEGLLQAGSTIVENLR TYNQPAFVYI PMAGELR
GGAWVVVDSKINPDRIECYAERTAKGNVLEPQGLIEIKRSEELQDCMGRLDPELINLKAKLQDVNHGNGSLPD
IEGIRKSIEARTKQLLPLYTQIAIRFAELHDTSLRMAAGV I KKVVDWEESRSFFYKRLRRRIAEDVLAK EIRQ
IVGDKFTHQLAMELIKEWYLASQATTGSTGWDDDDAFVAKDSPENYKGHIQKLRAQKVSHSLSDLADSSDLQ
AFSQGLSTLLDKMDPSQRAKFVQEVKKVLD

FIGURE 10A

>AF029895_Triticum aestivum

ATGGGATCCACACATTTGCCCATTTGTCGGCCTTAATGCCTCGACAACACCATCGCTATCCACTATTCGCCCGGTAAA
TTCAGCCGGTGCTGCATTCCAACCATCTGCCCTTCTAGAACCTCCAAGAAGAAAAGTCGTCGTGTTGAGTCATTAA
GGGATGGAGGCGATGGAGGCGTGTGAGACCTAACAGTCTATTCCGCAAGGTCTTGCCGGCATATTGACCTCCCA
AAGGAGGGCACATCAGCTCCGGAGTGGATATTTACATGGGTCCGAAGAACCAGGGGCTCCTACCAATGAATGG
GATACTGAATGAAGCACATAATGGGAGGCATGCTTCGCTGTCTAAGGTTGTCGAATTTGTATGGCATTGGGCGGCA
AAACACCAATTCACAGTGTATTAGTTGCGAACATGGAATGGCAGCAGCTAAGTTCATGCGGAGTGTCCGAACATGG
GCTAATGAAACATTTGGGTGAGAGAAGGCAATTCAGTTGATAGCTATGGCTACTCCAGAAGACATGAGGATAAATGC
AGAGCACATTAGAATTGCTGATCAATTTGTTGAAGTACCCGGTGGAAACAAACAATAACAATATGCAAATGTCCAAC
TCATAGTGGAGATAGCAGTGAGAACCGGTGTTTCTGCTGTTTGGCCTGGTTGGGGCCATGCATCTGAGAATCCTGAA
CTTCCAGATGCACTAAATGCAAACGGAATGTTTTTCTTGGGCCACCATCATCATCAATGAACGCACTAGGTGACAA
GGTTGGTTCAGCTCTCATTGCTCAAGCAGCAGGGGTTCGACTCTTCCTTGGAGTGGATCAGAGTGGAAATTCAT
TAGAAGTTTGTGGACTCGATACCCCGGAGATGTATAGGAAAGCTTCTGTAGTACTACGGAGGAAGCACTTGCG
AGTTGTCAGATGATTGGGTATCCCGCCATGATTAAGCATCATGGGTGGTGGTAAAGGGATCCGAAAGGTTAA
TAATGACGATGATGTGAGGCACTGTTTAAGCAAGTGAAGTTCCTGGCTCCCAATATTTATCATGAGAC
TTGCATCTCAGAGTCGACATCTTGAAGTTCAGTTGCTTTGTGATCAATATGGCAATGTAGCTGCCGTTTACAGTCTG
GACTGCAGTGTGCAACGGCGACACCAAAAGATTATTGAGGAAGGACCAGTTACTGTTGCTCCTCGGAGACAGTGAA
AGAGCTAGAGCAAGCAGCAAGGAGGCTTGCTAAGGCTGTGGGTATGTTGGTGTGCTACTGTTGAATATCTCTACA
GCATGGAGACTGGTGAATACTATTTTCTGGAATTAATCCACGGTTGAGGTTGAGCATCCAGTCAACGAGTGGATA
GCTGAAGTAACTTGCTGCAGTCAAGTTCAGTTCGAAATGGGTATACCCCTTTGGCAGGTTCCAGAGATCAGACG
TTTTCTATGGAATGGACAAATGGAGGAGGCTATGACATTTGGAGGAAAACAGCAGCTCTTGCTACTCCATTTAAGTTCG
ATGAAGTGGATTCTCAATGGCCAAAGGGTCATTGTGTAGCAGTTAGGATAACCAAGTGGAGATCCAGATGACGGATTC
AAGCCTACCGTGGAAAGTAAAGGAGATCAGTTTAAAAGCAAGCCAAATGTTTGGGCTATTTCTCTGTTAAGTC
CGGTGGAGGCATTATGAATTTGCTGATTCTCAGTTTGGACATGTTTTTGCATATGGAGTGTCTAGAGCAGCAGCAA
TAACCAACATGTCTCTTGGCTAAAAGAGATTCAAATTCGTGGAGAAATTCATTCAAATGTTGATTACACAGTGTAT
CTCTTGAATGCCTCAGACTTCAAAGAAAACAGGATTCATACTGGCTGGCTGGATAACAGAATAGCAATGCGAGTCCA
AGCTGAGAGACCTCCGTGGTATATTTCACTGGTTGGAGGAGCTCTATATAAAACAATAACGAGCAACACAGACACTG
TTTCTGAATATGTTAGCTATCTCGTCAAGGGTCAGATTCCACCGAAGCATATATCCCTTGTCCATTCAACTGTTCCT
TTGAATATAGGAAAGCAATATACAATTGAACTATAAGGAGCGGACAGGTTAGCTACAGATTGCGAATGAATGG
ATCAGTTATTGAGCAATGTCCAAACATTTATGTGATGGTGGACTTTTAATGCAAGTGGATGGAACAGCCATGTAA
TTTATGCTGAAGAAGAGGCGGTTACACGGCTTCTAATTGATGGAAAGACATGCTTGTACAGAATGATCAGGAT
CCTTCAAGGTTATTAGCTGAGACACCTGCAAACCTCTTCGTTTCTGGTTGCCGATGGTGCTCATGTTGAAGCTGA
TGTACCATATGCGGAAGTTGAGGTTATGAAGATGTGCATGCCCTCTTGTCACTGCTGCTGGTGTCTTAATGTTT
TGTTGCTGAGGGCCAGCCTATGCAGGCTGGTGATCTTATAGCAAGACTTGATCTTGATGACCCCTCTGCTGTGAAG
AGAGCTGAGCCATTTAACGGATCTTTCCAGAAATGAGCCTTCTATTGCTGCTTCTGGCCAAGTTCACAAAAGATG
TGCCACAAGCTTGAATGCTGCTCGATGGTCTTGCAGGATATGATCACCCGATCAACAAAGTTGTACAAGATCTGG
TATCCTGTCTAGATGCTCCTGAGCTTCCTTTCCTACAATGGGAAGAGCTTATGTCTGTTTATAGCAACTAGACTTCCA
AGGCTTCTTAAAGAGCGAGTTGGAGGGTAAAACAGTGAATATAAGTTAAATGTTGECATGGGAAGAGCAAGGATTT
CCCTTCCAAGATGCTAAGAGAGATAATCGAGGAAAATCTTGACATGGTTCTGAGAAGGAAATTTGCTACAAATGAGA
GGCTTGTGAGCCTCTTATGAGCCTACTGAAGTCAATGAGGGTGGCAGAGAAAGCCATGCACACTTATTGTGAAG
TCCCTTTTCGAGGACTATCTCTCGGTTGAGGAATTTTCACTGATGGCATTCACTCTGATGTGATTGAACGCTGCG
CCAACAACATAGTAAAGATCTCCAGAAGTTGTAGACATTTGTTGCTCACCAGGGTGTGAGAAACAAAACCTAAGC
TGATACTAACACTCATGGAGAACTGGTCTATCCAAACCTGCTGTCTACAAGGATCAGTTGACTCGCTTTTCTCC
CTCAATCACAAGATATTTAAGTTGGCCCTTAAAGCTAGCGAGCTTCTTGAACAAACCAAGCTTAGTGAGCTCCG
CACAAGCATTGCAAGGAGCCTTTGAGAACTGAGATGTTTACTGAAGAAAGGACGCCATTAGTGAGATCATGGGAG
ATTTAGTGACTGCCCCACTGCCAGTTGAAGATGCACTGGTTTCTTTGTTGATGTAGTGATCAAACCTCTTCAGCAG
AGGGTGATCGAGACGTACATATCTCGATTATACCAGCCTCATCTTGTCAAGGATAGTATCCAGCTGAAATATCAGGA
ATCTGGTGTATTGCTTTATGGGAATTCGCTGAAGCGCATTGAGAGAGAGATTGGGTGCTATGGTTATTGTGAAGT
CGTTAGAATCTGTATCAGCAGCAATTGGAGCTGCACTAAAGGGTACATCACGCTATGCAAGCTCTGAGGGTAAACATA
ATGCATATTGCTTTATTGGGTGCTGATAATCAAATGCATGGAACGAAGACAGTGGTGATAACGATCAAGCTCAAGT
CAGGATAGACAACTTTCTGCGACACTGGAACAAAATACTGTCACAGCTGATCTCCGTGCTGCTGGTGTGAAGGTTA

TTAGTTGCATTGTTCAAAGGGATGGAGCACTCATGCCATATGCGCCATACCTTCTCTTGTCGGATGAAAAGCTTTGT
TATGAGGAAGAGCCGGTTCTCCGGCATGTGGAGCCTCCTCTTCTGCTCTTCTTGAGTTGGGTAAAGTTGAAAGTGAA
AGGATACAATGAGGTGAAGTATACACCGTCACGTGATCGTCAGTGGAACATATACACACTTAGAAAATACAGAGAACC
CCAAAATGTTGCACAGGGTGTTTTTCCGAACCTCTTGTCAGGCAACCCGGTGTCCAAACAAATTCACATCAGGCAAC
ATCAGTGATGTTGAAGTGGGAGGAGCTGAGGAATCCTTTTCATTTACATCGAGCAGCATATTAAGATCGCTGATGAC
TGCTATAGAAGAGTTGGAGCTTCACGCGATTAGGACAGGTCACCTCTCATATGTTTTGTGCATATTGAAAGAGCAAA
AGCTTCTTGATCTTGTTCCCGTTTCAGGGAACAAAGTTTGGGATATTGGCCAAGATGAAGCTACTGCATGCTTGCTT
CTGAAAAGAAATGGCTCTACAGATACATGAACCTTGTTGGGTGCAAGGATGCATCATCTTCTGTATGCCAATGGGAGGT
GAAACTTAAGTTGGACAGCGATGGGCCCTGCCAGTGGTACCTGGAGAGTTGTAACAACCAATGTTACTAGTCACACCT
GCACGTGGATATCTACCGTGAGGTGGAAGATACAGAATCAGAGAACTAGTGTACCCTCTGCTCCATCGTCATCT
GGTCTTTGCATGGCGTTGCACTGAATACTCCATATCAGCCTTTGAGTGTATTGATCTGAAACGTTGCTCCGCTAG
AAATAACAGAACTACATACTGCTATGATTTTCCGTTGGCATTTGAAACTGCAGTGCAGAAGTCATGGTCTAACATTT
CTAGTGACACTAACCGATGTTATGTTAAAGCGACGGAGCTGGTGTGCTCACAAGAACGGGTCATGGGGCACTCCT
GTAATTCCTATGGAGCGTCTGCTGGGCTCAATGACATTGGTATGGTAGCTTGGATCTTGGACATGTCCACTCCTGA
ATATCCCAATGGCAGGCGAGATTGTTGTCATCGCAAATGATATTACTTTTAGAGCTGGATCGTTTGGTCCAGGGGAAG
ATGCAATTTTTGAAACTGTTACCAACCTAGCTTGTGAGAGGAAGCTTCCTCTCATCTACTTGGCAGCAAACTCTGGT
GCTCGGATCGGCATAGCAGATGAAGTAAAATCTTGCTTCCGTTGGATGGTCTGATGATGGCAGCCCTGAACGTGG
GTTTCAATATATTTATCTGACTGAAGAAGACCATGCTCGTATTAGCGCTTCTGTTATAGCGCACAAGATGCAGCTTG
ATAATGGTGAAATTAGGTGGGTATTGATTCTGTTGTAGGGAAGGAGGATGGGCTAGGTGTGGAGAACATACATGGA
AGTGCTGCTATTGCCAGTGCCTATTCTAGGGCCTATGAGGAGACATTTACGCTTACATTTGTGACTGGAAGGACTGT
TGGAATAGGAGCATATCTTGCTCGACTTGGCATACGGTGCATACAGCGTACTGACCAGCCATTATCCTAACTGGGT
TCTCTGCCTTGAACAAGCTTCTTGCGCCGGGAAGTTACAGCTCCCATGTCAGTTGGGTGGCCCCAAAATTATGGCG
ACAAACGGTGTTGTCCATCTGACAGTTTCAAGATGACCTTGAAGGTGTATCTAATATATTGAGGTGGCTCAGCTATGT
TCCTGCCAACATTTGGTGGACCTCTTCTATTACAAAATCTTTGGACCCACCTGACAGACCCGTTGCTTACATCCCTG
AGAAATACATGCGATCCTCGTGTGCCATCAGTGGCATTGATGATAGCCAAGGGAATGGTTGGGGGGCATGTTTCGAC
AAAGACAGTTTTGTGGAGACATTTGAAGGATGGGCGAAGTCAGTTGTTACTGGCAGAGCGAAACTCGGAGGGATTCC
GGTGGGTGTTATAGCTGTGGAGACACAGACTATGATGCAGCTCATCCCTGCTGATCCAGGCCAGCTTGATTCCCATG
AGCGATCTGTTCTCGTCTGGGCAAGTCTGGTTTCCAGATTGAGCTACTAAGACAGCGCAGGCAATGCTGGACTTC
AACCGTGAAGGATTACCTCTGTTTCATCCTTGCTAACTGGAGAGGCTTCTCTGGTGGACAAAGAGATCTTTTTGAAGG
AATCCTTCAGGCTGGGTCAACAATTGTTGAGAACCTTAGGACATACAATCAGCCTGCCTTTGTATATATCCCCAAGG
CTGCAGAGCTACGTGGAGGGGCTTGCGTGTGATTGATAGCAAGATAAATCCAGATCGCATTGAGTTCTATGCTGAG
AGGACTGCAAAAGGGCAATGTTCTCGAACCTCAAGGGTTGATCGAGATCAAGTTCAAGGTGAGGGAATCCAGAGTG
CATGGGTAGGCTTGATCCAGAATTGATAAATCTGAAGGCAAGGCTCCAGGGAGTAAAGCATGAAATGGAAGTCTAC
CTGAGTCAGAATCCCTTCAGAAGAGCATAGAAGCCCGGAAGAAACAGTTGTTGCCCTTGTATATCAAAATTGCGGTA
CGGTTGCTGAATTGCATGACACTTCCCTTAGAATGGCTGCTAAGGGTGTGATTAAAGAGGTTGTAGACTGGGAAGA
TTCTAGGTGCTTCTTCTACAAGAGATTACGGAGGAGGATATCCGAGGATGTTCTTGCGAAGGAAATAGAGGTGTAA
GTGGCAAGCAGTTTTCTCACCBAATCGGCAATCGAGCTGATCCAGAAATGGTACTTGGCCTCTAAGGGAGCTGAAACA
GGAAGCACTGAATGGGATGATGACGATGCTTTTGTGCTGGAGGGAAAACCTGAAAACCTACCAGGAGTATATCAA
AGAACTCAGGGCTCAAAGGGTATCTCAGTTGCTCTCAGATGTTGCAGACTCCAGTCCAGATCTAGAAGCCTTGCCAC
AGGGTCTTTCTATGCTATTAGAGAAGATGGATCCCTCAAGGAGAGCACAGTTTGTGAGGAAGTCAAGAAAGTCTTT
AAATGA

FIGURE 10B

>AAC39330_Triticum aestivum

MGSTHLPVGLNASTTFLSTIRPVNSAGAAFPQPSAPSRTSKKKSRRVQSLRDGGDGGVSDPNQSIRQGLAGII
DLPKEGTSAPFVDISHGSEEPGRSYQMNGILNEAHNGRHASLSKVVEFCMALGGKTPHHSVLVANNGMAAAKFM
RSVRTWANETFGSEKAIQLIAMATPEDMRINAHRIADQFVEVPGGTNNNNYANVQLIVEIAVRTGVS AVWPG
WGHASENPFLPDALNANGIVFLGPPSSSMNALGDKVGSALIAQAAGVPTLPWSGSQVEIPLLEVCLDSIPAEMYR
KACVSTTEALASCQMIGYPAMIKA SWGGGGKGIRKVNDDDDVRALFKQVQGEVPGSPIFIMRLASQSRHLEVQ
LLCDQYGNVAALHSRDCSVQRRHQKIIIEEGPVTVAPRETVKELEQAARRLAKAVGYVGAATVEYLYSMETGEYY
FLELNPRLQVEHPVTEWIAEVLNLPAAQVAVGMGIPLWQVPEIRRFYGMNNGGGYDIWRKTAALATPFNFDEVDS
QWPKGHCVAVRITSEDDDGFKPTGGKVKEISFKSKPNVWAYFSVKSGGGIHEFADSQFGHVFAYGVSRAAAIT
NMSLALKEIQIRGEIHSNVDYTVDLLNASDFKENRIHTGWL DNRIAMRVQAERPWPYISVVGALYKTITSNTD
TVSEYVSYLKVGQIPPKHISLVHSTVSLNIEESKYTIETIRSGQGSYRLRMNGSVIEANVQTLCDGGLLMQLDQ
NSHVIYAEAEAGGTRLLIDGKTCLLQNDHDP SRLLAETPCKLLRFLVADGAHVEADVPAEVEVMKMCMPLLSP
AAGVINVLLSEGQPMQAGDLIARLDLDDPSAVKRAEPNGSFPEMSLP IASGQVHKRCATSLNAARMVLAGYD
HPINKVVQDLVSCDAPELPFLQWEELMSVLATRLPRLLKSELEGKYSEYKLVNKGKSKDFPSKMLREIIEEN
LAHGSEKEIATNERLVEPLMSLLKSYEGGRESHAFIVKSLFEDYLSVEELFSDGIQSDVIERLRQHSKDLQK
VVDIVLSHQVRNKTCLILTLMEKLVYPNPAVYKDQLTRFSSLNHKRYYKLALKASELLEQTKLSELRTSIARS
LSELEMTTEERTAISEIMGDLVTAPLPVEDALVSLFDCSDQTLQQRVIETIYISRLYQPHLVKDSIQKLYQESGV
IALWEFAEAHSEKRLGAMVIVKSLESVSAAGAALKGTSRYASSEGNI MHIALLGADNQMHGTEDSGDNDQAQV
RIDKLSATLEQNTVTADLRAAGVKVISCIVQRD GALMPMRHTFLLSDEKLCYEEEPVLRHVEPPLSALLELCKL
KVKGYNEVKYTPSRDRQWNIYTLRNTENPKMLHRVFFRTLVRQPGASNKFTSGNISDVEVGAEESLSFTSSSI
LRSLMTAIEELELHAIRTGHSHEFLCILKEQKLLDLVPVSGNKVVDIGQDEATACLLLKEMALQIHELVGARMH
HLSVCQWEVKKLSDSGPASGTWRVVTNTVTSHTCTVDIYREVEDTESQKLVYHSAPSSSGPLHGVALNTPYQP
LSVIDLKRCSARNNRITYCYDFPLAFETAVQKSWSNISSDTNRCYVKATELVFAHKNQSWGTVPVIMERPAGLN
DIGMVAVILDMSTPEYPNGRQIVVIANDITFRAGSFGPREDAFFETVTNLACERKPLIYLAANS GARIGIADE
VKSCFRVGCWSDDGSPERGFQYIYLTEEDHARISASVIAHKMQLDNGEIRWVIDSVVGKEDGLGVENIHGSAAIA
SAYSRA YEETFTLTFTVGTGTVGIGAYLARLGIRCIQRTDQPIILTGFSALNKLLGREVYSSHMQLGCGPKIMATN
GVVHLTVSDDLEGVSNILRWLSYVPANIGGPLPITKSLDPPDRPVAYIPENTCDPRAAISGIDDSQGWLGGMF
DKDSFVETFEGWAKSVVTGRAKLGGPVGVIAVETQTMQLIPADPGQLDSHERSVPRAGQVWFPSATKTAQA
MLDFNREGLPLFILANWRGFGSGQRDLFEGILQAGSTIVENLRTYNQPAFVYIPKAAELRGGA VVVIDSKINPD
RIEFYAERTAKGNVLEPQGLIEIKFRSEELQECMGRLDPELINLKAKLQGVKHENGSLPESESLQKSI EARKKQ
LLPLYTQIAVRFAELHDTSLRMAAGVIKKVVDWEDSRFFYKRLRRRI SEDVLAKEIRGVSQKQFSHQSAIEL
IQKWYLASKGAETGSTEWDDDDAFVAWRENPENYQEYIKELRAQRVSQQLSDVADSSPDLEALPQGLSMLLEKM
DPSRRAQFVEEVKKVLK

FIGURE 11A

>AY219174 *Setaria italica* (foxtail millet)
ATGTGCAACTTGGATTAGCTGCAGCTGCCTCAAAGGCGCTGCCACTACTTCCTAATCGCCATAGAACTTCAGCTGG
AACTACATTCCCATCACCTGTATCATCGCGGCCCTCAAACCGAAGGAAAAGCCGCACTCGTTCACTTCGTGATGGAG
GAGATGGGGTATCAGATGCCAAAAAGCACAAACAGTCTGTCCGTCAAGGTCTTGTGGCATCATCGACCTCCCAAAT
GAGGCAACATCGGAAGTGGATATTTCTCATGGATCCGAGGATCCAGGGGGCCAAACCGATTCTATATCAAATGAATGG
GATTGTAAGTGAAGCACATAATGGCAGACATGCCTCAGTGTCCAAGGTTGTTGAATTTTGTGCGGCGCTAGGTGGCA
AAACACCAATTACAGTATACTAGTGGCCAAACATGGAATGGCAGCAGCAAGTTTCATGAGGAGTGTCCGGACATGG
GCTAATGATACTTTTGGATCGGAGAAGGCGATTAGCTCATAGCTATGGCAACTCCAGAAGACATGAGGATAAATGC
AGAACACATTAGAATTGCTGATCAATTTCTGGAGGTGCCTGGTGGAAACAAACAATAACAACATATGCAAAATGTTCAAC
TCATAGTGGAGGTAGCAGAAAGAATAGGTGTTTCTGCTGTTTGGCCTGGTTGGGGTCATGCTTCTGAGAATCCTGAA
CTTCCAGATGCATTGACCGCAAAGGAGTGTGTTTCTTGGGCCACCTGCGGCATCAATGAATGCATTGGGAGATAA
GGTCGGTTCACTCTCATGTCTCAAGCAGCTGGGGTCCCGACCTTTCTGTTGAGTGGATCAGATGTTGAAGTTCAT
TAGAGTGTCTGTAGATGCGATACCTGAGGAAATGTATAGAAAAGCTTGTGTACTACCACAGAAGAAGCTGTTCGG
AGTTGTGAGGTGGTTGGTTATCTGCTGCTGATTAAAGGCATCTCTGGGAGGTGGTGGTAAAGGAATAAGAAAGGTTCA
TAATGACGATGAGGTTAGAGCACTGTTTAAAGCAAGTACAAGGTGAAGTCCCTGGCTCCCAATATTTATCATGAGGC
TTGCATCCAGAGTGTGATCTTGAAGTTCAGTTGCTTTGTGATCAATATGGCAATGTGGCAGCACTTCACAGTGT
GATTGCAGTGTGAACGGCGACACCAAAAGATTATTGAGGAAGGCCAGTTACTGTTGCTCCTCGTGAGACAGTTAA
AGCGCTTGAGCAGGCAGCAAGGAGGCTTGCTAAGGCTGTGGGTTATGTTGGTGTCTGCTACTGTTGAATACCTTTACA
GCATGGAGACTGGGGAATACTATTTTCTGGAGCTTAATCCAGATTACAGGTCGAGCATCCAGTCACTGAGTGGATT
GCTGAAGTAAATCTTCTGCAGCTCAAGTTGCAGTTGGAATGGGCATACCTCTTTGGCAGATTCCAGAAATCAGACG
TTTCGATGGAATGGACTATGGAGGAGGATATGACATTTGGAGGAAAACAGCAGCTCTTGCCACACCATTTAATTTTG
ATGAAGTAGATTCTCAATGGCCAAAGGGCCATTGTGTAGCAGTTAGAATTACTAGCGAGGATCCAGATGATGGTTTC
AAACCTACTGTGGGAAAGTGAAGGAGATAAGTTTAAAGCAAGCCTAATGTTTGGGCTACTTCTCAGTAAAGTC
TGGTGGAGGCATTATGAATTTGTTGATTCTCAGTTTGGGCATGTTTTTGCATATGGGCTCTCTAGATCAGCAGCAA
TAACGAACATGCTCTTGCATTAAAAGAGATTCAAAATCGTGGAGAAATTCATTCAAATGTTGATTACACAGTTGAT
CTCTTAAATGCTTCAGACTTCAGAGAAAATAAGATTCTACTGGCTGGCTTGATACCAGAAATAGCTATGCGTGTTC
AGCTGAGAGGCCCCCATGGTATATTTCACTGGTTGGAGGAGCTCTATATAAAACAGTAAGTCCCAATGCAGCCACTG
TTTCTGATTATGCTCAGTTATCTCACCAGGGCCAGATTCCACCAAGGCATATATCCCTTGTGAGTTCAACAGTTAAT
CTGAATATCGAAGGGAGCAAATACACAGTTGAACTGTAAGGACTGGACATGGTAGCTACAGATTACGAATGAATGA
TTCAGCAATTTGAAGCGAATGTACAATCCTTATGTGATGGAGGCCTCTAATGCGAGTTGGATGGAAATAGCCATGTAA
TTTACCGCGAAGAAGAAGCTGGTGGTACACGACTTCTGATTGATGGAAAGACATGCTTGTACAGAATGATCATGAT
CCATCAAAGTTATTAGCTGAGACACCCTGCAAACTCTCTCGGTTCTTGGTTGCTGATGGTGCCCATGTTGATGCTGA
TGTACCATATGCGGAAGTTGAGGTTATGAAAATGTGCATGCCTCTCTGTCGCTGCTTCTGGTGTCTTCATCATGTTA
TGATGTCTGAGGGCCAGGCATTGAGGCTGGTGATCTTATAGCAAGGCTGGATCTTGATGACCTTCTGCTGTGAAA
AGAGCTGAACCATTTTCATGGAATATTTCCACAAATGGACCTTCTGTTGCTGCTCTAGCCAAAGTACACAAAAGATA
TGCTGCAAGTTGGAATGCTGCTGCAATGGTCTTGCAGGATACGAGCATAATATCAATGAAGTTGTACAAGATTGG
TATGCTGCCTGGATGATCCCGAGCTTCCCTTCTACAGTGGGATGAACCTTATGTGAGTTCTAGCAACTAGGCTTCCA
AGAAATCTTAAGAGTGAGTTAGAGGATAAATACATGGAATACAAGTTGAACCTTTACCATGGGAAAAACAAGGACTT
CCCGTCCAAGCTGCTGAGAGACATCATTGAGGCAATCTTGCAATATGGTTGAGAGAAGGAAAAAGCTACGAATGAGA
GGCTTATTGAGCCTCTTATGAGCCTACTTAAGTCATATGAGGGTGGGAGAGAAAGCCATGCTCATTGTTGTCTCAAG
TCCCTTTTCAAGGAGTACCTTGGTGTGGAAGAAGCTTTTCAAGTATGGGATTGAGTCTGATGTGATTGAAACCTGCG
TCATCAGCACAGTAAAGACTTGACAGAAGGTTGTAGACATTGTGTTGTCTCACCAGGGTGTGAGGAACAAAGCTAAGC
TTGTAAACAGCACTTATGGAAGGCTGGTTTATCCAAATCCTGCTGCTTACAGGGATCTGTTGGTTGCTTTTCTTCA
CTCAATCATAAAAGATATTATAAGTTGGCCCTTAAAGCAAGCGAACTTCTTGAACAACTAACTAAGTGAATCCG
TGCAAGCATCGCAAGAAGCCTTTCTGATCTGGGGATGCATAAGGGAGAAATGACTATTGAAGATAGCATGGAAGATT
TAGTCTCTGCCCCATTACCTGTGCAAGATGCACTTATTTCTTTGTTTATTACAGTGATCCAAGTGTTCAGCAGAAA
GTGATCGAGACATACATATCTGATTGTATCAGCCTCTTCTGTGAAAGATAGCATCCAAGTGAATTTAAGGAATC
TGGTGCCTTTTGTCTTATGGGAATTTTCTGAAGGGCATGTTGATACTAAAAATGGACAAGGGACCGTTCTTGGTGGAA
CAAGATGGGGTGCCATGGTAGCTGTCAATCAGTTGAATCTGCACGAACAGCCATTGTAGCTGCATTAAAGGATTG
GCACAGCATGCCAGCTCTGAGGGCAACATGATGCACATTGCCTTATTGAGTGTGAAAATGAAAATATATCAGTGA
TGATCAAGCTCAACATAGGATGGAAAACTTAACAAGATACTCAAGGATACTAGTGTGCGAAATGATCTTCGAGCTG
CTGGTTTGAAGGTTATTAAGTTGCATTGTTCAAAGAGATGAAGCACGCATGCCAATGCGCCACACATTACTTGGTCA
GATGAAAAGAGTTGTTATGAGGAAGAGCAGATTCTTCGGCATGTGGAGCCTCCCTCTCCATGCTTCTTGAATGGA
TAAGTTGAAAGTGAAGGATACAATGAAATGAAGTATACTCCATCACGTGATCGTCAATGGCATATCTACACACTAA

GAAATACTGAAACCCCAAAATGTTGCATAGGGTATTTTCCGAACCTATTGTCAGGCAACCCAAATGCAGGCAACAAG
TTTATATCAGCCCAAATTTGGCGACACTGAAGTAGGAGGTCCTGAGGAATCTTTGTCAATTACATCTAATAGCATTTT
AAGAGCCTTGATGACTGCTATTGAAGAATTAGAGCTTCATGCAATTAGGACTGATCATCTCACATGTATTTGTGCA
TATTGAAAGAACAAAAGCTTCTTGATCTCATTCGGTTTTTCAGGGAGCACAATCGTCGATGTTGTCCAAGACGAAGCT
ACTGCTTGTTCACTTTTAAAATCAATGGCTTTGAAGATACACGAACCTGTTGGTGCACAGATGCATCATCTTCTGT
ATGCCAGTGGGAGGTGAAACTCAAGTTGTAAGTGGGCTGCCAGTGGCACCTGGAGAGTTGTAACACAAATG
TTACTAGTCACTTGCACCGTTGATATCTACCGGAAGTGAAGATACTGAATCGCAGAAGTTAGTATACCATTCA
GCTTCTCCGTGAGCTAGTCCCTTGCATGGTGTGGCCCTGGATAATCCGTATCAACCTTTGAGTGTCAATTGATCTAAA
ACACTGCTCTGCTAGGAACAACAGAATACTATATTGCTATGATTTTCCACTGGCATTGAAACTGCCCTGCAGAAGT
CATGGCAGTCCAATGGCTCCAGTGTCTTGAAGGCAGTGAATAATAGTAGGTCTTATGTGAAAGCAACAGAGCTGGTG
TTTGCTGAAAAACATGGGTCCCTGGGGCACTCCTATAATTTCCATGGAGCGTCCCGCTGGGCTCAATGACATTGGCAT
GGTAGCTTGGATCTTAGAGATGTCCACTCCTGAATTTCCCAATGGCAGGCAGATTATGTCTATAGCAAATGATATTA
CTTTTCAGAGCTGGATCATTTGGCCCAAGGGAAGATGCGTTTTTTGAAGCTGTACGAACCTGGCCTGCGAGAGGAAG
CTTCTCTTATATACTTGGCAGCAAACCTCGGTGCTAGGATTGGCATAGCCGATGAAGTGAATCTTGCTCCGTGT
TGGGTGGTCCGATGAAGGCAGCCCTGAACGGGGTTTTTCAGTACATTTATCTGACTGACGAAGACTATGCCCGTATTA
GCTTGTCTGTTATAGCACACAAGCTGCAGCTGGATAATGGTGAATTAGGTGGATTATTGACTCTGTTGTGGGCAAG
GAGGATGGGCTTGGTGTGAGAAATATACATGGAAGTGTCTGCTATTGCCAGTGTCTTATCTAGGGCATATGAGGAGAC
ATTTACACTTACATTTGTGACTGGGCGGACTGTTGGAATAGGAGCATATCTTGCTCGGCTCGGTATACGGTGCATAC
AGCGTCTTGACCAGCCTATTATTTTAACTGGGTTTTCTGCCCTGAACAAGCTTCTTGGGCGGGAAGTGTACAGCTCC
CACATGCAGTTGGGTGGTCTTAAGATCATGGCGACCAATGGTGTGTCCACTTGACTGTTTCAGATGACCTTGAAGG
TGTTTTCCAATATATTGAGGTGGCTCAGCTATGTTTCTGCCAACATTGGTGGACCTCTTCTATTACAAAACCTTTGG
ACCCACCAGACAGACCTGTGTCATACATCCCTGAGAACACATGTGATCCGCGCGCAGCCATTGCTGGTGTAGATGAC
AGCCAAGGGAAATGGTTGGGTGGTATGTTTGACAAAGACAGCTTTGTGAGACATTTGAAGGATGGGCGAAAACAGT
GGTTACGGGCGAGACAAAGCTTGGAGGAATTCCTGTGGCGTCTATAGCTGTGGAGACACAAACCATGATGCAGCTTA
TCCCTGCTGATCCAGGCCAGCTTGATTCCCATGAGCGATCTGTTCTCGGCTGGACAAGTGTGGTTCCAGATTCT
GCAACCAAGACAGCTCAGGCATTGTTGGACTTCAACCGTGAAGGATTGCCGCTGTTTCATCCTTGCTAACTGGAGAGG
ATTCTCTGGTGGACAAAGAGATCTGTTTGAAGGAATCTTTCAGGCTGGGTCAACAATGTTGAGAACCTTAGGACAT
ACAATCAGCCTGCTTTTGTCTACATTCCTATGGCTGGAGAGCTGCGTGGAGGAGCTTGGGTTGTTGGTTGATAGCAA
ATAAATCCAGACCGAATTGAGTGTTATGCTGAGAGGACTGCTAAAGGCAATGTTCTGGAACCTCAAGGGTTAATTGA
AATCAAATTCAGATCAGAGGAGCTCCAAGACTGTATGGTAGGCTTGACCCAGGGTTGATAAATCTGAAAGCAAAAC
TCCAAGGTGCAAAGCTTGGAAATGGAAGCCTAACAGATGTAGAATCCCTTCAGAAGAGTATAGATGCTCGTACGAAA
CAGTTGTTGCCCTTTATACACCCAGATTGCAATACGGTTTGTCTGAATTGCATGATACTCCCTCAGAATGGCAGCTAA
AGGTGTGATTAAGAAAGTTGTAGATTGGGAAGAATCACGTTCTTTCTTCTACAGAAGGCTACGGAGGAGGATCTCTG
AAGATGTTCTTGCAAAAGAAATAAGAGGAATAGCTGGTGACCACTTCACTCACCAATCAGCAGTTGAGCTGATCAAG
GAATGGTACTTGGCTTCTCAAGCCACAACAGGAAGCACTGAATGGGATGATGATGATGCTTTTGTGCTGGAAGGA
GAATCCTGAAAACATAAGGGATATATCCAAGAGTTAAGGGCTCAAAGGTGTCTCAGTCGCTCTCCGATCTTGACAG
ACTCCAGTTTCAGATCTAGAAGCATTCTCACAGGGTCTTTCCACATTATTAGATAAGATGGATCCCTCTCAGAGAGCC
AAGTTCATTACGGAAGTCAAGAAGGTCTGGGTGA

FIGURE 11B

>AA062902_Setaria italica (foxtail millet)
 MSQGLGAAAAASKALPLLNRHRTSAGTTFPSVSSRPSNRKSRTRSLRDGGDGVSDAKKHNSVRQGLAGIID
 LPNEATSEVDISHGSEDPGRPTDSYQMNGIVSEAHNGRHASVSKVVEFCAALGGKTPIHSLVANNGMAAAKFM
 RSVRTWANDTFGSEKAIQLIAMATPEDMRINAHRIADQFVEVPGGTNNNNYANVQLIVEVAERIGVSAVWPG
 WGHASENPCLPDALTAKGVVFLGPPAASMNALGDKVGSALIAQAAGVPTLSWSGSHVEVPLECCLDAIPEEMYR
 KACVTTTEEAVASCQVVGYPAMIKASWGGGKGIRKVHNDDEVRLFKQVQGEVPGSPIFIMRLASQSRHLEVQ
 LLCDOYGNVAALHSRDCSVQRRHQKIEEGPVTAPRETVKALEQAARRLAKAVGYVGAATVEYLYSMETGEYY
 FLELNPRLQVEHPVTEWIAEVNLPAAQVAVGMGIPLWQIPEIRRFDMGYGGGYDIWRKTAALATPFNFDEVDS
 QWPKGHCVAVRITSEDDDGFKPTGGKVKEISFKSKPNVWAYFSVKSGGGIHEFVDSQFGHVFAVGLSRSAIT
 NMALALKEIQIRGEIHSNVDTVDLLNASDFRENKIHTGWLDTRIAMRVQAERPPWYISVVGALYKTVTANAA
 TVSDYVSYLTKGQIPPKHISLVSSTVNLNIEGSKYTVETVRTGHGSYRLRMNDSATEANVQSLCDGGLLMQLDG
 NSHVIYAEAEAGGTRLLIDGKTCLLQNDHDPKLLAETPCKLLRFLVADGAHVADVPYAEVEVMKMCMLLSP
 ASGVIHVMMSGQALQAGDLIARLDLDDPSAVKRAEPFHGIFPQMDLPVAASSQVHKRYAASWNAARMVLAGYE
 HNINEVVQDLVCCLDPELPFLQWDELMSVLATRLPRNLKSELEDKYMEYKLNFYHGKNKDFPSKLLRDIIEAN
 LAYGSEKEKATNERLIEPLMSLLKSYEGGRESHAFVKSFLKEYLAVEELFSDGIQSDVIEFLRHQHSKDLQK
 VVDIVLSHQGVRNKAKLVTALMEKLVYPNPAAYRDLLVRFSSLNHKRYKLALKASELLEQTKLSELRASTARS
 LSDLGMHKGEMTIEDSMEDLVSAPLPVEDALISLFDYSDPTVQQKVIETYISRLYQPLLVKDSIQVKFKESGAF
 ALWEFSEGHVDTKNGQGTVLGRTRWGAMVAVKSVESARTAIVAALKDSAQHASSEGNNMHIALLSAENENNISD
 DQAQHRMEKLNKILKDTSVANDLRAAGLKVISCIQRDEARMPMRHTLLWSDEKSCYEEEQILRHVEPPLSMLL
 EMDKLKVKGYNEMKYTFSRDRQWHIYTLRNTENPKMLHRVFFRTIVRQPNAGNKFTISAQIGTEVGGPEESLSF
 TSNSILRALMTAIEEELHAIRTDHSHMYLCILKEQKLLDLIPFSGSTIVDVVQDEATACSLKSMALKIHELIV
 GAQMHLSVCQWEVKLKLKLYCDGPASGTWRVVTNVTSHCTCTVDIYREVEDTESQKLVIYHSASPSASPLHGVALD
 NPYQPLSVIDLKHCASARNRRTTYCYDFPLAFETALQKSWQSNSSVSEGSSENSRSYVKATELVFAEKHGSWGTP
 IISMERPAGLNDIGMVAWILEMSTPEFPNGRQIIVIANDI TFRAGSFGPREDAFFEAVTNLACERKPLIYLA
 NSGARIGIADDEVKSCFRVGSDEGSPERGFQYIYLTDEYARISLSVIAHKLQLDNGEIRWIIDSVVGKEDGLG
 VENIHGSAAIASAYSRAYEETFTLTFTVGTGRVIGAYLARLGIRCIQRDQPIILTGFSALNKLKGREYSSHM
 QLGGPKIMATNGVVHLTVSDDLEGVSNILRWLSYVPANIGGPLPITKPLDPPDRPVAYIPENTCDPRAAIRGVD
 DSQGWKLGGMFDKDSFVETFEGWAKTVVTGRAKLGIPVGVIAVETQTMQLIPADPGQLDSHERSVPRAGQVW
 FPD SATKAQALLDFNREGLPLFILANWRGFGSGQORDLFEGLQAGSTIVENLRTYNQPAFVYIFMAGELRGA
 WVVVDSKINPDRIECYAERTAKGNVLEPQGLIEIKFRSEELQDCMGRLDPLINLAKLQGAQLGNGSLTDVES
 LQKSIDARTKQLPLYTQIAIRFAELHDTSLRMAAGVIKKVVDWEESRSFFYRRLRRRISEDLAKEIRGIAG
 DHFTHQSAVELIKEWYLASQATTGSTEWDDDDAFVAWKENPENYKGYIQELRAQKVSQSLSDLADSSSDLEAFS
 QGLSTLLDKMDPSQRAKFIQEVKKVLG

FIGURE 12A

>AY219175 _Setaria italica (foxtail millet)
ATGTCGCAACTTGGATTAGCTGCAGCTGCCTCAAAGGCGCTGCCACTACTTCCTAATCGCCATAGAACTTCAGCTGG
AACTACATTTCCCATCACCTGTATCATCGCGGCCCTCAAACCGAAGGAAAAGCCGCACTCGTTCACTTCGTGATGGAG
GAGATGGGGTATCAGATGCCAAAAGCACAACCAGTCTGTCCGTCAAGGTCTGTGCTGGCATCATCGACCTCCCAAAT
GAGGCAACATCGGAAGTGGATATTTCTCATGGATCCGAGGATCCCAGGGGGCCAACCGATTCAATCAATGAATGG
GATTGTAAATGAAGCACATAATGGCAGACATGCCTCAGTGTCCAAGGTTGTTGAATTTGTGCGCGCTAGGTGGCA
AAACACCAATTCACAGTATACAGTGGCCAAACAATGGAATGGCAGCAGCAAAGTTTCATGAGGAGTGTCCGGACATGG
GCTAATGATACTTTTGGATCGGAGAAGGCGATTGAGCTCATAGCTATGGCAACTCCAGAAGACATGAGGATAAATGC
AGAACACATTAGAATTGCTGATCAATTTGTAGAGGTGCCCTGGTGGAAACAAACAATAACAACATATGCAAAATGTTCAAC
TCATAGTGGAGGTAGCAGAAAGAATAGGTGTTTCTGCTGTTTGGCCTGGTGGGGTCATGCTTCTGAGAATCCTGAA
CTTCCAGATGCATTGACCGCAAAGGAATGTTTTCTTGGGCCACCTGCGGCATCAATGAATGCATTGGGAGATAA
GGTCGGTTCAGCTCTCATTGCTCAAGCAGCTGGGGTCCCCGACCTTTTCGTGGAGTGGATCACATGTTGAAGTTCCTAT
TAGAGTGCTGCTTAGATGCCATACCTGAGGAAATGTATAGAAAAGCTTGTGTTACTACCACAGAAGAAGCTGTTGCG
AGTTGTCAGGTGGTTGGTTATCCTGCCATGATTAAAGCATCCTGGGGAGGTGGTGGTAAAGGAATAAGAAAGGTTCA
TAATGACGATGAGGTTAGAGCACTGTTTAAAGCAAGTACAAGGTGAAGTCCCTGGCTCCCAATATTTATCATGAGGC
TTGCATCCCAGAGTCGTCATCTGAAGTTCAGTTGCTTTGTGATCAATATGGCAATGTGGCAGCACTTCACAGTCGT
GATTGCAGTGTGCAACGGCGACACCAAAAGATTATTGAGGAAGGCCAGTTACTGTTGCTCCTCGTGAGACAGTTAA
AGCGCTTGAGCAGGCAGCAAGGAGGCTTGCTAAGGCTGTGGGTTATGTTGGTGCTGCTACTGTTGAATACCTTTTACA
GCATGGAGACTGGGGAATACTATTTTCTGGAGCTTAATCCAGATTACAGGTGAGCATCCAGTCACTGAGTGGATT
GCTGAAGTAAATCTTCTGCACTCAAGTTGCACTTGGAAATGGGCATACCTCTTGGCAGATTCCAGAAATCAGACG
TTTCTATGGAATGGACTATGGAGGAGGATATGACATTTGGAGGAAAACAGCAGCTCTTGCCACACCATTAAATTTTG
ATGAAGTAGATTCTCAATGGCCAAAGGCCATTGTGTAGCAGTTAGAATTACTAGCGAGGATCCAGATGATGGTTTC
AAACCTACTGGTGGGAAAGTGAAGGAGATAAGTTTAAAGCAAGCTAATGTTTGGGCTACTTCTCAGTAAAGTTC
TGGTGGAGGCATTCAATGAATTTGCTGATTCTCAGTTTGGGCATGTTTTTGCATATGGGCTCTCTAGATCAGCAGCAA
TAACGAACATGGCTCTTGCATTAAAAGAGATTCAAATTCCTGGAGAAATTCATTCAAATGTTGATTACACAGTTGAT
CTCTAAATGCTTCAGACTTCAGAGAAAATAAGATTCACTACTGGCTGGCTTGATACCAGAATAGCTATGCGTGTTC
AGCTGAGAGGGCCCCATGGTATATTTTCAGTGGTTGGAGGAGCTCTATATAAAACAGTAAGTCCCAATGCCAGCCACTG
TTTCTGATTATGTCAGTTATCTCACCAGGGCCAGATTCCACCAAAGCATATATCCCTTGTGCTTCAACAGTTAAT
CTGAATATCGAAGGGAGCAAATACACAGTTGAAACTGTAGGAGTGGACATGCTAGCTACAGATTACGAATGAATGA
TTCAGCAATGAAGCGAATGTACAATCTTTATGTGATGGAGGCTCTTAATGCAGTTGGATGGAAATAGCCATGTAA
TTTACGCGGAAGAAGAGCTGGTGGTACACGACTTCTGATTGATGGAAAGACATGCTTGTACAGAATGATCATGAT
CCATCAAAGTTTATTAGCTGAGACACCCCTGCAAACCTTCTTCGGTTCTTGGTTGCTGATGGTGCTCATGTTGATGCTGA
TGTACCATATGCGGAAGTTGAGGTATGAAATGTGCATGCCCTCTCTTGTGCGCTGCTCTGGTGTCATTATGTTA
TGATGTCTGAGGGCCAGGCATTGCAGGCTGGTGTATCTATAGCAAGGCTGGATCTTGATGACCTTCTGCTGTGAA
AGAGCTGAACCATTTTCATGGAATATTTCCAAATGGACCTTCTGTTGCTGCTCTAGCCAAAGTACACAAAAGATA
TGCTGCAAGTTTGAATGCTGCTCGAATGGTCTTGCAGGATACGAGCATAATATCAATGAAGTTGTACAAGATTTGG
TATGCTGCCTGGATGATCCCGAGCTTCCCTTCCTACAGTGGGATGAACCTTATGTGCTTCTAGCAACTAGGCTTCCA
AGAAATCTTAAAGAGTGAATGAGGATAAATACATGGAATACAAGTTGAACCTTTTACCATGGGAAAAACAGGACTT
CCCGTCCAAGCTGCTGAGAGACATCATTGAGGCAATCTTGCATATGGTTCAGAGAAGGAAAAAGCTACGAATGAGA
GGCTTATTGAGCCTCTTATGAGCCTACTTAAGTCATATGAGGGTGGGAGAGAAAGCCATGCTCATTTTGTGTCAAG
TCCCTTTTCAAGGAGTACCTTGTGTGGAAGAACTTTTCAGTGATGGGATTGAGTCTGATGTGATTGAAACCCCTGCG
TCATCAGCACAGTAAAGACTTGCAGAAGGTTGTAGACATTGTGTTGTCTCACCAGGGTGTGAGGAACAAAGCTAAGC
TTGTAACAGCACTTATGGAAAAGCTGGTTATCCAAATCCTGCTGCTACAGGGATCTGTTGGTTGCTTTTCTTCA
CTCAATCATAAAAGATATTATAAGTTGGCCCTTAAAGCAAGCGAAGTCTTGAACAAACTAACTAAGTGAAGTCCG
TGCAAGCATCGCAAGAAGCCTTTCTGATCTGGGATGCATAAGGGAGAAATGACTATTGAAGATAGCATGGAAGATT
TAGTCTCTGCCCCATTACCTGTGCAAGATGCACTATTTCTTGTGTTGATTACAGTATGCAACTGTTGAGCAGAAA
GTGATCGAGACATACATATCTGATTGTATCAGCCTCTTCTTGTGAAAGATAGCATCCAAGTGAATTTAAGGAATC
TGGTGCCTTTGCTTTATGGGAATTTTCTGAAGGCATGTTGATATAAAATGGACAAGGGACCGTTCTTGGTGGAA
CAAGATGGGGTGCATGGTAGCTGTCAAATCAGTTGAATCTGCACGAACAGCCATTGTAGCTGCATTAAAGGATTG
GCACAGCATGCCAGCTCTGAGGGCAACATGATGCACATTGCTTATTGAGTGCTGAAAATGAAAATAATATCAGTGA
TGATCAAGCTCAACATAGGATGGAAAACTTAACAAGATACTCAAGGATACTAGTGTGCAATGATCTTCGAGCTG
CTGGTTTGAAGGTTATAAGTTGCATTGTTCAAAGAGATGAAGCACGCATGCCAATGCGCCACACATTACTCTGGTCA
GATGAAAAGAGTTGTTATGAGGAAGAGCAGATTCTCGGCATGTGGAGCCTCCCCTCTCCATGCTTCTTGAAATGGA
TAAGTTGAAAGTGAAGGATACAATGAAATGAAGTATACTCCATCAGTGATCGTCAATGGCATATCTACACACTAA

GAAATACTGAAAACCCCAAAATGTTGCATAGGGTATTTTTCCGAACCTATTGTCAGGCAACCCAAATGCAGGCAACAAG
TTTATATCAGCCCAAATGGCGACACTGAAGTAGGAGGTCCTGAGGAATCTTTGTCATTTACATCTAATAGCATTTT
AAGAGCCTTGATGACTGCTATTGAAGAATTAGAGCTTCATGCAATTAGGACTGGTCATTCTCACATGTATTTGTGCA
TATTGAAAGAACAAAAGCTTCTTGATCTCATTCCGTTTTTCAGGGAGCACAATCGTCGATGTTGGCCAAGACGAAGCT
ACTGCTTGTTCACTTTTAAAATCAATGGCTTTGAAGATACACGAACCTGTTGGTGACAGATGCATCATCTTTCTGT
ATGCCAGTGGGAGGTGAAACTCAAGTTGTACTGCGATGGGCTGCCAGTGGCACCTGGAGAGTTGTAACACAAATG
TTACTAGTCACACTTGCACCATTGATATCTACCGGAAGTGGAAAGTACTGAATCGCAGAAGTTAGTATACCATTCA
GCTTCTCCGTGAGCTAGTCTTTGTCATGGTGTGGCCCTGGATAATCCGTATCAACCTTTGAGTGTCAATTGATCTAAA
ACGCTGCTCTGCTAGGAACAACAGAATACATATTGCTATGATTTTCCACTGGCATTGAAACTGCCCTGCAGAAGT
CATGGCAGTCCAATGGCTCCAGTGTTTTCTGAAGGCAGTGAAAATAGTAGGCTTATGTGAAAGCAACAGAGCTGGTG
TTTGCTGAAAACATGGGTCTGGGGCACTCCTATAATTTCCATGGAGCGTCCCGCTGGGCTCAATGACATTGGCAT
GGTAGCTTGGATCTTAGAGATGTCCACTCCTGAATTTCCCAATGGCAGGCAGATTATTGTATAGCAAAATGATATTA
CTTTTCAGAGCTGGATCATTTGGCCCAAGGAAGATGCGTTTTTTGAAGCTGTACGAACCTGGCCTGCGAGAGGAAG
CTTCCTCTTATATACTTGGCAGCAAACCTCCGGTGCTAGGATGGCATAGCCGATGAAGTGAAATCTTGCTTCCGTGT
TGGGTGGTCCGATGAAGGCAGCCCTGAACGGGGTTTTTCAGTACATTTATCTGACTGACCAAGACTATGCCCGTATTA
GCTTGTCTGTTATAGCACACAAGCTGCAGCTGGATAATGGTGAAATTAGGTGGATTATTGACTCTGTTGTGGGCAAG
GAGGATGGGCTTGGTGTGAGAATCTACATGGAAGTGCTGCTATTGCCAGTGCTTATTCTAGGGCATATGAGGAGAC
ATTTACACTTACATTTGTGACTGGGCGGACTGTTGGAATAGGAGCATATCTCGCTCGGCTCGGTATACGGTGCATAC
AGCGTCTTGACCAGCCTATTATTTTAACTGGGTTTTCTGCCCTGAACAAGCTTCTTGGGCGGGAGGTGTACAGCTCC
CACATGCAGTTGGGTGGTCTAAGATCATGGCGACCAATGGTGTGTCCACTTGACTGTTTCAGATGACCTTGAAGG
TGTTTTCCAATATATTGAGGTGGCTCAGCTATGTTCTGCCAACATTGGTGGACCTCTTCTTATTACAAAACCTTTGG
ACCCACCAGACAGACCTGTTGCATACATCCCTGAGAACACATGTGATCCGCGCGCAGCCATTCTGTTGTAGATGAC
AGCCAAGGGAAATGGTTGGGTGGTATGTTTGACAAAGACAGCTTTGTCGAGACATTTGAAGGATGGGCGAAAACAGT
GGTTACGGGCGCAGACAAAGCTTGGAGGAATTCCTGTTGGTGTGATAGCTGTGGAGACACAAACCATGATGCAGCTTA
TCCCTGCTGATCCAGGCCAGCTTGATTTCCATGAGCGATCTGTTCTCGGGCTGGACAAGTGTGTTTCCAGATTCT
GCAACCAAGACAGCTCAGGCATTGTTGGACTTCAACCGTGAAGGATTGCCGCTGTTTCATCCTTGCTAACTGGAGAGG
ATTCTCTGGTGCACAAAGAGATCTGTTTGAAGGAATTCCTCAGGCTGGGTCAACAATGTTGAGAACCTTAGGACAT
ACAATCAGCCTGCTTTTGTCTACATTCCCTATGGCTGGAGAGCTGCGTGGAGGAGCTTGGGTTGTGGTTGATAGCAAA
ATAAATCCAGACCGAATTGAGTGTTATGCTGAGAGGACTGCTAAAGGCAATGTTCTTGAACCTCAAGGGTTAATTGA
AATCAAATTCAGATCAGAGGAGCTCCAAGACTGTATGGGTAGGCTTGACCCAGAGTTGATAAATCTGAAAGCAAAAC
TCCAAGGTGCAAGCTTGGAAATGGAAGCCTAACAGATGTAGAATCCCTTCAGAAGAGTATAGATGCTCGTACGAAA
CAGTTGTTGCCCTTTATACCCAGATTGCAATACGGTTTGTGAATTGCATGATACTTCCCTCAGAATGGCAGCTAA
AGGTGTGATTAAGAAAGTTGTAGATTGGGAAGAATCAGCTTCTTTCTTCTACAGAAGGCTACGGAGGAGGATCTCTG
AAGATGTTCTTGCAAAAGAAATAAGAGGAATAGCTGGTGACCATTCACTACCAATCAGCAGTTGAGCTGATCAAG
GAATGGTACTTGGCTTCTCAAGCCACAACAGGAAGCACTGAATGGGATGATGATGATGCTTTTGTGCTTGGAAAGGA
GAATCCTGAAAATATAAGGGATATATCCAAGAGTTAAGGGCTCAAAGGTGCTCAGTCGCTCTCCGATCTTGCAG
ACTCCAGTTCAGATCTAGAAGCATCTCACAGGGTCTTTCCACATTATTAGATAAGATGGATCCCTCTCAGAGAGCC
AAGTTCATTAGGAAGTCAAGAAGGTCTGGGTTGA

FIGURE 12B

>AAO62903_Setaria italica (foxtail millet)
MSQLGLAAAASKALPLLPNRHRTSAGTTFPSPVSSRPSNRKRSRTRSLRDGGDGVSDAKKHNSVRQGLAGIID
LPNEATSEVDISHGSEDPRGPTDSYQMNIGVNEAHNGRHASVSKVVEFCAALGGKTPHISILVANNGMAAAKFM
RSVRTWANDTFGSEKAIQLIAMATPEDMRINAEHIRIADQFVEVPGGTNNNNYANVQLLIVEVAERIGVSAVWPG
WGHASENPELPDALTAKGIVFLGPPAASMNALGDKVGSALIAQAAGVPTLSWSGSHVEVPLECCLDAIPEEMYR
KACVTTTEEAVASCQVVGYPAMIKASWGGGKGIRKVNHDDEVRLFKQVQGEVPGSPIFIMRLASQSRHLEVQ
LLCDQYGNVAALHSRDCSVQRRHQKIIIEGFPVTVAPRETVKALEQAARRLAKAVGYVGAATVEYLYSMETGEYY
FLELNPRLQVEHPVTEWIAEVLNLPAAQVAVGMGIPLWQIPEIRRFYGMDDYGGGYDIWRKTAALATPFNFDEVDS
QWPKGHCVAVRITSEDDDDGFKPTGGKVKEISFKSKPNVWAYFSVKSGGGIHEFADSQFGHVFAAYGLSRSAIT
NMALALKEIQIRGEIHSNVDYTVDLLNASDFRENKIHTGWLDTRIAMRVQAERPPWYISVVGALYKTVTANAA
TVSDYVSYLTKGQIPPKHISLVSSTVNLNIEGSKYTVETVRTGHGSYRLRMNDSAI EANVQSLCDGGLLMQLDG
NSHVIYAEAEAGGTRLLIDGKTCLLQNDHDP SKLLAETPCKLLRFLVADGAHVADVPYAEVEVMKMCMPLLSP
ASGVIHVMMEGQAIQAGDLIARLDLDDPSAVKRAEPFHGIFPQMDLPVAASSQVHKRYAASLNAARMVLAGYE
HNINEVVDLVCCLDDELPFLQWDELMSVLATRLPRNLKSELEDKYMAYKLNFYHGKNKDFPSKLLRDI EAN
LAYGSEKEKATNERLIEPLMSLLKSYEGGRESHAHFVVKSLFKEYLAVEELFSDGIQSDVIETLRHQHSDQLQK
VVDIVLSHQGVRNKAQLVTALMEKLVYPNPAAYRDLVRFSSLNHKRYKALALKASELLEQTKLSELRAIARS
LSDLGMHKGEMTIEDSMEDLVSAPLPVEDALISLFDYSDPTVQKVIETIYISRLYQPLLKDSIQVKFKEGAF
ALWEFSEGHVDTKNQCTVLGRTRWGAMVAVKSVESARTAIVAALKDSAQHASSEGNNMHIALLSAENENNISD
DQAQHRMEKLNKILKDTSVANDLRAAGLKVISCIQRDEARMPMRHTLLWSDEKSCYEEEQILRHVEPPLSMLL
EMDKLVKGYNEMKYTPSRDRQWHIYTLRNTENPKMLHRVFFRTIVRQPNAGNKFI SAQIGDTEVGGPEESLSF
TSNSILRALMTAIEEELHAI RTGHSHMYLCILKEQKLLDLIPFSGSTIVDVGQDEATACSLKSMALKIHEL
GAQMHHLSVCQWEVKLKLYCDGPASGTWRVVTNVTSTHTCTIDIYREVEDTESQKL VYHSASPSASPLHGVALD
NPYQPLSVIDLKRC SARNNRTTYCYDFPLAFETALQKSWQSNSSVSEGSSENSRSYVKATELVFAEKHGSWGTP
IISMERPAGLNDIGMVAVILEMSTPEFPNGRQIIVIANDITFRAGSFGPREDAFFEAVTNLACERKLPLIYLA
NSGARIGIADDEVKSCFRVGSDEGSPERGFQYIYLTDYARISLSVIAHKLQLDNGEIRWIIDSVVGKEDGLG
VENLHGSAAIASAYSRA YEETFTLTFTVGTGRTVGIGAYLARLGIRCIQRDQPIILTGFSALNKLLGREVYSSHM
QLGGPKIMATNGVVHLTVSDDLEGVSNILRWLSYVPANIGGPLPITKPLDPPDRPVAYIPENTCDPRAAIRGVD
DSQGWLGGMFDKDSFVETFEGWAKTVVTGRAKLGGIPVGVIAVETQTMQLIPADPGQLDSHERSVPRAGQVW
FPDSATKTAQALLDFNREGLPLFILANWRGFGSGQRDLFEIGILQAGSTIVENLRTYNQPAFVYIPMAGELRGA
WVVVDSKINPDRIECYAERTAKGNVLEPQGLIEIKFRSEELQDCMGRLDPELINLAKLQGA KLNGSLTDVES
LQKSIDARTKQLLPLYTQIAIRFAELHDTSLRMAAKGVIKKVVWDWEESRSFFYRRLRRRI SEDVLAKEIRGIAG
DHFTHQSAVE LIKEWYLASQATTGSTEWDDDDAFVAWKENPENYKGYIQELRAQKVSQSLS DLADSSSDLEAFS
QGLSTLLDKMDPSQRAKFIQEVKKVLG

FIGURE 13A

>AF294805_Setaria italica (foxtail millet)
ATGTCGCAACTTGGATTAGCTGCAGCTGCCTCAAAGGCGCTGCCACTACTTCCTAATCGCCATAGAACTTCAGCTGG
AACTACATTTCCCATCACCTGTATCATCGGGCCCTCAAACCGAAGGAAAAGCCGCACTCGTTCACTTCGTGATGGAG
GAGATGGGGTATCAGATGCCAAAAGCACAACCAAGTCTGTCCGTCAAGGTCTTGCTGGCATCATCGACCTCCCAAT
GAGGCAACATCGGAAGTGGATATTTCTCATGGATCCGAGGATCCAGGGGGCCAACCGATTATATCAAATGAATGG
GATTGTAAATGAAGCACATAATGGCAGACATGCCTCAGTGTCCAAGGTTGTTGAATTTGTGCGGCGCTAGGTGGCA
AAACACCAATTACAGTATACTAGTGGCCAACAATGGAATGGCAGCAGCAAAGTTTATGAGGAGTGTCCGGACATGG
GCTAATGATACTTTTGGATCGGAGAAGGCGATTACAGTCTATAGCTATGGCAACTCCAGAAGACATGAGGATAAATGC
AGAACACATTAGAATTGCTGATCAATTTGTAGAGGTGCCTGGTGAACAAACAATAACAATATGCAAATGTTCAAC
TCATAGTGGAGGTAGCAGAAAGAATAGGTGTTTCTGCTGTTTGGCCTGGTTGGGTCATGCTTCTGAGAATCCTGAA
CTTCCAGATGCATTGACCGCAAAAGGAATGTTTTCTTGGGCCACCTGCGGCATCAATGAATGCATTGGGAGATAA
GGTCGGTTCAAGTCTCATTGCTCAAGCAGCTGGGGTCCCGACCTTTCGTGGAGTGGATCAGATGTTGAAGTTCAT
TAGAGTGCTGCTTAGATGCGATACCTGAGGAAATGTATAGAAAAGCTTGTTACTACCACAGAGAAGGCTGTGCG
AGTTGTGAGGTGGTTGGTTATCTGCCATGATTAAAGCATCCTGGGAGGTGGTGGTAAAGGAATAAGAAAGGTTCA
TAATGACGATGAGGTTAGAGCACTGTTTAAAGCAAGTACAAGGTGAAGTCCCTGGCTCCCAATATTTATCATGAGGC
TTGCAATCCAGAGTCTCATCTTGAAGTTCAGTTGCTTTGTGATCAATATGGCAATGTGGCAGCACTTCACAGTCTG
GATTGCAGTGTGCAACGGCGACACCAAAAGATTATTGAGGAAGGCCAGTTACTGTTGCTCCTCGTGAGACAGTTAA
AGCGGTTAGCAGGCAGCAAGGAGGCTTCTAAGGCTGTGGGTTATGTTGGTGTGCTACTGTTGAATACCTTTACA
GCATGGAGACTGGGGAATACTATTTCTGGAGCTTAATCCCAGATTACAGGTGAGCATCCAGTCACTGAGTGGATT
GCTGAAGTAAATCTTCTGCAAGTTCAGTTGCAAGTGGGATGGGCATACCTCTTGGCAGATTCCAGAAATCAGACG
TTTCTATGGAATGGACTATGGAGGAGGATATGACATTTGGAGGAAACAGCAGCTCTTGCCACACCATTTAATTTTG
ATGAAGTAGATTCTCAATGGCCAAAGGGCCATTTGTGAGCAGTTAGAATTACTAGCGAGGATCCAGATGATGGTTTC
AAACCTACTGGTGGGAAAGTGAAGGAGATAAGTTTAAAAGCAAGCCTAATGTTTGGGCTACTTCTCAGTAAAGTC
TGGTGGAGGCATTATGAATTTGCTGATTCTCAGTTTGGGATGTTTGTGATATGGGCTCTCTAGATCAGCAGCAA
TAACGAACATGGCTCTTGCATTTAAAGAGATTCAAATTCGTGGAGAAATTCATTCAAATGTTGATTACACAGTTGAT
TCTTAAATGCTTCAGACTTCAGAGAAAATAAGATTCTACTGGCTGGCTTGATACCAGAATAGCTATCCGTTTCA
AGCTGAGAGGCCCCATGGTATATTTTCAAGTGGTTGGAGGAGCTCTATATAAAACAGTAACTGCCAATGCAGCCACTG
TTTCTGATTATGTGAGTTATCTCACCAGGGCCAGATTCCACCAAGCATATATCCCTTGTGAGTTCAACAGTTAAT
CTGAATATCGAAGGAGCAAATACACAGTTGAAACTGTAAAGGACTGGACATGGTAGCTACAGATTACGAATGAATGA
TTCAGCAATTGAAGCGAATGTACAATCTTTATGTGATGGAGGCTCTTAATGCAGTTGGATGGAATAGCCATGTAA
TTTACGCGGAAGAAGAAGCTGGTGGTACACGACTTCTGATTGATGGAAAGACATGCTTGTACAGAATGATCATGAT
CCATCAAAGTTATTAGCTGAGACACCCTGCAAACCTCTTCGGTTCTTGGTTGCTGATGGTGTCTGATGTTGATGCTGA
TGTACCATATCGGGAAGTTGAGGTTATGAAATGTGCATGCTCTCTGTGCGCTGCTCTGGTGTCAATCATGTTA
TGATGTCTGAGGGCCAGGCATTGCGAGCTGGTGATCTTATAGCAAGGCTGGATCTTGATGACCCCTCTGCTGTGAAA
AGAGCTGAACCATTTTATGGAATATTTCCAAATGGACCTTCTGTTGCTGCCTCTAGCCAAGTACACAAAAGATA
TGCTGCAAGTTTGAATGCTGCTCGAATGGTCTTGCAAGGATACGAGCATAATATCAATGAAGTTGTACAAGATTGG
TATGCTGCTGGATGATCCCGAGCTTCCCTTCTTACAGTGGGATGAAGTTATGTGAGTTCTAGCAACTAGGCTTCCA
AGAAATCTTAAGAGTGAATGAGGATAAATACATGGAATACAAGTTGAAGTTTACCATGGGAAAAACAAGGACTT
CCCGTCCAAGCTGCTGAGAGACATCATTTAGGCAAACTCTTGCAATATGGTTTCAAGAGAAGGAAAAGCTACGAATGAGA
GGCTTATTGAGCCTCTTATGAGCCTACTTAAGTCATATGAGGTTGGGAGAGAAAGCCATGCTCATTTTGTGTTCAAG
TCCCTTTTCAAGGAGTACCTTGTGTTGGAAGAACTTTTCAAGTATGGGATTCAAGTCTGATGTTGATTGAAACCCCTGCG
TCATCAGCACAGTAAAGACTTGCAGAAGTTGTAGACATTGTGTTGCTCACCAGGGTGTGAGGAACAAAGCTAAGC
TTGTAACAGCACTTATGGAAGGCTGGTTTATCCAAATCCTGCTGCTTACAGGGATCTGTTGGTTCGCTTTTCTTCA
CTCAATCATAAAAGATATATAAGTTGGCCCTTAAAGCAAGCGAAGTCTTGAACAACTAACTAAGTGAAGTCCG
TGCAAGCATCGCAAGAAGCCTTTCTGATCTGGGGATGCATAAGGGAGAAATGACTATTGAAGATAGCATGGAAGATT
TAGTCTCTGCCCCATTACCTGTGCAAGATGCATTATTTCTTGTGTTGATTACAGTATCAACTGTTTCAAGCAGAAA
GTGATCGAGACATACATATCTCGATTGTATCAGCCTCTTCTGTGAAAGATAGCATCCAAGTGAATTTAAGGAATC
TGGTGCCTTTGCTTTATGGGAATTTTCTGAAGGGCATGTTGATACTAAAAATGGACAAGGGACCGTTCTTGGTTCGAA
CAAGATGGGGTGCCATGGTAGCTGTCAAATCAGTTGAATGTGACGACGACAGCATTGTAGTGCATTAAAGGATTGCG
GCACAGCATGCCAGCTCTGAGGGCAACATGATGCACATTGCCTTATTGAGTGTGAAAATGAAAATATATCAGTGA
TGATCAAGCTCAACATAGGATGGAAAACTTAAACAAGATACTCAAGGATACTAGTGTGCAATGATCTTCGAGCTG
CTGGTTTGAAGGTTATAAGTTGCATTGTTCAAAGAGATGAAGCAGCATGCCAATGCGCCACACATTACTCTGGTCA

GATGAAAAGAGTTGTTATGAGGAAGAGCAGATTCTTCGGCATGTGGAGCCTCCCCTCTCCATGCTTCTTGAAATGGA
TAAGTTGAAAGTGAAGGATACAATGAAATGAAGTATACCTCCATCACGTGATCGTCAATGGCATATCTACACACTAA
GAAATAGTGAAAACCCCAAAATGTTGCATAGGGTATTTTTCCGAACATTGTGCAGGCAACCCAATGCAGGCAACAAG
TTTATATCAGCCCAAAATGGCGACACTGAAGTAGGAGGTCCTGAGGAATCTTGTGTCATTACATCTAATAGCATTTT
AAGAGCCTTGATGACTGCTATTGAAGAATTAGAGCTTCATGCAATTAGGACTGGTCATTCTCACATGTATTTGTGCA
TATTGAAAGAACAAAAGCTTCTTGATCTCATTCCGTTTTTCAGGGAGCACAAATCGTCGATGTTGGCCAAGACGAAGCT
ACTGCTTGTTCACTTTTAAATCAATGGCTTTGAAGATACACGAACCTGTTGGTGACAGATGCATCATCTTTCTGT
ATGCCAGTGGGAGGTGAACTCAAGTTGTAAGTGGCCTGCCAGTGGCACCTGGAGAGTTGTAACACAAATG
TTACTAGTCACACTTGCACCGTTGATATCTACCGGAAGTGAAGATACTGAATCGCAGAAGTTAGTATACCATTCA
GCTTCTCCGTGAGCTAGTCTCTTGCATGGTGTGGCCCTGGATAATCCGTATCAACCTTTGAGTGTCTTGTATCTAAA
ACGCTGCTCTGCTAGGAACAACAGAATACATATTGCTATGATTTTCCACTGGCATTGAAACTGCCCTGCAGAAGT
CATGGCAGTCCAATGGCTCCAGTGTCTTGAAGGCAGTGAAAAATAGTAGGTCTTATGTGAAAGCAACAGAGCTGGTG
TTTGCTGAAAAACATGGGTCTGGGGCACTCCTATAATTTCCATGGAGCGTCCCGTGGGCTCAATGACATTGGCAT
GGTAGCTTGGATCTTAGAGATGCCACTCCTGAATTTCCCAATGGCAGGCAGATTATGTGTCATAGCAAAATGATATTA
CTTTGAGAGCTGGATCATTGGCCCAAGGGAAGATGCGTTTTTGAAGCTGTACGAACCTGGCCTGCGAGAGGAAG
CTTCCCTCTTATATACCTGGCAGCAAACTCCGGTGCTAGGATTGGCATAGCCGATGAAGTGAATCTTGCTTCCGTG
TGGGTGGTCCGATGAAGGCAGCCCTGAACGGGTTTTTCACTACATTTATCTGACTGACGAAGACTATGCCCGTATTA
GCTTGTCTGTTATAGCACACAAGCTGCAGCTGGATAATGGTGAAATTAGGTGGATTATGACTGTGTTGTGGGCAAG
GAGGATGGGCTTGGTGTGAGAAATATACATGGAAGTGTCTGCTATTGCCAGTGTCTATTCTAGGGCATATGAGGAGAC
ATTTACACTTACATTTGTGACTGGGCGGACTGTTGGAATAGGAGCATATCTTGCTCGGCTCGGTATACGGTGCATAC
AGCGTCTTGACCAGCCTATATTTTAACTGGGTTTTCTGCCCTGAACAAGCTTCTTGGGCGGGAAGTGTACAGCTCC
CACATGCAGTTGGGTGGTCTAAGATCATGGCGACCAATGGTGTGTCCACTGACTGTTTCAGATGACCTTGAAGG
TGTTTCCAATATATTGAGGTGGCTCAGCTATGTTCTGCCAACATTGGTGGACCTCTTCTATTACAAAACCTTTGG
ACCCACACAGACAGACCTGTGTCATACATCCCTGAGAACACATGTGATCCGCGCGCAGCCATTCTGTTGTGATGAC
AGCCAAGGGAAATGGTTGGGTGGTATGTTTGACAAAGACAGCTTTGTGAGACATTTGAAGGATGGGCGAAAAACAGT
GGTTACGGGCGAGAGCAAGCTTGGAGGAATTCCTGTTGGTGTCTAGCTGTGGAGACACAAACCATGATGCAGCTTA
TCCCTGCTGATCCAGGCCAGCTTGATTTCCATGAGCGATCTGTTCTCGGGCTGGACAAGTGTGGTTCCCAGATTCT
GCAACCAAGACAGCTCAGGCATTGTTGGACTTCAACCGTGAAGGATTGCCGCTGTTCTATCTCTTGAACCTTAGGACAT
ATTCTCTGGTGGACAAAGAGATCTGTTGAAGGAATCTTTCAGGCTGGGTCAACAATTTGTTGAGAACCTTAGGACAT
ACAAATCAGCCTGCTTTTGTCTACATTCCTATGGCTGGAGAGCTGCGTGGAGGAGCTTGGGTTGTGGTTGATAGCAAA
ATAAATCCAGACCGAATTGAGTGTATGCTGAGAGGACTGCTAAAGGCAATGTTCTGGAACCTCAAGGGTTAATTGA
AATCAAATTCAGATCAGAGGAGCTCCAAGACTGTATGGGTAGGCTTGACCCAGAGTTGATAAATCTGAAAGCAAAAC
TCCAAGGTGCAAAAGCTTGAAATGGAAGCCTAACAGATGTAGAATCCCTTCAGAAGAGTATAGATGCTCGTACGAAA
CAGTTGTTGCCCTTTATACACCCAGATTGCAATACGGTTTTGCTGAATTGCATGATACTTCCCTCAGAATGGCAGCTAA
AGGTCTGATTAAGAAAGTTGTAGATTGGGAAGAATTACGTTCTTTCTTCTACAGAAGGCTACGGAGGAGGATCTCTG
AAGATGTTCTTGCAAAAGAAATAAGAGGAATAGCTGGTGACCACTTCACTCACCATCAGCAGTTGAGCTGATCAAG
GAATGGTACTTGGCTTCTCAAGCCACAACAGGAAGCACTGAATGGGATGATGATGATGCTTTTGTGCTTGGGAAGGA
GAATCCTGAAAATATAAGGGATATATCCAAGAGTTAAGGGCTCAAAAGGTGTCTCAGTCGCTCTCCGATCTTGCAG
ACTCCAGTTCAGATCTAGAAGCATTTCTCACAGGGTCTTTCCACATTATTAGATAAGATGGATCCCTCTCAGAGAGCC
AAGTTTATTGAGGAAGTCAAGAAGGTCTGGGTTGA

FIGURE 13B

>AAL02056_Setaria italica (foxtail millet)
MSQLGLAAAASKALPLLPNRHRTSAGTTFPSVPSSRPSNRRKSRTSLRDGGDGVSDAKKHNSVRQGLAGIID
LPNEATSEVDISHGSEDPGPTDSYQMNGIVNEAHNGRHASVSKVVEFCAALGGKTPIHSLVANNGMAAAKFM
RSVRTWANDTFGSEKAIQLIAMATPEDMRINAEHIRIADQFVEVPGGTNNNNYANVQLIVEVAERIGVSAVWPG
WGHASENPCLPDALTAKGIVFLGPPAASMNALGDKVGSALIAQAAGVPTLSWSGSHVEVPLECCCLDAIPEEMYR
KACVTTTEEAVASCQVVGYPAMIKASWGGGGKGIKRVHNDDEVRLFKQVQGEVPGSPIFIMRLASQSRHLEVO
LLCDQYGNVAALHSRDCSVQRRHQKIIIEGFPVTAPRETIVKALEQAARRLAKAVGYVGAATVEYLYSMETGEYY
FLELNPRQLQVEHPVTEWIAEVNLPAAQVAVGMGIPWQIPEIRRFYGMIDYGGGYDIWRKTAALATPFNFDEVDS
QWPKGHCVAVRITSEDPDDGFKPTGGKVKELISFKSKPNVWAYFSVKSGGGIHEFADSQFGHVFAAYGLSRSAIT
NMALALKEIQIRGEIHSNVDYTVDLLNASDFRENKIHTGWLDTIAMRVQAERPWPYISVVGALYKTVTANAA
TVSDYVSYLTKGQIPPKHISLVSSTVNLNIEGSKYTETVRTGHGSYRLRMNDSAI EANVQSLCDGGLLMQLDQ
NSHVIYAEAEAGGTRLLIDGKTCILLQNDHDP SKLLAETPCKLLRFLVADGAHVADVPYAEVEVMKMCMPLLSP
ASGVIHVMMSGQALQAGDLIARLDLDDPSAVKRAEPFHGIFPQMDLPVAASSQVHKRYAASLNAARMVLAGYE
HNINEVVQDLVCCLDDELPFLQWDELMSVLATRLPRNLKSELEDKYMAYKLNIFYHGKNKDFPSKLLRDI EAN
LAYGSEKEKATNERLIEPLMSLLKS YEGGRESHAFVVKSLFKEYLAVEELFSDGIQSDVIEFTRHQHSKDLQK
VVDIVLSHQGVRNKAKLVLTALMEKLVYPNPAAYRDLVRFSSLNHKRYKALALKASELLEQTKLSELRASARS
LSDLGMHKGEMTIEDSMEDLVSAPLPVEDALISLFDYS DPTVQQKVIETIYISRLYQPLL VKDSIQVKFKEGAF
ALWEFSEGHVDTKNGQGTVLGRTRWGAMVAVKSVESARTAI VAALKDSAQHASSEGNNMHIALLSAENENNISD
DQAQHRMEKLNKILKDTSVANDLRAAGLKVISCI VQRDEARMPMRHTLLWSDEKSCYEEEQILRHVEPPLSMLL
EMDKLVKVGYNEMKYTPSRDRQWHIYTLRNTENPKMLHRVFFRTIVRQPNAGNKFISAQIGDTEVGGPEESLSF
TSNSILRALMTAIELELHAIRTGHS MYLCILKEQKLLDLIPFSGSTIVDVGQDEATACSLKSMALKIHELIV
GAQMHLSVCQWEVKLKLYCDGPASGTWRVVTTNVT SHTCTVDIYREVEDTESQKL VYHSASPSASPLHGVALD
NPHYQPLSVIDLKRCSARNNRRTTYCYDFPLAFETALQKSWQSNSSVSEGSNSRSYVKATELVFAEKHGSWGTP
IISMERPAGLNDIGMVAWILEMSTPEFPNGRQI IVIANDITFRAGSFGPREDAFFEAFTNLACERKLPLIYLAA
NSGARI GIADDEVKSCFRVGSDEGSPERGFQYIYLTDEDYARISLSVIAHKLQLDNGEIRWIIDSVVGKEDGLG
VENIHGSAAIASAYSRA YEETFTLTFTVGTGRTVGIGAYLARLGIRCIQRLDQPIILTGFSALNKL LGREYSSHM
QLGGPKIMATNGVVHLTVSDDLEGVSNILRWLSYVPANIGGPLPITKPLDPPDRPVAYIPENTCDPRAAIRGVD
DSQGWLGGMFDKDSFVETFE GWAKTVVTGRAKLG GIPVGVIAVETQTMQLIPADPGQLDSHERSVPRAGQVW
FPDSATKTAQALLDFNREGLPLFILANWRGFSGGQRD LFE GILQAGSTIVENLR TYNQPAFVYIPMAGELRGGA
WVVVDSKINPDRIECYAERTAKGNVLEPQGLIEIKFRSEELQDCMGRLDPELINLKAKLQGA KLNGSLTDVES
LQKSIDARTKQLLPLYTQIAIRFAELHDTSLRMAAGV I KKVVDWEELRSFFYRRLRRRI SEDVLAK EIRGIAG
DHFTHQSAVELIKEWYLASQATTGSTEWDDDDAFVAVKENPENYKGYIQELRAQKVSQSLS DLADSSSDLEAFS
QGLSTLLDKMDPSQRAKFIQEVKKVLG

FIGURE 14A

ATGCGGATCCACGATCTGCCCATTTGTCGGGTTTTAATGCATCCACACACCATCGTATCCACTCTTCGCCAGATAAA
 CTCAGCTGCTGCTGCATTTCCAATCTTCGTCCTCCCTTCAAGGTCATCCAAGAGAAAGCCAGCTGTAAAGTCAATAA
 GGGATGATGGCGATGGAAGCGTCGCACAGCTCGAGCCATGCGGCATCTATTGCGAAGTCTCGCTGGCATCATC
 GACCTCCCAAAGGAGGGCGCATCAGCTCCAGATGTGGACATTTACATGGGTCTGAAGACCACAAGGCCTCCTACCA
 AATGAATGGGATACTGAATGAATCACATAACGGGAGGCAAGCCTCTCTGTCTAAAGTTTATGAATTTTGCACGGAAAT
 TGGGTGGAAAAACACCAATTCACAGTGTATTAGTGCCTAACAAATGGAATGGCAGCAGCTAAGTTCATGCGGAGTGTCT
 CGGACATGGGCTAATGATACATATTTGGCTCAGAGAAGGCGATTCAGTTGATAGTATGGCACTCGGAAGACATGAG
 AATAAATGCGAGACCATTTAGAATTCGTGATCAGTTTGTGAAGTACCTCGGTGGAACAAACAAATAACAACATATGCAA
 ATGTCCAACATCATAGTGCAGATAGCAGAGAGAACTGGTGTCTCCGCCGTTTGGCCTGGTTGGGGCCATGCATCTGAA
 AATCCTGAACCTTCAGATGTCATTAAGTGCAAAAGGAATGTCTTTCTTGGGCCAACAGCATCATCAATGAACGCACAT
 AGGCGACAAGGTTGGTTTTCAGCTCTCATTGCTCAAGCAGCAGGGGTTCCCACTCTTGGTGGATGGATCAGATGTGG
 AAATTCATTAGAATCTTTGTTGGACTCGATAGGAGATGTATAGAAAGCCTGTGTATCAACCGCTGATGAA
 GCAGTTTGCAGATTTGTCTAGATGATTTGGTTTACCCTGCCATGATCAAGGCATCCTGGGGTGGTGGTGGTAAAGGGATTAG
 AAAGGTTAATAATGATGACGAGGTGAAAGCACTGTTTAAAGCAAGTACAGGGTGAAGTTCCTGGCTCCCCGATATTTA
 TCATGAGACTTTGCATCTCAGAGTCGTCTCTTGAAGTCCAGCTGCTTTGTGATGAATATGGCAATGTAGACGACATTA
 CACAGTCGTGATTGTCAGTGTGCAACGACGACACCAAGGATTTACGAGGAGGACCCAGTTACTGTTGCTCCTCGTTA
 AACAGTGAAGAAGCTTAGAGCAAGCAGCAAGGAGCTTGCTAAGCCGCTGGTGTACGTGGTGTGCTGCTACTGTTGAAT
 ATCTCTACAGCATGGAGACTGGTGAATACTATTTTCTGGAGCTTAATCCACGGTTGCAGGTTGAGCACCAGTCACC
 GAGTCGATAGCTGAAGTAAATTTGCCTGCAGCCCAAGTTGCAGTTGGGATGGGTATACCCCTTTGGCAGATTTCCAGA
 GATCAGACGTTTCTACGGAATGGACAAATGGAGGAGGCTATGATATTTGGAGGAAAACACAGCAGCTCTCGCTCATCCAT
 TCAACTTTGATGAAGTACATTTGCAATGGCCGAAGGCTCATTTGTGGCAGTTAGATTAACCATGAGCAATCCAGAT
 GATGGATTTCAGCGCTACTGGTGCAAAAGTAAAGGAGATTAAGTTTAAAGTAAGCCAAATGCTTGGGGATATTTCTC
 AGTTAAGTCTGGTGGAGGCATTCATCAATTTGCGGATTCAGTTTGGACACGTTTTTGCTATGGAGAGACTAGAT
 CAGCAGCAATAACAGCATGTCTCTTGCCTATAAAGAGATTCAAATTCGTGGAGAAATTCATACAAACGTTGATTAC
 ACGGTTGATCTCTTGAATGCCCCAGACTTCAGAGAAAACACGATCCATACCGGTTGGCTGGAATACCAAGATAAGCTAT
 GCGGTGTTCAAGCTTAGAGAGGCCCTCCCTGGTATATTTCAAGTGGTTGAGAGGCTCTATATAAACAATTAACCAACG
 CGGAGACCGGTTTCTGAATATGTTAGCTATCTCATCAAGGTCAGATTCCACCAAGCACATATCCCTTGTCCATTCA
 ACTATTTCTTTGAATATAGAGGAAAGCAATATACAATTTGAGATTGTGAGGAGTGGACAGGGTAGCTACAGATTGAG
 ACTGAATGGATCACTTATTTGAAGCCCAATGTACAAACATTATGTGATGGAGGCCCTTTAATGTCAGCTGGATGGAAATA
 GCGATGCTTATTTATGCTGAAGAAGAGCGGGTGTACACGGCTCTTATTGATGGAAGAAACATGCTTGCTACAGAAT
 GACCATGATCCGTCAAGGTTATTAGCTGAGACACCTGCAAACTTCTTCGTTTCTTGATTGCCGATGGTGTCTCATGT
 TGAATGCTGATGTACCATACGCGGAAGTTGAGGTTATGAAGATGTGCATGCCCTCTTGTGCGCTGCTGCTGTGTGCA
 TTAATGTTTTGTTGTCGAGGGCCAGGCGATCGAGGCTGCTGATCTTATAGCGAGACTTGATCTCGATGACCTTCT
 GCTGTGAAGAGAGCCGAGCCATTTGAAGGATCTTTTCCAGCAATGAGCCTTCTTATGCTGCTTCTGGCCAGGTTCA
 CAAAGATGTGCTGCAAGTTTGAACGCTGCTCGAATGGTCTTGCAGGATATGACCATGCGGCCAACAAAGTTGTGC
 AAGATTTGGTATGGTGCCTTGATACACCTGCTCTTCTTTTCTTACAATGGGAAGAGCTTATGCTGTGTTTTAGCAAC
 AGACTTCCAAGAGCTCTTAAGAGCGAGTTGGAGGGCAAAATACAATGAATACAAGTTAAATCTTGACCATGTGAAGAT
 CAAGGATTTCCCTACCGAGATGCTTAGAGAGACATCAGGAAAACTTGATGTGTTTCCGAGAAGGAATGGTGA
 CAATTGAGAGGCTTTGTTGACCTCTGATGAGCCTGCTGAAGTATACGAGGGTGGGAGAGAAGCCATGCCCACTTT
 ATTGTCAAGTCCCTTTTTGAGGAGTATCTCTCGGTTGAGGAACATTTAGTGATGGCATTGATCTGACGTGATTGA
 ACGCCTGCGCTACAATATAGTAAAGACCTCCAGAAGGTTGTAGACATTTGTTTGTCTCACCAGGGTGTGAGAACA
 AAACAAGAGCTGATATCGCGCTCATGAGGAAACTGGTCTATCCAACCCCTGCTGCCACAGAGATCAGTTGATTCGC
 TTTTCTTCCCTCAACCAATAAAGATATTAAGTTGGCTCTTAAAGCTAGTGAATCTTTGAACAAACCAAGCTCAG
 CGAATCCGACAGCATGCTGAAGGAACCTTTCAGCGCTGATATGTTTACCAGGAGAAAGGAGCATTTTCTCCTGCG
 AAGACAGAAAATTTGCCATTAATGAGAGCATGGGAGATTTAGTCACTGCCCCACTGCCAGTTGAAGATGCATTTGTT
 TCTTTGTTTGAATGTACGTGATCAAACTCTTCAGCAGAGATGATTGACAGATACATATCTCGATATATACCAGCTCA
 ACTTTGTGAAGGATAGCATCCAGCTGAAATATCAGGATCTGGTGTATTGCTTTATGGGAATTCATGAAGGAAATC
 ATGAGAAGAGATTTGGTGTCTATGTATTCCTGAAGTCACTAGAATCTGTGTCAACAGCCATTTGAGCTGCTCTAAAG
 GATGCATCAACATTTAGCAAGCTCTGCGGGCAACACGGTGCATATTGCTTTGTTGGATGCTGATACCCAACCTGAATAC
 AACTGAAGATAGTGGTGATAATGACCAAGCTCAAGACAGATGGATAAACTTCTTTGTACTGAACAAAGATGTTG
 TCATGGCTGATCTACGTGCTGCTGATGCTCAAGGTTGTATGCTGTCATTTGTTCAAAGAGATGAGCAATGATGCCATATG
 CGCGTACCTTCTCTTGTGATGAGGAAAACTTTTGTACGAGGAAGAGCCGATTTCTGGCATGTCGAGCCTCCACT
 TCTGCACTTCTTGAGTTGGATTAATTTGAAGTGAAGGATACAATGAGATGAAGTATACACCGTCAAGTGTCTGCTC

AGTGGCATATATACACACTTAGAAATACTGAAAAATCCAAAAATGCTGCACAGGGTATTTTCCGAACACTTGTGAGA
CAACCCAGTGCAGGCAACAGGTTTACATCAGACCATATCACTGATGTTGAAGTAGGACACGCAGAGGAACCTCTTTC
ATTTACTTCAAGCAGCATATTTAAATCGTTGAAGATTGCTAAAGAAGAATTGGAGCTTCACGCCGATCAGGACTGGCC
ATTCTCATATGTACTTGTGCATATTGAAAGAGCAAAAGCTTCTTGACCTTGTCTGTTCAGGGAACACTGTTGTG
GATGTTGGTCAAGATGAAGCTACTGCATGCTCTCTTTGAAAGAAATGGCTTTAAAGATACATGAACCTTGTGGTGC
AAGAATGCATCATCTTTCTGTATGCCAGTGGGAAGTGAACTTAAGTTGGTGAGCGATGGGCCCTGCCAGTGGTAGCT
GGAGAGTTGTAACAACCAATGTTACTGGTCACACCTGCACCTGTGGATATCTACCGGGAGGTCGAAGATACAGAATCA
CAGAACTAGTATACCACTCCACCGCATTTGTCTGCTGGTCCCTTTCATGGTGTGCACTGAATACTTCGTATCAGCC
TTTGAGTGTTATTGATTTAAACGTTGCTCTGCCAGGAACAACAAACTACATACTGCTATGATTTTCCATTGACAT
TTGAAGCTGCAGTGCAGAGTCTGGTCTAACATTTCCAGTGAAACAACCAATGTTATGTTAAAGCGACAGAGCTT
GTGTTGCTGAAAAGAATGGGTCCTGGGGCACTCCTATAATTCCATGACAGCGTGTCTGCTGGGCTGAATGACATTGG
TATGGTAGCCTGGATCTTGGACATGTCCACTCCTGAATTTCCAGCGGCAGACAGATCATTGTTATCGCAAAATGATA
TTACATTTAGAGCTGGATCATTGGCCCAAGGGAAGATGCATTTTTCGAAGCTGTAACCAACCTGGCTTGTGAGAAG
AAGCTTCCACTTATCTACTTGGCTGCAAACTCTGGTGTCTCGGATTGGCATTGCTGATGAAGTAAATCTTGCTTCCG
TGTTGGATGGAGTGTATAGCAGCCCTGAACGTGGATTTAGGTACATTTATATGACTGACGAAGACCATGATCGTA
TTGGCTCTTCAGTTATAGCACACAAGATGCAGCTAGATAGTGGCGAGATCAGGTGGGTTATTGATTCTGTTGTGGGA
AAAGAGGATGGACTAGGTGTGGAGAACATACATGGAAGTGCTGCTATTGCCAGTGCCATTCTAGGGCGTACGAGGA
GACATTTACACTTACATTGTTACTGGACGAAGTGTGGAATCGGAGCCTATCTTGTCTGACTTGGCATAACGGTGCA
TACAGCGTATTGACAGCCCATTTTGGACCGGTTTCTGCCCTGAACAAGCTTCTTGGGCGGGAGGTGTACAGC
TCCCACATGCAGTTGGGTGGTCCCAAAATCATGGCGACGAATGGTGTGTCCATCTGACTGTTCCAGATGACCTTGA
AGGTGTTTCTAATATATTGAGGTGGCTCAGCTATGTTTCCGCAAAACATTGGTGGACCTCTTCCATTACAAAAATCTT
TGGACCCAATAGACAGACCCGTTGCATACATCCCTGAGAATACATGTGATCCTCGTGCAGCCATCAGTGGCATTGAT
GACAGCCAAGGGAATGTTGGGTGGCATGTTTGACAAAGACAGTTTGTGGAGACATTGAAGGATGGGCGAAGAC
AGTAGTTACTGGCAGAGCAAACTTGGAGGGATTCTGTTGGTGTATAGCTGTGGAGACACAGACCATGATGCAGC
TCGTCCCGCTGATCCAGGCCAGCCTGATTTCCACGAGCGGTCTGTTCCCTCGTGTGGGCAAGTTTGGTTTCCAGAT
TCTGTACCAAGACAGCGCAGGCGATGTTGGAATTCACCCGTGAAGGATTACCTCTGTTTCATACTTGCTAACTGGAG
AGGCTTCTCTGGAGGGCAAAGAGATCTTTTGAAGGAATTCTGCAGGCTGGGTCAACAATTGTTGAGAACCTTAGGA
CATACAATCAGCTGCCCTTGTATATATCCCCAAGGCTGCAGAGCTACGTGGAGGAGCCTGGGTGCTGATTGATAGC
AAGATAAACCCAGATCGCATCGAGTGCTATGCTGAGAGGACTGCAAAAGGTAATGTTCTCGAACCTCAAGGGTTGAT
TGAGATCAAGTTCAGGTGAGGGAAGTCAAGAAATGCATGGGTAGGCTTGATCCAGAATGATAGATCTGAAAGCAA
GACTCCAGGGAGCAAAATGGAAGCCTATCTGATGGAGAATCCCTTCAGAAGAGCATAGAAGCTCGGAAGAAACAGTTG
CTGCCTCTGTACACCCAAATCGCGGTACGTTTGGCGAATTGCACGACACTTCCCTTAGAATGGCTGCTAAAGGTGT
GATCAGGAAAGTGTAGACTGGGAGACTCTCGGTCTTTCTTCTACAGAGATTACGGAGGAGGCTATCCGAGGACG
TTCTGGCAAAGGAGATTAGAGGTGTAATGGTGAGAAGTTTCTCACAAATCAGCGATCGAGCTGATCAAGAAATGG
TACTTGGCTTCTGAGGCAGCTGCAGCAGGAAGCACCGACTGGGATGACGACGATGCTTTTGTGCGCTGGAGGGAGAA
CCCTGAAAACATAAGGAGTATATCAAAGAGCTTAGGGCTCAAAGGGTATCTCGGTTGCTCTCAGATGTTGCAGGCT
CCAGTTCGGATTTACAAGCCTTGCCGAGGGTCTTCCATGCTACTAGATAAGATGGATCCCTCTAAGAGAGCACAG
TTTATCGAGGAGGTGATGAAGTCTCTGAAATGA

FIGURE 14B

>CAC84161_Alopecurus myosuroides (black-grass)
MGSTHLPIVGFNASTTPSLSTLRQINSAAAAFQSSSPSRSSKKKSRRVKSIRDDGDGSVPDPAGHGQSIRQGIA
GIIDLKPEGASAPDVIDISHGSEDHKASYQMNGILNESHNGRHASLSKVYEFCTELGGKTPIHSVLVANNGMAAA
KFMRSVRTWANDTFGSEKAIQLIAMATPEDMRINAEHIRIADQFVEVPGGTNNNNYANVQLIVEIAERTGVS
WPGWGHA SENPELPDAITAKGIVFLGPPASSMNALGDKVGSALIAQAAGVPTLAWSGSHVEIPLELCLDSIPEE
MYRKACVTTADEAVASCQMIGYPAMIKASWGGGGKGIRKVNNDDEVKALFKQVQGEVPGSPIFIMRLASQSRHL
EVQLLCDEYGNVAALHSRDCSVQRRHQKIIEEGPVTVAPRETVKELEQAARRLAKAVGYVGAATVEYLYSMETG
EYYFLELNPRLQVEHPVTESIAEVNLPAAQVAVGMGIPLWQIPEIRRIFYGMDNGGGYDIWRKTAALATPFNFDE
VDSQWPKGHCVAVRITSENPDGFKPTGGKVKEISFKSKPNVWGYFSVKSGGGIHEFADSQFGHVFAGETRSA
AITSMSLALKEIQIRGEIHTNVDTYVDLLNAPDFRENTIHTGWLDTRIAMRVQAERPPWYISVVGALYKTITT
NAETVSEYVSYLKQGIPPKHISLVHSTISLNIEESKYTIEIVRSGQGSYRLRLNGSLIEANVQTLCDGGLLMQ
LDGNHSHVIAEEEEAGGTRLLIDGKTCLLQNDHDP SRLLAETPCKLLRFLIADGAHVADAVPYAEVEVMKCMPL
LSPAAGVINVLVLLSEGOAMQAGDLIARLDLDDPSAVKRAEPFEGSFPEMSLPAAAGQVHKRCAASINAARMVLA
GYDHAANKVVQDLVWCLDTPALPFLQWEELMSVLATRLPRRLKSELEGKYNEYKLVNDHVKIKDFPTEMLRETI
EENLACVSEKEMVTIERLVDPLMSLLKSYEGGRESHAFIVKSLFEEYLSVEELFSDGIQSDVIERLRLQYSKD
LQKVVDIVLSHQGVNRNKKLILALMEKLVYPNPAAYRQDLIRFSSLNHKRYYKLALKASELLEQTKLSELRTSI
ARNLSALDMFTEEKADFSLODRKLAINESMGDLVTAPLPVEDALVSLFDCTDQTLQQRVIQTYISRLYQPPQIVK
DSIQLKYQDSGVIALWEFTEGNHEKRLGAMVILKSLESVSTAIGALKDASHYASSAGNTVHIALLDADTQJLNT
TEDSGDNDQAQDKMDKLSFVLKQDVVMADLRAADV KVVSCI VQRDGAIMP MRRTFLLSEEKLCYEEEPILRHVE
PPLSALLELDKLVKGYNEMKYTPSRDRQWHIYTLRNTENPKMLHRVFFRTLVRQPSAGNRFTSDHITDVEVGH
AEEPLSFTSSSILKSLKIAKEEELHAI RTGHSHMYLCILKEQKLLDLPVSGNTVVDVGQDEATACSLKEMA
LKIHEL VGARMHHL SVCQWEVKLKLVS DGPASG SWRVVTTNVTGHTCTVDIYREVEDTESQKLVYHSTALSSGP
LHGVALNTSYQPLSVIDLKRC SARNNKTTYCYDFPLTFEAAVQKSWSNISSENNQCYVKATELVFAEKNGSWG
PIIPMQRAAGLNDIGMVAWILDMSTPEFPGRQIIVIAN DITFRAGSF GPREDAFFEAVTNLACEKKLPLIYLA
ANSGARIGIADDEVKSCFRVGTDDSSPERGFRYIYMTDEDHDRIGSSVIAHKMQLDSEIRWVIDSVVGKEDGL
GVENIHGSAAIASAYSRA YEETFTLTFTVTGRTVGIGAYLARLGIRCIQRIDQPIILTGFSALNKL LGREYVSSH
MQLGGPKIMATNGVVHLTPDDLEGVSNILRWLSYVPANIGGPLPTKSLDPIDRPVAYIPENTCDPRAAISGI
DDSQGWLGGMFDKDSFVETFEGWAKTVVTGRAKLG GIPVGVIAVETQTMMLVPADPGQPD SHERSVPRAGQV
WFPDSATKTAQAMLDFNREGLPLFILANWRGFSGGQ RDLFEGILQAGSTIVENLRTYNQPAFVYIPKAAELRG
AWVVIDSKINPDRIECYAERTAKGNVLEPQGLIEIKFRSEELKECMGRLDPELIDLKARLQGANGLSDGESIQ
KSIEARKKQLLPLYTQIAVRFAELHDTSLRMAAKGVIRKVVWDWEDSRSEFFYKRLRRRLSEDVLAK EIRGVIGE
K FPHKSAIELIKKWLASEAAAAAGSTDWDDDAFVAWRENPENYKEYIKELRAQRVSRLLSDVAGSSSDLQALPQ
GLSMLLDKMDPSKRAQFIEEVMKVLK

FIGURE 15A

>EU660897 *Aegilops tauschii* (jointed goatgrass)
ATGGGATCCACACATTTGCCATTGTGCGCCTTAATGCCTCGACAACACCATCGCTATCCACTATTGCCCCGGTAA
TTCAGCCGGTGCTGCATTCCAACCATCTGCCCTTCTAGAACCTCCAAGAAGAAAAGTCGTGTTTTCAGTCATTAA
GGGATGGAGGCGATGGAGGCGTGTGAGACCCTAACCACTTATTCGCAAGGTCTTGCCGGCATCATTTGACCTCCA
AAGGAGGGGCACATCAGCTCCGGAAGTGGATATTTACATGGGTCCGAAGAACCAGGGGCTCCTACCAATGAATGG
GATACTGAATGAAGCACATAATGGGAGGCATGCTTCGCTGTCTAAGSTTGTGCAATTTTGTATGGCATTGGGCGGCA
AAACACCAATTCATAGTGTATTAGTTGCGAACATGGAATGGCAGCAGCTAAGTTCATGCGGAGTGTCCGAACATGG
GCTAATGAAACATTTGGGTGAGAGAAGGCAATTCACTTGATAGCTATGGCTACTCCAGAAGACATGAGGATAAATGC
AGAGCACATTAGAATTGCTGATCAATTTGTTGAAGTACCCGGTGGAAACAAACAATAACAACATATGCAAATGTCCAAC
TCATAGTGGAGATAGCAGTGAGAACCGGTGTTTCTGCTGTTTGGCCTGGTTGGGGCCATGCATCTGAGAATCCTGAA
CTTCCAGATGCACTAAATGCAAACGGAATTGTTTTCTTGGGCCACCATCATCATCAATGAACGCACTAGGTGACAA
GGTTGGTTGAGCTCTCATTTGCTCAAGCAGCAGGGGTTCCGACTCTTCTTGGAGTGGATCACAGGTGGAAATTCAT
TAGAAGTTTGTGGACTCGATACCTGCGGATATGTATAGGAAAGCTTGTGTAGTACTACGGAGGAAGCACTTGGC
AGTTTGTGATGATTGGGTATCCAGCCATGATTAAGCATCATGGGGTGGTGGTGGTAAAGGGATCCGAAAGGTTAA
TAACGACGATGATGTGAGAGCACTGTTTAAAGCAAGTCAAGGTGAAGTTCCTGGCTCCCAATATTTATCATGAGAC
TTGCATCTCAGAGTCGACATCTTGAAGTTCAGTTGCTTTGTGATCAATATGGCAATGTAGCTGCGCTTCACAGTCTG
GACTGCAGTGTGCAACGGCGACACCAAAAGATTATTGAGGAAGGACCACTTACTGTTGCTCCTCGGAGACAGTGAA
AGAGCTAGAGCAAGCAGCAAGGAGGCTTGCTAAGGCTGTGGGTATGTTGGTGTGCTACTGTTGAATATCTCTACA
GCATGGAGACTGGTGAATACTATTTTCTGGAACCTTAATCCACGGTTGCAGGTTGAGCATCCAGTCACCGAGTGGATA
GCTGAAGTAAACTTGCCTGCAGCTCAAGTTCAGTTGGAATGGGTATACCCCTTTGGCAGGTTCCAGAGATCAGACG
TTTCTATGGAATGGACATGGAGGAGGCTATGACATTTGGAGGAAAACAGCAGCTCTTGCTACCCCATTTAACTTTG
ATGAAGTGGATTCTCAATGGCCAAAGGGTCATTGTGTAGCAGTTAGGATAACCACTGAGGATCCAGATGACCGATT
AAGCCTACCGGTGGAAAAGTAAAGGAGATCAGTTTTAAAGCAAGCCAAATGTTTGGGCTATTCTCTGTGTTAAGTC
CGGTGGAGGCATTGATGAATTTGCTGATTCTCAGTTTGGACATGTTTTTGCATATGGAGTGTCTAGAGCAGCAGCAA
TAACCAACATGTCTCTTGGCTAAAAGAGATTCAAATTCGTGGAGAAATTCATTCAAATGTTGATTACACAGTTGAT
CTCTTGAATGCCTCAGACTTCAAAGAAAACAGGATTCATACTGGCTGGCTGGATAACAGAATAGCAATGCGAGTCCA
AGCTGAGAGACCTCCGTGGTATATTTTCACTGGTTGGAGGAGCTCTATATAAAACAATAACGAGCAACACAGACACTG
TTTCTGAATATGTTAGCTATCTCGTCAAGGGTCAGATTCACCCGAAGCATATATCCCTTGTCCATTCAACTGTTTCT
TTGAATATAGAGGAAAGCAAATATACAATTGAACTATAAGGAGCGGACAGGTTAGCTACAGATTGCGAATGAATGG
ATCAGTTATTGAAGCAAATGTCCAAACATTATGTGATGGTGGACTTTAATGCAAGTTGGATGGAAACAGCCATGTAA
TTTATGCTGAAGAAGAGGCCGGTGGTACACGGCTTCTAATTGATGGAAGACATGCTTGTACAGAATGATCAGCAT
CCTTCAAGGTTATTAGCTGAGACACCCTGCAAACCTCTTCTGTTTCTTGGTTGCCGATGGTGCTCATGTTGAAGCTGA
TGTACCATATGCGGAAGTTGAGGTTATGAAGATGTGCATGCCCTCTTGTACCTGCTGCTGGTGTCAATTAATGTTT
TGTTGTCTGAGGGCCAGCCTATGCAAGGCTGGTGTATCTATAGCAAGACTTGATCTTGATGACCTTCTGCTGTGAAG
AGAGCTGAGCCGTTTAAAGGATCTTCCAGAAATGAGCCTTCTTATGCTGCTTCTGGCCAGTTTCAAAAAGATG
TGCCACAAGCTTGAATGCTGCTCGGATGGTCCCTTGCAAGATATGATCACCCGATCAACAAAGTTGTACAAGATCTGG
TATCTGTCTAGATGCTCCTGAGCTTCTTCTTCTACAATGGGAAGAGCTTATGTCTGTTTATGCAACTAGACTTCCA
AGGCTTCTTAAAGAGCGAGTTGGAGGTTAAATACAGTGAATATAAGTTAAATGTTGGCCATGGAAAGAGCAAGGATTT
CCCTTCCAAGATGCTAAGAGAGATAATCGAGGAAAATCTTGACATGGTTCTGAGAAGGAAATGCTACAAATGAGA
GGCTTGTGAGCCTCTTATGAGCCTACTGAAGTCATATGAGGGTGGCAGAGAAAGCCATGCACACTTTATTTGTGAAG
TCCCTTTTTCGAGGACTATCTCTCGGTTGAGGAACCTATTCACTGATGGCATTCACTCTGATGTGATTGAACGCTGCG
CCAACAACATAGTAAAGATCTCCAGAAGGTTGTAGACATTGTGTTGTCTCACCAGGGTGTGAGAAACAAAACCTAAGC
TGATACTAACACTCATGGAGAACTGGTCTATCCAACCCCTGCTGCTACAAGGATCAGTTGACTCGCTTTTCTCTCC
CTCAATCAAAAAGATATTATAAGTTGGCCCTTAAAGCTAGCGAGCTTCTTGAACAAACCAAGCTTAGTGAGCTCCG
CACAAGCATTGCAAGGAGCCTTTTCAAACTTGAGATGTTTACTGAAGAAAGGACGCGCCATTAGTGAGATCATGGGAG
ATTTAGTGACTGCCCCACTGCCAGTTGAAGATGCAGTGGTTTCTTTGTTGATTGTAGTGATCAAACCTCTTCAGCAG
AGGGTGATCGAGACGTACATATCTCGATTATACCAGCCTCATCTTGTCAAGGATAGTATCCAGCTGAAATATCAGGA
ATCTGGTGTATTGCTTTATGGGAATTCGCTGAAGCGCATTCAAGAGAAGAGATTGGGTGCTATGGTTATTGTGAAGT
CGTTAGAATCTGTATCAGCAGCAATTGGAGCTGCACTAAAGGGTACATCACGCTATGCAAGCTCTGAGGGTAAACATA
ATGCATATTGCTTTATTGGGTGCTGATAATCAAATGCATGGAAGTGAAGACAGTGGTGATAACGATCAAGCTCAAGT
CAGGATAGACAACTTTCTGCGACACTGGAACAAAATACTGTACAGCTGATCTCCGTGCTGCTGGTGTGAAGGTTA
TTAGTTGCATTGTTTCAAAGGGATGGAGCACTCATGCTATGCGCCATACCTTCTCTTGTGCGATGAAAAGCTTTGT
TATGAGGAAGAGCCGTTCTCCGGCATGTGGAGCCTCCTCTTCTGCTCTTCTGAGTTGGGTAAAGTTGAAGTGAA
AGGATACAATGAGGTGAAGTATACACCGTCACGTGATCGTCAGTGGAAACATATACACACTTAGAAATACAGAGAACC

CCAAAATGTTGCACAGGGTGTTCCTCCGAACCTCTGTGTCAGGCAACCCGGTGCTTCCAACAAATTCACATCAGGCAAC
ATCACTGATGTTGAAGTGGGAGGAGCTGAGGAATCTCTTTTACATTCAGCAGCATATTAAGATCGCTGATGAC
TGCTATAGAAGAGTTGGAGCTTCACGCGATTAGGACAGGTCACCTCTCATATGTTTTTGTGCATATTGAAAGAGCAAA
AGCTTCTTGATCTTGTTCCTGTTCCCGTTTCAGGGAACAAAGTTGTGGATATTGGCCAAGATGAAGCTACTGCATGCTTGCTT
CTGAAAGAAATGGCTCTACAGATACATGAACCTTGTGGGTGCAAGGATGCATCATCTTTCTGTATGCCAATGGGAGGT
GAACTTAAGTTGGACAGCGATGGGCCTGCCAGTGGTACCTGGAGAGTTGTAACAACCAATGTTACTAGTCACACCT
GCACTGTGGATATCTACCGTGAGGTTGAAGATACAGAATCACAGAACTAGTGTACCCTCTGCTCCATCGTCATCT
GGTCTTTTGATGCGGTTGCACTGAATACTCCATATCAGCCTTTGAGTGTTATTGATCTGAAACGTTGCTCCGCTAG
AAATAACAGAACTACATACTGCTATGATTTTCCGTGGCATTGAACTGCAGTGCAGAAGTCATGGTCTAACATTT
CTAGTGACACTAACCGATGTTATGTTAAAGCGACGAGCTGGTGTGTTGCTCACAAGAACGGGTGATGGGGCACTCCT
GTAATTCCTATGGAGCGTCTGCTGGGCTCAATGACATTGGTATGGTAGCTTGGATCTTGGACATGTCCACTCCTGA
ATATCCCAATGGCAGGCAGATTGTTGTCTCGCAAATGATATTACTTTTAGAGCTGGATCGTTTGGTCCAGGGAAG
ATGCATTTTTTGAACCTGTTACCAACCTAGCTTGTGAGAGGAAGCTTCTCTCATCTACTTGGCAGCAAACTCTGGT
GCTCGGATCGGCATAGCAGATGAAGTAAATCTTGCTTCCGTGTTGGATGGTCTGATGATGGCAGCCCTGAACGTGG
GTTTCAATATATTATCTGACTGAAGAAGACCATGCTCGTATTAGCGCTTCTCTTATAGCGCACAAGATGCAGCTTG
ATAATGGTGAAATTAGGTGGGTTATTGATTCTGTTGTAGGGAAGGAGGATGGGCTAGGTGTGGAGAACATACATGGA
AGTGTCTGCTATTGCCAGTGCTTATTCTAGGGCCTATGAGGAGACATTTACGCTTACATTTGTGACTGGAAGGACTGT
TGGAATAGGAGCATATCTTGTGCTGACTTGGCATAACGGTGCATTGAGCGTACTGACCAGCCCATTTATCCTAACTGGGT
TCTCTGCCTTGAACAAGCTTCTTGGCCGGGAAGTGTACAGCTCCCATCATGCAGTTGGGTGGCCCCAAAATTTATGGCC
ACAAACGGTGTGTCCATCTGACAGTTTCAGATGACCTTGAAGGTGATCTAATATATTGAGGTGGCTCAGCTATGT
TCCTGCCAACATTGGTGGACCTCTTCCCTATTACAAAATCTTGGACCCACCTGACAGACCCGTTGCTTACATCCCTG
AGAATACATGTGATCCTCGTGCGCCATCAGTGGCATTGATGATAGCCAAGGGAATGGTTGGGGGGTATGTTGAC
AAAGACAGTTTTGTGGAGACATTTGAAGGATGGGCGAAGTCAGTAGTTACTGGCAGAGCGAACTCGGAGGGATTCC
GGTGGGTGTTATAGCTGTGGAGACACAGACTATGATGCAGCTCATCCCTGCTGATCCAGGTGAGCTTGATTTCCCATG
AGCGGTCTGTTCTCGTGCTGGGCAAGTCTGGTTTCCAGATTCAGCTACTAAGACAGCGCAGGCAATGCTGGACTTC
AACCCTGAAGGATTACCTCTGTTTCATCCTTGCTAACTGGAGAGGCTTCTCTGTTGGGCAAAGAGATCTTTTTGAAGG
AATCCTTCAGGCTGGGTCAACAATTGTTGAGAACCTTAGGACATACAATCAGCCTGCCTTTGTATATATCCCCAAGG
CTGCAGAGCTACGTGGAGGGGCTTGGGTGCTGATGATAGCAAGATAAATCCAGATCGCATTGAGTTCTATGCTGAG
AGGACTGCAAGGGCAATGTTCTTGAACCTCAAGGGTTGATTGAGATCAAGTTGAGGTGAGGAACTCCAAGAGTG
CATGGGCAAGCTTGACCCAGAATTGATAAATTTGAAGGCAAAACTCCTGGGAGCAAAGCATGAAATGGAAGTCTAT
CTGAGTCAGAAATCCCTTCAGAAGAGCATAGAAGCCCGGAAGAAACAGTTGTTGCCTTTGTATACTCAAATGCGGTA
CGGTTGCTGATGATGACACTTCCCTTAGAATGGCTGCTAAGGTTGTGATTAAGAAGGTTGTAGACTGGGAAGA
TTCTAGGTCTTTCTTCTACAAGAGATTACGGAGGAGGATATCCGAGGATGTTCTTGCAAAGGAATTAGAGGTGTAA
GTGGCAAGCAGTTTTCTCACCAATCGGCAATCGAGCTGATCCAGAAATGGTACTTGGCCTCTAAGGGAGCTGAAACG
GGAAACACTGAATGGGATGATGACGATGCTTTTGTGCTGGAGGGGAAACCCTGAAACTACCAGGAGTATATCAA
AGAACTCAGGGCTCAAAGGGTATCTCAGTTGCTCTCAGATGTTGCAGACTCCAGTCCAGATCTAGAAGCCTTGCCAC
AGGGTCTTTCTATGCTACTAGAGAAGATGGATCCCTCAAGGAGAGCACAGTTGTTGAGGAAGTCAAGAAGGCCCTT
AAATGA

FIGURE 15B

>ACD46679_Aegilops tauschii (jointed goatgrass)
MGSTHLPIVGLNASTTPSLSTIRPVNSAGAAFPAPSRTSKKKSRRVQSLRDGGDGGVSDPNQSIROGLAGII
DLPKEGTSAPFVDISHGSEEPGRSYQMNGILNEAHNGRHASLSKVVEFCMALGGKTFIHSVLVANNGMAAAKFM
RSVRTWANETFGSEKAIQLIAMATPEDMRINAEHIRIADQFVEVPGGTNNNNYANVQLIVEIAVRTGVS AVWPG
WGHASENFELPDALNANGIVFLGPPSSSMNALGDKVGSALIAQAAGVPTLPWSGSQVEIPELVCLDSIPADMYR
KACVSTTEEALASCQMIGYPAMIKASWGGGGKGIRKVNDDVRLFKQVQGEVPGSPIFIMRLASQSRHLEVQ
LLCDQYGNVAALHSRDCSVQRRHQKIIIEGPVTVAPRET VKELEQAARRLAKAVGYVGAATVEYLYSMETGEYY
FLELNPRLQVEHPVTEWIAEVLNLPAAQVAVGMGIPLWQVPEIRRFYGMNNGGYDIWRKTAALATPFNFDEVDS
QWPKGHCAVRITSEDPDDGFKPTGGKVKEISFKSKPNVWAYFSVKSGGGIHEFADSQFGHVFAYGVSRAAAT
NMSLALKEIQIRGEIHSNVDYTVDLLNASDFKENRIHTGWLNDRIAMRVQAERPPWYISVVGALYKTITSNTD
TVSEYVSYLKVGQIPPKHISLVHSTVSLNIEESKYTIETIRSGQGSYRLRMNGSVIEANVQTLCDGGLLMQLDG
NSHVIYAEAEAGGTRLLIDGKTCLLQNDHDP SRLLAETPCKLLRFLVADGAHVEADVPAEVEVMKMCMPLLSP
AAGVINVLLESGQPMQAGDLIARLDLDDPSAVKRAEPFNGSFPFEMS LPIAASGQVHKRCATSLNAARMVLAGYD
HPINKVVQDLVSCDLAPELPFLQWEELMSVLATRLPRLKSELEGKYSEYKLVNGHGKSKDFPSKMLREIIEEN
LAHGSEKEIATNERLVEPLMSLLKSYEGGRESHAHFIVKSLFEDYLSVEELFSDGIQSDVIERLRQQHSDKLQK
VVDIVLSHQGVRNKTCLIITLMEKLVYPNPAAYKDQLTRFSSLNHKRYKALALKASELLEQTKLSELRTSIARS
LSELEMTTEERTAISEIMGDLVTAPLPVEDALVSLFDCSDQTLQQRVIETIYISRLYQPHLVKDSIQLKYQESGV
IALWEFAEAHSEKRLGAMVIVKSLESVSAAGAAALKGTSRYASSEGNIMHIALLGADNQMHGTEDSGDNDQAOV
RIDKLSATLEQNTVTADLRAAGVKVISCIQVRDQALMPMRHTFLLSDEKLCYEEEPVLRHVEPPLSALLELGKL
KVKGYNEVKYTPSRDRQWNIYTLRNTENPKMLHRVFFRTLVRQPGASNKFTSGNISDVEVGGAEESSLFTSSSI
LRSLMTAIEELELHAIRTGHSMLFCILKEQKLLDLVPVSGNKVVDIGQDEATACLLLKEMALQIHELVGARMH
HLSVCQWEVKLKLDSGPASGTWRVVTNTVTSHTCTVDIYREVEDTESQKLVYHSAPSSSGPLHGVALNTPYQP
LSVIDLKRCSARNNRTTYCYDFPLAFETAVQKSWSNISSDTNRCYVKATELVFAHKNNGSWGTPVIMERPAGLN
DIGMVAVILDMSTPEYPNGRQIVVIANDITFRAGSFGPREDAFFETVTNLACERKPLIYLAANS GARIGIADE
VKSCFRVCWSDDGSPERGQYIYLTEEDHARISASVIAHKMQLDNGEIRWVIDSVVGKEDGLGVENIHGSAATA
SAYSRA YEETFTLTFTVTRTVGIGAYLARLGIRCIQRTDQPIILTGFSALNKLLGREVYSSHMQLGGPKIMATN
GVVHLTVSDDLEGVSNILRWLSYVPANIGGPLPITKSLDPPDRPVAYIPENTCDPRAAISGIDDSQGWLGGMF
DKDSFVETFEGWAKSVVTGRAKLGIPVGVIAVETQTMQLIPADPGQLDSHERSVPRAGQVWFPSATKTAQA
MLDFNREGLPLFILANWRGFSGGQRLDFEGLQAGSTIVENLRITYNQPAFVYIPKAAELRGGAWVVIDSKINPD
RIEFYAERTAKGNVLEPQGLIEIKFRSEELQECMGRLDPELINLAKALLGAKHENGSLSESESLQKSIEARKKQ
LLPLYTQIAVRFAELHDTSLRMAAGVIKKVVDWEDSRSFYKRLRRRISEDLAKEIRGVSGKQFSHQSAIEL
IQKWYLASKGAETGNTTEWDDDDAEVAVWRENPENYQEYIKELRAQRVSQLLSDVADSSPDLEALPQGLSMLLEKM
DPSRRAQFVEEVKKALK

FIGURE 16

ACCase Mutation	Selections Agent	#exp	#ies	#		Putative TE	#		Confirmed TE	escapes	%
				Putative events	Confirmed events		Putative events	Confirmed events			
RLM185	pursuit	2	27	15	14	56%			52%		4%
	cycloxydim	2	29	0	0	0%			0%		0%
	tepraloxymdim	2	29	0	0	0%			0%		0%
I7831L	pursuit	2	40	22	21	55%			53%		3%
	cycloxydim	2	50	16	15	32%			30%		2%
	tepraloxymdim	2	50	0	0	0%			0%		0%
I1781L, W202C	pursuit	2	40	10	9	25%			23%		3%
	cycloxydim	2	50	20	20	40%			40%		0%
	tepraloxymdim	2	50	11	11	22%			22%		0%
I1781L, I2041N	pursuit	2	40	10	9	25%			23%		3%
	cycloxydim	2	50	12	12	24%			24%		0%
	tepraloxymdim	2	50	14	14	28%			28%		0%
I7831A	pursuit	2	35	16	14	46%			40%		6%
	cycloxydim	2	50	0	0	0%			0%		0%
	tepraloxymdim	2	50	0	0	0%			0%		0%
Wild Type	pursuit	2	30	16	15	53%			50%		3%
	cycloxydim	2	50	0	0	0%			0%		0%
	tepraloxymdim	2	50	0	0	0%			0%		0%




FIGURE 18

```

1  MGSTHLPVIG  FNASTTPSLS  TLRQINSAAA  AFQSSSPSRS  SKKKSRRVKS  IRDDGDGSVP
61  DPAGHGQSIR  QGLAGIIDLP  KEGASAPDVG  ISHGSEDHKA  SYQMNGILNE  SHNGRHASLS
121  KVEYFCTELG  GKTPIHSLV  ANNGMAAAKF  MRSVRTWAND  TFGSEKAIQL  IAMATPEDMR
181  INAEHIRIAD  QFVEVPGGTN  NNNYANVQLI  VEIAERTGVS  AVWPGWGHAS  ENPELDPALT
241  AKGIVFLGPP  ASSMNALGDK  VGSALIAQAA  GVPTLAWSGS  HVEIPLELCL  DSIPEEMYRK
301  ACVTTADEAV  ASCQMIGYPA  MIKASWGGGG  KGIRKVNND  EVKALFKQVQ  GEVPGSPIFI
361  MRLASQSRHL  EVQLLCDEYG  NVAALHSRDC  SVQRRHQKII  EEGPVTVAPR  ETVKELEQAA
421  RRLAKAVGYV  GAATVEYLYS  METGEYYFLE  LNPRLQVEHP  VTESIAEVNL  PAAQVAVGMG
481  IPLWQIPEIR  RFGMDNGGG  YDIWRKTAAL  ATPFNFEVD  SQWPKGHCA  VRITSENDD
541  GFKPTGGKVK  EISFKSKPNV  WGYFSVKS GG  GIHEFADSQF  GHVFAYGETR  SAAITSMSLA
601  LKEIQIRGEI  HTNVDYTVDL  LNAPDFRENT  IHTGWLDTRI  AMRVQAERPP  WYISVVGAL
661  YKTITNAET  VSEYVSYLK  GQIPPKHISL  VHSTISLNE  ESKYTIEIVR  SGQGSYRLRL
721  NGSLIEANVQ  TLCDDGGLMQ  LDGNSHVIA  EEEAGGTRLL  IDGKTCLLQN  DHDPRLLA
781  TPCKLLRFLI  ADGAHVDAV  PYAEVEVMKM  CMLLSPAG  VINVLSEGO  AMQAGDLIAR
841  LDLDPSAVK  RAEPFEGSFP  EMSLPIAAS  QVHKRCAAS  NAARMVLGY  DHAANKVVQD
901  LVWCLDTPAL  PFLQWHEELM  VLATRLPRRL  KSELEGKYNE  YKLVNDHVKI  KDFPTEMLRE
961  TIEENLACVS  EKEMVTIERL  VDPLMSLLKS  YEGGRESHAH  FIVKSLFEEY  LSVEELFSDG
1021  IQSDVIERLR  LQYSKDLQKV  VDIVLSHQGV  RNKTKLILAL  MEKLVYPNPA  AYRDQLIRFS
1081  SLNHKRYKYL  ALKASELLEQ  TKLSELRTSI  ARNLSALDMF  TEEKADFSLO  DRKLAINESM
1141  GDLVTAPLPV  EDALVSLFDC  TDQTLQQRVI  QTYISRLYQP  QLVKDSIQLK  YQDSGVIALW
1201  EFTEGNHEKR  LGAMVILKSL  ESVSTAIGAA  LKDASHYASS  AGNTVHIAL  DADTQLNTE
1261  DSGDNDQAQD  KMDKLSFVLK  QDVVMADLRA  ADVKVVSCIV  QRDGAIMPMR  RTFLLSEEKL
1321  CYEEEPILRH  VEPPLSALLE  LDKLKVKGYN  EMKYTPSRDR  QWHIYTLRNT  ENPKMLHRVF
1381  FRTLVRQFSA  GNRFTSDHIT  DVEVGHAEEP  LSFTSSSILK  SLKIAKEELE  LHAIRTGHS
1441  MYLCILKEQK  LLDLVPVSGN  TVVDVGQDEA  TACSLKEMA  LKIHVLVGAR  MHLHSLVCWE
1501  VKLKLVS DGP  ASGSRVVT  NVTGHTCTVD  IYREVEDTES  QKLVYHSTAL  SSGPLHGV
1561  NTSYQPLSVI  DLKRC SARNN  KTTYCYDFPL  TFEAAVQKSW  SNISSENNQC  YVKATELVFA
1621  EKNGSWGTP  IPMORAAGLN  DIGMVAWILD  MSTPEFFPSGR  QIIVIANDIT  FRAGSFGPRE
1681  DAFFEAVTNL  ACEKKPLIY  LAANS GARIG  IADEVKSCFR  VGWTDSSPE  RGFRYIYMTD
1741  EDHDRIGSSV  IAHKMQLDSG  EIRWVIDSVV  GKEDGLGVEN  IHGSAAIASA  YSRAYEETFT
1801  LTFVTGRVTG  IGAYLARLGI  RCIQRIDQPI  ILTGFSALNK  LLGREVYSSH  MOLGGPKIMA
1861  TNGVHLTV  DDLEGVSNIL  RWLSYVPANI  GGPLPITKSL  DPIDRPVAYI  PENTCDPRAA
1921  ISGIDDSQ GK  WLGGMFDKDS  FVETFE GWAK  TVVTGRAKLG  GIPVGVIAVE  TOTMMQLVPA
1981  DPGQPD SHER  SVPRAGQVWF  PDSATKTAQA  MLDFNREGLP  LFILANWRGF  SGGQRDLFEG
2041  LQAGSTIVE  NLRTYNQPAF  VYIPKAAELR  GGAWVVIDSK  INPDRIECYA  ERTAKGNVLE
2101  PQGLIEIKFR  SEELKECMGR  LDP ELIDLKA  RLOGANGSL  DGESLOKSIE  ARKKQLLEPLY
2161  TQIAVRFAEL  HDTSLRMAAK  GVIRKVV DWE  DSRSEFFYKRL  RRRLESDVLA  KEIRGVIGEK
2221  FPHKSAIELI  KKWYLASEAA  AAGSTDWDD  DAFVAWREN  ENYKEYIKEL  RAQRVSRLLS
2281  DVAGSSSDLQ  ALPQGLSMLL  DKMDPSKRAQ  FIEEVMKVLK

```

FIGURE 19

	1	60
AmACCI [CAC84161]	(1) MGSTHLPVGFNASTTTPSLSTLRQINSAAAFQSSSPSRSSKKKSRRVKSIRDDGDGSP	
OSIACCI [BGIOSIBCE018385]	(1) MTSTHVATLGVGAQAPPRHQ---KKSAGTAFVSSGSSRPSYRKNQQRTRSLREESNGGVS	
OsJACCI [EAZ33685]	(1) MTSTHVATLGVGAQAPPRHQ---KKSAGTAFVSSGSSRPSYRKNQQRTRSLREESNGGVS	
	61	120
AmACCI [CAC84161]	(61) DPAGHGQSIRQGLAGIIDLPKEGASAPDVIDISHGSEDHKA-----SYQMNGILNESHNGR	
OSIACCI [BGIOSIBCE018385]	(58) DSKKLNHSIRQGLAGIIDLPNDAAS--EVDISHGSEDPRGPTVPGSYQMNGIINETHNGR	
OsJACCI [EAZ33685]	(58) DSKKLNHSIRQGLAGIIDLPNDAAS--EVDISHGSEDPRGPTVPGSYQMNGIINETHNGR	
	121	180
AmACCI [CAC84161]	(116) HASLSKVVEFCTELGGKTPHISVLVANNGMAAAKFMRSVRTWANDTFGSEKAIQLIAMAT	
OSIACCI [BGIOSIBCE018385]	(116) HASVSKVVEFCTALGGKTPHISVLVANNGMAAAKFMRSVRTWANDTFGSEKAIQLIAMAT	
OsJACCI [EAZ33685]	(116) HASVSKVVEFCTALGGKTPHISVLVANNGMAAAKFMRSVRTWANDTFGSEKAIQLIAMAT	
	181	240
AmACCI [CAC84161]	(176) PEDMRINAEHRIADQFVEVPGGTNNNNYANVOLIVEIAERTGVSAYWPGWGHASENP	
OSIACCI [BGIOSIBCE018385]	(176) PEDLRINAEHRIADQFVEVPGGTNNNNYANVOLIVEIAERTGVSAYWPGWGHASENP	
OsJACCI [EAZ33685]	(176) PEDLRINAEHRIADQFVEVPGGTNNNNYANVOLIVEIAERTGVSAYWPGWGHASENP	
	241	300
AmACCI [CAC84161]	(236) PDALTAKGIVFLGPPASSMHALGDKVGSALIAQAAGVPTLAWSGSHVEIPELCLDSIPE	
OSIACCI [BGIOSIBCE018385]	(236) PDALTAKGIVFLGPPASSMHALGDKVGSALIAQAAGVPTLAWSGSHVEVPECLCLDSIPD	
OsJACCI [EAZ33685]	(236) PDALTAKGIVFLGPPASSMHALGDKVGSALIAQAAGVPTLAWSGSHVEVPECLCLDSIPD	
	301	360
AmACCI [CAC84161]	(296) EMYRKACVTTADEAVASCQMI GYPAMIKASWGGGKGIRKVNNDDEVKALFKQVQGEVPG	
OSIACCI [BGIOSIBCE018385]	(296) EMYRKACVTTTEEAVASCQVVGYPAMIKASWGGGKGIRKVHNDDEVRTLKQVQGEVPG	
OsJACCI [EAZ33685]	(296) EMYRKACVTTTEEAVASCQVVGYPAMIKASWGGGKGIRKVHNDDEVRTLKQVQGEVPG	
	361	420
AmACCI [CAC84161]	(356) SPIFIMRLASQSRHLEVQLLCDQYGNVAALHSRDCSVQRRHQKIIIEEGPVTVPRETVKE	
OSIACCI [BGIOSIBCE018385]	(356) SPIFIMRLAAQSRHLEVQLLCDQYGNVAALHSRDCSVQRRHQKIIIEEGPVTVPRETVKE	
OsJACCI [EAZ33685]	(356) SPIFIMRLAAQSRHLEVQLLCDQYGNVAALHSRDCSVQRRHQKIIIEEGPVTVPRETVKE	
	421	480
AmACCI [CAC84161]	(416) LEQAARRLAKAVGVGAATVEYLYSMETGEYFLELNPRLQVEHPVTEWIAEVLNLPAAQV	
OSIACCI [BGIOSIBCE018385]	(416) LEQAARRLAKAVGVGAATVEYLYSMETGEYFLELNPRLQVEHPVTEWIAEVLNLPAAQV	
OsJACCI [EAZ33685]	(416) LEQAARRLAKAVGVGAATVEYLYSMETGEYFLELNPRLQVEHPVTEWIAEVLNLPAAQV	
	481	540
AmACCI [CAC84161]	(476) AVGMGIPLWQIPEIRRFYGMNNGGGYDIWRKTAALATPFNFDEVDSQWPKGHCAVAVRITS	
OSIACCI [BGIOSIBCE018385]	(476) AVGMGIPLWQIPEIRRFYGMNNGGGYDLWRKTAALATPFNFDEVDSQWPKGHCAVAVRITS	

OsJACCI [EAZ33685]	(476)	AVGMGIPLWQIPEIRRFYGMNHGGGYDLWRKTAALATPFNFDEVDSKWPKGHCVAVRITS	
	541		600
AmACCI [CAC84161]	(536)	ENPDDGFKPTGGKVKEISFKSKPNVWGYSVKSGGGIHEFADSQFGHV FAYGETRSAAIT	
OSIACCI [BGIOSIBCE018385]	(536)	EDPDDGFKPTGGKVKEISFKSKPNVWAYFSVKSGGGIHEFADSQFGHV FAYGTRSAAIT	
OsJACCI [EAZ33685]	(536)	EDPDDGFKPTGGKVKEISFKSKPNVWAYFSVKSGGGIHEFADSQFGHV FAYGTRSAAIT	
	601		660
AmACCI [CAC84161]	(596)	SMSLALKEIQIRGEIHTNVDYTVDLLNAPDFRENTIHTGWLDTRIAMRVQAEPPWYISV	
OSIACCI [BGIOSIBCE018385]	(596)	TMALALKEVQIRGEIHSNVDYTVDLLNASDFRENKIHTGWLDTRIAMRVQAEPPWYISV	
OsJACCI [EAZ33685]	(596)	TMALALKEVQIRGEIHSNVDYTVDLLNASDFRENKIHTGWLDTRIAMRVQAEPPWYISV	
	661		720
AmACCI [CAC84161]	(656)	VGGALYKTITNAETVSEYVSYLKQIIPPKHISLVHSTISLNIEESKYTIEIVRSGQGS	
OSIACCI [BGIOSIBCE018385]	(656)	VGGALYKTVTANTATVSDYVGYLTGQIIPPKHISLVYTTVALNIDGKKYTIDTVRSGHGS	
OsJACCI [EAZ33685]	(656)	VGGALYKTVTANTATVSDYVGYLTGQIIPPKHISLVYTTVALNIDGKKYTIDTVRSGHGS	
	721		780
AmACCI [CAC84161]	(716)	YRLRLNGSLIEANVQTLCDGGLMQLDGNSHVIYAEFEAGSTRLLIDGKTCMLQNDHDP	
OSIACCI [BGIOSIBCE018385]	(716)	YRLRMNGSTVDANVQILCDGGLMQLDGNSHVIYAEFEASGSTRLLIDGKTCMLQNDHDP	
OsJACCI [EAZ33685]	(716)	YRLRMNGSTVDANVQILCDGGLMQLDGNSHVIYAEFEASGSTRLLIDGKTCMLQNDHDP	
	781		840
AmACCI [CAC84161]	(776)	RLLAETPCKLLRFLVADGAHVADVPYAEVEVMKMCMPLLSPAAGVINVLSEGGAMQAG	
OSIACCI [BGIOSIBCE018385]	(776)	KLLAETPCKLLRFLVADGAHVADVPYAEVEVMKMCMPLLSPASGVHVVMSSEGAMQAG	
OsJACCI [EAZ33685]	(776)	KLLAETPCKLLRFLVADGAHVADVPYAEVEVMKMCMPLLSPASGVHVVMSSEGAMQAG	
	841		900
AmACCI [CAC84161]	(836)	DLIARLDLDDPSAVKRAEPFEGSFPEMSLPAAAGQVHKRCAASLNAAVMVLAGYDHAAN	
OSIACCI [BGIOSIBCE018385]	(836)	DLIARLDLDDPSAVKRAEPFEDTFPQMGLPIAASGQVHKLCAASLNACRMILAGYEHDID	
OsJACCI [EAZ33685]	(836)	DLIARLDLDDPSAVKRAEPFEDTFPQMGLPIAASGQVHKLCAASLNACRMILAGYEHDID	
	901		960
AmACCI [CAC84161]	(896)	KVVQDLVWCLDTPALPFLQWEELMSVLATRLPRRLKSELEGKYNEYKLNVDHVKIDFPT	
OSIACCI [BGIOSIBCE018385]	(896)	KVVPPELVYCLDTPELPFLQWEELMSVLATRLPRNLKSELEGKYEEYKVKFDSGIINDFPA	
OsJACCI [EAZ33685]	(896)	KVVPPELVYCLDTPELPFLQWEELMSVLATRLPRNLKSELEGKYEEYKVKFDSGIINDFPA	
	961		1020
AmACCI [CAC84161]	(956)	EMLRETIEENLACVSEKEMVTIERLVDPLMSLLKSYEGGRESHAFIVKSLFEEYLSVEE	
OSIACCI [BGIOSIBCE018385]	(956)	NMLRVIIIEENLACGSEKEKATNERLVEPLMSLLKSYEGGRESHAFVVKSLFEEYLYVEE	
OsJACCI [EAZ33685]	(956)	NMLRVIIIEENLACGSEKEKATNERLVEPLMSLLKSYEGGRESHAFVVKSLFEEYLYVEE	
	1021		1080
AmACCI [CAC84161]	(1016)	LFSDGIQSDVIERLRLQYSKDLQKVVDIVLSHQSVRNKTKLILALMEKLVYPNPAAYRDQ	
OSIACCI [BGIOSIBCE018385]	(1016)	LFSDGIQSDVIERLRLQHSKDLQKVVDIVLSHQSVRNKTKLILKLMESLVYPNPAAYRDQ	
OsJACCI [EAZ33685]	(1016)	LFSDGIQSDVIERLRLQHSKDLQKVVDIVLSHQSVRNKTKLILKLMESLVYPNPAAYRDQ	

	1081	1140
AmACCI [CAC84161]	(1076) LIRFSSLNKHRYKALKASELLEQTKLSELRTSIARNLSALDMFTEEKADFSLQDRKLA	
OSIACCI [BGIOSIBCE018385]	(1076) LIRFSSLNKHAYKALKASELLEQTKLSELRLARIARSLSELEMTTESKGLSMHKREIA	
OsJACCI [EAZ33685]	(1076) LIRFSSLNKHAYKALKASELLEQTKLSELRLARIARSLSELEMTTESKGLSMHKREIA	
	1141	1200
AmACCI [CAC84161]	(1136) INESMGDLVTAFLPVEDALVSLFDCTDQTLQQRVIQTYISRLYQFQLVKDSIQLKYQDSG	
OSIACCI [BGIOSIBCE018385]	(1136) IKESMEDLVTAFLPVEDALISLFDCTDQTLQQRVIQTYISRLYQFQLVKDSIQLKYQDSG	
OsJACCI [EAZ33685]	(1136) IKESMEDLVTAFLPVEDALISLFDCTDQTLQQRVIQTYISRLYQFQLVKDSIQLKYQDSG	
	1201	1260
AmACCI [CAC84161]	(1196) VIALWEFTEGNEHKEK-----LGAMVILKSLESVSTAIGAALDASHYASSAGNTV	
OSIACCI [BGIOSIBCE018385]	(1196) VIALWEFTEGNEHKEK-----LGAMVILKSLESVSTAIGAALDASHYASSAGNTV	
OsJACCI [EAZ33685]	(1196) VIALWEFTEGNEHKEK-----LGAMVILKSLESVSTAIGAALDASHYASSAGNTV	
	1261	1320
AmACCI [CAC84161]	(1246) HIALLDADTQLNNTTEDSGDNDQAQDKMDKLSFVLKQDVVMADLRAADVKKVSCIVQRDEA	
OSIACCI [BGIOSIBCE018385]	(1256) HIALLGADNKMHIQESG---DDADRIAKLPLILKDN--VTDLHASGVKTIISFIVQRDEA	
OsJACCI [EAZ33685]	(1256) HIALLGADNKMHIQESG---DDADRIAKLPLILKDN--VTDLHASGVKTIISFIVQRDEA	
	1321	1380
AmACCI [CAC84161]	(1306) IMPMRRTFLLSEEKLCYEEEPILRHVEPPLSALLELDKLVKGYNEMKYTPSRDRQWHIY	
OSIACCI [BGIOSIBCE018385]	(1311) RMTMRRTFLWSDEKLSYEEEPILRHVEPPLSALLELDKLVKGYNEMKYTPSRDRQWHIY	
OsJACCI [EAZ33685]	(1311) RMTMRRTFLWSDEKLSYEEEPILRHVEPPLSALLELDKLVKGYNEMKYTPSRDRQWHIY	
	1381	1440
AmACCI [CAC84161]	(1366) TLRNTENPKMLHRVFFRTLVRQPSAGNRFTSDHITDVEVGHAEEPLSFTSSILKSLKIA	
OSIACCI [BGIOSIBCE018385]	(1371) TLRNTENPKMLHRVFFRTLVRQPSVSNKFSSGQIGDMEVGSAAEPLSFTSTSLRLMTA	
OsJACCI [EAZ33685]	(1371) TLRNTENPKMLHRVFFRTLVRQPSVSNKFSSGQIGDMEVGSAAEPLSFTSTSLRLMTA	
	1441	1500
AmACCI [CAC84161]	(1426) KEELELHAIRTGHSYMLCILEQKLLDLVPVSGNTVVDVGQDEATACSLKEMALKIHE	
OSIACCI [BGIOSIBCE018385]	(1431) IEELELHAIRTGHSYMLHVLKEQKLLDLVPVSGNTVLDVGQDEATAYSLKEMAMKIHE	
OsJACCI [EAZ33685]	(1431) IEELELHAIRTGHSYMLHVLKEQKLLDLVPVSGNTVLDVGQDEATAYSLKEMAMKIHE	
	1501	1560
AmACCI [CAC84161]	(1486) LVGARMHLSVCQWEVKLVSDGPASGSRVVTNTVGTCTVDIYREVEDTESQKLIVY	
OSIACCI [BGIOSIBCE018385]	(1491) LVGARMHLSVCQWEVKLVSDGPASGTWRIVTNTVGTCTVDIYREMEDKESRKLIVY	
OsJACCI [EAZ33685]	(1491) LVGARMHLSVCQWEVKLVSDGPASGTWRIVTNTVGTCTVDIYREMEDKESRKLIVY	
	1561	1620
AmACCI [CAC84161]	(1546) HSTALSSGPHLGVALNTSYQPLSVIDLKRC SARNNKTTYCYDFPLT FEA AVQKSWSNISS	
OSIACCI [BGIOSIBCE018385]	(1551) HPATPAAGPLHGVALLNPNYQPLSVIDLKRC SARNNRTTYCYDFPLAFETAVRKSWSSTS	
OsJACCI [EAZ33685]	(1551) HPATPAAGPLHGVALLNPNYQPLSVIDLKRC SARNNRTTYCYDFPLAFETAVRKSWSSTS	
	1621	1680
AmACCI [CAC84161]	(1606) -----ENNQC YV KATELVFAEKNGSWGTPIIPMQRAAGLNDIGMVAWILDMSTPEFFPSG	

OSIACCI [BGIOSIBCE018385]	(1611)	GASKGVENAQCYVKATELVFADKHGSGWGTPLVQMDRPAGLNDIGMVAWTLKMSTPEFPFG	
OsJACCI [EAZ33685]	(1611)	GASKGVENAQCYVKATELVFADKHGSGWGTPLVQMDRPAGLNDIGMVAWTLKMSTPEFPFG	
	1681		1740
AmACCI [CAC84161]	(1660)	RQIIVIANIDITFRAGSFGPREDAFFEAVTNLACEKKLPLIYLAANSGARIGIADEVKSCF	
OSIACCI [BGIOSIBCE018385]	(1671)	REIIVVANDITFRAGSFGPREDAFFEAVTNLACEKKLPLIYLAANSGARIGIADEVKSCF	
OsJACCI [EAZ33685]	(1658)	REIIVVANDITFRAGSFGPREDAFFEAVTNLACEKKLPLIYLAANSGARIGIADEVKSCF	
	1741		1800
AmACCI [CAC84161]	(1720)	RVGWTDDSSPERGFRYIYMTDEDEHGRIGSSVIAHKMQLDSGEIRWVIDSVVGKEDGLGVE	
OSIACCI [BGIOSIBCE018385]	(1731)	RVGWSDDGSPERGQYIYLSEEDYARIGTSVIAHKMQLDSGEIRWVIDSVVGKEDGLGVE	
OsJACCI [EAZ33685]	(1718)	RVGWSDDGSPERGQYIYLSEEDYARIGTSVIAHKMQLDSGEIRWVIDSVVGKEDGLGVE	
	1801		1860
AmACCI [CAC84161]	(1780)	NIHGSAAIASAYSRAYEETFTLTFTVGTGTVGIGAYLARLGIRCIQRIDQPIILTGFSA LN	
OSIACCI [BGIOSIBCE018385]	(1791)	NIHGSAAIASAYSRAYKETFTLTFTVGTGTVGIGAYLARLGIRCIQRIDQPIILTGYSALN	
OsJACCI [EAZ33685]	(1778)	NIHGSAAIASAYSRAYKETFTLTFTVGTGTVGIGAYLARLGIRCIQRIDQPIILTGYSALN	
	1861		1920
AmACCI [CAC84161]	(1840)	KLLGREVYSSHMQLGGPKIMATNGVVHLTVPDDLEGVSNILRWLSYVPANIGGELPITKS	
OSIACCI [BGIOSIBCE018385]	(1851)	KLLGREVYSSHMQLGGPKIMATNGVVHLTVSDDLEGVSNILRWLSYVPAYIGGELPVTTP	
OsJACCI [EAZ33685]	(1838)	KLLGREVYSSHMQLGGPKIMATNGVVHLTVSDDLEGVSNILRWLSYVPAYIGGELPVTTP	
	1921		1980
AmACCI [CAC84161]	(1900)	LDPIDRPVAYIPENTCDPRAAISGIDDSQGKWLGGMFDKDSFVETFEGWAKTVVTTGRAKL	
OSIACCI [BGIOSIBCE018385]	(1911)	LDPIDRPVAYIPENS CDPRAAIRGVDDSGKWLGGMFDKDSFVETFEGWAKTVVTTGRAKL	
OsJACCI [EAZ33685]	(1898)	LDPIDRPVAYIPENS CDPRAAIRGVDDSGKWLGGMFDKDSFVETFEGWAKTVVTTGRAKL	
	1981		2040
AmACCI [CAC84161]	(1960)	GGIPVGVI AVETQTMQLVPADPGQPD SHERSVPRAGQVWFFDSATKTAQAMLD FNRGL	
OSIACCI [BGIOSIBCE018385]	(1971)	GGIPVGVI AVETQTMQTIPADPGQLDSREQSVPRAGQVWFFDSATKTAQALLDFNRGL	
OsJACCI [EAZ33685]	(1958)	GGIPVGVI AVETQTMQTIPADPGQLDSREQSVPRAGQVWFFDSATKTAQALLDFNRGL	
	2,041		2100
AmACCI [CAC84161]	(2020)	PLFILANWRGFGGGQRDLEFEGILQAGSTIVENLR TYNQPAFVYIPKAAELRGGA WVVIDS	
OSIACCI [BGIOSIBCE018385]	(2031)	PLFILANWRGFGGGQRDLEFEGILQAGSTIVENLR TYNQPAFVYIPMAAELRGGA WVVDS	
OsJACCI [EAZ33685]	(2018)	PLFILANWRGFGGGQRDLEFEGILQAGSTIVENLR TYNQPAFVYIPMAAELRGGA WVVDS	
	2101		2160
AmACCI [CAC84161]	(2080)	KINPDRIECYAERTAKGNVLEPQGLIEIKFRSEELKECMGRLDPELIDLKARLQGAN-GS	
OSIACCI [BGIOSIBCE018385]	(2091)	KINPDRIECYAERTAKGNVLEPQGLIEIKFRSEELQDCMSRLDPTLIDLKAKLEVANKNG	
OsJACCI [EAZ33685]	(2,078)	KINPDRIECYAERTAKGNVLEPQGLIEIKFRSEELQDCMSRLDPTLIDLKAKLEVANKNG	
	2161		2220
AmACCI [CAC84161]	(2139)	LSDGESLQKSIEARKQLPLLYTQIAVRFAELHDTSLRMAAKGVIKKVVDWEDSR SFFYK	
OSIACCI [BGIOSIBCE018385]	(2151)	SADTKSLQENIEARTKQIMPLYTQIAIRFAELHDTSLRMAAKGVIKKVVDWEDSR SFFYK	
OsJACCI [EAZ33685]	(2138)	SADTKSLQENIEARTKQIMPLYTQIAIRFAELHDTSLRMAAKGVIKKVVDWEDSR SFFYK	

	2221		2280
AmACCI [CAC84161]	(2199)	RLRRRLSEDLAKEIRGVIGKFPKSAIELIKKWYLASEAAAAGSTDWDDDDAFVAWRE	
OSIACCI [BGIOSIBCE018385]	(2211)	RLRRRISEDLAKEIRAVAGEQFSHQPAIELIKKWYSASHAA-----EWDDDDAFVAWMD	
OsJACCI [EAZ33685]	(2198)	RLRRRISEDLAKEIRAVAGEQFSHQPAIELIKKWYSASHAA-----EWDDDDAFVAWMD	
	2281		2340
AmACCI [CAC84161]	(2259)	NPENYKEYIKELRAQRVSRLSDVAGSSSDLQALPQGLSMLLDKMDPSKRAQFIEEVMKV	
OSIACCI [BGIOSIBCE018385]	(2266)	NPENYKDYIQYLKAQRVSQSLSSLDSSSDLQALPQGLSMLLDKMDPSRAQLVEEIRKV	
OsJACCI [EAZ33685]	(2253)	NPENYKDYIQYLKAQRVSQSLSSLDSSSDLQALPQGLSMLLDKMDPSRAQLVEEIRKV	
	2341		
AmACCI [CAC84161]	(2319)	LK	
OSIACCI [BGIOSIBCE018385]	(2326)	LG	
OsJACCI [EAZ33685]	(2313)	LG	